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1.1 General Introduction 
The research in this thesis was performed to obtain knowledge on the structure and 
dynamics of the Cytochrome P450 (CYP) enzyme and CYP2D6-ligand interactions. 
Computational approaches will be used to predict and rationalize drug metabolism by this 
enzyme. The aim of the current chapter is to give a general introduction into the 
background and context of the research presented in the thesis. Paragraph 1.2 deals with 
the clinical significance of drug metabolism and paragraph 1.3 with the role of ADME 
prediction in drug development. A general description of the use of computational 
chemistry in drug metabolism studies is provided in paragraph 1.4. In the next paragraph 
1.5 the clinical significance of Cytochrome P450 enzyme systems are described, with 
special focus on the human CYP2D6 isoenzyme, which will be the main subject of this 
thesis. In the final paragraphs 1.6 and 1.7, the aim, scope, and outline of this thesis is 
presented. 
 
1.2 Drug metabolism and clinical significance 
Drug metabolism determines the fate of a compound entering the body, ultimately 
controlling whether that compound exerts pharmacological or toxicological effects, or is 
excreted from the body before doing so. Ideally, drugs and other xenobiotics are degraded 
to harmless, water soluble metabolites, which are easily excreted via the urine or bile. 
Occasionally though, an otherwise innocuous compound is converted to a harmful 
metabolite in a process known as metabolic toxification.1,2 Other xenobiotic compounds 
may give rise to drug-drug interactions by inducing or inhibiting the activity of metabolic 
enzymes, thus affecting the normal detoxification of co-administered drugs. These 
processes can all lead to clinically significant adverse drug reactions (ADRs).3,4 
Biotransformation of drugs is usually divided into three phases.5 Phase I reactions involve 
the introduction of functional groups by hydrolysis, reduction and/or oxidation. In phase II 
reactions, endogeneous cofactors react directly with substrates or with the functional 
groups introduced in phase I. The phase II reactions involved are glucoronidation, 
sulphonation, acetylation, methylation and conjugation with amino acids or glutathione. 
Phase III metabolism constitutes the further metabolism of the products derived from 
phase II conjugation reactions. In Figure 1, an example is given of possible clinical 
implications in the case of codeine metabolism. Cytochrome P450  enzymes (CYPs) are the 
most important phase I drug metabolizing enzymes, implicated in many hundreds of cases 
of metabolic toxification and clinically significant drug-drug interactions.6 Understanding 
these enzymes and their mechanisms of action is therefore invaluable in the process of 
drug discovery and development. 
In many cases, ADRs have been shown to be associated with genetic polymorphisms in 
specific drug targets, such as GPCRs,7 or in specific drug metabolizing enzymes, such as 
CYPs.3,4 It has for example been estimated that: (i) ADRs cost the US society, US $100 
billion8; (ii) ADRs cause 100.000 deaths annually in the USA9; and that (iii) up to 7% of all 
hospital admissions in the UK and Sweden are due to ADRs, increasing the length of 
hospital stays by at least two days at an increased cost of ~$2500 per patient.10 In 
addition, the costs of treating patients with polymorphic forms of CYPs are much higher 
than those required to treat patients who possess non-polymorphic alleles.11 ADRs are also 
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one of the most common causes of drug withdrawals, which may have enormous financial 
implications for the pharmaceutical industry. Furthermore, the number of non-responding 
patients to drug therapy is high and represents 30–60% of subjects treated with drugs.12 
According to Phillips et al., 56% of drugs that are cited in ADR studies are metabolized by 
polymorphic phase I enzymes, of which 86% are CYPs.13 Particularly CYP1A2 and CYP2D6 
were found to be relevant in this regard, as they were found to be involved in the 
metabolism of respectively 75% and 38% of the relevant ADR drugs. Only 20% of the 































Figure 1: Metabolic fate of codeine in man, showing phase I O-demethylation and N-demethylation 
catalysed by CYPs, and phase II O-methylation and glucuronidation catalysed by catechol-O-
methyltransferase (COMT) and uridine 5’-triphosphate glucuronosyl-transferase 2B7 (UGT2B7), 
respectively. The thickness of the arrows indicates the relative importance of the pathways. Notice 
that formation of morphine, which is responsible for opioid activity in the brain, is normally only 
observed in relatively small amounts, but that in persons with an ultra-rapid metabolism (UM) 
CYP2D6 phenotype this pathway becomes more important. Increased formation of morphine and 
decreased formation of norcodeine (e.g. as a result of CYP3A4 inhibition due to drug-drug 
interactions) leads to excessive formation of glucuronides, resulting in acute renal failure. On the 
other hand, for persons with a poor metabolism (PM) CYP2D6 phenotype, codeine therapy will fail 
because of a decreased formation of the active morphine metabolite. Adapted from Gasche et al.14 
 
Absent or reduced activity of enzymes involved in drug biotransformation can lead to 
therapeutic failure or adverse drug effects by the following mechanisms (see also Figure 
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•   Decreased first pass metabolism and drug elimination. For drugs that are highly 
dependent on biotransformation to inactive metabolites by a specific (genetically 
polymorphic) enzyme: i)  individuals with a poor metabolizing phenotype (PMs), may 
experience a larger drug response and/or be at greater risk of toxicity; ii) co-administered 
inhibitors can diminish enzyme activity, which may result in a larger drug response as well 
as in toxic effects. 
•  Decreased pro-drug metabolism. When the conversion of a drug into an active 
metabolite is primarily mediated by a specific enzyme (e.g. conversion of codeine to 
morphine by CYP2D615), the drug may be ineffective in PMs or, when enzyme inhibitors 
are co-administered, lead to therapeutic faillure. 
 
Increased activity of enzymes involved in drug biotransformation can lead to therapeutic 
failure or adverse drug effects as well, e.g. by the following mechanisms: 
• Increased first-pass metabolism and drug elimination. For drugs that are highly 
dependent on biotransformation to inactive metabolites by specific (genetically 
polymorphic) enzymes: i)  people with an ultra-rapid metabolizers phenotype (UMs), 
may have a lower drug response; ii) co-administered inducers can significantly increase 
enzyme activity and result in lower drug response and therapeutic faillure as well. 
• Increased formation and accumulation of toxic metabolites formed by drug 















Figure 2: Effects of drug-drug interactions (inhibitors, inducers) and genetic polymorphisms (poor 
metabolizing phenotype (PM), ultra-rapid metabolizing phenotype (UM)) on metabolism, affecting 
the clinical impact of drugs (toxicity and therapeutic failure). “+” and “-“ indicate an increase or 
decrease of the subsequent clinical effect. 
 
In conclusion, drugs metabolism determines the fate of a compound entering the body, 
and absent, reduced or increased activity of enzymes involved in drug biotransformation 
can lead to therapeutic failure or adverse drug effects. Understanding these enzymes and 
their mechanisms of action is therefore invaluable in the process of drug discovery and 
development. The next paragraph describes the interplay between in silico, in vitro and in 
vivo studies to predict processes controlling the fate of drugs: absorption, disposition, 
metabolism and excretion (ADME). 
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1.3 The role of ADME(T) in drug discovery: The interplay between in 
silico, in vitro and in vivo studies 
High throughput synthesis and screening of potential drug candidates yields hundreds of 
thousands of compounds. High-throughput screening (HTS) tests are performed for 
various properties, ranging from solubility and metabolic stability to drug potency and 
toxicity.16 The number of high-quality lead compounds derived from such HTS tests is 
rather low, and several studies suggest that poor pharmacokinetics (PK) and toxicity are 
among the most important causes of late-stage failures of compounds in drug 
development.17,18 Early consideration of drug potency, ADME-properties (absorption 
disposition, metabolism and excretion) and toxicity is therefore increasingly seen as 
essential for efficient discovery and development of new drugs and drug candidates.16,19 
High-throughput in vitro methods are generally used to screen previously synthesized 
compound libraries while library design now also includes in silico predictions to increase 
the critical hit/lead ratio. Figure 3 presents two approaches in which ADME/Tox analyses 
are incorporated in the drug discovery and development process.20 In the first (“serial”) 
model, compounds are tested for potency first via high-throughput screening (HTS), 
followed by serial examinations of their absorption, distribution, metabolism, and excretion 
(ADME) and toxicity (Tox) profiles. Compounds failing appropriate ADME/Tox profiling 
require new analogues to be synthesized and submitted through the cycle. In the second 
(“parallel”) model, libraries of ‘pre-synthesized’ analogues are submitted to multiple in 
silico and in vitro tests in parallel, building a database of potency, ADME, and toxicity 
profiles. Best-option molecules are selected for further optimization. This simultaneous 
optimisation of the pharmacokinetic, toxicological, and pharmacological properties remains 


























Figure 3: “Serial” (left scheme) and “parallel” (right scheme) models of lead optimisation (see 




Pre-experimental prediction of pharmacological and non-pharmacological drug-
properties with in silico ADME-Tox screening21,22 is likely to be one of the most challenging 
developments with a great scientific and practical impact. Figure 4 shows the interplay 
between in silico models, in vitro screening, and in vivo testing in drug lead finding and 
optimization. 
 
























Figure 4: The interplay between in silico models, in vitro screening, and in vivo testing in drug lead 
finding and optimization (including the optimization of drug potency and ADME properties, and the 
minimization of drug toxicity). In iterative cycles, in silico models are built, refined and validated by 
in vitro screening. Subsequently, optimized leads are tested in vivo. Adapted from Beresford et al.20 
 
Figure 5 gives a schematic overview of predictive in silico models necessary for guiding 
drug lead finding and optimization. In silico studies have been applied to predict intestinal 
absorption and drug distribution including permeation across the blood-brain barrier.19,23 
Based on the assumption that oral bioavailability of metabolically stable compounds are 
determined by the rate of absorption, some of these methods were also used to predict 
oral bioavailability. Since the fraction of the oral dose that reaches systemic circulation is 
influenced by both absorption and first-pass metabolism, prediction techniques for 
metabolic stability are needed. Lipinski has analyzed large drug databases and identified 
molecular criteria that should be fulfilled in order to obtain appropriate oral delivery: i) 
molecular weight, MW < 500 Daltons, ii) octanol/water partition coefficient, log(P) < 5, iii) 
number of hydrogen bond donors, Ndonor <5, iv) number of hydrogen bond acceptors, Nacc. 
< 10.18 In silico prediction of drug potency, ADME properties, and toxicity (Tox) can be 
performed using various approaches, such as database modelling, 1D/2D-quantitative-
structure-activity relationships modelling, and ligand and protein target structure-based 
modelling, reviewed by refs 19,23. A virtual screening cascade typically follows these 
different approaches in subsequent steps: i) filters like the above mentioned Lipinski rule-
of-fives are applied to eleminate compounds possessing non-drug-like properties; ii) 
topocological 1D/2D searches from known ligands; iii) 3D-similarity or 3D-pharmacophore 
searches; iv) protein structure-based virtual screening.24 Computational methods used for 





Figure 5: Schematic overview of predictive in silico models necessary for guiding drug lead 
optimization. The emphasis is on ADME (Absorption, Distribution, Metabolism, Excretion) processes 
(apart from the optimization of drug potency and minimization of drug toxicity) and their ultimate 
effect on drug fate (indicated by arrows). CYP(2D6) metabolism models described in this thesis are 
highlighthed in bold and enclosed by a dashed box. Abbreviations: AD, alcohol dehydrogenase; 
NAT, N-acetyl transferase; GST, glutathione S-transferase ; SUT, sulfotransferase, COMT, catechol-
O-methyltransferase; UGT, uridine 5’-triphosphate glucuronosyltransferase; AHR, aryl hydrocarbon 
receptor; CAR; constitutive androsterone receptor, MRP, multidrug resistance protein; OATP, 
organic anion transporter protein; OCTP, organic cation transport protein; P-gp, P-glycoprotein; 
PXR, pregnane receptor. Adapted from Ekins et al.25 
 
Early consideration of drug potency, ADME-properties (absorption disposition, metabolism 
and excretion) and toxicity is increasingly seen as essential for efficient discovery and 
development of new drugs and drug candidates. Drug lead compounds are discovered and 
optimized by an integrative process of in silico modeling, in vitro screening, and in vivo 
testing. The next paragraph focuses on the in silico prediction of metabolism. 
 
1.4 Prediction of drug metabolism in silico 
Since activity, toxicity, bioavailability, distribution, and final elimination all depend on 
metabolic biotransformations, the prediction of metabolic stability and the identification of 
potential sites of metabolism in a putative drug molecule can be a significant help in 
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designing new compounds with a better pharmacokinetic profile.26-28  When the site of 
metabolism is known, metabolically labile compounds can be stabilized by removing, 
replacing or protecting metabolically susceptible groups. Similarly, the formation of toxic 
metabolites can be avoided by chemically protecting the labile moieties. Finally, knowing 
the site of metabolism is essential for the design of pro-drugs, where the compound needs 
to be metabolized in order to become active, and also for drugs showing excessively long 
half lives. Modifying functional groups in drug lead compounds that are essential for 
binding to metabolic enzymes may affect the binding affinity for these enzymes as well as 
their metabolic regiospecificity.26-28 Figure 5 gives a schematic overview of predictive in 
silico models currently used for guiding drug lead finding and optimisation and highlights 
models describing drug metabolism. 
Computational chemistry is an especially suitable tool to predict metabolic stability and 
sites of metabolism in potential drugs. In silico approaches to predict metabolism can be 
divided into i) predictive databases, ii) quantitative structure-relationships (QSARs) derived 
from physicochemical (‘1D’) and topological (‘2D’) properties of biotransformation enzyme 
substrates, and iii) structure-based (‘3D’) approaches.19,29 The first two approaches 
provide robust but rough classifications of the inhibition potency of ligands without yielding 
much insight into the possible (molecular) background of the mode of action. The 
structure-based (‘3D’) molecular modeling methods, on the other hand, aim to be 
insightful as well as predictive.22,30 The latter approaches can be divided into ligand-based 
(including QM calculations on substrates, pharmacophore models, and 3D-QSAR models), 
protein-based (including protein crystal structures and homology models) and ligand-
protein interaction based models (including issues like binding orientation, ligand dynamics 
and binding affinity).29 CYPs are of special clinical importance because of their great 
impact on phase I drug metabolism.1,2 These are therefore the most extensively studied 
drug metabolizing enzymes, in vivo, in vitro as well as in silico. Examples of computational 
approaches that use databases to predict drug metabolism are MetabolExpert, META, and 
Meteor.31 1D-QSARs predicting CYP metabolism have been very recently reviewed by 
Hansch et al.32 Several successful 2D-QSAR models predicting CYP metabolism and 
inhibition have been reported as well.33-36 An extensive overview of structure-based 
computational investigations used to understand, rationalize and predict CYP structure and 
function is provided in Chapter 2. Molecular modeling studies of other human 
biotransformation enzymes than CYPs are relatively scarce, although they have been 
increasingly reported in the past few years: see for example studies on epoxide 
hydrolase,37 alcohol dehydrogenase,38 esterases,39 sulfotransferase (SUT),40 catechol-O-
methyltransferase (COMT),41,42 glutathione S-transferase (GST),43,44 N-acetyl transferase 
(NAT),45,46 uridine 5’-triphosphate glucuronosyltransferase (UGT),47-49 and cysteine 
cunjugate beta-lyase.50 
Examples of future and as yet unresolved challenges in computational drug metabolism 
research are: i) The accurate quantitative prediction of metabolite formation ratios and 
turnover rates, and ii) the construction of combined models for multiple biotransformation 
enzymes, enabling the prediction of the relative kinetics of different reaction pathways and 
prediction of the relative affinities of drugs for different enzymes. This would give insight 
into the relative importance of different enzymes in the formation of different metabolites 
and might finally lead to the prediction of (the kinetics of) complete metabolic pathways of 
drugs. 
The next paragraph focuses on the family of Cytochrome P450  enzymes (CYPs), the 
most important phase I drug metabolizing enzymes, able to catalyse a wide variety of 
reactions, and implicated in many hundreds of cases of metabolic toxification and clinically 




1.5 Clinical significance of Cytochromes P450 
Cytochromes P450 (CYPs) are hemoproteins which catalyse the oxidation and reduction of 
a wide variety of endogenous and xenobiotic compounds.51,52 Originally, they were named 
Cytochrome because they were a pigment (in Greek: chromos) from within the cells (in 
Greek: cyto), and P450 because they were the pigment that gave a typical absorbance 
band at 450 nm.53,54 CYPs generally detoxify pharmacologically active and potentially 
hazardous compounds, but in a number of cases non-toxic parent compounds are 
bioactivated into pharmacologically or toxicologically active metabolites, or procarcinogens 
into their ultimate carcinogens.1,2 There are 4500 uniquely named sequences of CYPs 
known (drnelson.utmem.edu). They are named according to sequence homology. In 
general, when the amino acid sequences of two CYPs are less than 40% identical, the 
enzymes are assigned to different gene families, indicated by a number. When sequences 
are between 40 and 55% identical, they belong to the same family but are assigned to 
different subfamilies, indicated by a capital letter. When the sequences are more than 
55% identical they are classified as members of the same subfamily, but the isoenzyme is 
indicated by a number.55 For instance, a CYP from the family 2, subfamily D, isoenzyme 6 
is thus named CYP2D6. This paragraph describes some general features of CYPs, in 
particular their catalytic activity, their role in drug metabolism, and factors influencing their 
clinical significance, such as genetic polymorphisms and drug-drug interactions. Special 
attention is given to CYP2D6, the isoenzyme studied in this thesis. An extensive overview 
of computational investigations used to understand, rationalize and predict CYP structure 
and function is provided in Chapter 2. 
  
CYP catalytic activities 
CYPs catalyse a wide variety of reactions (Table 1). The catalytic activities of CYPs can be 
divided into (i) monooxygenase activity, usually resulting in the incorporation of an oxygen 
atom into the substrate, (ii) oxidase activity, resulting in the formation of superoxide anion 
radicals or hydrogen peroxide (uncoupling of the catalytic cycle, see Figure 6, 2e- oxidase 
and 1 e- oxidase activity), and (iii) substrate reductase activity usually producing free 
radical intermediates under anaerobic conditions.52,56 Of these three enzymatic functions of 
CYPs, attention has been almost exclusively on the monooxygenase activity and its 
proposed mechanisms of action. The two most commonly encountered mechanisms of 
action, the H-atom abstraction/oxygen rebound57 and the electron 
oxidation/recombination58 have by far been investigated most. Figure 6 schematically 
shows the CYP reaction cycle where these three activities and associated reactions are 
indicated. The CYP catalytic cycle begins with reversible substrate (R) binding, which 
converts the six-coordinate, low-spin form (species 1) of the enzyme to the five-
coordinate, high spin FeIII substrate complex (species 2).  Addition of the first electron 
reduces the enzyme to the five-coordinate FeII substrate complex (species 3). Binding of 
molecular oxygen gives the six-coordinate FeII-O2 dioxygen intermediate (species 4). 
Addition of a second electron and two protons followed by cleavage of the oxygen-oxygen 
bond produces a molecule of water and an oxidizing species, the so-called oxygen 
intermediate (species 7). Insertion of the iron-bound oxygen into the substrate leads to 
species 8 and subsequent product release. Species 5 and 6 represent alternative possible 
species along the reaction pathway. The studies described in this thesis focus on (the 
transition between) species 1 and 2, the binding of the substrate in the active site. 
For the bacterial CYP101, the most extensively studied CYP, only small changes in the 
protein conformation and in the substrate position and orientation are observed by X-ray 
crystallography during the catalytic cycle (Figure 6). Also the substrate orientation in the 
bacterial CYP107A was observed to be largely unaffected by binding of dioxygen.59 For 
CYP102, on the other hand, it has been suggested that  conformational changes of the 
Chapter 1 
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protein, driven by electron-transfer, trigger the movement of the substrates into effective 
orientations for hydroxylation.60  
 
Table 1: Types of reactions catalyzed by Cytochrome P450 isoenzymes (in bold Italics) with an 
example for each reaction. All types of reactions mediated by CYP2D6 are exemplified for this 
isoenzyme. 56,61 
Aliphatic hydroxylation 





































































Acetaminophen dehydrogenation by CYP2E1, 







Cleavage of esters 












Oxidative group transfer 
















In presence of NAPQI CYP1A reduces oxygen (between species 4 and 2 in Figure 6) 
(Fe2+ O2 RH ) → (Fe3+ RH ) + O2• - 
 
Indeed a balance exists between the kinetics of the heme-iron-oxygen reduction and the 
dynamics of the substrate binding. Changes in the oxygen species may occur faster than 
substrate binding orientation and relaxation times, leaving the substrate in steps 2-8 of the 
catalytic cycle in an orientation that was optimal for a previous, but no longer present 
oxygen species. Nevertheless, small conformational changes in the protein have been 
hypothesized to facilitate the different steps along the reaction pathway.62 In the case of 
CYP101, an  important conformational change seems to be the re-orientation of D251 and 
T251 in the I-helix.63 This might facilitate stabilization of and proton delivery to the 
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dioxygen complex (species 4 and 5), eventually leading to the formation of the oxygen 
intermediate (species 7). For a proper description of the effects of such subtle 
conformational changes on the reaction cycle, and the types of reactions catalyzed by 
CYPs (Table 1), the use of quantum mechanics (QM) or combined quantum 
































Figure 6: Cytochrome P450 reaction cycles, currently known and described in the text, and the 
molecular modelling methods to describe the different species in these cycles: homology modelling 
(HM), automated docking (AD), molecular dynamics simulation (MD), and quantum mechanical 
calculations (QM). This thesis focuses on (the transition between) species 1 and 2. Panels 
surrounding the catalytic cycle show the active site of crystal structures of species 1,[64] 3,[65] 4, [65] 
7,[65] and 8[66] of CYP101 (protein carbon atoms in green, substrate carbon atoms in yellow) 
compared to the structure of species 2 [65] (protein and substrate carbon atoms in purple). The 
heme iron atom is depicted in white; water oxygen atoms are colored blue. Only minor changes in 
the protein conformation and in the position and orientation of the substrate are observed during 
the catalytic cycle. These small conformational and orientational changes however are hypothesized 
to facilitate the different steps in the catalytic cycle.62 
 
Indeed, models for species 4, 5, 6, and 8 have only been described by QM or combined 
QM/MM methods,67-71 while the other species have also been subjected to (combinations 
of) other molecular modelling approaches.29,72 The buried active site of many CYPs, 
however, implies that the protein must undergo dynamic motions to allow substrates to 
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between species 8 and 1, respectively).73 Indeed, conformational changes seem to occur 
during ligand binding, as comparisons between ligand-bound and ligand-free crystal 
structures of different CYP isoenzymes showed ligand induced changes in size, shape and 
hydration of the active site.29 This conformational flexibility of the active site is likely to 
underlie the capacity of many CYP isoenzymes to metabolize structurally diverse 
substrates of different sizes and to bind substrates in multiple binding modes (generating 
different metabolic products). Computational chemistry techniques like MD and automated 
docking are especially suitable to gain insight into this dynamical process of ligand 
(un)binding. Consideration of species 2 (and the transition between species 1 and 2) using 
these techniques is sufficient for proper description and prediction of CYP-ligand 
interactions and structures (see Chapter 2). 
 
Drug metabolism by CYPs 
The human genome encodes for 80 CYP proteins, of which approximately fifteen are 
classified to be primarily involved in the metabolism of xenobiotic compounds (i.e. 
CYP1A1, 1A2, 1B1, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4, 3A5 and 3A7). 
 
A)        B) 
 
C)             D)       
 
 
Figure 7: Panel A shows the relative contributions of CYP isoenzymes to the clearance of 315 
drugs in 1997 (grey)74 and to the metabolism of the top 200 drugs prescribed in 2002 (black).75 
Total contribution of CYPs to the phase I metabolism of all drugs currently marketed76 are 
presented in panel B. Relative amounts of major CYPs involved in hepatic metabolism75 are given in 
panel C. The frequencies of alleles of clinically relevant genetic polymorphisms are given in panel D 
(white=Caucasians, grey=Orientals).77,78 CYP2A6 and CYP2C8 (not included in the graphs) are 
present in the liver in high amounts (resp. 17% and 4%)79 and clinically significant genetic 
polymorphisms for these isoenzymes have been reported,77,78 but their relative contributions to 




All together these CYPs account for the phase I metabolism of about 70-80% of currently 
marketed drugs.74-76 In Figure 7C the distribution of the major human liver CYP 
isoenzymes involved in drug metabolism in a group of 30 Caucasian patients is shown. 
CYP3A4 is the most abundant isoenzyme, followed by the CYP2C family members, and 
then CYP1A.79 When it comes to the amount of drugs for which a CYP isoenzyme is 
involved in metabolism again CYP3A4 takes the largest share (~50%), followed by the 
CYP2C family members (~25%) and CYP2D6 (~15%) (Figure 7A). So although CYP2D6 
only accounts for a small percentage of all hepatic CYPs (~2%), its role in drug 
metabolism is significantly higher than its hepatic occurence. However, there seems to be 
a decreasing trend in the relative importance of CYP2D6 versus CYP2C9 and especially 
CYP2C19 (see Figure 7A). Early reviews estimated that CYP2D6 was involved in the 
clearance of 25%-30% of the drugs metabolized by CYPs, while the relative contributions 
of CYP2C19 and CYP2C9 were estimated to be ~15%, ~5%, respectively.74 More recent 
reviews estimate the relative contributions of CYP2D6, CYP2C9 and CYP2C19 to be ~15%, 
~15%, and ~10%, respectively.75,76 This could be an indication of the fact that CYP2D6 
metabolism is more often actively considered in the design of novel drugs. 
 
CYP substrate selectivity and characteristics 
Substrates for the different human CYP isoforms can be roughly characterized based on 
their physicochemical properties (1D),32 as well as their topology (2D).80 A summary of the 
characteristics of the major hepatic CYPs involved in drug metabolism is provided in Table 
2.  
  
Table 2: Characteristics of major human hepatic drug metabolizing CYPs. The information 
represents a summary of several studies reviewed by refs 78,81,82 
 
a) Majority of typical substrates of the specific isoenzyme is considered to be planar or non-planar, as 
measured by the ratio of the substrate molecular area (a) and depth squared (d2) (considering a/d2 = 3 as a 
cut-off); b) Majority of typical substrates of the specific isoenzyme have a l(ow) (~<230 Å3), m(edium) (~230-
300 Å3) or h(igh) (~>300 Å3) solvent accessible surface volume; c) Majority of typical substrates of the 
specific isoenzyme has a low (l), medium (m) or high (h) lipophilicity as measured by log(P), the logarithm of 
the octanol/water partition coefficient and or (in brackets) log(D7.4), the logarithm of the octanol/water 
partition coefficient at pH 7.4; l(ow): ~<0.5),  m(edium): ~0.5-1.5; h(igh): ~>1.5); d) Majority of typical 
substrates of the specific isoenzyme are acidic/negatively charged(-), weakly acidic (0-), neutral (0), weakly 
basic (0+), or basic/positively charged (+). e) Marker substrate. It should be noted that the substrate can also 
(too minor extent) be metabolized by other CYP isoforms. Abbreviations: methoxyresorufin (m-resorufine), 
ethoxyresorufin (e-resorufine), dextromethorphan (d-methorphan). f) Marker inhibitor. It should be noted that 
the compound can also inhibit other CYP isoforms (too minor extent). g) Isoenzyme inducible by: polyclic 
aromatic hydrocarbons (PAH), Phenobarbital (PB), ethanol, or dexamethasone (DM); CYP2D6 is considered to 
be non-inducible. h) Clinical significance of genetic polymorphisms: significant (+); very significant (++); not 
significant (-) i) Availability of an X-ray structure for the isoenzyme. j) Crystal structure of (an) isoenzyme(s) of 
the same subfamily has been resolved. 
 
CYP substrate characteristics Substratee Inhibitorf Inducerg GPh X-rayi 
 planara Volb lipoc chd      
1A1 yes m h(m)   0 m-resorufine furafyline PAH - no 
1A2 yes l h(m)  0+ e-resorufine fluvoxamine PAH + no 
2A6 no l m(m)  0+ coumarine  pilocarpine PB + yes83 
2B6 no m m(m)  0+ phenobarbital orphenadrine PB + noc,84 
2C8 no m h(m) 0- taxol trimethoprim PB + yes85 
2C9 no m h(h)  0+ tolbutamide sulphaphenaz PB ++ yes86,87 
2C19 no m h(m) - S-mephenytoin omeprazole PB ++ noc 
2D6 no m h(l) + d-metorphan quinidine none ++ yes88 
2E1 yes l m(l) 0 chlorzoxazone isoniazid ethanol - no 
3A4 no h h(h) 0 nifedipine ketoconazole DM - yes89,90 
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1D/2D-QSARs models for CYPs have provided robust but rough classifications of the 
inhibition potency of ligands, but do not give much insight into the possible (molecular) 
background of the mode of action. The structure-based (‘3D’) molecular modeling 
methods on the other hand, aim to be insightful as well as predictive. The latter 
approaches are for example needed in the many cases in which the same substrate is (to 
different extents) metabolized by different CYP isoforms (yielding different metabolites), 
as for example is the case for clozapine (CYP2D6, 1A2, 2C9, 2C19, and 3A4),91 imipramine 
(CYP2D6, 1A2, 2C19 and 3A4),92 and MDMA (CYP2D6, 2B6 and 3A4).93 
 
Genetic polymorphism of CYPs 
The efficacy and pharmacokinetics of a drug can be determined genetically. Genes 
encoding for proteins involved in the pharmacological effects, transport, or metabolism of 
the drug for instance, can be present in the population in two or more allelic forms which 
may therefore result in varying therapeutic activities and safety margins of the drug. When 
at least two alleles have frequencies greater than 1% this is called a genetic 
polymorphism. In some cases these polymorphisms are caused by a mutation, deletion or 
insertion of just a single nucleotide, called single nucleotide polymorphisms (SNPs). Many 
drug-metabolizing enzymes are known to be polymorphic: aldehyde dehydrogenase, UDP-
glucoronyltransferases (UGT2 family members), sulfotransferase (SUT1A3), catechol O-
methyl transferase, N-acetyl transferases (NAT1 and NAT2), glutathion S-transferase 
(STM1 and GSTT1), and many CYPs.94 There are as many as 22 human CYPs expressed 
from different alleles (www.imm.ki.se/CYPalleles).95 Nevertheless, of these 22 enzymes, 
only few were found with significant clinical effects caused by the genetic polymorphisms 
(see Figure 7D). Genetic polymorphisms in enzymes may lead to abolished, reduced, 
altered, or increased enzyme activity.3 Minor clinical effects were reported for CYPs 1A2, 
2A6, 2B6 and 2C8, and major clinical effects of polymorphism were reported for CYPs of 
the 2 family, namely CYP2C9, CYP2C19 and CYP2D6 (see Tables 2-4).11 
 
The Cytochrome P450 2D6 isoenzyme 
Although the expression levels of CYP2D6 represent only 2% of all hepatic CYPs (Figure 
7C), it is the second most important drug metabolizing enzyme after CYP3A4, and 
involved in the metabolism of about 15-30% of the currently marketed drugs (Figure 
7A).96,97 Large interindividual differences exist in CYP2D6 activity, due to gene multiplicity 
and polymorphisms further emphasizing its clinical importance (Figure 7D, 8, Tables 2-
4).11,94,98 The early identification of potential CYP2D6 substrates and prediction of their 
metabolism is therefore advantageous in the discovery and development of new drugs.  
CYP2D6 catalyzes a broad variety of reactions (Table 6) and is responsible for the 
metabolism of many broadly prescribed pharmaceuticals, including anti-arrhythmics, 
antidepressants, anti-psychotics, beta-blockers, and analgesics (Table 4).61,96,99 The 
preference for drugs acting on the central nervous system is interesting, suggesting 
overlap between CYP2D6 specificity and the specificity of proteins involved in 
neurotransmission processes in the brain, such as serotonine transporters and GPCRs. In 
general, these drugs are lipophilic, basic, medium sized, positively charged at neutral pH 
(which decreases their lipophilicity) (Table 2).81 In addition, it has been shown that 5-
methoxytrypamine, a metabolite and precursor of melatonin, is a specific and high 
turnover endogeneous substrate of CYP2D6 that is being converted to the 
neurotransmitter serotonin.100 The broad substrate specificity of CYP2D6 makes this CYP-
isoform prone to inhibition by numerous drugs from these and other therapeutically 
important classes, setting the stage for clinically significant drug-drug interactions. 
Quinidine, clemastine, fluoxetine, paroxetine, terbinafine, and ritonavir are just a few 
inhibitors of CYP2D6, which have the potential to block the metabolism of other drugs 
prescribed simultaneously (Table 4).6  
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The enzyme expression levels are, in contrast to other hepatic xenobiotic metabolising 
cytochrome P450s, not regulated by any known environmental agents and are not 
inducible by known hormones. CYP2D6 is primarily expressed in the liver, but low 
expression levels of CYP2D6 are also found in the skin,101 the gastrointestinal tract,102 and 
in the brain.103 A frameshift mutation in the pseudogene CYP2D7 led to a brain specific 
expression of a splice variant of this enzyme in Indian people.104 This enzyme was shown 
to be even more active than wild-type CYP2D6 in morphine formation from codeine. In 
addition to the earlier mentioned preference of CYP2D6 for the metabolism of 
psychoactive drugs, and its association with serotonin metabolism, the latter study further 
supports the important role of CYP2D6 in influencing mood and mental health. 
In the 1970s it was shown that debrisoquine, an antihypertensive drug, and sparteine, 
an anti-arrhythmic drug, were found to be inefficiently metabolized in some individuals, 
thus causing unexpected adverse reactions.105,106 Later studies suggested that these and 
other drug metabolism defects were caused by the same genetic deficiency;107-109 it was 
for the first time that genetic polymorphisms were related to drug metabolizing enzymes. 
In the 1980s, first rat debrisoquine hydroxylase110 and later the responsible human 
enzyme111 were purified and biochemically characterized and the genetic basis behind the 
debrisoquine polymorphism was elucidated. The CYPIID genetic locus was isolated112 and 
sequenced113,114 and defective alleles could be isolated and sequenced to characterize the 
molecular defect at the level of genomic DNA.115 After establishment of the official 
cytochrome P450 nomenclature in 1993, the unique name CYP2D6 was given to the 
human debrisoquine hydroxylase.55 
To date more than 80 mutant alleles of the CYP2D6 gene have been identified (see 
http://www.imm.ki.se/CYPalleles/CYP2D6.htm). The consequence of these different alleles 
is varying activity of the enzyme between different individuals (Figure 7D, Table 3). 
Phenotypes of the CYP2D6 activity, are divided into the extensive, poor, and ultrarapid 
metabolizers (EM, PM, and UM, respectively) according to the enzymatic activities (Table 
3, Figure 8).97 
 
 
Figure 8: Variation in drug metabolism and nortriptyline dosing in the European population, based 
on CYP2D6 activity (1’-hydroxylation of R-bufuralol). Within the population four phenotypes can be 
identified: poor metabolizers (white, PMs), extensive metabolizers (grey, EMs), and ultrarapid 
metabolizers (black, UMs), and optionally, in between PMs and EMs, intermediary metabolizers 
(grey, IMs) (see text). The doses of nortriptyline that are required to achieve therapeutic levels in 
all phenotypes are given. Despite this variation in metabolizing capability, population-based dosing 
is used today, and is based on the average plasma levels obtained in a given population for a given 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The PM phenotype, with no CYP2D6 being expressed, is caused by a gene deletion or single 
nucleotide polymorphism in the gene. In PM (~20% of Caucasian population and 5% of 
Asian population), CYP2D6 substrates are metabolised at a reduced rate and, therefore, 
higher plasma concentrations than expected are observed at conventional doses. In contrast, 
the UM phenotype, carrying additional copies of a functional CYP2D6 gene (1*xN or 2*xN 
allele, up to ~5% of the Caucasian and up to 15% of the Ethiopian population), shows an 
increased rate of drug metabolism and requires a higher dose than normally recommended 
to achieve a therapeutic plasma drug concentration.99 In between PM and UM are the normal 
extensive metabolizing (EM) phenotype, with one or two functional genes and the 
intermediate metabolizing (IM) phenotype, characterized by at least one partially deficient 
allele.96 Absent or reduced CYP2D6 activity can lead to ADRs by the same mechanisms 
described earlier in paragraph 1.2 and Figure 2. Table 4 gives an overview of the clinical 
effect of genetic polymorphisms and drug-drug interactions on CYP2D6-mediated 
metabolism of selected drugs, belonging to specific classes. 
 
1.6 Scope & Objectives 
As outlined in this introduction, CYPs and particularly CYP2D6 play an important role in drug 
metabolism. CYP2D6 is the second most important drug metabolizing enzyme after CYP3A4. 
Large interindividual differences exist in CYP2D6 activity due to polymorphisms, further 
emphasizing its clinical importance. The early identification of potential CYP2D6 substrates 
and prediction of their metabolism is therefore advantageous in the discovery and 
development of new drugs. Computational chemistry is a very suitable tool to predict 
metabolic stability and sites of metabolism in potential drugs. In silico predictive database 
approaches and quantitative structure-activity relationships (QSARs) derived from 
physicochemical (1D) and topological (2D) properties of CYP ligands provide robust but 
rough classifications of the inhibition potency of ligands, without yielding much insight into 
the possible (molecular) background of the mode of action. The structure-based (‘3D’) 
molecular modeling methods, on the other hand, aim to be insightful as well as predictive30 
and were applied in this thesis to obtain novel knowledge on the structure and dynamics of 
CYP2D6-ligand interactions. Of all human CYPs the human CYP2D6 isoenzyme is a 
particularly suited model system to investigate the structure and dynamics of protein-ligand 
interactions. Apart from the intrinsic relevance of this isoenzyme, considerable computational 
research has been performed and offers  a starting point for new modelling investigations. At 
the beginning of this research no experimentally determined structure was available, but 
several important ligand-protein interactions could be described by pharmacophore 
models.115,117-124 From these models it became clear that CYP2D6 specifically binds 
compounds containing a basic nitrogen and an aromatic moiety. The structural specificity is 
not as pronounced as for e.g. CYP101, and not as diverse as for e.g. CYP3A4. Moreover, 
CYP2D6 has been shown to metabolise drug substrates at different sites, suggesting the 
existence of multiple binding modes. Therefore, at the start of these in investigations in 
2002, CYP2D6 represented a manageable challenge to study ligand-protein interactions, 
from which general insights could be derived. 
 
High-quality protein models 
At the start of this study, several CYP2D6 protein homology models had already been 
constructed and successfully used to predict substrate and inhibitor selectivity and 
regiospecificity of metabolism.50,60,117,122,125-129 The availability of crystal structures of stronger 
homologous CYP isoforms, and improvements of computational modelling techniques, create 
new possibilities to improve the predictive quality of these models. In the past few years, 
crystal structures of many mammalian CYPs have become available: CYP2A6,83 CYP2B4,84,130 
CYP2C5,131-133 CYP2C8,85 CYP2C9,86,87 and CYP3A4.89,90 And very recently, during the final 
writing process of this thesis, a substrate-free crystal structure of CYP2D6 was solved.88 
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However, as was mentioned above, comparisons between ligand-bound and ligand-free 
crystal structures of many CYPs showed ligand induced changes in size, shape and hydration 
of the active site. The construction, refinement and validation of an accurate substrate-
bound three-dimensional protein model of CYP2D6 is therefore still a crucial first stage in 
modeling CYP2D6-ligand interactions. 
 
Protein structure-based virtual screening methods 
At the start of this study, several classical ligand-based pharmacophore models of CYP2D6 
had already been developed and optimized, facilitating the prediction of possible involvement 
of CYP2D6 in the metabolism of substrates as well as likely sites of catalysis.115,117-124 
Pharmacophore and 3D-QSAR models derive information on the active site of proteins from 
the shape, electronic properties and conformations of ligands (substrates, inhibitors or 
metabolic products) and are constructed by superimposing abstracted descriptors of 
essential functional groups and topologies of the ligands. In addition to 3D-QSAR models, 
successful QSAR models derived from physicochemical (1D)32 and topological (2D)35 ligand 
properties of CYP2D6 ligands had been reported as well. These in silico physico-chemical, 
topological and ligand structure-based models are suitable to make predictions at a very 
early stage of the drug-development process, in a high-throughput fashion and at low 
costs.21 As was already mentioned, structure-based approaches offer more insight into the 
molecular background of the mode of action of drug candidates. Among structure-based 
approaches, ligand-based methods have two major weaknesses compared to protein-based 
methods: i) at least a partial solution of the molecular alignment of ligands is needed; ii) it is 
difficult to build accurate models based on ligands (and aimed at finding ligands) having 
different underlying chemotypes.134  
Automated ligand-protein docking is the most commonly used protein-based virtual 
screening approach.135,136 Automated docking algorithms generate energetically favorable 
conformations and orientations of ligands in the binding pocket of a protein and scoring 
functions are used to predict the tightness of the protein-ligand interactions. The accuracies 
of these predictions, however, are found to be highly dependent of the docking-scoring 
combination used, suggesting that a docking-scoring strategy should be specifically 
optimised for the system under study.137-150 Other unresolved issues in automated docking 
are the consideration of protein flexibility and the inclusion or omission of explicit water 
molecules in the ligand binding pocket.151,152 When a structural model of a CYP isoenzyme is 
available, docking methods can be used to predict the substrate catalytic site and binding 
affinity for CYP ligands (substrates and inhibitors), to identify potential CYP substrates in a 
chemical database (protein-based virtual screening), and to identify amino acid residues 
involved in substrate binding. The heme prosthetic group, the presence of water in the 
active site, the relatively large size and large conformational flexibility of the active site, the 
broad range of substrates and abundance of catalytic sites in most substrates, make CYPs 
rather challenging docking targets. 
Although ligand-based and protein-based virtual screening can be equally successful and 
can be used in a complementary way,24,134 protein-based virtual screening still has as an 
advantage over ligand-based virtual screening as it: i) visualises the actual binding mode of a 
ligand in the protein; ii) enables the identification of ligands with different binding modes 
and different binding modes for the same ligand, by addressing novel interaction sites that 
not have yet been used by known ligands.24 
 
Molecular dynamics of protein-ligand interactions 
As was discussed above, the few studies offering experimental information on the structures 
of CYP catalytic cycle intermediates suggest that once the substrate is bound, the 
conformation of CYPs does not change to a very large extent with the different stages.63,65 
The buried active site of many CYPs, however, implies that the protein must undergo motion 
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to allow substrates to enter the active site and products to leave the active site.73 Indeed, 
conformational changes seem to occur during ligand binding, as comparisons between 
ligand-bound and ligand-free crystal structures of different CYP isoenzymes show ligand 
induced changes in size, shape and hydration of the active site.29 This conformational 
flexibility of the active site is likely to underlie the capacity of many CYP isoenzymes to 
metabolize structurally diverse ligands of different sizes and to bind substrates in multiple 
binding modes (resulting in different metabolic products). Although docking methods that 
allow partial treatment of protein flexibility have recently been reported,153-157 no automated 
ligand-protein docking methods that attempt to explicitly consider the full flexibililty of both 
the ligand and protein structure, have been validated extensively.136,151 Furthermore, 
automated docking alone is not suitable for accurate determination of relative probabilities of 
different substrate binding modes and for discrimination between substrates and enzymes of 
high similarity, such as regio/stereoisomers and mutants of enzymes.  
Molecular dynamics (MD) simulations describe the movements of atoms according to 
Newton’s classical equations of motions and can give detailed insight in the behavior of 
molecular systems, in both space and time. To describe the dynamics of CYP2D6-ligand 
interactions and to take full protein and ligand flexibility into account, molecular dynamics 
simulations of CYP2D6-ligand complexes have to be performed. Performing multiple MD 
simulations starting from different ligand docking poses as starting structures might even 
further increase conformational sampling of the protein-ligand complex. 
 
Aims of this thesis 
The primary aim of the investigations described in this thesis was to obtain knowledge on 
the structure and dynamics of CYP2D6-ligand interactions, enabling the prediction and 
rationalization of drug metabolism by this specific Cytochrome P450 enzyme, and offering 
new approaches for the study of CYP-ligand interactions in general. 
Our work particularly focused on three challenging aspects of CYP research: 
1) The construction of a high-quality CYP2D6 homology model suitable for designing 
and rationalizing experimental studies. 
2) The development of protein structure-based virtual screening methods for the 
prediction of CYP2D6-ligand interactions in a high-throughput fashion. 
3) The description of the dynamics of CYP2D6-ligand interactions by using multiple 
experimental and in silico techniques in an integrative way.   
 
To summarize, CYP2D6 homology models constructed from the recently reported more 
homologous and higher resolution crystal structures, finally are suitable enough to be 
subjected to more detailed analysis using molecular modelling methods like 3D-QSAR 
modelling, automated ligand-protein docking, and (long time) molecular dynamics 
simulations. In addition, the molecular modelling techniques mentioned have rapidly evolved 
over the past few years, and are considered valuable in silico tools for the optimization and 
evaluation of structural models and for the description of (the dynamics of) ligand-protein 
interactions. Another clear trend observed in many recent computational studies is the 
combination of several modelling techniques, to arrive at meaningful and successful 
rationalizations of experimental data and at interpretations of CYP function. Finally, 
computational chemistry is especially suitable to gain insight into the dynamics of ligand 
binding, but in silico models need to be validated using experimental techniques. In this 
thesis a basis is laid to study the dynamics of human CYP2D6 using novel computational 
approaches in conjunction with experimental research. The present studies have been 
performed within the framework of the Chemistry of Complex Molecules (CCM) research 
program at the Vrije Universiteit Amsterdam. The CCM program brings a number of chemical 
disciplines together in order to gain more insights in how complex molecular systems, like 
proteins, function in space and time. With a combined approach of quantum chemical 
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calculations, computer modeling, time resolved and static spectroscopy, enzymology, and 
mutagenesis studies this goal could be reached. This offered oppurtunities to use new 
experimental data to validate and optimize our in silico models and, vice versa, using our 
models to design and rationalize experimental studies, as well as to develop new integrative 
approaches for the molecular modelling of CYP2D6-ligand interactions. 
 
1.7 General outline of this thesis 
The research presented in this thesis describes the structure and dynamics of CYP2D6-ligand 
interactions using various in silico modelling techniques, in conjunction with in vitro 
experimental data, enabling the prediction and rationalization of drug metabolism mediated 
by this Cytochrome P450 enzyme. Three different lines of research correspond to the aims 
described in the previous paragraph: 1) the construction and validation of a high-quality 
CYP2D6 homology model; 2) The development of methods for the prediction of CYP-ligand 
interactions in a high-throughput fashion; 3) The description of the dynamics of CYP-ligand 
interactions by using multiple different experimental and in silico techniques in an integrative 
way. These three lines are addressed in the different chapters of this thesis. 
Chapter 1 gives a general introduction into the background and context of the research 
presented in the thesis and into the model enzyme system investigated: human Cytochrome 
P450 2D6. It deals with the clinical impact of drug metabolism, the role of the prediction of 
metabolism in drug discovery and development, the use of computational chemistry in drug 
metabolism studies and the catalytic activity and clinical significance of the human CYP2D6 
isoenzyme. Chapter 2 reviews in an integrative manner the computational approaches used 
to understand, rationalize, and predict the activity and substrate selectivity of CYPs, as well 
as the possibilities and limitations of these approaches now and in the future.  
Chapter 3 focuses on research line 1 and describes the construction and optimization of 
the CYP2D6 homology model, its comparison to the very recently solved CYP2D6 crystal 
structure, and its use to design experimental site-directed mutation studies to probe the 
enzyme active site and to validate the molecular modelling work.  
The next two chapters cover research line 2. Automated docking strategies, considering 
active-site water molecules and rescoring, are evaluated and optimized with respect to their 
capacity to reproduce the binding modes of X-ray crystal structures of Cytochrome P450 and 
thymidine kinase protein-ligand complexes and to predict the sites of catalysis of the 
different ligands (Chapter 4). The same docking strategies are subsequently used for the 
catalytic site prediction and virtual screening of substrates in our CYP2D6  homology model 
(Chapter 5).  
In the next three chapters, focusing on research line 3, a combination of automated 
docking and molecular dynamics is used to predict the regio- and stereo-specificity of 
catalysis of MDMA and MDMA-analogs (Chapter 6) and the relative binding affinity of 
propranolol stereo-isomers (Chapter 7) towards wild-type and mutant CYP2D6, and to 
explore substrate access and product exit channels in CYP2D6 (Chapter 8).  
The final Chapter 9 summarizes the overall conclusions of the investigations desribed in 
this thesis and provides an outlook for future computational research to understand, 
rationalize and predict Cytochrome P450 structure, function, and dynamics. 
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The current chapter presents in an integrative manner structure based computational 
approaches used to understand, rationalize and predict the activity and substrate 
selectivity of CYPS, as well as the possibilities and limitations of these approaches now and 
in the future. One can divide structure-based models and methods into: i) ligand-based 
models (QM calculations on substrates, pharmacophore, and QSAR models), ii) protein-
based models (crystal structures, homology models and various ways in which this 
structural information is analyzed and used), and ligand-protein interaction based models 
(e.g. automated docking and molecular dynamics simulations to describe ligand binding 
orientation, protein-ligand dynamics and ligand binding affinity). Apart from the earlier 
mechanism-based ab initio calculations on substrates, also pharmacophore modeling of 
ligands (i.e. both substrates and inhibitors) and protein homology modeling in combination 
with automated docking and molecular dynamics simulations have been used successfully 
for the rationalization and prediction of metabolite formation by several  CYP isoenzymes. 
In the past six years, the number of available crystal structures, especially for mammalian 
and human isoforms, has increased significantly. In addition, the lack of detailed structural 
knowledge from crystallography for many other isoforms is being overcome in part by the 
prediction of CYP structures using computer-aided homology modeling techniques in 
combination with pharmacophore or small molecule models and mechanism-based ab 
initio and semi-empirical calculations. It has been shown that a great variety of in silico 
modeling approaches have been applied to CYP enzymes, thereby successfully adding to 
our understanding of CYP structure and function in a way that is complementary to 
experimental studies. Another clear trend in many recent computational studies is the 
combination of multiple modeling techniques to arrive at meaningful and successful 
rationalization of experimental data, and interpretations and predictions of  CYP function. 
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2.1 Introduction 
Cytochromes P450 (CYPs) constitute the most important family of biotransformation 
enzymes involved in drug metabolism, playing an important role in the disposition of 
drugs, and their pharmacological and toxicological effects. Early consideration of ADME-
properties (absorption disposition, metabolism and excretion) is increasingly seen as 
essential for efficient discovery and development of new drugs and drug candidates1. 
Apart from in vitro tools, this necessitates the application of novel in silico tools that can 
accurately predict ADME properties of drug candidates already in early stages of the lead 
finding and optimization process.2,3 
CYPs generally detoxify potentially harmful xenobiotic compounds and in a number of 
cases non-toxic compounds are bioactivated to toxic reactive intermediates, and pro-
carcinogens into ultimate carcinogens. Furthermore, CYPs catalyze key reactions in the 
formation of endogenous compounds, such as hormones and steroids4. The catalytic 
activities of CYPs can be divided into i) monooxygenase activity, usually resulting in the 
incorporation of an oxygen atom into the substrate, ii) oxidase activity, resulting in the 
formation of superoxide anion radicals or hydrogen peroxide (uncoupling of the catalytic 
cycle), and iii) substrate reductase activity usually producing free radical intermediates 
under anaerobic conditions.5 Figure 1 schematically shows the CYP reaction cycle where 
these three activities and associated reactions are indicated, for more details we refer to a 
comprehensive review by Guengerich.6 Apart from the classical incorporation of oxygen 
into substrates, other reactions can be performed by CYPs, e.g. de-saturation, 
dehydrogenation, ring formation and dehalogenation. CYPs can be classified according to 
the electron transfer chain that delivers the electrons for the one-electron reductions from 
NAD(P)H: class I CYPs are found in bacteria and in eukaryotic mitochondrial membranes 
and require a flavin adenine dinucleotide (FAD) containing reductase and an iron-sulfur 
protein (putidaredoxin); class II CYPs are bound to the endoplasmic reticulum and interact 
directly with a cytochrome P450 reductase containing FAD and flavin mononucleotide 
(FMN).7 
In all known CYP crystal structures available today, the same general three-dimensional 
fold is present with a conserved core region containing the C-terminal half of helix I, 
helices L, E, K, and K’, and the heme coordination region.8 The three-dimensional structure 
of these regions is well conserved despite a low sequence homology. Other regions (e.g., 
the active site region containing the B’ helix, the loops between helices C and D, the 
region spanning helices F and G, and most of the β-strands) are more variable. The 
largest structural variations are found in the B’ helix and helices F and G and their 
connecting loop, which makes sense since these regions are known to be involved in 
substrate access and recognition.7 Six substrate recognition sites (SRS’s) have been 
assigned based on mutagenesis and sequence alignment studies with representative 
members of the CYP2 family and CYP101 (cam).9 Selected recent example CYP structures 
are given in Figure 2 that shows CYP2C9 with two different substrates bound, CYP3A4 
without ligand, and a homology model of CYP2D6. Figure 3-B illustrates the organization 
of SRS’s and secondary structure elements in CYP2D6, which shares all major features of 
CYPs. 
In general terms, the prediction of enzyme activity and selectivity includes everything 
from substrate binding through the complete catalytic process, including the input of 
electrons and protons, to product exit. Many of the steps involved are reversible, so the 
combined kinetics of all steps determines final products, or the ratio between possible 
products, formed. A comprehensive approach that provides a complete in silico description 
of this process would allow a complete in silico prediction of enzyme reactivity, and would 
include the prediction of such diverse components as enzyme/active site structure, 
substrate binding orientation and conformation and binding affinity including multiple 
binding modes and/or water mediated binding, intrinsic (regio-specific) substrate 
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reactivity, orientation and/or conformation dependent reactivity, and product affinity.10 




Figure 1: The generalized CYP reaction cycle; the main reaction cycle corresponds to the general 
mono-oxygenase function that can produce several reactions (carbon hydroxylation, heteroatom 
release or oxygenation, epoxydation and group migration). Not for all CYPs is the order of substrate 
and oxygen binding established, therefore the substrate (‘R-H’) enters the cycle in two possible 
places and is drawn in gray for part of the cycle. Three alternative reaction pathways are indicated 
with dashed arrows, and correspond to the 1- and 2-electron oxidase uncoupling reactions and the 
peroxide shunt.6 The 1-electron oxidase produces a superoxide radical which in turn can produce a 
radical derivative of the substrate. The peroxide shunt is an alternative way to produce an activated 
iron-oxygen species. Indicated are the heme-iron species (FeN) and oxidation state (N), the 
substrate and an alternate reducing peroxide agent (R'OOH). In the resting state (at the top of the 
cycle) a water molecule (or hydroxy anion11) is assumed to be bound to the FeIII.  
 
The state of the art of computational methods used in CYP modeling varies considerably, 
as does the reliability of the results obtained. The quality of a homology model is often not 
sufficient for reliable docking of a substrate, unless the sequence homology with the 
crystal structure template is very high. Binding affinities are notoriously hard to predict 
quantitatively, certainly not without reliable knowledge of ligand binding orientations12, 
and likewise details of product formation are hard to predict without knowing the binding 
orientations. 
For accurate prediction of reactivities the dependence on kinetic factors and the 
influence of the active site electrostatic potential should be accounted for, and, in turn, 
this can depend on details of the protein structure and the binding conformation and 
orientation of the substrate. Finally, the absence of a certain predicted metabolite may be 
due to slow conversion compared to other metabolic reactions, from competing metabolic 
pathways or from other enzymes. In many cases it is possible to identify rate-limiting 
steps (which may vary between CYP isoforms, between substrates in the same isoform, 
and between different environments), implying that product formation will be dominated 
by the characteristics of that particular step and thereby greatly simplifying the complexity 
of the prediction.13 































Figure 2: Representative CYP crystal structures. Central in the structures is the heme group in 
orange with the iron as a space-filling sphere. The ligands (in green) and key interacting residues in 
the binding pockets are shown in ball-and-stick. Panels (A) and (B) show the 2C9 crystal structures 
with S-Warfarin (SWF)14 and S-Flurbiprofen (FLP)15 bound, respectively. Panel (C) shows the 
ligand-free 3A4 crystal structure16. The similarity in fold and topology between the isoforms is 
evident. Most notable differences which determine the overall size and shape of the binding cavity 
are in SRS2 and 3 (helices F and G, respectively), the connecting FG-loop, SRS1 (helix B’) and SRS6 
(sheet 4). Secondary structure elements are colored analogous to Figure 3. The CYP topology is 
schematically shown in Figure 3B. The figures were generated using Molscript and Raster3D (see 
Table 4). 
 
A remaining challenge in predicting product formation in CYPs is the elucidation of the 
relevant reactive heme-iron-oxygen species that is ultimately responsible for the chemistry 
of the enzyme reaction, and the coupling between the kinetics of the reaction cycle of the 
heme-iron-oxygen moiety and the dynamics of substrate and oxygen and release of the 
product. Elucidation of the reaction cycle of CYPs is complicated by the differences in 
influence of substrate, sequence of events and rate-limiting step between different 
isoforms.13 Modeling approaches dealing with these details of the reaction cycle, mainly 



















Figure 3: Protein homology model, topology and tertiary organization of CYP2D6. α-Helices are 
colored purple, and β-strands are yellow. In red the substrate recognition sites (SRS’s, after Gotoh9) 
are indicated in their relative orientation to each other and to the heme catalytic center. Panel (A) 
shows the CYP2D6 homology model 3D-structure with dextromethorphan bound18 (in green) and 
key interacting residues in the binding pockets in ball-and-stick. A corresponding depiction of a 
CYP2D6 pharmacophore model (with bufuralol) is shown in Figure 4 in the same orientation. Panel 
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The primary aim of this paper is to present in an integrative manner computational 
approaches used to understand, rationalize and predict the activity and substrate 
selectivity of CYPs, as well as the possibilities and limitations of these approaches now and 
in the future. Apart from the earlier mechanism-based ab initio calculations on substrates, 
also pharmacophore modeling of ligands (i.e. both substrates and inhibitors)19 and protein 
homology modeling in combination with automated docking and molecular dynamics 
simulations have been used successfully for the rationalization and prediction of metabolite 
formation by several CYP isoenzymes. In recent years, the number of available crystal 
structures, especially for mammalian and human isoforms, has increased significantly. In 
addition, the lack of detailed structural knowledge from crystallography for many other 
isoforms is being overcome in part by the prediction of CYP structures using computer-
aided homology modeling techniques in combination with pharmacophore or small 
molecule models and mechanism-based ab initio and semiempirical calculations. 
Quantitative structure-activity relationship (QSAR) approaches, derived from 
physicochemical (‘1D’) and topological (‘2D’) properties20 or the 3D structure21 of CYP 
ligands, have been used as well for the prediction of drug metabolism by CYPs. A 
pragmatic, rapid and rather successful approach to this are topological screening methods 
recently developed for CYP2D622 and CYP3A423, which provide robust but rough 
classifications of the inhibition potency of ligands without much insight into possible 
(molecular) background of the mode of action. The structure-based (‘3D’) molecular 
modeling methods on the other hand, aim to be insightful as well as predictive. It has 
been concluded that not one computational approach is capable of rationalizing and 
reliably predicting metabolite formation by CYPs, but that it is rather the combination of 
the various complimentary approaches.10 
In this paper, we divide structure-based models and methods into ligand based, protein 
based, and ligand-protein interaction based. In the corresponding sections each of the 
categories is described, giving an overview of the methodology applied, a general 
background on each of these, some highlight examples of applications, and conclusions. 
Finally, a general summary and conclusions are presented, and an outlook of expected 
developments in the field. The first section 2 ´Ligand Based Models´, deals with QM 
calculations on substrates, pharmacophore, and QSAR models. Section 3 ´Protein 
Structure and Analysis´ deals with crystal structures, homology models and various ways 
in which this structural information is analyzed and used. Finally, in section 4, ´Ligand-
Protein Interactions´, issues on binding orientation, ligand dynamics and binding affinity 
are covered. Four comprehensive tables are supplied that list most important pharmaco-
phore models (Table 1), all available CYP crystal structures (Table 2), most important 
homology models (Table 3), and most commonly used software for CYP molecular 
modeling (Table 4). 
 
2.2 Ligand Based Models 
2.2.1 Introduction 
Models for the active sites of CYP isoenzymes and CYP-ligand interactions can be derived 
from ligand based models, based on a set of known CYP isoenzyme-specific substrates or 
inhibitors. Ligand based models can be divided into two broad categories, namely 
quantum mechanical (QM) and pharmacophore models. QM calculations are based on 
certain levels of ab initio or semiempirical QM theory and produce numbers on activation 
barriers, charge distributions and minimum energy conformations. Pharmacophore 
modeling concerns empirical techniques to (indirectly) derive information on the active site 
from the shape, electronic properties, and conformations of substrates, inhibitors, or 
metabolic products. An example of a pharmacophore model is shown in Figure 4.  
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The so-called “classical” pharmacophore models are constructed by superimposing 
substrate and/or inhibitor molecules onto each other by matching chemically similar 
groups. Current approaches, however, utilize the three-dimensional quantitative structure-
activity relationship (3D-QSAR) approaches in which abstracted descriptors of essential 
functional groups and topologies of the molecules are superimposed, possibly 
supplemented by details of the surrounding active site. (This distinction is not 
fundamental; a molecule consisting of atoms and bonds in a “classical” pharmacophore 
model can be viewed as a type of “abstracted descriptor”, although rather detailed, in a 
3D-QSAR model.) Recent reviews on CYP pharmacophore and 3D-QSAR methods are 
provided by Ekins and de Groot.19,21 
In this section, methods used to construct CYP pharmacophore and 3D-QSAR models 
will be described. A summary of most recently published CYP pharmacophore models is 
provided in Table 1 and selected successful applications will be highlighted using 
examples from this table. Commonly used software for CYP pharmacophore model 

















Figure 4: Examples of the pharmacophore model for CYP2D6 illustrated by a molecular interaction 
field (MIF)24 of a carboxylic probe (in red at E216) and a hydrophobic probe (yellow at F120 and 
between L213, V308 and F483) for S-bufuralol (in purple). Selected side chains are shown as stick 
models, the rest of the active site is shown as green ribbon. The complete structure of the 
homology model is shown in Figure 2. 
 
2.2.2 Quantum-chemistry 
Quantum-chemistry Methods Background 
In CYP enzymes, quantum-chemical calculations can yield valuable information on 
activation barriers for substrates or heme-oxygen species during the catalytic cycle, and 
relative energies between species and relevant geometries. Gas phase calculations, 
commonly at the Hartree-Fock (HF) level, are mainly applied to isolated substrates in order 
to assess relative reactivities for a given reaction at different sites in the substrate. Using 
density-functional theory (DFT) instead of HF calculations allows extension of the 
quantum-system to include the heme-oxygen species and the associated fifth ligand 
cysteine. Recently, hybrid quantum-mechanical/molecular-mechanical (QM/MM) methods 
have been applied that include the complete enzyme environment in a molecular 
mechanics (MM) description as well.25-27 
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Of the three enzymatic functions of CYPs (monooxygenase, oxidase and reductase as 
summarized by Goeptar et al.5 and Guengerich6, and indicated the reaction cycle in Figure 
1) attention has been almost exclusively on the monooxygenase activity and its proposed 
mechanisms of action. The two most commonly encountered mechanisms of action, the H-
atom abstraction/oxygen rebound28 and the electron oxidation/recombination29 have been 
investigated the most by far. 
 
Quantum-chemistry Applications 
Gas phase ab initio calculations with two sequential one-election oxidation steps, radical 
intermediates, statistical spin-distribution and hydroxyl-radical recombination have been 
used to rationalize metabolite formation for CYPs in general30,31 and in more depth for 
CYP2D6.32 Very recently, Sing et al.33 developed a rapid semi quantitative model based on 
a trend vector model (derived from AM1 semi-empirical calculations) for estimating H-
abstraction energy and surface area exposure of the H-atom to predict the relative 
susceptibilities of different sites on 50 drug molecules to metabolism by CYP3A4. The 
regiospecific hydroxylation of S- and R-nicotine34, 5 camphor analogs35, and carbofuran36 
by CYP101 (cam) and 6-deoxyerythronolide B by CYP107A (EryF)37 was successfully 
predicted employing geometric criteria obtained from molecular dynamic simulations of 
enzyme-substrate interactions in conjunction with thermodynamic criteria of relative 
radical energetics derived from ab initio and semiempirical quantum mechanics. Park and 
Harris38 employed DFT calculations on CYP2E1 homology models and substrate 
conformations from automated docking and molecular dynamics simulations to predict 
metabolism for seven substrates. Relative radical energies were in good agreement with 
differential H-abstraction activation energies by oxyferryl heme, and optimized oxyferryl-
heme-ligand geometries were in good agreement with MD-sampled conformations. DFT 
calculations were performed to estimate stabilization energies on cooperative steroid-
substrate interaction in the active site of a CYP3A4 homology model39. Recently, for 
CYP2B4 the effects of ligand binding on the high/low spin equilibrium were explored with 
DFT calculations, showing that strong interactions with the heme favor the low iron spin-
state40. The two-state abstraction/oxygen rebound mechanism of CYP monooxygenase 
activity, as proposed by Groves et al.28 was supported by recent studies on CYP101 (cam) 
and of the mechanisms of C-H hydroxylation.27 
Gas phase calculations on the activation energy barrier for breaking a C-H bond in 
alkanes and fatty acids, as described by Jones et al.41, could not explain observed product 
formation for CYP102 (BM3) wild-type and several mutants (Feenstra et al., unpublished 
results). In this approach a hydroxyl radical is used to activate the C-H bond, thereby 
mimicking the catalytic effect of the heme-iron-oxygen species of CYP enzymes, and it is 
based on unrestricted HF at the semi-empirical AM1 level. Significant modulation of 
activation energy barrier heights by addition of the electrostatic environment of the CYP 
protein were observed, underlining the importance of incorporation of the active site 
properties of the enzyme in determining accurate regiospecific reactivities. Combination of 
these reactivities with binding statistics derived from MD simulations, give trends in 
predictions of product formation that correspond to experimental observations, as will be 
described in more detail in section 2.4.3 ‘Molecular Dynamics’. 
 
Quantum-chemistry Conclusions 
While early applications of quantum chemical calculations on isolated substrates in the gas 
phase have yielded valuable information about the intrinsic regio-specific susceptibility of 
molecules to metabolism by CYP enzymes in general, it has become clear that gas phase 
QM calculations are insufficient to explain product formations for all CYP isoforms and 
substrates. In some cases, a combination of the QM derived substrate susceptibilities with 
predicted binding orientations, e.g. from a pharmacophore model or from docking and MD 
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simulations in a protein structure, yields a more realistic estimate of product formation, as 
has been done for the CYPs 101 (cam), 107A (EryF), 2E1, 2B4 and in ongoing work for 
CYP102 (BM3). Although many QM studies have been devoted to the identification of 
heme-iron compounds in the enzyme redox cycle (which is outside the scope of this 
paper), so far few studies have addressed details of the actual reaction with substrates. 
Several QM studies on CYP101 (cam) have found the two-state abstraction/oxygen 
rebound mechanism to be the most important for C-H hydroxylation. 
Finally, the steady increase in computational power brings some sophisticated novel 
methods into the range of feasibility, that make it possible to include substantial parts of 
the active site in the QM calculation, e.g. the heme-iron moiety and nearest charged 
amino acid residues. Promising examples are methods based on the fragment molecular 
orbital (FMO) approach that in principle allow the incorporation of the whole protein into 
the quantum HF or DFT calculations. These methods eliminate the need for arbitrary selec-
tions of a restricted quantum system, as used in e.g. a QM/MM approach, and the many 
artifacts and uncertainties that arise from that restriction. Although successful application 
of a full-protein DFT calculation to cytochrome C has been reported42, to date these have 
not been applied to cytochromes P450. 
 
 
2.2.3 Classical Pharmacophore Models 
Classical Pharmacophore Models Methods Background 
Pharmacophore models derive information on the active site from the shape, electronic 
properties and conformations of substrates, inhibitors or metabolic products. The so-called 
“classical” pharmacophore models are constructed by superimposing these molecules onto 
each other by matching chemically similar groups, possibly supplemented by details of the 
surrounding active site. This approach can be used to perform catalytic site prediction 
(CSP) and (qualitative) predictions with respect to CYP activity and (binding) affinity (Ks, 
Ki, IC50, Km). Primary assumptions for this methodology are that all ligands share the same 
binding site and binding mode in the active site (both electronically and sterically) and that 
the minimum energy conformation of the ligands in vacuum corresponds to the biologically 
active conformation. Moreover, it must be stressed that CYP active sites allow some 
degree of flexibility and therefore may allow multiple pharmacophores to exist43, as is 
described in more detail in section 2.3.2 ’Crystallographic Protein Models Active Site’. 
During the past two decades, pharmacophore models have not only represented useful 
tools to rationalize properties of CYP active sites in the absence of properly validated 
crystallographic or homology model structures for these enzymes but have also been 
combined with these structural models to improve capabilities of predicting CYP substrate 
selectivity and metabolism, as demonstrated in Table 1 and Table 3. 
Building a pharmacophore model is an iterative process of repeated cycles of selection 
of relevant substrates and/or inhibitors and their functional groups, structure minimization 
and superposition, and validation, as is outlined in a flowchart in Figure 5. Commonly 
used software for CYP pharmacophore model building is listed in Table 4. When building 
a pharmacophore model for substrates or inhibitors of a specific enzyme by the “classical” 
pharmacophore method, i.e. manual or automated superposition of 3D-structures, a 
primary requisite is an appropriate template molecule. This molecule ideally is a ligand 
that: i) is specifically metabolized by the (iso-)enzyme under investigation, ii) is large, iii) is 
relatively rigid, in order to limit conformational freedom, iv) contains essential functional 
groups, and v) is regio- and/or stereoselectively metabolized. After selection of a template 
molecule, additional ligands are superimposed onto the template ligand, matching some 
essential functional groups, such as H-bond acceptors/donors or aromatic rings, or by 
using conformations generated by automated docking in a CYP (homology) model. A 
check whether the superimposed structures are in an energetically favorable conformation 
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can be done before, during or after the fitting, using rigid pre-energy-minimized (EM) 
structures, distance restrained EM, or EM or energy calculation of the fitted structures, 
respectively.44 Models for CYP inhibitors are generally more difficult to construct compared 
to substrate models as the site of catalysis is lacking in inhibitors and can therefore not be 
used as an easily identifiable site to be superimposed. The development in classical 

















Figure 5: Flowchart for pharmacophore and QSAR modeling. The cycle is iterated to improve the 
model; the improved model can yield better choices for pharmacophoric groups or QSAR 
descriptors. Functional alignments in QSAR, and superposition of substrate in the pharmacophore 
model can also be improved by knowledge from a homology model and analysis of structural details 
of a homology model can help in the final pharmacophore or QSAR model validation. 
 
Classical Pharmacophore Models Applications 
Early pharmacophore models of CYP2C9 suggested a H-bond donor or acceptor within the 
active site.45 A second pharmacophore model, supported by data of 10 tienilic-acid 
analogues, superimposed substrates using their sites of oxidation and brought all anionic 
heteroatoms in the substrate within 3.5-4.8 Å of a (hypothetical) cationic site within the 
CYP2C9 protein. This model was later updated, leading to the inclusion of a hydrophobic 
zone between the hydroxylation site and the cationic site of the protein.46 The first 
combined pharmacophore-homology model of de Groot et al.41 includes an aromatic region 
for which F476 is suggested, and an anionic ligand binding site that may involve R108. 
Evidence for the importance of an anionic site in the substrates was strengthened by site-
directed mutagenesis experiments highlighting the importance of arginine residues within 
the CYP2C9 active site47. In the recent CYP2C9 crystal structure14 F476 indeed interacts 
with S-warfarin, however, no Arg is present in the binding pocket, while in a more recent 
substrate bound crystal structure F114 and R108 interact with S-flurbiprofen15, as can be 
seen in Figure 2 and described in more detail in section 2.3.2. 
Early pharmacophore models for CYP2D6 had a basic nitrogen at distances of either 5 
Å48 or 7 Å49 from the site of oxidation as well as an aromatic ring system, but none could 
explain the other group of substrates. An extended model50 combined these models by 
indicating a distance between 5 and 7 Å and in addition contained the oxygen bound 
heme moiety. 15 compounds could be fitted onto the template debrisoquine, and one was 




































binding the basic nitrogen atom of the substrate was first included by Koymans et al.51, 
thereby also explaining both the 5 Å and 7 Å distances, and allowed the prediction of four 
compounds giving 14 possible 2D6-dependent metabolites, of which 13 were 
experimentally verified initially. Several additional metabolites were rationalized using a 
refined version of the model52, and the model was extended with more substrates53. 
Adding the heme moiety and I-helix as predicted from homology modeling identified D301 
as the source of the carboxylate group4 which was later experimentally confirmed54, while 
further studies included E216 as key determinant for binding and the source of the 
carboxylate group, and a possible indirect role of D301.55  
A combined pharmacophore and homology model for CYP2D6, consisting of distinct 
pharmacophores for O-dealkylation and N-dealkylation, was able to predict the metabolism 
of a variety of compounds.56 Finally, an inhibitor model of 2D657 appeared to share many 
features with the previous substrate models4,50,51 suggesting they may be combined. The 
main features of the currently known CYP2D6 pharmacophore models are highlighted in 
Figure 4 where molecular interaction fields (MIFs, explained further section 2.2.4) 
calculated for bufuralol and overlaid on the substrate docked into the CYP2D6 active site 
clearly correlate with the specific residues responsible for substrate interaction. 
 
Classical Pharmacophore Models Conclusions 
The earlier CYP substrate/inhibitor pharmacophore models were based on comparison of 
ligand properties only, and in that respect were relatively crude. The more recent 
pharmacophore models are constructed using also structural information of protein 
models, as can be seen in Table 1 for CYP2C9 and CYP2D6 and most other CYP isoforms 
as well. Conversely, most recent homology models have been built using knowledge from 
an existing pharmacophore model or in parallel with building a new pharmacophore 
model, as is described in section 2.3.3 ’Homology Based Protein Models’. The CYP2C9 
pharmacophore model involves an anionic and a hydrophobic/aromatic site; the aromatic 
site could be attributed to F476 and several other residues in the crystal structure. In 
CYP2D6, the pharmacophore model involves a basic nitrogen and an aromatic site; the 
nitrogen is thought to bind to E216 and/or D301 based on homology models and site-
directed mutagenesis studies. Recent classical pharmacophore models predict possible 
involvement of CYP2D6 or CYP2C9 (and some other isoforms) and likely sites of catalysis 
in the metabolism of substrates, but for the quantitative prediction of CYP binding affinity 
parameters 3D-QSAR models are necessary (see section 2.2.4). 
 
 
2.2.4 3D-QSAR Pharmacophore Models 
3D-QSAR Pharmacophore Models Methods Background 
In 3D-QSAR methods58 spatial atomic descriptors, e.g. molecular interaction fields (MIFs), 
functional groups and their (relative) orientations, electronic properties, or shape, of a 
training set of molecules are characterized in three-dimensional space, and condensed into 
a matrix. Subsequently, this matrix is analyzed using multivariate analysis like Principal 
Component Analysis (PCA) to extract and condense the information contained in the 
matrix by discovering patterns, trends and clusters and further analyzed using regression 
techniques like Partial Least Squares (PLS) analysis to explain the chemical properties of 
these molecules, e.g. (binding) affinities (Kd, Ki, IC50, Km). The constructed 3D-QSAR 
model can be used to perform quantitative predictions of properties for molecules that 
were not used to build the QSAR model and to predict sites of catalysis of CYP substrates. 
It is generally advantageous if the molecules used in 3D-QSAR studies both cover wide 
ranges in molecular structure and affinity to maximize conformational/chemical space and 
to gain as much information as possible regarding the binding site in order to increase the 
statistical significance of the model. Several parameters directly or indirectly related to CYP 
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binding affinity have been used to construct and validate 3D-QSAR models, like Michaelis-
Menten constants (Km), inhibition constants (Ki), concentration required for 50% inhibition 
of the metabolism of a specific substrate (IC50), and actual binding constants (Ks). It is 
important to note that for CYPs Ks binding constants are spectroscopically determined 
parameters, whereas Km, Ki and IC50 are activity measurements. This can lead to 
differences due to binding modes or experimental conditions that do not reflect different 
binding properties59. When an inhibitor is not metabolized by the CYP studied, Ki can be 
similar to Ks, unlike the Km of a substrate, which is usually not equal to the Ks. IC50 and Ki 
values of an inhibitor which is metabolized depend on the affinity of the substrate(s) 
competing with the inhibitor.60 In most cases Ks will provide the most direct measure of 
the binding site properties of the CYP isoenzyme. 
Like classical pharmacophore models, 3D-QSAR approaches have not only represented 
useful tools in understanding CYP active sites in the absence of proper crystallographic or 
homology model structures for these enzymes, but they have also been combined with 
structural protein models to improve the prediction of CYP substrate specificity and 
metabolism. Figure 6 shows an example of a correlation between predicted and 
experimentally determined Ki values for CYP2C9, Figure 4 shows an example of MIFs of a 
substrate docked into a CYP2D6 homology model, and Figure 3-A the corresponding 
CYP2D6 homology model. 
Traditionally, methods for performing 3D-QSAR rely upon alignment of the training set 
molecules. Energetically favorable conformations of substrates and/or inhibitors can be 
generated using energy minimization and/or automated docking of ligands into a CYP 
(homology) model. This often is time-consuming and can introduce user bias, the resulting 
model being dependent upon and sensitive to the alignment used. Commonly used 
software for CYP pharmacophore/3D-QSAR model building is listed in Table 4, examples 
being CoMFA, Catalyst, PLS MS-WHIM, and ALMOND. ALMOND is a recent 3D-QSAR 
program specifically developed for generating and handling alignment independent 
descriptors, e.g. grid independent descriptors (GRIND). However, even when using this 
approach, models usually depent on the ligand conformations. The possibility of 
constructing conformer independent 3D-QSAR models for CYPs was explored very recently 
by the use of flexible GRIND MIFs.24,61 A strategy for the incorporation of water molecules 
present in a ligand binding site into 3D-QSARs has also been described.62 In addition to 
ligand-based 3D-QSAR pharmacophore models, protein-based inverse pharmacophore 
models can also be derived from the analysis of MIFs in active sites of several protein 
targets using consensus principal component analysis (CPCA). Very recently, methods for 
homology and inverse 3D-QSAR pharmacophore model building have been evaluated for 
CYP2C5 and 2C9. They were concluded to depend critically on the alignment strategy, on 
the quality of the template crystal structure, as well as on the optimization procedures 
applied.63 
Alignment-dependent 3D-QSAR models for CYP inhibitors are generally more difficult to 
construct than substrate models, as the site of catalysis is lacking in inhibitor models and 
can therefore not be used as an easily identifiable site to be superimposed. However, until 
now, more inhibitor models than substrate models have been developed (see Table 2), 
probably because Ks data for CYP ligands (i.e. substrates as well as inhibitors) are 
relatively scarce. The possibilities and limitations in 3D-QSAR pharmacophore modeling will 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3D-QSAR Pharmacophore Models Applications 
One of the first COMFA models for CYP2C9 predicted two anionic sites, an aromatic region 
and a steric region near the site of metabolism as important features.45 This model 
predicted 13 inhibitors correctly out of 14 and inclusion of additional substrates did not 
change the model appreciably.75 Based on a homology model of CYP2C9, F110 and F114 
were implicated in aromatic, and Arg105 and Asp293 in electronic interactions, 
respectively75. Using Catalyst and PLS-WHIM with three different sets of inhibition constants 
(Ki’s), models for 2C9 have been constructed that included at least one hydrophobic region 
and at least one H-bond acceptor43, similar to the previous COMFA model. A combined 3D-
QSAR-homology model for 2C9 inhibitors, based on a training set of 21 inhibitors and 
using automated docking for conformer selection, was able to predict the Ki of eight other 
compounds to within 0.5 log units76, as is shown in Figure 6. An inverse, protein-based, 
pharmacophore model of 2C9 was generated by the analysis of molecular interaction fields 
(MIFs) in active sites of the CYP2C isoforms 8, 9, 18, and 19 using consensus PCA 
(CPCA).70 CYP2C8 was the most different, with changes at positions 114 (Ser in 2C8, Phe 
in the others), 205 (Phe in 2C8, Ile in 2C9/19, and Leu in 2C18), and 476 (Ile in 2C8, Phe 
in the others) causing different size and hydrophobicity of the binding pocket. 
 
 
Figure 6: Correlation for a combined CYP2C9 3D-QSAR-homology inhibitor model of Afzelius et al. 
[Mol. Pharmacol. 2001 59 909]76 between measured and predicted pKi’s, with r2 = 0.947 and q2 = 
0.730. (triangles) training set (n=21); (squares) test set (n=8). 
 
Using alignment-independent GRIND descriptors in ALMOND, a CYP2C9 inhibitor model 
was constructed with two H-bond donors at 6 Å distance from each other, a hydrophobic 
region and a H-bond donor 13 Å from each other, and a nitrogen interaction point and a 
H-bond donor 12 to 15 Å from each other77. For construction and validation of this model, 
automated docking of template molecules in a CYP2C9 homology model was used for 
conformer selection of 35 inhibitors (21 for the training set, 14 for the test set) and 46 
non-inhibitors (21 for the training set, 25 for the test set). 74% of the compounds were 
correctly predicted to be either inhibitor or non-inhibitor, and 11 out of 12 Ki’s of inhibitors 
not used to derive the model were predicted within 0.5 log-units. An inverse alignment-
independent protein-based CYP2C9 3D-QSAR pharmacophore model was combined with a 
homology model to represent substrates as a set of fingerprints for each H-atom present 
in the molecules.79 This model was able to predict sites of catalysis of 39 out of 43 
substrates. A Catalyst model based on 36 CYP2C9 heteroactivators contained one H-bond 
acceptor, one aromatic ring and two hydrophobic regions.78 94% of the training set of 
heteroactivators was predicted within 1 log unit. The model also correctly identified close 
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to 70% of inhibitors as high-affinity CYP2C9 binders, suggesting that heteroactivators and 
inhibitors share some common structural 2C9 binding features. Using ALMOND, a 
conformer- and alignment-independent CYP2C9 model based on 22 flexible inhibitors was 
built very recently by the use of flexible, alignment independent MIFs, and was able to 
predict the Ki’s of 11 out of 12 other inhibitors to within 0.5 log units.61 
For CYP2D6, a set of two Catalyst 3D-QSAR models has been created containing a H-
bond acceptor and a H-bond donor and two to three hydrophobic regions82. Both models, 
based on a training set of respectively 20 and 31 inhibitors, were only capable of 
predicting 7 out of 15 Ki’s of inhibitors not used to derive the model within 0.5 log units. A 
CoMFA model for CYP2D6, with an additional distance component included was based on a 
training set of 24 substrates with a basic nitrogen at either 5, 7, or 10Å from the site of 
catalysis predicted Km’s of 13 out of 15 other substrates to within 0.5 log unit.83 A 
combined Catalyst 3D-QSAR/homology model for CYP2D6 has been constructed based on 
a training set of 24 substrates and an alignment from fluoxetine docked into the homology 
model using GOLD, contained one H-bond acceptor, two hydrophobic regions, and one 
cationic site.69 The model was found statistically significant, however it could predict Km’s 
of only 14 out of 28 other substrates within 0.5 log units. 
 
3D-QSAR Pharmacophore Models Conclusions 
The recent 3D-QSAR models for several CYP isoforms show generalized features and 
molecular properties of CYP substrates/inhibitors. These features have been correlated 
with and used for the prediction of qualitative properties like site of catalysis, and they 
have been used for prediction of quantitative properties like (binding) affinity, as is 
illustrated in the QSAR correlation plot in Figure 6. Table 1 lists for each of the current 
models reported, the key features as well as the relevant predicted substrate/inhibitor 
properties. Especially for CYP2C9, and also CYP2D6 and CYP3A4, several models with 
quantitative predictive value for Ki are available and for other isoforms often IC50 values 
and sometimes Km values are predicted. In many cases the QSAR model was not validated 
against a test-set. Almost all recent classical and 3D-QSAR pharmacophore models have 
been improved by including details of the active site structure, and in turn they have been 
used to improve details of the alignment and structure of homology models for CYPs 17, 
1A2, 2B6, 2C8/9/18/19, 2D6 and 3A4.  
Alignment-independent 3D-QSAR models, as applied for CYP2C9, are not limited by a 
suitable template compound for superposition, so they can be constructed in a fairly 
automated fashion. In contrast, classical pharmacophore models must be built manually, 
and can only be used for qualitative predictions. Other recent developments in 3D-QSAR 
methods consider active site water molecules, not yet applied to CYP’S, and the 
construction of conformer-independent models by the use of flexible molecular interaction 
fields (MIFs), very recently applied to CYP2C9. These developments will make it possible 
to build models without an alignment rule for chemically diverse ligands and without using 
information about the protein structure.  
 
2.2.5 Conclusions Ligand-based Models 
Intrinsic regio-specific susceptibilities of molecules to CYP metabolism have been predicted 
using available QM methodologies successfully for CYPs in general. Significant 
improvements in the prediction of site of catalysis have been reported for CYPs 101 (cam), 
107A (eryF), 2E1, 2B4 and in ongoing work for CYP102 (BM3) by inclusion of known or 
predicted substrate binding orientations in the active site or of relative orientations in a 
pharmacophore model. Further improvements have been seen from including a description 
of the relevant heme-iron-oxygen activated reactive species at a higher level in the QM 
calculations, and of inclusion of more of the active site and protein surroundings that can 
have significant influence on electronic properties of the substrate mainly through 
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electrostatic interactions. Classical CYP pharmacophore models have been successful for 
the prediction of qualitative properties like substrate selectivity and site of catalysis, 
especially in the cases of CYP2C9 and CYP2D6, see Table 1. More recent 3D-QSAR 
pharmacophore models have in addition been used for the quantitative prediction 
(binding) affinity, especially for CYP2C9, as is listed in Table 1.  
The future role of pharmacophore/QSAR models seems to be to consolidate available 
experimental data on substrates and inhibitors and to combine these with structural details 
included in CYP crystallographic and homology model structures (see also the next 
section 2.3.2 ‘Protein Structure and Analysis’). On the other hand, the use of alignment 
and conformer independent models make it possible to build models without alignment 
rules for chemically diverse ligands and without using information about the protein 
structure. Predictions based on QM calculations on the substrate will likely be used as a 
complementary source of information obtained from pharmacophore/QSAR models. 
 
 
2.3 Protein Structure and Analysis 
2.3.1 Introduction 
A wealth of detailed information on CYP enzyme action and substrate or inhibitor 
interactions with the binding cavity becomes accessible when a structure of the CYP 
protein is available. The main source for these structures is X-ray crystallography, which 
are summarized in Table 2, but an even larger number of CYP structures have been built 
on the basis of these crystal structures using homology modeling techniques, which are 
summarized in Table 3. The progress in fields of X-ray crystallography and homology 
model building, as well as their mutual complementarity, will be illustrated and discussed 
in the following sections. Commonly used software for CYP homology model building and 
CYP protein structure analysis is listed in Table 4. 
 
2.3.2 Crystallographic Protein Models 
Crystallographic Protein Models Structure Determination 
Crystal structures have been solved for several cytosolic bacterial (n = 77), cytosolic 
eukaryotic (n = 24), and, recently, also of membrane-bound mammalian (n = 13) CYP 
oxygenases (by the end of 2004). In addition to these 114 CYP oxygenase structures, 
including 3 CYP102 (BM3) oxygenase-reductase complexes, 6 individual CYP reductase 
structures have been solved. Table 2 presents an overview of all currently available CYP 
oxygenase crystal structures, including information on X-ray resolution, bound ligands, 
mutants and heme oxidation state. In addition, several new structures have recently 
become available on the Protein Databank, most notably the human CYP3A4.16 The 
progress in CYP crystallography has recently culminated in a fair number of a human 
CYPs, of which CYP2C914 was the first. Figure 2 shows two ligand-bound structures of 
CYP2C9 (panels A and B), and a ligand-free structure of CYP3A4 (panel C). 
In several cases, different protein conformations have been found in crystal structures for 
the same isoform, and the question arises which of those is (the most) relevant for describing 
the catalytic properties of the enzyme. For example, in the first CYP2C9 crystal structure14, the 
distance of the bound S-warfarin substrate to the heme iron is large (~10Å), see Figure 2-A, 
which makes it unlikely that this crystal structure corresponds to a catalytically active state. In 
line with this suggestion, Arg 105 and Arg 108, implicated in the formation of putative anionic-
binding sites by mutagenesis, pharmacophore and homology modeling studies (see sections 
2.2.3, 2.2.4 and 2.3.3) both point away from the active site. In a more recent substrate 
bound CYP2C9 crystal structure, however, the substrate S-flurbiprofen is within a catalitically 
reactive distance from the heme iron (~5Å), see Figure 2-B, and interacts with F114 and 
R108.15 In the substrate-bound CYP102 (BM3) structures, unreasonably long substrate-heme 
distances have been found previously.96,97 It has been suggested that protein conformational 
changes driven by electron-transfer trigger the movement of these substrates into effective 
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positions for hydroxylation.98 In crystal structures of CYP101 (cam)99,100 and CYP2C5101, 
multiple ligand binding modes were observed. In CYP107A (EryF)102 homotropic cooperativity 
of multiple ligands was observed. These effects probably result from ligand-induced 
conformational changes of the active site and the relatively large volume of the active site as 
compared to the volume occupied by the ligand, as described in more detail below in section 
’Crystallographic Models Active Site’.  
Although crystallographic protein structures are firmly based on experimental data, it must 
be borne in mind that for resolutions of around 2Å and worse, the electron density maps are 
not sufficiently detailed to resolve individual atoms. In order to circumvent this problem, 
molecular modeling techniques are often applied and usually yield reliable structural models 
that better represent the measured diffraction patterns103. However, the likelihood of errors in 
the structure, like wrong rotamer states, mis-threading, or misplacement of secondary 
structure elements, increases rapidly with diminishing resolution. Furthermore, non-active site 
mutations introduced to facilitate crystallization of mammalian membrane-bound CYP crystal 
structures might cause significant conformational changes compared to crystal structures of 
less extensively modified constructs, as was recently observed for CYP2C915,16 and is clearly 
visible in Figure 2-A and B. In some cases, it is more appropriate to characterize these 
structures as crystallographic protein models to emphasize the distinction with atomic-
resolution crystallographic structures – hence the title for this section: ‘’Crystallographic Protein 
Models. Like the homology models discussed in section 2.3.3 ‘Homology Based Protein 
Models’, these crystallographic models warrant additional validation. 
 
Crystallographic Protein Models Access & Exit Channels 
A thermal motion pathway analysis of B-factors in the crystal structure of CYP101 (cam) 
with camphor bound revealed the existence of three distinct pathway families. Exit 
channels were explored by molecular dynamics (MD) simulations by imposing an artificial 
expulsion force on the substrate in addition to the standard MD force field.104 This random 
expulsion molecular dynamics (REMD) method was later also tested in simulations of the 
palmitoleic acid bound structure of CYP102 (BM3), a system for which a substrate-access 
channel is closed in the substrate-bound and open in the substrate-free crystal structure105 
and the closing motion has been reproduced by MD simulations.106,107 It was applied to 
complexes of CYP101 (cam) with camphor, endo-borneol allyl ether and 5-hydroxy 
camphor (product of camphor). The three ligand expulsion pathways of CYP101 observed 
by REMD matched well with three putative ligand channels found by thermal motion 
pathway analysis.108 In a complementary study, estimates of the relative probabilities of 
ligand passage through the three channels were computed using steered molecular 
dynamics (SMD) and adiabatic mapping.109 The REMD and SMD approaches combined with 
essential dynamics (ED) analysis were used for 6-deoxyerythronolide B bound CYP107A 
(EryF), and the results obtained for this complex were compared to those for CYP101 
(cam) and 102 (BM3).110 Several possible exit/entrance routes in each enzyme were 
identified and one route, located between the F/G loop, the β1 sheet and either the B’ 
helix (CYP101 and 102) or B’/B loop (EryF) (see Figure 4), was common to all three 
proteins. The mechanisms of substrate entrance and/or product exit along this pathway, 
however, were different for each of the three isoforms and apparently adapted to the 
properties of the substrate. Based on this observation, it is suggested that the 
characteristics of the active site itself may not be the only determinant of substrate 
specificity. The access channel properties may thus play a key role by kinetic modulation 
of substrate recognition.110 Very recently, open channels leading to the active site of 
currently available CYP crystal structures (see Table 2) were analyzed, providing 
experimental evidence for the existence of four substrate exit/entrance routes that were 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Crystallographic Protein Models Active Site 
Helms and Wade calculated the free energies of hydration of two cavities in the active site 
of two liganded complexes of CYP101 (cam) by multiconfigurational thermodynamic 
integration (TI) calculations.135 Based on computed free energy differences, they 
concluded that a crystallographically well-defined water molecule mediating H-bonds 
between 2-phenylimidazole and CYP101 is energetically favorable, while solvation of 
camphor bound CYP101 is energetically unfavorable. Free energy calculations for having 
five to eight water molecules in the active site cavity of the unliganded enzyme showed 
that occupation by five to six water molecules is thermodynamically most favorable, which 
is in agreement with estimates from crystal structures and studies employing hydrostatic 
pressure. Potential of Mean Force (PMF) calculations were used to identify functional water 
channels in CYPs 101 (cam), 102 (BM3), 108 (terp), and 107A (EryF)136 and proton-
transfer pathways in CYP101.137 
Recently, ligand induced changes in the active sites of several proteins, among which 
CYP101 (cam), were analyzed using classical molecular interaction potentials, in 
conjunction with protein geometry and protein cavity calculations.138 It was found that the 
binding of CYP101 ligands introduces small perturbations at the binding site of the 
proteins, and in some structures of CYP101 these perturbations result in important 
alterations in the recognition pattern for ligand binding. Comparisons between ligand-
bound and ligand-free crystal structures of other isoenzymes, i.e. CYPs 102 (BM3)105, 107A 
(EryF)114, 119139, 51 (14α)140, and 2C5101,141, showed ligand induced changes in size, shape 
and hydration of the active site. This conformational flexibility of the active site is likely to 
underlie the capacity of many CYP isoenzymes to metabolize structurally diverse ligands of 




















Figure 7: Electrostatic potential surfaces of the active site of (A) CYP2D1; (B) CYP2D2; (C) 
CYP2D3; (D) CYP2D4; and (E) CYP2D6. Red, blue and white indicate negative, positive and neutral 
electrostatic potentials, respectively. The electrostatic potential surfaces are shown in the same 
orientation as the protein secondary structure shown in (F), with the heme-group at the bottom of 
the active site. Modified after Venhorst et al. [J Med Chem 2003 46 74]10  with permission. 
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In human and rat CYP2D isoenzymes, electrostatic potential calculations on the binding 
pocket residues showed large differences in the negative charge of active sites of different 
isoenzymes, as is shown in Figure 6. These differences correlated with observed IC50’s10. 
This observation provided novel insights into differences in active site topology of human 
and rat 2D-isoforms and on the validity of the rat as a model for human CYP2D6 activity. 
 
Crystallographic Protein Models Conclusions 
The first human CYP crystal structure (i.e. 2C9) together with some other crystal 
structures of mammalian CYPs (rabbit 2B4 and 2C5 and human 2A6, 2C8, 2D6 and 3A4) 
provide a still growing basis for protein homology modeling work. Examples of crystal 
structures are shown in Figure 2, for CYPs 2C9 and 3A4. Table 2 presents an overview 
of all currently available CYP oxygenase crystal structures (by the end of 2004) and the 
growth in available CYP crystal structures is shown in Figure 8. Especially in the cases of 
CYP101, 102, and 107A, these structures have successfully been used as the basis for 
studies on structural and dynamic properties of active site hydration, substrate access and 
binding, and product exit. Structural differences between substrate-free and substrate-
bound CYP isoenzymes, as seen for the crystal structures of CYPs 101, 102, 107A, 119, 51, 
2B4, 2C5, and 2C9, indicate that conformational flexibility of the active site is likely to 
undelie the capacity of many CYP isoenzymes to metabolize structurally diverse substrates 
of different sizes and to generate different metabolic products from these substrates. 
Furthermore, CYP crystal structures are used as templates for CYP homology modeling. 
The most recent homology models are based on the rabbit CYP2C5 structure, as shown in 
Table 3 and described in the section 2.3.3, and it is expected that new homology 
models will be based on the new mammalian structures (e.g. CYPs 2A6, 2B4, 2C8, 2C9, 




Figure 8: The number of new crystal structures, homology models and pharmacophore models 
published over the years. The overall steady increase is clearly visible, as is the increase in 
homology and pharmacophore models during (temporary) declines in number of crystal structures, 
suggesting the complementary nature of experimental structure determination and model building. 
The structures of isoforms that have been or will be extensively used for homology model building 
are indicated at the top. 
 
When using crystal structures for CYP-modeling studies, special attention should be 
given to the state in which the CYP was crystallized, as this may not correspond to a 
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catalytically active state. It is possible to combine such a structure with a relevant active 
site loop structure from a related CYP crystal structure in which the loop is known to be in 
an active state. Although the resulting protein model would often be classified as ‘only’ a 
homology model, when rigorously validated it could be more relevant for predicting 
enzyme activity than the crystal structure. 
 
2.3.3 Homology-based Protein Models 
Homology-based Protein Models Methods Background 
In addition to X-ray crystal structures, CYP protein homology model structures can be a 
valuable source of detailed information on binding cavity characteristics and other details 
of the ligand-protein interactions. In addition, a variety of biochemical, spectroscopical and 
mutational data may be incorporated during the model building process, providing a 
powerful way to consolidate and rationalize the different experimental insights into the 
structure and function of the CYP enzyme. Commonly used software for CYP homology 
model building is listed in Table 4 and a selection of the many homology models built so 
far based on available CYP crystal structures (by the end of 2004) is presented in Table 3.   
Building a homology model of a protein is a highly iterative process involving (often 
many) cycles of sequence or structural alignments, and model building, and analysis and 
validation, as is depicted in the flowchart in Figure 9.142 Starting with the sequence of the 
target CYP protein, homologous sequences are found by scanning against sequences of 
proteins in the Protein Databank using one of the many search algorithms available, such 
as PSI-BLAST, more are listed in Table 4. This is step 1 in the top cycle in Figure 9. 
Often first a multiple sequence alignment is performed against homologous sequences of 
the CYP subfamily, as available from sequence databases, which is step 2 in this cycle. 
The sequence alignment of templates must then be validated, e.g. using mutational 
studies and isoenzyme specificity data to verify if the location of essential amino acids is 
correct, which is step 3 in this cycle, and if necessary it has to be further refined by 
structural alignments, step 4 in the top cycle in Figure 9. Although all CYPs share the 
same fold, variations in length and position of secondary structure elements between 
isoforms make structural alignments less than straightforward. Alignments can be carried 
out in two different ways7. The first method is to align the sequence according to a 
superposition of available protein crystal structures. Using this approach, Hasemann et al. 
made the first CYP structural sequence alignment using crystal structures of CYPs 101 
(cam), 102 (BM3), and 108 (ter).8 The second method focuses on local structural 
similarities between equivalent structure elements. Jean et al. developed an algorithm to 
define the so-called ‘common structure building blocks’ (CBS’s) by comparing torsion 
angles of protein backbones143. From the same three CYP crystal structures 15 CBS’s were 
derived, consisting of most CYP secondary structure elements except helices A and B’ (see 
also Figures 2 and 3). Very recently, other methods for homology model building have 
been evaluated for CYP2C5 and 2C9 and concluded to depend critically on the alignment 
strategy, on the quality of the template crystal structure, as well as on the optimization 
procedures applied.63 Use of manually optimized multiple sequence alignments 
corroborated with experimental data (most notably mutagenesis data) generally improves 
the models, as does careful optimization using molecular dynamics simulations. 
Once the templates have been aligned, step 1 in the central cycle and step 4 in the top 
cycle in Figure 9, the amino acid sequence of the target protein is aligned with them, this 
is step 2 in the central cycle, and this alignment must be validated using mutational 
studies to verify that the location of essential amino acids is correct, which is step 3 in the 
central cycle. For the parts of the target protein that have the best alignment with the 
template structure, or one of the template structures, the coordinates of the backbone of 
the target are taken from the homologous parts of the backbone of the template. Side 
CYP in silico 
 63
chain coordinates are transferred as well using the ‘maximum overlap’ principle to keep 
the coordinates of all atoms from the template residue sidechain that have topologically 
corresponding atoms in the target. Missing sidechain atoms are added, and conformations 
are generated for inserted residues and loops and, finally, the structure can be optimized 
using, e.g., energy minimization, simulated annealing, or ‘room temperature’ MD 
simulations. Based on basic protein structure quality parameters (e.g. Ramachandran 
distributions, packing quality) one of several generated model structures is selected. 


























Figure 9: Flowchart for protein homology modeling modified after Kirton et al. [Adv Drug Deliv Rev 
2002 54 385].142 The highly iterative processes in alignment, model building, model analysis and 
validation, involving three connected cycles, are visible. Details from a pharmacophore model can 
be used to optimize sequence alignments, to choose arrangements of certain important groups 
during model building and for final validation. 
 
The 3D homology model of the protein structure is validated as much as possible with 
experimental data, like mutagenesis data, NMR spin-relaxation measurements10,98, active 
site chemical probe studies144 and predictions of CYP substrate and/or inhibitor binding 
and regioselective metabolism and isoenzyme specificity, using for example automated 
docking (section 2.4.2) and MD simulations (section 2.4.3), which is step 5 in the 
central cycle in Figure 9. Depending on the quality of the model as indicated by the 
validations used, it will be refined by additional cycles of structure optimization and 
repeated model building, which is the bottom-right cycle in Figure 9 and also involves 
steps 3 and 4 of the central cycle, as well as by improving the alignment with the template 
sequence(s) and/or structure(s) (top cycle) and repeating all steps in the central cycle.  
Table 3 shows a selection of the many homology models built so far based on available 












































homology modeling has increased considerably, see Figure 8. For each CYP isoform only 
the most recent and most properly refined and validated homology models are included in 
this review. The dependency of homology model building on the availability of (quality) 
crystal structures is obvious, the correlated growth in published crystal structures and 
homology models is clearly visible in Figure 8. In total we counted about 144 homology 
models published of which 62 are included in Table 3, and nearly all of the earlier models, 
until 2000, were discussed by Ter Laak et al.44. The progress in homology modeling will be 
demonstrated below by the case of CYP2D6. 
 
Homology-based Protein Models Applications 
The first preliminary homology model for the human CYP2D6, containing only active site 
regions of the protein (11 segments) indicated D301 as an important amino acid residue 
for catalytic activity.145 For one of the first complete CYP2D6 homology models, a 
structural sequence alignment of the crystal structures of bacterial CYP101, 102, and 108 
isoenzymes8 was aligned with a multiple sequence alignment for members of the CYP2-
family using site-directed mutagenesis data.4 Three known substrates and one inhibitor 
were docked into the active site of the CYP2D6 model4 indicating that the protein model 
was able to accommodate large substrates and inhibitors. The docked conformations 
indicated a crucial H-bond with the amino acid D301, which was in turn used to improve 
the previously described pharmacophore model for CYP2D6 substrates (see sections 
2.2.3 and 2.2.3 on ‘classical’ and 3D-QSAR pharmacophore models, respectively). Two 
amino acids for which site-directed mutagenesis data were available, namely D30154 and 
Val374 were part of the active site of the protein model4. Later, a cluster of 51 manually 
superimposed and energy minimized substrates was docked and evaluated in a refined 
model explaining 72 metabolic pathways catalyzed by CYP2D656. It appeared that this 
model could predict correctly six out of eight metabolites observed in a test set of 
compounds. A CYP2D6 model was published together with models of CYP1A2 and CYP3A4 
based on four bacterial crystal structures146. In total, 14 CYP2D6 substrates and 4 
nonspecific substrates known to be metabolized by 2D6 were successfully automatically 
docked into the active site. Almost all substrates had important Van der Waals interactions 
with Val307, F483, and Leu484, whereas D301 was always involved in charge-reinforced 
H-bonds with the protonated nitrogen atom of the substrates. A novel approach for the 
construction of CYP2D6 protein models was introduced by Modi et al.98, who used NMR 
spin-relaxation rate derived distance restraints for codeine and MPTP to guide the 
homology modeling process.  
Recently, 4 different sets of comparative models of CYP2D6 (including the first 2D6 
homology models based on rabbit CYP2C5, the first mammalian CYP crystal structure131), 
were constructed using different structural alignments of combinations of 4 bacterial 
and/or CYP2C5 crystal structure templates142. Selection of the best model was based on 
stereochemical quality and side chain environment. The resulting model was further 
refined and validated by automated docking in combination with NMR-derived distance 
restraints mentioned above98,147 and GRID/GOLPE-analysis of the active site. This latter 
analysis suggested that both D301 and E216 are required for metabolism of basic 
substrates, as E216 was identified as a key determinant in the binding of the basic moiety 
of substrates while D301 might exert indirect effects on protein-ligand binding by 
movement of the B’-C loop and creating a net negative charge together with E216. This 
hypothesis was later confirmed by site-direct mutagenesis studies which showed that 
neutralizing both E216 and D301 alters CYP2D6 substrate recognition.55  
More recently, a new homology model of CYP2D6 based on rabbit CYP2C5 was 
reported10. The model was validated on its ability to i) accommodate codeine in the 
binding orientation determined by NMR by Modi et al.98, ii) reproduce the binding 
orientations corresponding to metabolic routes of 10 substrates with rigid docking studies, 
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iii) remain stable during unrestrained molecular dynamics at 300 K and iv) reproduce 
inhibition characteristics of 11 CYP2D6 model-ligands. Analogous homology models were 
generated for the rat CYP2D-isoforms, 2D1/2/3/4.10 Electrostatic potential calculations on 
the binding pocket residues showed large differences in the negative charge of active sites 
of the different isoenzymes, as is shown in Figure 7. These differences correlated well 
with measured IC50’s.10 Interestingly, in addition to D301 and E216, this study also 
indicated F483 and F120 as key interaction residues. The importance of F120 in CYP2D6 
metabolism was recently confirmed by site-directed mutagenesis studies.18,148 Very 
recently, a substrate-free CYP2D6 crystal has been solved.133 Chapter 3 describes the 
construction, refinement and validation of the CYP2D6 homology model used in this thesis, 
and its comparison with the recently solved CYP2D6 crystal structure.133 
In summary, protein homology models of CYP2D6 have provided a detailed insight in 
the overall protein structure as well as in the active site topology. The availability of the 
first crystal structure of a membrane bound CYP, i.e. the rabbit CYP2C5, as well as more 
advanced computational modeling techniques, e.g. molecular dynamics simulations, have 
significantly improved the predictive quality of the resulting protein models. The very 
recent human CYP2C9 crystal structure has so far only been used in the construction of a 
new CYP2B4 model.40 Homology models can be already very suitable to predict specificity 
and sites of metabolism for CYP substrates, but the quantitative prediction of (binding) 
affinities and turnover rates remains a challenge for the near future. 
 
Homology-based Protein Models Conclusions 
As shown in Table 3, the trend in CYP homology model building is clearly towards a multi-
integrated approach using multiple sequence alignments, (multiple) structural alignments, 
in combination with mutational, spectroscopic and enzyme kinetic experimental data and 
new or available pharmacophore models, automated docking, and molecular dynamics 
(MD) simulations. Mutational data and experimental knowledge of SRS’s are very 
frequently used to optimize sequence and structural alignments and to validate final 
homology models. Recent homology models show good agreement with site-directed 
mutagenesis studies, especially in the case of CYP2D6 where F120, F483, E216, and D301 
were indicated as key determinants of selectivity and regiospecificity of substrate binding 
and catalysis by this isoenzyme. Several cases are known in which CYP protein homology 
models are combined with pharmacophore models (i.e. CYPs 1A2, 2B6, 2C8/9/18/19, and 
2D6) or QM calculations (i.e. CYPS 2E1 and 3A4). In recent studies, for nearly all CYP 
isoforms, predictions of site(s) of catalysis in substrates, substrate-selectivity, isoenzyme 
specificity, e.g., CYPs 1A2, 2D6 and 3A4146, 2B1/4/5149, and 2C8/9/18/1970, and ligand 
(binding) affinity by automated docking and MD simulations have been used during the 
model building process to evaluate intermediate stages, as well as for a first validation of 
the final model. An upcoming and potentially powerful approach is the use of MD 
simulation techniques for optimization of the final model, e.g. for CYP2B6.150 Although CYP 
homology models are rarely used for quantitative binding affinity predictions (e.g. CYP1A1, 
as described in section 2.4.4), CYP homology models for many isoforms have been used 
successfully for the prediction of substrate selectivity and site of metabolism by automated 
docking and MD (see sections 2.4.2 and 2.4.3, respectively). 
 
2.3.4 Conclusions Protein Structure and Analysis 
The growth in available CYP crystal structures, as presented in Table 2 and Figure 8, has 
inspired many studies on detailed analysis of CYP structures and of CYP-ligand 
interactions, and it has been the basis for much homology modeling work (Table 3 and 
Figure 8). In that respect, homology modeling has been complementary to X-ray 
crystallography, especially for mammalian CYPs where crystal structures have become 
available very recently, i.e. rabbit CYPs 2B4 and 2C5, and human CYPs 2C8, 2C9 and 3A4. 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Several CYP isoforms have only been crystallized in a non-active ligand-bound state, and 
for some it is not known whether the crystal structure corresponds to an active state or 
not. Ligand-induced changes can be observed in the size, shape and hydration of the 
active sites of several CYPs, i.e. 101, 102, 107A, 119, 51, 2C5, and 2C9 (see Figure 2-A 
and B) and these are likely to undelie the capacity of many CYP isoenzymes to metabolize 
structurally diverse substrates of different sizes and to generate different metabolic 
products from these substrates. 
The trend in CYP homology model building is clearly towards an integrated approach of 
multiple sequence and structural alignments, combination with new or available 
pharmacophore models, automated docking, molecular dynamics (MD) simulations and 
validation with mutational, spectroscopic, structural and enzyme kinetic experimental data. 
Notably, recent models of CYP2D6 show very good agreement with site-directed mutation 
studies. Predictions of substrate selectivity, site of metabolism and isoenzyme specificity 
have been successful using homology models of many CYP isoforms. 
 
2.4 Ligand-Protein Interactions 
2.4.1 Introduction 
One of the critical issues in predicting CYP metabolism is the combination of statistical, 
orientational and energetic factors that each contributes to various degrees in different 
CYP enzymes. A first step is made by automated docking programs that aim to predict 
energetically favorable binding conformations of ligands in the active site cavity. Further 
exploration of binding conformations and relative probabilities can be done using 
molecular dynamics simulations, which can also be used for predictions of binding 
affinities. Commonly used software for study of CYP-ligand interaction predictions is listed 
in Table 4. 
 
2.4.2 Automated Ligand-Protein Docking 
Automated Ligand-Protein Docking Methods Background 
Automated ligand-protein docking methods predict energetically favorable conformations 
and orientations of ligands in the binding pocket of a protein. Algorithms to generate 
different poses (docking) are combined with scoring functions that consider the tightness 
of the protein-ligand interactions186. When a structural model of a CYP isoenzyme is 
available, from X-ray crystallography or homology model building, docking methods can be 
used for predictions of the catalytic site and binding affinity for CYP ligands (substrates 
and inhibitors), and to identify potential CYP substrates in a chemical database (protein-
based virtual screening). In addition, automated docking can be used to generate input 
structures for pharmacophore modeling (see sections 2.2.3 and 2.2.4) and MD-
simulations (see section 2.4.3). The heme prosthetic group, the presence of water in the 
active site, the relatively large size and large conformational flexibility of the active site, 
the broad range of substrates and many catalytic sites in most substrates, as described in 
section 2.3.2, make CYPs rather challenging docking targets. 
Several docking algorithms and scoring functions have been described in the past few 
years, the most commonly used for CYPs are GOLD, FlexX, DOCK and AutoDock, and the 
scoring functions from C-Score (TRIPOS Inc., St. Louis); more are listed in Table 4. 
Docking accuracy, i.e. structure prediction, and scoring accuracy, i.e. prediction of binding 
free energy, of docking-scoring combinations vary considerably with the selected target 
protein and physicochemical details of target-ligand interactions187, and even depend on 
fine details of the CYP protein structure, as shown for CYP101 (cam)188. Therefore, a 
docking-scoring strategy must be tailored to the system of interest, based on a test-set of 
ligand-bound protein crystal structures. For CYP crystal structures, such a methodological 
evaluation was performed very recently18 and so far has not been explored for CYP 
homology models. Water molecules can play an essential role in ligand-protein binding189, 
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and water-mediated ligand-protein interactions have been observed in crystal structures of 
most CYP isoforms, e.g. rabbit CYP2C5101,141 and human CYP2C9.14,15 Most docking tools, 
however, ignore the possibility of water-mediated interactions between protein and 
ligand.190,191 Ligand-induced changes in the active sites of CYPs can lead to important 
alterations in ligand recognition patterns (see 2.3.2 ‘Crystallographic Protein Models Active 
Site’ and are accounted for in some new methods190,192 but the inclusion of full protein 
flexibility in automated ligand-protein docking gives an enormous increase in 
complexity186,190, and until now no such method has been validated extensively.191 
 
Automated Ligand-Protein Docking Applications 
Automated docking has primarily been applied to refine and validate CYP pharmacophore 
models and protein homology models (see Table 3), and manual docking has been 
extensively used for this purpose as well in the past. Validation is achieved by comparing 
predicted binding modes of substrates with reported metabolic product(s), and was used 
during the homology modeling process of CYPs 1A2146, 2B669,150, the 2C subfamily70,71, 
2D610,142,146, 2E1165, 3A471,146,169, and 6B1.173 In Figures 4 and 3-A dextromethorphan is 
shown in its docked binding orientation in the binding cavity of the CYP2D6 homology 
model. 
Experimentally determined binding affinities of 11 different CYP101(cam)-ligand 
complexes showed no clear correlation with values from different C-Score scoring 
functions on CYP101(cam)-ligand crystal structures nor on complexes produced by the 
automated docking program FlexX.193 Nevertheless, the docking and scoring could still be 
used to prioritize in silico screening hits of a chemical database. For wildtype CYP101 
(cam) DOCK was used for in silico screening to identify potential substrates194, and 
imidazole inhibitors.59 The automated docking program GOLD was recently used to predict 
binding of octane, octanoic, and lauric acid to CYP102 (BM3) (Feenstra et al., unpublished 
results). Predicted binding modes were further analyzed with MD simulations and QM 
calculations on substrate reactivity, as described in more detail in sections 2.4.3 and 
2.2.2, respectively. Marked differences were seen in the probabilities of different binding 
modes in wild type CYP102 and three mutants, and these trends were comparable to 
experimental product formation. 
Recently, three popular automated docking programs AutoDock, FlexX and GOLD were 
evaluated on their ability to predict the binding mode of ligands from 19 crystallized 
complexes of CYPs and ligands, either without water, with crystal waters or with water in 
positions based on predictions by GRID. Although the individual programs showed variable 
performance, pooling and rescoring of all solutions improved the prediction accuracy 
significantly. Binding mode predictions were strongly improved by including either crystal 
or predicted water, and even with higher deviation from the reference crystal structure, 
correct predictions of catalytic sites (CSPs) were still obtained.18 
 
Automated Ligand-Protein Docking Conclusions 
Manual docking has been extensively used in the past and automated docking approaches 
are nowadays successfully applied for the prediction of the site of catalysis in substrates, 
the refinement and validation of CYP homology models (i.e. CYPs 1A2, 2B6, the 2C 
subfamily, 2D6, 2E1, 3A4, and 6B1, see Table 3 and Figure 9), and the construction of 
pharmacophore models (i.e., CYPs of the 2C subfamily, see Table 1 and Figure 6). 
Docking algorithms are successful in determining binding conformations and orientations 
of CYP-ligand complexes, but docking scoring functions are still not suitable for the 
accurate prediction of ligand binding affinity, as will be described in more detail in section 
2.4.4. Despite the fact that database docking methods have been successfully applied to 
crystal structures187 as well as protein homology models195, structure-based in silico 
screening studies on CYPs have so far only been reported for CYP101 (cam). 
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New docking strategies, considering explicit water molecules, partial protein flexibility, 
and (consensus) re-scoring of docking poses have already been found to improve binding 
mode prediction of CYP ligands. It is expected that these improved docking strategies will 
also be used more and more for in silico CYP screening studies in the future. However, 
inclusion of explicit water molecules and especially the inclusion of flexibility for the whole 
enzyme, leads to significantly higher complexity. Without proper algorithmical treatment of 
this complexity, this can lead to a final lower reliability of the docking results. The 
combination of docking with MD simulations (next section, 2.4.3) to improve docking 
predictions and to explore conformational flexibility of substrates and CYP enzymes to a 
greater extent, as well as the explicit inclusion of water, is seen in an increasing number of 
studies and shows much promise. 
 
2.4.3 Molecular Dynamics 
Molecular Dynamics Methods Background 
The role of CYPs as biotransformation enzymes and the broad substrate selectivity of 
many CYPs is reflected by the size of the active site, which is generally large compared to 
the size of substrates. Furthermore, many substrates and inhibitors exhibit high degrees of 
internal flexibility, and large conformational changes of the CYP protein structure upon 
ligand binding are known to play an important role in the CYP reaction cycle. Using 
molecular dynamics (MD) simulations, these processes associated with CYP-ligand 
interaction can be described and understood in atomic detail107,196. 
Molecular dynamics (MD) simulations provide detailed insight in the behavior of 
molecular systems, in both space and time, with ranges of up to nanometers and 
nanoseconds attainable for a system of the size of a CYP enzyme in solution. However, 
MD-simulations are based on empirical molecular mechanics force field descriptions of 
interactions in the system, and depend therefore directly on the quality of the force field 
parameters197. Commonly used MD programs for CYPs are AMBER, CHARMm, GROMOS, 
and GROMACS, and results seem to be comparable between methods.  These programs 
are also listed in Table 4. For validation, direct comparisons between measured 
parameters and parameters calculated from MD simulations are possible, e.g. for 
fluorescence198 and NMR (cross-)relaxation.199 In many applications where previously only 
energy minimization would be applied, it is now common to perform one or several MD 
simulations as well, as is for example performed in studies of substrate entrance and 
product exit by Wade and co-workers.110 
Starting conformations of MD simulations are generally obtained from automated 
docking methods (see also the previous section, 2.4.2). Conversely, structural snapshots 
from MD runs can be used, with or without energy minimization, to include protein 
flexibility into docking simulations. Due to limited time scales of simulations, results can 
remain dependent on the starting conformations. The state-of-the-art is to solvate the 
simulated system in explicit water in a periodic box which, although computationally more 
expensive than continuum solvent or limited solvation schemes, avoids many of the 
possible pitfalls associated with them. Furthermore, several methodological developments 
to increase the efficiency of simulations of proteins (and ligand) in water are coming 
available, e.g., by using methods that allow increased time steps200, or by placing ligands 
in a pre-simulated environment.201 Analysis methods are available to estimate statistics of 
ligand-binding and -orientation, and energies of ligand-protein interactions or free energies 
of binding.202 
 
Molecular Dynamics Applications 
Many applications of MD can be found in refinement and optimization of homology 
models, as highlighted in section 2.3.3 and Table 3. This use of MD simulations is 
rapidly expanding. In some cases, the dynamics of the ligand is included and, e.g., 
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distance of oxidation site in the substrate to the heme iron during the simulation is taken 
as a quality measure for the homology model being constructed, e.g. CYP2B6150 and 
CYP2D6.10 
Extensive MD simulations were used to identify key conformational changes upon ligand 
binding for CYP102 (BM3).106,107 MD simulations were also used to study substrate access 
and product exit, as described in section 2.3.2 ‘Crystallographic Models Acces and Exit 
Channels’, by random expulsion simulations and related methods for CYPs 101 (cam), 102 
(BM3), and 107A (EryF).104,108-110 Free energy of hydration of the active site of CYP101 has 
been studied using thermodynamic integration (TI).135,203 Putative protein domain 
boundaries of CYP102-BM3 were identified using dynamical cross-correlation (DCMM) 
analysis204. Based on MD simulations of substrates in the bound state in the enzyme and 
free state in solution, substrate binding affinities have been predicted with the LIE method 
for CYP10134,74 and CYP1A1152, free energy perturbation (FEP) for CYP101203 and normal 
modes and Poisson-Boltzmann for CYP2B440, as is described further in section 2.4.4. 
For the prediction of regiospecific substrate oxidation, QM calculations and MD 
simulations have been combined to account for differences in reactivity in the substrate as 
well as distributions of multiple binding conformations, as applied for CYPs 101 (cam)34-36, 
107A (EryF)37 and 2E1165, as presented in more detail in section 2.2.2.  
In ongoing work (Feenstra et al, unpublished results) on CYP102 (BM3), probabilities for 
substrate orientation based on statistics of substrate binding from MD simulations were 
combined with probabilities for substrate reaction based on QM calculations of H-atom 
abstraction by a hydroxyl radical.41 The experimental known preference for sub-terminal, 
distal hydroxylation of octane, octanoic acid, and lauric acid are reproduced. 
 
Molecular Dynamics Conclusions 
MD is used in various ways to study CYP-ligand interactions. As shown in Table 3, 
applications for homology model optimization and validation of model stability and the 
prediction of sites of catalysis in substrates are becoming common practice. Prediction of 
substrate and inhibitor binding affinity and orientation have been reliable in the cases of 
CYPs 101 (cam), 2B4 and 1A1, and combined with QM calculations on the substrate for 
predictions of product formation for CYPs 101 (cam), 107A (EryF), and 2E1 and in ongoing 
work for CYP102 (BM3). 
Currently, most MD studies have been limited to short (~100 picoseconds, ps) or even 
very short (~10 ps) simulation times and only a single simulation. A notable exception is 
Winn et al.110 who performed seventeen simulations of several hundreds of pico- to a few 
nanoseconds to describe substrate entrance to and product exit from CYPs 101 (cam), 102 
(BM3) and 107A (EryF). For a proper description of ligand dynamics, and conformational 
changes in the enzyme, simulation times exceeding tens or hundreds of nanoseconds may 
well be needed. 
 
2.4.4 Binding Affinity 
Binding Affinity Methods Background 
Binding affinity calculations of compounds to CYPs are a crucial ingredient to successful in-
silico ADME(T) approaches, e.g. in database screening applications and during early stages 
of drug discovery. Methods for calculating binding affinity fall into two major categories, 
one in which the structure of the protein is used, and one in which it is not. In the first 
category, the assumption is made that similarity in biological response is reflected by 
chemical similarity of the ligands, and the second considers geometrical and chemical 
complementarities between the ligand and protein.12 3D-QSAR methods belong to the first 
category and are discussed in 2.4.4. In the second category, scoring functions from 
automated ligand-protein docking programs (as described in section 2.4.2) can predict 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Molecular dynamics (MD) and Monte Carlo (MC) methods, as described in the previous 
section, 2.4.3, explicitly include the statistics of protein-ligand interactions and can 
therefore be considered as a more appropriate tool to include flexibility on a large scale243. 
Conformations derived from MD/MC are used in traditional free energy calculations, i.e. 
free energy perturbation (FEP) or thermodynamic integration (TI)244, and in the linear 
interaction energy (LIE) approximation152 to determine or predict the free energy 
difference between two states (e.g., one ligand in bound and unbound state, two ligands 
bound, or two mutant proteins).  
 
Binding Affinity Applications 
Scoring functions available in docking programs show little or no correlation with 
(experimental) binding affinity of CYP101 (cam)193, 2D6148, and 3A471. However, using LIE, 
the absolute and relative binding energies of 11 CYP101 complexes were generally well 
produced (mean errors of 0.55 and 0.77 kcal/mol respectively)74. Binding free energies of 
two out of three CYP1A1 substrates could be computed within 0.9 kcal/mol of 
experimentally observed values by LIE152 using coefficients from the previous study74. The 
binding free energy of camphor to CYP101 (cam) could be computed within 0.8 kcal/mol 
from experimental values by FEP with full treatment of solvent degrees of freedom203, 
while the binding free energy difference of S- and R-nicotine to CYP101 could be 
computed within 0.3 kcal/mol.34 Free energy of binding of methoxyflurane, benzphetamine 
and 4-phenylimidazole to CYP2B4 was calculated based on a homology model using a 
combination of MD simulations, normal modes analysis for estimating entropic contribution 
and Poisson-Boltzmann solvation energy (MMPB-SA), to within 0.5 to 2 kcal/mol.40 
 
Binding Affinity Conclusions 
Predictions of binding affinities based on the scoring functions of docking algorithms are in 
general not accurate, in contrast to 3D-QSAR affinity predictions for CYPs (see section 
2.4.4). The applications of FEP, LIE and MMPB-SA methods to CYPs 101 (cam), 1A1 and 
2B4 are significantly more accurate than the QSAR results, although they are limited to a 
more narrow range of chemical diversity and computationally much more costly. For e.g. 
the estrogen receptor for which ligands are much less diverse, successful application of 
LIE for a large set of ligands and a wide range of affinities is reported245. The challenges 
specific to CYP enzymes arise from specific characteristics of the CYP enzyme family, 
namely a very broad range of substrates, of which many are highly charged and/or highly 
flexible. It is known that the MD simulations and forcefields used in the FEP, LIE and 
MMPB-SA methods perform best for substrates with little or only moderate charge and 
flexibility. 
 
2.4.5 Conclusions Ligand-Protein Interactions 
Automated docking approaches are nowadays successfully applied for prediction of the 
site of catalysis in substrates for many CYP isoforms, for the refinement and optimization 
of CYP homology models (i.e. CYPs 1A2, 2B6, the 2C subfamily, 2D6, 2E1, 3A4, and 6B1) 
and for the construction of pharmacophore models (i.e. CYPs of the 2C subfamily). 
Docking is still not suitable for the quantitative prediction of ligand binding affinity, and 
structure-based in silico screening studies on CYPs have so far only been reported for 
CYP101 (cam), which may be attributed at least in part to lack of proper consideration of 
active site water and protein flexibility. MD simulations allow the inclusion of explicit water 
and full protein flexibility but at the expense of greatly increased computational demands. 
MD based methods have shown to be reliable for prediction of binding affinities for CYPs 
101(cam), 1A1, and 2B4, for finding a more comprehensive description of multiple sites of 
catalysis for several CYP substrates, and for exploring ligand binding in CYP homology 
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models and the protein flexibility of the homology model in more detail, e.g. for CYP2B6 
and CYP2D6. 
A remaining hurdle in the accurate calculation of CYP ligand binding affinity is the 
diversity of binding modes of substrates, reflected in a flexible binding cavity that is large 
in relation to the size of the substrates, and, subsequently, for many substrates the 
binding mode in CYPs is not as strictly defined as is the case for many other more 
substrate specific enzymes. This restricts the application of MD based methods that can 
provide the most accurate free-energy calculations. 
 
2.5 Summary & Conclusions 
2.5.1 Introduction 
Early consideration of properties of the cytochrome P450 (CYP) family of biotransformation 
enzymes involved in drug metabolism is increasingly seen as essential for efficient 
discovery and development of new drugs and drug candidates. Apart from the application 
of in vitro tools, this necessitates the application of in silico tools that can accurately 
predict metabolic properties of drug candidates already in early stages of the lead finding 
and optimization process.  
The state of the art of computational methods used in CYP modeling varies 
considerably, as does the reliability of the results obtained. This arises from limitations of 
the methods applied as well as from difficulties related to the complexity of the CYP 
enzymatic action itself. Mechanism-based quantum-chemical calculations on substrates 
and the enzyme, pharmacophore modeling of ligands and protein homology modeling in 
combination with automated docking and molecular dynamics simulations have been used 
for the rationalization and prediction of ligand binding and metabolite formation. A 
remaining challenge in predicting product formation by CYPs is the elucidation of the 
relevant reactive heme-iron-oxygen species that is ultimately responsible for the chemistry 
of the enzyme reaction, and the coupling between the kinetics of the reaction cycle of the 
heme-iron-oxygen moiety and the dynamics of substrate and oxygen and the release of 
product. It may be concluded that not one computational approach is capable of 
rationalizing and reliably predicting metabolite formation by CYPs, but that it is rather the 
combination of the various complimentary approaches. 
The primary aim of this paper was to present an integrative modeling approach to 
understand, rationalize and predict the activity and substrate selectivity of CYPs, as well as 
the possibilities and limitations of these approaches now and in the future. Software that 
implements these computational methods and has been applied to CYPs is listed in Table 
4. We divided the models and methods into ligand based, protein based, and ligand-
protein interaction based. Results for (ligand based) pharmacophore models are listed in 
Table 1, for (protein based) crystal structures in Table 2 and homology model structures 
in Table 3. Results for ligand-protein interaction based models were presented in section 
2.4, and are mentioned in some instances for pharmacophore models in Table 1 and 
homology models in Table 3. In the following sections, a summary and general 
conclusions will first be presented for the different modeling methods applied to CYPs, 
then for each of the most important CYP isoforms, and finally for CYPs in general. 
 
2.5.2 Methods 
Quantitative structure-activity relationship (QSAR) approaches, derived from 
physicochemical and topological properties or the 3D structure of CYP ligands, have been 
used often for the prediction of drug metabolism by CYPs.19-21 A pragmatic, rapid and 
rather successful approach to this are topological screening methods recently developed 
for some CYPs, which provide robust but rough classifications of inhibitory potency of 
ligands without much insight in the possible (molecular) background of the mode of 
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action.23 The structure-based molecular modeling methods on the other hand, aim to be 
insightful as well as predictive.  
Intrinsic regio-selective susceptibilities of molecules to CYP metabolism have been 
predicted using available quantum mechanical (QM) methodologies for CYPs, and 
significant improvements in the prediction of site of catalysis have been achieved for 
several CYPs by inclusion of known or predicted substrate binding orientations in the 
active site or of relative substrate orientations in pharmacophore models.34,35,37,165 Further 
improvements have been seen from including a description of the relevant heme-iron-
oxygen activated reactive species at a higher level in the QM calculations.25,27 Additional 
improvements were seen from inclusion of more of the active site and protein 
surroundings that can have a significant influence on electronic properties and activation 
energies of the substrate mainly through electrostatic interactions (Feenstra et al. 
unpublished results). Classical CYP pharmacophore models have been successful for the 
prediction of qualitative properties like substrate selectivity and site of catalysis, and the 
more recent 3D-QSAR pharmacophore models have in addition been used for the 
quantitative prediction of binding affinities19,21, as is listed in Table 1. 
The growth in available CYP protein structures from X-ray crystallography, presented in 
Figure 8, has inspired several investigators to detailed analysis of CYP structure and of 
CYP-ligand interaction8,111,135-138, and it has been the basis for much homology modeling 
work44,142, see Table 2 for crystal and Table 3 for homology model structures. In this 
respect, homology structures have been complementary to crystal structures, especially 
for the mammalian CYPs now that mammalian crystal structures have very recently 
become available.14,16,131,132,246 Several CYP isoforms have only been crystallized in a non-
active ligand-bound state, and for some it is not known whether the crystal structure 
corresponds to an active state or not.14,96,97 It is important to realize that this may make 
the crystallized structure of a certain CYP isoenzyme not directly applicable to e.g. 
explaining observed substrate selectivity and product formation of the enzyme. Ligand-
induced changes in the size, shape and hydration of the active sites of several CYPs are 
also observed105,114,139-141, and these are likely to undelie the capacity of many CYPs to 
metabolize structurally diverse substrates of different sizes and to generate different 
metabolic products from these substrates.  
Automated docking approaches186 are successfully applied for prediction of the binding 
mode of ligands and for prediction of sites of catalysis in substrates for several CYP 
isoforms, for the refinement and optimization of homology models10,69-71,146,150,165,169,173 and 
for the construction of pharmacophore models.41,61,70,71,76,77 Docking is still not suitable for 
quantitative prediction of ligand binding affinity71,148,193, which may be attributed at least in 
part to the lack of proper consideration of active site water and protein flexibility.18,191 
Structure-based in silico screening studies on CYPs have so far been reported only for 
CYP101 (cam).59,193,194 Molecular dynamics based methods for prediction of binding 
affinities34,40,74,152,203, for finding a more comprehensive description of multiple sites of 
catalysis in substrates34-37,165, for exploring ligand binding and for exploring protein 
flexibility of CYP crystal structures and homology models in more detail104,106-110,204, have 
shown to be more reliable in several cases. 
 
2.5.2 CYP Isoforms 
Results and conclusions for the most studied, and most interesting, CYP isoforms are 
summarized for each isoform, and additional details of the relevant data and references 
can be found in the method sections 2-4 and in the Tables 1-3. Bacterial and 
eukaryotic isoforms, and general conclusions are treated in three separate sections. 
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Bacterial CYPs 
CYP101 (cam) was the first CYP to be crystallized112, and remains the most extensively 
studied CYP by X-ray crystallography. Based on this first structure and the very many 
ligand-bound and ligand-free structures solved later, extensive QM, docking, and MD 
studies have been performed, as well as homology model building for other isoforms. Only 
minor ligand-induced conformational changes in the protein were observed in the crystal 
structures. Calculations on the protein structures revealed water channels and proton-
transfer pathways136,137, but did not clearly show possible substrate access and product 
exit channels.111 Analysis of B-factors and MD-simulations revealed the existence of several 
distinct access/exit channels.104,108,109 Differences in entrance and exit mechanisms in CYPs 
102 (BM3) and 107A (EryF) are thought to contribute to substrate recognition for these 
isoforms.110 Substrate binding has been studied by automated docking to accurately 
predict substrate catalytic sites and for the selection of substrates and inhibitors from 
databases.59,193,194 Substrate binding affinities and free energy of hydration of the active 
site of CYP101 were calculated based on MD simulations.34,35,74,135,203 QM calculations of 
the rate-limiting H-atom abstraction step of C-H hydroxylation reactions of the enzyme, 
based on conformations from MD simulations, could describe additional details of product 
formation, and supported a two-state abstraction/oxygen rebound mechanism of the CYP 
mono-oxygenase activity.34-36 
CYP102 (BM3), the second CYP to be crystallized, spurred much MD and homology 
modeling work. The ligand-bound and ligand-free conformations differ considerably and 
these differences revealed the existence of a substrate access and product exit channel105. 
MD simulations have given plausible descriptions of the ligand-induced changes and could 
confirm the access and exit channels as well.106,107 Calculations on the structures revealed 
water channels and proton-transfer pathways.136 Even in the ligand-bound structures the 
distances between ligand and the heme-iron catalytic center are too large for catalytic 
activity, and additional conformational changes driven by the electron-transfer process are 
thought to precede substrate metabolism.96-98 Differences in entrance and exit 
mechanisms with CYPs 101 (cam) and 107A (EryF) are thought to contribute to substrate 
recognition for these isoforms.108-110 Analysis of correlated dynamics in MD simulations 
revealed three domains in the protein, while analysis of the protein structure only 
identified two.204 Catalytic site prediction in substrates based on docking, MD simulations 
and QM calculations is the subject of ongoing work (Feenstra et al, unpublished results). 
For CYP107A (EryF) several ligand-bound crystal structures have been solved and QM, 
docking, and MD studies have been performed, and in combination with some other 
bacterial CYPs used for homology model building for other isoforms. Ligand-induced 
conformational changes were observed in different ligand-bound crystal structures.114 
Calculations on the structures revealed water channels and proton-transfer pathways.136 
MD simulations revealed the existence of several distinct access/exit channels.110 
Differences in entrance and exit mechanisms with CYPs 101 (cam) and 102 (BM3) are 
thought to contribute to substrate recognition for these isoforms.110 QM calculations of the 
formation of the twice-reduced activated oxygen species, based on conformations from 
MD simulations, could describe additional details of product formation, and identified 
Glu360 as a plausible source for the proton necessary in this reaction.37 
For CYP108 (terp) one ligand-free crystal structure has been solved, and in combination 
with some other bacterial CYPs it has been used for homology model building for other 




Early eukaryotic homology models, as reviewed by Ter Laak et al44, have been based on 
bacterial template crystal structures, e.g. CYPs 101, 102, 107A and 108. Most have since 
Chapter 2 
 78 
been superseded by newer models based, at least in part, on more appropriate eukaryotic 
template crystal structures, mainly CYP2C5. It stands to reason that in the near future new 
homology models will be built using the new CYP3A4 and CYP2C9 crystal structures as 
well. 
For the CYP1A1 and CYP1A2, several pharmacophore models have been constructed64, 
and homology models64,152,154 have been built based on the CYP101 and CYP102 crystal 
structures and later CYP2C5 crystal structures. Details of the alignment and structure of 
the homology models have been improved based on CYP1A1/2 pharmacophore models, 
and validated using a combination of 3D-QSAR and automated docking. Substrate binding 
affinities have been calculated for CYP1A1 with linear interaction energy calculations, 
based on the homology model structure. 
For several members of the CYP2A subfamily, i.e. 2A1/4/5/6, pharmacophore models67 
and homology models156,157, based on the CYP102 and CYP2C5 crystal structures, have 
been constructed separately, and recently X-ray crystal structures of CYP2A6 have been 
solved.129 
For several members of the CYP2B subfamily, i.e. 2B1/2/4/5/6, homology 
models40,69,149,159-161 have been built based on the CYPs 101, 102, 107A, 108 and 2C5 
crystal structures, and QM, docking, and MD studies have been performed. For CYP2B4 
recently an open, unbound246 and a closed, inhibitor bound130 X-ray crystal structure have 
been solved and extensive conformational changes in the regions between helices B and C 
(where helix B’  can be present) and between helices F and G are observed.  Two CYP2B6 
homology models69,150 based on the CYP2C5 crystal structure have been the most 
extensively refined and validated using pharmacophore models, automated docking, MD 
simulations and CYP2B subfamily isoenzyme specificity. Ligand binding and spin-state 
equilibria were found to be connected in QM studies on CYP2B4, and in combination with 
conformations from MD simulations additional details of product formation could be 
described.40 
For CYP2C5 ligand-bound101,141 and ligand-free131 crystal structures have been solved, 
which have been used extensively for homology model building work for other isoforms. 
Ligand-induced conformational changes, multiple substrate binding modes and water-
mediated ligand binding were observed in different ligand-bound crystal structures. 
CYP2C9 was the first human CYP for which a crystal structure was solved14, see Figure 
2-A. Many QM, 3D-QSAR, docking, and MD studies have been performed. Pharmacophore 
(mostly 3D-QSAR)41,43,45,46,61,75-79 and homology models41,70,162, based on crystal structures 
of CYPs 101, 102 and 2C5, have been constructed separately as well as in conjunction 
with each other. The homology model structures have been extensively refined and 
validated using pharmacophore models, automated docking and MD simulations. 
Pharmacophore models for CYP2C9 inhibitors and substrates predict binding affinities 
reasonably well, and suggest substrates bind an aromatic and a cationic site for which 
respectively F476 and R108 were suggested based on homology modeling work. 
Involvement of these residues was confirmed by site-directed mutagenesis experiments. 
The first ligand-bound CYP2C9 crystal structure shows interactions with F47614, see 
Figure 2-A, while in contrast to this, a more recent substrate bound crystal structure 
shows interactions with F114 and R10815, see Figure 2-B. 
For several members of the CYP2C subfamily, i.e. 2C8/9/18/19, homology models have 
been built70,71,163 in conjunction with a pharmacophore model, based on the CYPs 101, 
102, 107A, 108 and 2C5 crystal structures, and many QM, 3D-QSAR, docking, and MD 
studies have been performed. The very recent CYP2C8 crystal structure132 adds to the 
growing experimental structural basis for homology modeling work of human CYPs. 
Predictions of CYP2C subfamily isoenzyme specificity were based on 3D-QSAR, docking, 
and MD studies. 
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For CYP2D6, homology models based on crystal structures of CYPs 101, 102, 107A, 108 
and 2C5 have been constructed4,10,56,69,81,98,142,145-147 separately as well as in conjunction 
with each other. The homology model structures have been extensively refined and 
validated using automated docking, MD simulations and comparison with site-directed 
mutagenesis studies and NMR spin-relaxation rate measurements. The latest CYP2D6 
homology model is shown in Figure 3-A. Many QM, pharmacophore, docking and MD 
studies have been performed. Gas phase QM calculations involving radical formation, 
redistribution and recombination could rationalize CYP2D6 metabolite formation30,32. 
Pharmacophore models (notably 3D-QSAR) 48-51,56,57,69,80-83 for CYP2D6 inhibitors and 
substrates predict binding affinities well, and suggest substrates bind two or three 
aromatic/hydrophobic sites and a carboxylic site for which F120 and F483, respectively 
E216 or D301 were suggested in combination with homology modeling work and 
supported by mutagenesis studies. Figure 4 shows molecular interaction fields for 
dextromethorphan overlaid on the corresponding sidechains in the CYP2D6 active site. 
Differences between rat CYP2D isoforms (2D1/2/3/4) and human CYP2D6, and details of 
the 2D6 active site topology, could be described by the electrostatic properties of the 
active site and hydrophobic substitutions at the 120 position.10 Very recently a substrate-
free CYP2D6 crystal has been solved133, which is described in Chapter 3 in more detail. 
For CYP2E1, pharmacophore43 and homology models164,165 based on the CYPs 102, 2C5 
and 2C9 crystal structures, have been built, and QM, docking, and MD studies have been 
performed165. The homology models were refined by comparison of species differences 
between rat, mouse and human, and validated by catalytic site prediction based on QM, 
docking and MD calculations for several substrates. QM calculations on substrate radical 
species, based on conformations produced by docking and MD simulations, could predict 
binding affinities and could describe additional details of product formation. These 
calculations supported a hydrogen-abstraction mechanism of the CYP mono-oxygenase 
activity involving radical intermediates. 
For CYP3A4, homology models have been built71,146,169 based on the CYP 101, 102, 107A, 
108 and 2C5 crystal structures, and QM, 3D-QSAR, docking, and MD studies have been 
performed. Very recently ligand-bound16 and ligand-free16,134 crystal structures have been 
solved. The highest resolution ligand-free structure is shown in Figure 2-C. The 
homology models were refined and verified using automated docking, MD simulations, QM 
calculations and comparison with pharmacophore models.39,166,167 3D-QSAR 
pharmacophore models could predict ligand binding affinities accurately. QM calculations 
of the rate-limiting H-atom abstraction step of a C-H hydroxylation reaction of the enzyme, 
based on conformations from MD simulations, could predict plausible catalytic sites in a 
number of substrates and, in combination with the homology model protein structure, 
could describe stabilizing and cooperative effects of multiple ligand binding. 
For CYP19 (arom), pharmacophore models have been developed90-92 and homology 
models have been built177,178 based on the CYP 101 and 102 crystal structures. The 
homology models were refined and verified using predictions of catalytic sites and 
comparison with pharmacophore models. 3D-QSAR pharmacophore models could predict 
inhibitor binding reasonably well. 
For CYP51 (14α), pharmacophore models have been developed93-95 and homology 
models have been built180 based on the CYP 101, 102 and 107A crystal structures. Several 
ligand-bound and ligand-free crystal structures have been solved and MD studies have 
been performed. Ligand-induced conformational changes were observed in different 
crystal structures.140 The homology models were refined and verified using MD simulations 
and comparison with pharmacophore models. 3D-QSAR pharmacophore models could 




CYPs in General 
The bacterial CYPs 101 (cam), 102 (BM3), and 108 (terp) were used for building the first 
structural alignment8 and later a new alignment was built with the addition of 107A (EryF), 
from which also an identification of common structural building blocks (CSBS) was 
made.143 This alignment and the CSBs have been the basis of many homology models for 
other CYP isoforms. Identification of substrate recognition sites (SRS’s) was based on 
additional alignment of the bacterial CYPs with members of the CYP2 subfamily9. The 
SRS’s are shown structurally and topologically in Figure 3. 
CYPs generally have broad substrate selectivities and often substrates are found in 
multiple binding modes99-101, instead of in a shape-complementary fit that is common for 
other enzymes with high specificities (and some CYPs as well). For several CYP isoforms it 
is known that water-mediated ligand binding plays an important role.15,101,141  
Another important factor is the possible effect of atomic or molecular oxygen bound to 
the heme iron, and to know which oxygen species, if any, is present during ligand binding. 
Moreover, a balance exists between the kinetics of the heme-iron-oxygen reduction and 
the dynamics of the substrate binding. Changes in the oxygen species may occur faster 
than substrate binding orientation relaxation times, leaving the substrate during the actual 
reaction in an orientation that was optimal for a previous, but no longer present oxygen 
species. Additionally, the existence of substrate-bound crystal structures where the 
substrate apparently is not in a catalytically active position with respect to the heme-
iron14,96,97 may indicate the importance of the kinetics and dynamics of substrate binding 
and oxygen binding and reduction.98 
 
2.5.4 Future Prospects 
The previous sections have described the development of several modeling methodologies, 
and successful applications to understanding CYP structure and enzyme function, and 
predicting CYP metabolic activity. This field of computational medicinal chemistry and 
molecular toxicology is rapidly evolving. Current applications of several techniques can be 
expected to become more widespread, and (more) combinations of methods can be 
expected to be successful as well. This will be covered in the next section. Expected future 
developments of novel methodologies and of the application of existing methods not yet 
applied to CYPs, is covered in the final section 2.5.4.  
 
Current Applications 
A number of pharmacophore models have been derived for CYPs, either based on suitable 
template molecules or on a variety of substrates or inhibitors when a single compound 
was inappropriate as a template molecule.19,21 Several of these pharmacophore models, 
among which are those of CYP2D656,81 and CYP2C961, have been shown to have a good 
predictive value concerning qualitative metabolism and substrate/inhibitor selectivity, a 
property especially relevant for isoenzymes which are subject to genetic polymorphisms 
(e.g., CYP2D6 or the CYP2C subfamily). Despite potential benefits (especially for the 
pharmaceutical industry), the development of pharmacophore models for 
biotransformation enzymes has received relatively little attention yet, in contrast to 
pharmacophore models for receptor ligands. 
For the prediction of catalytically susceptible sites in the substrate, further improvements 
have been achieved by including a description of the relevant heme-iron-oxygen activated 
reactive species at a higher level in the QM calculations.25,27 Additional improvements were 
seen from inclusion of more of the active site and protein surroundings25 that can have a 
significant influence on electronic properties and activation energies of the substrate 
mainly through electrostatic interactions (Feenstra et al., unpublished results).  
An emerging role of pharmacophore/QSAR models is to consolidate available 
experimental data on substrates and inhibitors and to combine these with structural details 
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included in CYP X-ray crystallographic or homology model structures.56,71,76,81 On the other 
hand, the use of alignment and conformer independent models make it possible to build 
models without an alignment rule for chemically diverse ligands and without the use of 
information about the protein structure61. Predictions based on QM calculations on 
substrates will likely be used as a complementary source of information obtained from 
pharmacophore/QSAR models. 
It has been shown for CYP2D610,142 and CYP2C941,70 that good protein homology models 
can be built for CYPs, and used to obtain useful information concerning amino acids 
important for substrate and/or inhibitor binding. Due to relatively low sequence and 
structure homology in the ligand-binding site region of some CYPs, these predictions, 
however, have to be experimentally verified and carefully considered. For elucidation of 
the role of specific amino acids in the catalytic activity of CYPs, homology models are used 
as well to rationalize observed differences, however, the activities cannot yet be predicted 
accurately. Indications of substrate selectivity can be obtained qualitatively on the basis of 
homology models in specific cases, although these predictions should always be 
experimentally verified and carefully considered as well.  
The trend in CYP homology model building is clearly towards an integrated approach of 
multiple sequence and structural alignments, combination with new or available 
pharmacophore models, automated docking, molecular dynamics simulations and 
validation with mutational, spectroscopic, structural and enzyme kinetic data.10 Predictions 
of selectivity and site of metabolism have been successful for homology models of many 
CYP isoforms, and, for example, recent models of CYP2D6 show very good agreement 
with site-directed mutation studies as well18,148. Furthermore, the use of homology 
modeling building methods to enrich X-ray crystallographic structures with other 
experimental data, e.g. biochemical or spectroscopical, on activities and binding 
orientations of substrates, is a topic of ongoing research and expected to become 
important in the near future. 
CYPs generally have broad substrate selectivities and often substrates are found in 
multiple binding modes101, instead of in a shape-complementary fit that is common for 
other enzymes with high specificities (and some CYPs as well). This makes statistical 
considerations like relative weights of different binding modes crucial and in addition 
increases the flexibility of ligands within each binding mode109(Feenstra et al. unpublished 
results). Energetic consideration of detailed ligand-protein interactions gives insight in the 
(relative) importance of different sites of interaction between the ligand and the protein. 
Finally, the inclusion of explicit water molecules in the active site allows the elucidation of 
the (mediating) role of water in ligand binding.18,203 A remaining hurdle in the accurate 
calculation of CYP-ligand binding affinity is the prediction of multiple binding modes for 
substrates, reflected in a flexible binding cavity that is large compared to the size of the 
substrates, and, subsequently, for many substrates the binding mode is not as strictly 
defined as is the case for many other more substrate selective enzymes. This restricts the 
application of MD based methods that can provide the most accurate free-energy 
calculations. 
Evaluation of different scoring functions, docking algorithms and pooling of docking 
results from different programs, has been shown to be critical in obtaining good results for 
ligand docking in CYP crystal structures18 and also make docking into homology model 
structures feasible.247 Much additional gain is expected from these methodological 
developments. Moreover, addition of water bound at specific (predicted) locations in the 
active sites is the topic of current investigations and is expected to significantly improve 
the quality of docking results18. Another important factor is the possible effect of atomic or 
molecular oxygen bound to the heme iron, and the oxygen species, if any, present during 
ligand binding. Obviously, a balance exists between the kinetics of the heme-iron-oxygen 
reduction and the dynamics of the substrate binding. Changes in the oxygen species may 
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occur faster than substrate binding-orientation relaxation times. In that case, during the 
actual reaction the substrate may be left in an orientation that was optimal for a previous, 
but no longer present, oxygen species. This important issue has only occasionally received 
attention in literature, e.g., some studies were performed using MD simulations that 
investigate the formation of the active, bound complex with subsequent QM calculations of 
the reactivity.165 Additionally, the existence of substrate-bound crystal structures where 
the substrate apparently is not in a catalytically active position with respect to the heme-
iron may indicate the importance of the kinetics and dynamics of substrate binding and 






















Figure 10: The integrative modeling approach of cytochromes P450; schematic arrangement of 
modeling methods and the division into ligand-based, protein-based and ligand-protein interaction-
based methods, with relationships between methods and between method groups indicated with 
arrows. Ligand-based methods are quantum-mechanical (QM) calculations and classical and QSAR 
pharmacophore models, Protein-based methods are X-ray crystallography, protein homology model 
building and protein structure analysis; and Protein + Ligand-based methods are automated ligand 
docking, molecular dynamics (MD) simulations and affinity prediction calculations. 
 
Expected New Developments 
Generally speaking, it is clear that computational approaches in parallel with high(er) 
throughput experimental technologies are among the newer and fast developing 
approaches in drug discovery, drug metabolism, and toxicology. New links with other 
current developments, such as in neural network computing, genomics, proteomics and 
bioinformatics are within reach and successful exploitation of these links will allow signifi-
cant progress towards in silico prediction of drug activity, drug metabolism and toxicity10. 
Future developments towards a more complete in silico prediction of ADME(T) will need 
more accurate models for the prediction of drug absorption (A), disposition (D) and 
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(T). Furthermore, in general a better understanding of the key issues in drug activity 
should be developed.2,248 This type of pre-experimental prediction of non-pharmacological 
drug-properties with in silico ADME(T) screening1 is likely to be one of the challenging 
developments with a great scientific and practical impact. 
It has been shown that a great variety of in silico modeling approaches have been 
applied to CYP enzymes, thereby successfully adding to our understanding of CYP 
structure and function in a way that is complementary to experimental studies. Another 
clear trend in many recent computational studies is the combination of several modeling 
techniques to arrive at meaningful and successful rationalization of experimental data, and 
interpretations and predictions of CYP function. Indeed, much of the recent progress in 
this area stems from integration of different computational methods, as well as 
improvements of individual methods. In Figure 10, the integration of computational 
approaches is shown as connections between the modeling methods, and it is clear that 
not only between methods within the ‘ligand-based’, ‘protein-based’ and ‘ligand-protein 
interaction based’ groups of methods, but also between the three groups, extensive 
methodological connections are present. It is our conclusion that these connections, in 
fact, are due to a necessity of combining existing methodology into an integrative in silico 
approach for modeling of CYP function, which is the key for efficient, reliable and 
successful application of in silico approaches. Finally, it is concluded that the combination 
of new computational methods and solid experimental data will prove to be critical and 
essential for the elucidation of as yet unknown functional and structural properties and 
mechanisms of CYPs. 
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Experimentally, the active site of CYP2D6 can be probed by site directed mutagenesis 
studies. Such studies can be designed from structural models of enzyme-substrate 
complexes and the observed effect of mutations on metabolism and inhibition can 
subsequently be rationalized at an atomic resolution by modeling approaches. The current 
chapter will present the construction, refinement and validation of the CYP2D6 homology 
model used in our laboratory for the prediction and rationalisation of CYP2D6 substrate 
metabolism and CYP2D6-ligand interactions. The protein model could explain previously 
reported site-directed mutagenesis data (for example, mutations of E216 and D301). 
Furthermore, based on the model, new CYP2D6 mutants were constructed and studied in 
our laboratory, and also for these mutants a rationalization of experimentally observed 
characteristics could be achieved (I106E, F120A, T309V, F483A). CYP2D6-substrate 
interaction fingerprint analysis of docked substrates in our homology model suggests that 
several other active site residues are probably interacting with ligands as well, opening the 
way for further mutagenesis studies. Importantly, our homology model was found to 
agree with most of the details of the recently solved substrate-free CYP2D6 crystal 
structure [Rowland et al. J Biol Chem 2006, 281, 7614-7622]. Structural differences 
between our homology model and the crystal structure were the same as the differences 
observed between substrate-free and substrate-bound structures of other CYPs, 
suggesting that these conformational changes are required upon substrate binding. The 
CYP2D6 crystal structure further validates our homology modeling approach and clearly 
demonstrates on one hand the success and accuracy of state of the art CYP homology 
modeling. On the other hand, we show that computational chemistry is a useful and 
valuable tool to provide models for substrate-bound complexes of CYPs which give insight 











Cytochromes P450 (CYPs) are heme containing enzymes which can be found in virtually all 
living organisms. This large family of enzymes is capable of oxidizing and reducing a broad 
range of endogenous and exogenous substrates, such as steroids, carcinogens and 
drugs.1,2 In humans one of the most relevant drug metabolizing CYPs is CYP2D6. Although 
the expression levels of CYP2D6 are only 2% of all hepatic CYPs, following CYP3A4, it is 
the second most important drug metabolizing enzyme, involved in the metabolism of 
about 15-30% of the currently marketed drugs, including β-blockers, neuroleptics, 
antidepressants and antiarythmics.3-5 Large interindividual differences exist in CYP2D6 
activity, due to gene multiplicity and polymorphisms, thus further increasing its clinical 
importance.6,7 The rationalization and prediction of potential CYP2D6 substrates is 
therefore advantageous in the discovery and development of new drugs. 
A wealth of detailed information on CYP enzyme action and substrate or inhibitor 
interactions with the binding cavity becomes accessible when a structure of the CYP 
protein is available. In the past few years, crystal structures of many mammalian CYPs 
have become available: CYP2A68, CYP2B49,10, CYP2C511-13, CYP2C814, CYP2C915,16, and 
CYP3A4.17,18 Very recently, a substrate-free crystal structure of CYP2D6 was solved.19 
Comparisons between ligand-bound and ligand-free crystal structures of many CYPs 
however, showed ligand induced changes in size, shape and hydration of the active site. 
Therefore the construction of properly validated three-dimensional structural models 
describing substrate-bound complexes of CYP2D6 are still necessary to obtain knowledge 
on CYP2D6 structure and function, leading to a better understanding, rationalization and 
prediction of the catalytic activity, ligand specificity, and regiospecificity of metabolism of 
this CYP isoform. Such a computational structural model can be used in combination with 
other modeling techniques, like automated docking and molecular dynamics simulations, 
to design site-directed mutagenesis experiments to explore the active site for amino acid 
residues determining ligand binding and regiospecificity of metabolism by CYP2D6. The 
primary aim of this chapter is to present the building, refinement and validation of a 
CYP2D6 homology model and its usage to explain and design experimental site-directed 
mutagenesis studies. The evolution of this CYP2D6 model can be considered, as a case 
study demonstrating the possibilities and limitations in the development, validation and 
application of enzyme homology models. 
The increased number of available CYP protein structures from X-ray crystallography has 
been the basis for much homology modeling work (see Chapter 2).20,21 In this respect, 
homology models have been complementary to crystal structures, especially for the 
mammalian CYPs now that mammalian crystal structures have very recently become 
available. Several CYP isoforms have only been crystallized in a non-active ligand-bound 
state, and for some it is not known whether the crystal structure corresponds to an active 
state or not.15,22,23 It is important to realize that this may render the crystal structure of a 
certain CYP isoenzyme not directly applicable to e.g. explaining observed substrate 
selectivity and product formation by the enzyme. Ligand-induced changes in the size, 
shape and hydration of the active sites of several CYPs are also observed13,24-27, and these 
are likely to underlie the capacity of many CYPs to metabolize substrates that are diverse 
in size and structure and to generate different metabolic products from these substrates. 
In all known CYP crystal structures available today, the same general three-dimensional 
fold is observed. A recent structural alignment of CYP crystal structures showed that over 
28% of structurally aligned residues have their C-alpha atoms within a root-mean-square 
deviation of 2Å. This conserved core region contains the C-terminal half of helix I, helices 
L, E, K, and K’, and the heme coordination region.28,29 The three-dimensional structure of 
these regions is well conserved despite a low sequence homology (as low as ~15%).29 
Other regions (e.g., the active site region containing the B’ helix, the loops between 
helices C and D, the region spanning helices F and G, and most of the β-strands) are more 
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variable. The largest structural variations are found in the B’ helix and helices F and G and 
their connecting loop. These regions are suggested to be involved in substrate access and 
recognition.29,30 Six substrate recognition sites (SRS’s) have been assigned based on 
mutagenesis and sequence alignment studies with representative members of the CYP2 
family and CYP101 (cam).31 However, the modeling studies on CYP2D6 presented in this 
chapter suggest that only specific amino acid residues located in these SRSs are actually 
directly involved in CYP2D6-ligand binding (e.g. F12032 (SRS 1) and F48333 (SRS 6)), while 
other residues have an indirect effect on ligand binding and catalysis by i) influencing the 
protein conformation and shape of the active site (e.g. I10634 (SRS 1)); ii) stabilizing 
catalytically active heme-oxygen intermediates (e.g. T30935 (SRS 4)); iii) controlling 
substrate entrance and/or product exit from CYP2D6 (see Chapter 8).  
The current chapter will present the construction, refinement and validation of the 
CYP2D6 homology model used in this thesis and other work32-37 for the prediction and 
rationalisation of CYP2D6 substrate metabolism and CYP2D6-ligand interactions. The 
structure has been used to explain reported site directed mutagenesis data. Furthermore, 
the homology model is compared with the recently solved substrate-free CYP2D6 crystal 
structure19, discussing and demonstrating the value of computational chemistry in 
describing substrate-induced conformational changes in protein structures. This chapter 
will finally describe the design of site-directed mutagenesis studies from molecular 
modelling, exploring the active site of CYP2D6 for key determinants in CYP2D6-mediated 
ligand binding and metabolism. The experimental results of these mutagenesis studies, 
performed in our laboratory, are described in more detail elsewhere.32-36 
 
3.2. Homology modeling of CYP2D6 
A protein homology model of human CYP2D6 was constructed based on the crystal 
structures of rabbit CYP2C5 in complex with dimethylsulphophenazole derivative and a 
second structure of rabbit CYP2C5 in complex with diclofenac (PDB codes 1N6B11 and 
1NR613, respectively). In general, homology modeling, model refinement and model 
validation was performed according to the approach described earlier by Venhorst et al. 38. 
A flowchart scheme of the homology modeling, refinement, and validation process is 
shown in Figure 1. 
Using the amino acid alignment shown in Figure 2 (step 1), a hundred CYP2D6 models 
were generated with the restraint-based comparative modeling program Modeller39 (step 
2). The primary structures of CYP2C5 and CYP2D6 share 43% sequence identity and 68% 
sequence homology. Subsequently, three models were selected with best protein 
conformation and amino acid environment (step 3, Table 1). Finally, one single model 
was selected which could accommodate codeine best in the experimentally determined 
binding orientation (step 4). The final model is optimized and refined using the known 
ligand-based CYP2D6 pharmacophore model and geometry optimization (step 5).  This 
optimized model was validated and used in several applications that are described in this 
thesis (step 6). First, its ability to reproduce substrate binding orientations that lead to the 
formation of experimentally observed metabolites and its ability to perform virtual 
screening (VS) for high affinity CYP2D6 substrates in automated docking (AD) studies was 
explored (Chapter 5). Second, the substrate binding poses predicted by automated 
docking could be used to identify important active site residues influencing CYP2D6-
mediated metabolism (this chapter and refs 32-37). Third, a combination of docking and 
molecular dynamics (MD) was used to predict the regio- and stereo-specificity of catalysis 
of MDMA (methylenedioxymethamphetamine) and MDMA-analogs (Chapter 6). Fourth, 
the relative binding affinity of propranolol stereo-isomers towards wild-type and mutant 
CYP2D6  was rationalised (Chapter 7). Finally, the substrate access and product exit 
channels in the model were explored using random acceleration molecular dynamics 
(RAMD, Chapter 8).  





























Figure 1: Flow chart summarizing the construction, optimization, and validation of the protein 
homology model of CYP2D6 described in this chapter. The construction phase is covered in the first 
four steps: amino acid alignment to template X-ray crystal structures, model building and two 
subsequent steps of model selection. The model is optimized and refined using the known ligand-
based CYP2D6 pharmacophore model and geometry optimization. Validation studies of the final 
model, described in chapters 3, 5, 6, 7, 8 and refs 32-37 (in brackets), are enclosed by a dashed 
box. Molecular modeling methods and software programs used in the different steps are shown in 
Italics.  
Captions: a) Sequence alignment program40; b) Secondary structure prediction performed with Predict 
Protein41, JPred42, and NnPredict43; c) Comparative homology modeling program39; d) Program to 
evaluate the stereochemical quality of protein structures44; e) Program to evaluate the amino acid side 
chain environment (packing quality) of protein structures45; f) Program to measure the compatibility of a 
protein model with its sequence46; g) Automated docking (AD) performed with AutoDock47, FlexX48, 
GOLD-Goldscore49, GOLD-Chemscore50, CScore, SCORE51, and GRID52; h) Molecular dynamics 
simulations (MD) and energy minimization (EM) performed with Gromacs53 and the GROMOS force 
field54; i) Following the features of CYP2D6 pharmacophore models desrcribed before (e.g. refs 55-63); j) 
3D-QSAR performed with GRID/Almond64; k) (Random Accelleration) MD65 performed with AMBER66 
 
Template selection and amino acid sequence alignment 
The high degree of structure conservation among CYP crystal structures28,29, especially 
among crystal structures of members of the CYP2 family29, suggests that it should be 
possible to derive models of overall good quality for CYP2D6 using recently published 
substrate-bound CYP2C5 crystal structures (pdb codes 1N6B and 1NR6).11,13 These 
structures have a significantly higher resolution than the first resolved mammalian CYP 
crystal structure, the ligand-free CYP2C5 structure (1DT6)12, in which the F-G-loop is not 
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resolved at all. The substrate-bound CYP2C5 structures show high overall structural 
similarity (superimposing all C alpha atoms yields an RMSD of 0.7 Å), but are structurally 
different in portions of substrate binding pocket (B’, F and G helices). Inclusion of multiple 
templates is shown to improve the final quality of CYP homology models. In addition to 
the CYP2C5 structures, many more mammalian CYP crystal structures have been solved in 
the past few years. These structures became available during or after the performance of 
the modeling studies described and referred to in this chapter. It is not expected that the 
inclusion of these templates in the CYP2D6 modeling process would yield significantly 
better homology models as the latest crystallized CYPs do not have significantly higher 
sequence similarity (CYP2A6 (35%), CYP2B4 (40%), CYP2C8 (41%), CYP2C9 (40%), 
CYP3A4 (18%)). Secondly, for many of the latest mammalian CYP crystal structures 
regions which are part of or close to the active site are badly resolved or not resolved at 
all (e.g. F-G loop in CYP2C9 (1R9O) and CYP2D6 (2F9Q)). Thirdly, many of the new 
structures are believed to be in a catalytically non-active state, in which i) one CYP 
monomer is docked into the active site of the other monomer (1PO5 (CYP2B4); ii) the 
substrate is in the active site, but too far from the heme catalytic center (e.g. 1OG5 
(2C9)); iii) the substrate is binding to a peripheral binding site (e.g. CYP2C8 (1PQ2), 
CYP3A4 (1W0F)). Finally, the CYP2A6 structure is not believed to be more suitable for 
modeling CYP2D6 than CYP2C5, as the size of typical CYP2A6 substrates is much smaller 
than the size of typical CYP2D6 substrates (and therefore probably also the sizes of 















Figure 2: Amino acid sequence alignment between CYP2D6 and the CYP2C5 X-ray crystal structure 
template (sharing 43% sequence identity and 68% sequence homology). Secondary structure 
elements are assigned to the final CYP2D6 model using the DSSP program67 (CYP2D6 and CYP2C5 
share fairly the same fold and secondary structure organization). Six Structure Recognition Sites 
(SRSs) as defined by Gotoh31 are enclosed by boxes. Residues interacting with ligands, based on 
automated docking studies (see Table 2) are marked black. Triangles are assigned to residues 
which are mutated in our laboratory (filled) or by others (empty). 
 
In order to improve crystallization of CYP2C5 structures, the first 26 amino acid residues 
are truncated from the polypeptide chain. In addition, five amino acid positions in the F-G 
loop of CYP2C5 have been changed for the corresponding residues in CYP2C3. Although 
the N-terminus is believed to be anchored into the membrane, and parts of the F-G loop 
are believed to be embedded in the membrane as well, the crystal structures were shown 
to remain catalytically active.11-13 The first 33 amino acids of CYP2D6 are omitted from the 
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model as this part of the structure was also not present in the template crystal structures. 
The first amino acid sequence alignment was generated using the T-Coffee programme 40. 
This alignment was manually adjusted to avoid gaps and insertions in secondary structure 
elements, to concentrate gaps and insertions in short segments and to obtain a proper 
alignment of turns. The amino acid sequence alignment exhibits only minor gaps in the 
F/G loop and in the coil between the 3-3 and 4-1 β strands, and only minor insertions in 
the B´/C loop, F/G loop, and H/I loop. In the final alignment, CYP2C5 and CYP2D6 share 
43% sequence identity and 68% sequence homology. 
 
Table 1: Sequence homology between CYP2D6 and CYP2C5 and comparison of their protein 
structures in terms of mainchain stereochemistry and side-chain environment. 
 
 
% seq. sim. 
(homol.)c 
RMSD (Å) 






CYP2D6 model 43 (68)  - 77 96 (78) 92 194 
CYP2D6 (2F9Q) 43 (68) 2.9/2.3 (88/90) 85 98 (84) 95  198 
CYP2C5 (1N6B)a - 1.4 (97) 89 98 (86) 96 193 
CYP2C5 (1NR6)a - 1.4 (97) 88 99 (87) 98 195 
CYP2C5 (1DT6)b - 2.2 (91) 84 95 (71) 94 182 
a) Crystal structure templates used for the construction of the CYP2D6 model; b) Crystal structure not used 
for the construction of the CYP2D6 model; c) Sequence similarity and sequence homology (between brackets) 
following the alignment between CYP2D6 and CYP2C5 in Figure 2 and homology assignment according to ref 
68; d) Cα root-mean-square deviation (RMSD) from the CYP2D6 homology model; between brackets the 
percentage of Cα atoms within 2 Å distance from equivalent Cα atoms in the CYP2D6 homology model 
(according to the alignment in Figure 2). For the CYP2D6 (2F9Q) entry the second value refers to the same 
measure excluding residues 229-239 of the F-G loop.; e) Percentage of residues with mainchain angle 
conformation ‘within limits’ as defined in refs 44,69; f) Percentage of residues with ϕ, ψ conformation in the 
‘allowed’ and ‘most favoured’ (between brackets) regions of the Ramachandran plot44,70; g) Percentage of 
residues with patterns of non-bonded atomic interactions that satisfy the Errat definitions45; h) The total 
Verify3D46 score summed over all residues, measuring the compatibility of a protein model with its sequence. 
For a protein the same size as CYP2C5 and CYP2D6 a score of approximately 200 is expected and a score less 
than 100 would indicate an incorrect structure. 
 
Protein conformation and quality checks 
From the hundred models generated by Modeller39, three models were selected with the 
best loop conformations as determined by visual inspection, stereochemical parameters 
using PROCHECK44, and side-chain environment using Errat45 and Verify3D.46 In Table 1, 
the protein quality check scores of the final model are compared with the substrate-free 
CYP2D6 crystal structure (2F9Q19), the two substrate bound CYP2C5 crystal structures 
used as homology modeling templates (1N6B11 and 1NR613), and the substrate-free 
CYP2C5 crystal structure (1DT612), which was used for the modeling of earlier CYP2D6 
models.38,71 The final CYP2D6 model has approximately the same protein quality scores as 
the substrate-free CYP2D6 and substrate-bound CYP2C5 crystal structures, only the 
mainchain angles deviate more from the parameters defined by Engh and Huber.69 It 
should be stated however, that these deviations can be the result of slight discrepancies 
between the Engh and Huber bond-angle parameter set and the parameter set of the 
GROMOS forcefield54, used to optimize the final CYP2D6 model. Furthermore, the 
homology model has significantly better Ramachandran and Verify 3D scores than the 
substrate free CYP2C5 crystal structure, in which the F/G loop was not observed. The 
CYP2D6 homology model shows higher structural similarity to the substrate-bound CYP2C5 
crystal structures than to the substrate-free CYP2C5 and CYP2D6 crystal structures, as 
expressed by lower C alpha atom RMSD values and higher percentages of structurally 







Dextromethorphan was docked in the selected CYP2D6 model and the geometry of this 
protein-substrate complex was then optimized by subsequent energy minimization and a 
short MD simulation, using the GROMACS molecular simulation package53 and the 
GROMOS force field, parameter set 43A1.54 Heme parameters were taken from this 
parameter set, with an additional covalent bond defined between the heme iron atom and 
the sulfur atom of C443 with an ideal bond length of 0.240 nm. The enzyme, including 
substrate and heme, was energy minimized in vacuum using the steepest descent method, 
first, with harmonic position restraints using a force constant of 1000 kJ mol-1 nm-2 on all 
non-hydrogen atoms and, subsequently, without position restraints. Finally, the complex 
was relaxed during a 1 ps MD-simulation in vacuo. The MD simulation was carried out with 
a time step of 2 fs, a twinrange cutoff of 0.8/1.4 nm, and a relative dielectric constant of 
1.0. The LINCS algorithm72 was used to constrain the lengths of all covalent bonds. The 
temperature was maintained at 300 K by weak coupling to an external bath, with a 
relaxation time of 0.1 ps.73 Figure 3 shows a ribbon model of the final homology model of 
CYP2D6 in which the secondary structure elements relevant for ligand binding and the 



































Figure 3: Three-dimensional structure of CYP2D6 homology model. C-alpha atoms of amino acid 
residues subjected to site-directed mutagenesis studies are depicted as black (mutants studied in 
our group) and grey (mutants studied by others) spheres (see also Figure 2 and Table 3); 
positions of amino acid residues interacting with docked ligands not subjected to mutation studies 
(see also Figure 2 and Table 2) are indicated by transparent white spheres. The heme catalytic 
center is depicted in black sticks. Secondary structure elements comprising Substrate Recognition 
Sites31 are indicated: SRS 1 (B´-helix), SRS 2 (F-helix), SRS 3 (G-helix), SRS 4 (I-helix), SRS 5 (β1-
4), and SRS 6 (β4-1). 
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This model of wild-type CYP2D6 was used as a template to model the I106E, F120A, 
T309V, T312V, and F483A mutants. In order to construct structures for the mutants, the 
relevant residues were replaced using the homology module of InsightII (Biosym), after 
which an energy minimization and a 1 ps position restrained MD simulation was carried 
out with dextromethorphan in the active site as described above. Simulations of wild-type 
and mutant CYP2D6 with substrates bound in the active site, starting from different 
automatically docked poses and pre-equilibrated using the scheme described in ref 74, 
remained stable during 10 ns of unrestrained MD at 300 K, in explicit water. In these 
simulations the pressure was maintained at 1 bar using the weak coupling scheme with 
relaxation time 1.0 ps.73 Final backbone atom-positional root-mean-square deviation 
(RMSD) values of 1.3-3.8 Å and minor fluctuations in secundary structure organization 
were obtained.37,74 
 
Substrate Pharmacophore Fitting 
Pharmacophore models derive information on the active site from similarities in shape, 
electronic properties, and conformations of substrates, inhibitors, or metabolic products. 
The so-called “classical” pharmacophore models are constructed by superimposing these 
molecules onto each other by matching chemically similar groups. Current approaches, 
however, utilize the three-dimensional quantitative structure-activity relationship (3D-
QSAR) approaches in which abstracted descriptors of essential functional groups and 
topologies of the molecules are superimposed, possibly supplemented by details of the 
surrounding active site. (This distinction is not fundamental; a molecule consisting of 
atoms and bonds in a “classical” pharmacophore model can be viewed as a type of 
“abstracted descriptor”, although rather detailed, in a 3D-QSAR model.) Recent reviews on 
CYP pharmacophore and 3D-QSAR methods are provided by Ekins and de Groot.75,76 
 
The main features of the currently known CYP2D6 pharmacophore models are 
highlighted in (Figure 4 of Chapter 2) where molecular interaction fields (MIFs52) 
calculated for S-bufuralol are overlaid on the substrate docked into the CYP2D6 active site. 
A clear correlation with the specific residues listed in Table 2, responsible for substrate 
interaction, can be obtained. CYP2D6 substrates possess a positive electrostatic site (i.e. a 
positively charged nitrogen atom) 5, 7 or 10 Å away from the site of catatalysis, two 
hydrophobic regions (i.e. aromatic rings) at ca. 6-8 Å from the positive electrostatic site, 
and possibly also a H-bond acceptor ca. 6 Å from the positive electrostatic site.55-63 
Carboxylate group(s) in the protein (i.e. aspartate (D), glutamate (E)) are suggested to 
interact with the positively charged site in the substrate, while aromatic amino acid 
residues (phenylalanine (F), tyrosine (Y), tryptophane (W)) or other hydrophobic residues 
(alanine (A), valine (V), isoleucine (I), leucine (L)) are thought to interact with the 
hydrophobic regions in the substrate. The MIF due to a carboxylic probe clearly 
corresponds to the position of E216, while hydrophobic probe MIFs correspond to the 
position of F120 and a hydrophobic region composed by L213, V308 and F483. D301 was 
postulated to be involved in polar/ionic substrate interactions by earlier models, based on 
bacterial crystal structure templates56,77,78, but this interaction was not observed in our 
models (Table 2). 
 
Interaction Fingerprint Analysis using Automated Docking 
Automated molecular docking is a computational method to predict energetically favorable 
conformations and orientations of ligands in the interior of protein structures. By analysing 
the binding modes of protein-ligand complexes derived from automated docking 
simulations, the role of specific amino acid residues in ligand-binding can be predicted. 
Automated docking strategies successfully applied to binding mode predictions of ligands 
in CYP crystal structures79, were used for the catalytic site prediction (CSP) of 65 
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substrates in the CYP2D6 homology model.80 For each ligand, the highest ranked docking 
solutions according to SCORE51 corresponding to experimentally determined primary 
metabolites, selected from 200 pooled poses generated by AutoDock47, FlexX48, GOLD-
Goldscore49, and GOLD-Chemscore50 docking programs was used for an analysis of 
CYP2D6-ligand interactions. The results of this interaction fingerprint analysis are shown in 
Table 2 and Figure 4.  
 
Table 2: Occurrence of ligand-protein interactions based on the analysis of 65 automatically 
docked protein-substrate complexes. Interactions are divided in hydrophobic interactions (aliphatic 
or aromatic carbon-carbon interactions) and H-bond interactions (H-bond donor (amine/amide 
nitrogen, hydroxyl oxygen) or H-bond acceptor (amine/carbonyl/carboxylate/hydroxyl oxygen)). 
Amino acid residues mediating hydrophobic interactions with less than 10% of the ligands are not 
listed. A hydrophobic interaction is observed if aliphatic or aromatic carbons are within a distance of 
4 Å. A H-bond interaction is defined through contacts between H-bond donors and H-bond 
acceptors within 3.5 Å. 
 residue hydrophobic (%) H-bond 
donor(ligand)- 




V104 45 0 0 
T107 0 8 6 
F120 91 (61a) 0 0 
L121 37 0 0 
L213 50 0 0 
E216 0  62 (50b) 0 
S304 37 37 18 
A305 83 3 0 
V308 62 0 0 
V370 32 0 0 
V374 90 0 0 
F483 70 (42a) 0 0 
L484 52 0 0 
a) Aromatic interactions (%). It should be noted that 97% of the substrates has an aromatic moiety 
b) Ionic interactions (%). It should be noted that 97% of the substrates has a positively charged (nitrogen) 
atom. 
 
Figure 4: Relative contributions of amino acid residues to ligand-protein interactions (hydrophobic 
interactions + H-bond interactions). Residues are colored by Substrate Recognition Sites31: SRS1 
(V104, T107, F120, L121), SRS2 (L213, E216), SRS4 (S304, A305, V308), SRS5 (V370, V374), and 
SRS6 (F483, L484). 
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The analysis was used to compare the active sites of our CYP2D6 homology model and the 
recently reported substrate-free CYP2D6 crystal structure, to explain reported site directed 
mutagenesis data, and to design new site-directed mutagenesis experiments performed in 
our laboratory, as will be described in the next paragraphs. From the data in Table 2 it 
becomes clear that in this model residues F120, L213, A305, V308, V374, F483 and L484 
are responsible for most of the hydrophobic interactions, while the H-bond/ionic 
interactions are most prominently seen through E216. Interacting residues from all 
substrate recognition sites except for SRS3 could be identified. As can be seen from 
Figure 3, this SRS is positioned at a relatively large distance from the active site, making 
substrate interactions in the bound state unlikely. However, this SRS may be involved in 
recognition during substrate entrance (see Chapter 8). Interestingly, no mutants were 
reported involving residues in  SRS3 (Figure 2), so that no direct evidence for this SRS is 
available. 
 
Comparison between substrate-bound CYP2D6 homology model and substrate-
free crystal structure 
Very recently a X-ray crystal structure of substrate-free CYP2D6 was resolved at 3.0 Å 
resolution (pdb code 2F9Q).19 Like other crystallized mammalian CYPs, CYP2D6 was 
solubilized by truncation (residues 1-22) and mutation (residues 23-33) of the N-terminus 
and small mutations in the G-helix (L230D/L231R). Residues 23-33 of the N-terminus and 
42-51 of the A’ helix were not resolved in the crystal structure and residues 229-239 of the 
F-G loop were built only as alanines, as the electron density maps were insufficiently clear 
to unambiguously assign the correct residue side chains. 
The CYP2D6 homology model corresponds closely to the substrate-free CYP2D6 crystal 
structure in many regions, with 88% of the C alpha carbons within a root-mean-square 
deviation (RMSD) of 2 Å (Figure 5). The heme is anchored in the binding site in the same 
way (hydrogen bonding interactions with the side chains of R101, W128, R132, H376, 
S437 and R441, and the heme is pentacoordinated with C443), there is a good overlap 
with the proposed CYP reductase binding domain around residue R440, and the positions 
and orientations of most active site residues are similar (Figure 6). Both the homology 
model and the crystal structure show a so-called solvent channel, which passes between 
the E-helix, SRS2 in the F-helix, SRS4 in C-terminal end of the I-helix and the SRS6 turn 
region of β sheet 4. 
However, significant changes are seen in the N terminus (residues preceding residue 
54); between strands 1-1 and 1-2 (residues 73-76); in the helix B to helix C region (SRS 1, 
residues 104-116); in the C-D loop (residues 141-147); in the region encompassing helix F 
through the beginning of helix G (SRS 3, residues 217-240); in the G-H loop (residues 
264-266); in the H-I loop (residues 285-287); in strand 4-1 (SRS 6, residues 470-482). 
These differences are: 
i) far away from the active site (N terminus, strands 1-1 and 1-2, C-D, G-H and H-I 
loops). 
ii) not resolved (residues 23-33 and 42-51 in the N-terminus) or not well resolved 
(residues 229-239 of the F-G loop) in the crystal structure. 
iii) Mutated in the crystal structure construct to improve solubility (L230D/L231R). 
iv) the same structural differences observed upon substrate binding to other CYPs: 
CYP102 (F-G helical region), CYP119 (F-G helical region), CYP2C5 (B’ helix, F-G 
helical region, H/I loop, and strand 4-1) and CYP2C9 (strand 4-1). 
v) the same structural differences observed when comparing open and closed forms 
of CYP2B4 and when comparing CYP2C9 crystal structures determined by 
different laboratories (N-terminus, B’ helix, F-G helical region). 
This suggests that the most significant structural differences between the substrate-free 
CYP2D6 crystal structure and our CYP2D6 homology are caused by substrate-induced 
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conformational changes. In the homology model, which is based on substrate-bound 
CYP2C5 structures and is optimized as a substrate-bound complex, the B’ helix (SRS1) has 
moved towards the heme in the homology model to maximize hydrophobic contacts with 
the substrate. This movement increases the contact with the G-helix (SRS3) and facilitates 
hydrogen bonding of Q244 to the backbone of L110. This hydrogen bond is not observed 
in the crystal structure. The same movement of the B’ helix and facilitation of hydrogen 
bonding between the B’ helix and G helix are for example observed when comparing 
substrate-bound and substrate-free structures of CYP2C5 (formation of a hydrogen bond 
between the homologues K241 and V106 residues). In the CYP2D6 homology model, the F 
helix has two turns less than in the crystal structure and has moved across the surface of 
the I helix perpendicular to the axis of the I helix. This movement closes the solvent 
channel between helices F and I close to V308 and also results in reorientation of the side 
chain of residue F483, located in the loop between strands 4-1 and 4-2 (SRS6). In the 
homology model, the phenyl-ring of F483 has turned towards the active site, maximizing 
hydrophobic contacts with the substrate, while in the crystal structure, F483 forms an 
intermediate substrate binding pocket with E216 at the entrance of the solvent channel. 
Substrate binding to CYP102 and CYP2C5 also shows a rearrangement of the region from 
helix F through the N-terminal end of helix I. This is reflected by a lateral movement of the 
F and G helices across the surface of the I helix, closing a cleft above the substrate 
binding site. Substrate binding to CYP2C5 and CYP2C9 results in the same reorientation of 
the homologues substrate binding phenylalanine residue in SRS6 (F473 (CYP2C5), F476 
(CYP2C9)). 
Figure 5 shows the results of a comparison between the substrate free crystal structure 
(pdb-code 2F9Q) and substrate bound homology model of CYP2D6 and of a comparison 
between substrate free (1DT6) and substrate bound (1NR6) CYP2C5 crystal structures. The 
same structural differences are observed between substrate-bound and substrate-free 
CYP2C5 as the differences between the CYP2D6 homology model and substrate-free 
crystal structure.  
Figure 6 shows an overlay of the active sites of the CYP2D6 crystal structure and the 
homology model active site with dextromethorphan docked into the respective active sites 
according to the method described in refs 79,80. Almost all residues predicted to be 
involved in substrate binding in our homology model (see Table 2) are also located in the 
active site of the CYP2D6 crystal structure, with the exception of V104 and T107. L220 and 
Q244 are two residues located in the active site of the CYP2D6 crystal structure but are 
not part of the substrate binding pocket of the homology model. The location and 
orientation of most of the residues subjected to the mutagenesis studies carried out in our 
laboratory is about the same (e.g. F120, T309, T312). The location and orientation of I106 
is significantly different between the crystal structure and the homology model, but in both 
cases, I106 is within 5 Å distance from E216. The backbone of F483 is located at the same 
position, but the phenyl ring is differently directed towards the active site. In the 
homology model, F483 has turned towards the active site while in the crystal structure, 
F483 forms an intermediate substrate binding pocket with E216 at the entrance of the 
solvent channel. The E216 residue is slightly shifted but orientated in the same way 
towards the active site. Both in the crystal structure and in the homology model D301 
forms hydrogen bonds with the backbone NH groups of V119 and F120, and its 
carboxylate side-chain is not directed into the active site, suggesting that this residue 
primarily plays an important role in positioning the B-C loop, rather than being directly 
involved in substrate binding. S304 has approximately the same conformation in the 
homology model and the crystal structure, with its hydroxyl group pointing towards the 
carbonyl backbone of A305 as well as into the active site. In the crystal structure the 
residue at position 374 is a methionine, which is a valine (the actual residue in wild-type 
CYP2D6) in the homology model 81,82. The bigger methionine residue slightly displaces 
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F120 into a position more above the heme in the crystal structure. In the crystal structure, 
aromatic moieties of substrates can stack between F120 and L213, L220, A305 and V308, 



















Figure 5: Comparison of the substrate free crystal structure (pdb-code 2F9Q, magenta) and 
substrate bound homology model of CYP2D6 (green) in panel A, and a comparison between 
substrate free (1DT6, magenta) and substrate bound (1NR6, green) CYP2C5 crystal structures in 
panel B. The heme is depicted as sticks in black. Regions showing large differences and involved in 
substrate binding (B’ helix, and F-G helical region) are shown as cartoons. Part of the N-terminus in 























Figure 6: Overlay of the active sites of the 
active sites of the CYP2D6 crystal structure 
(magenta) and the CYP2D6 homology 
model (green). Most of the residues 
involved in substrate binding in the crystal-
structure and/or homology model are 
shown as sticks. Dextromethorphan is 
docked into the active sites considering 
active-site water molecules and using 
GOLD-Chemscore in combination with the 
SCORE scoring function, as described in ref 
80. In the homology model, the orientation 
of dextromethorphan (in light green) with 
its O-methyl pointing towards the heme is 
favoured, in the crystal an orientation 
supporting 7-hydroxylation (in magenta) is 

























3.3 Site-directed mutagenesis studies in CYP2D6  
For CYP2D6, homology models based on crystal structures of CYPs 101, 102, 107A, 108 
and 2C5 have been constructed separately as well as in conjunction with each 
other.38,56,57,71,77,78,83-86 Ligand-based CYP2D6 pharmacophore models suggest that ligands 
bind two or three aromatic/hydrophobic sites and a carboxylic site for which F120 and 
F483, respectively E216 or D301 were suggested in combination with homology models. 
Extensive reviews on CYP(2D6) modeling have appeared very recently 20,21. Active site 
residue predictions based upon substrate and protein models of CYP2D6 were often 
followed by mutagenesis studies to validate their roles. An overview of site-directed 
mutagenesis studies is presented in Table 3. The residues of interest are listed together 
with the mutations and the effects of the mutations. From a historical point of view, D301 
is the most studied residue.87-92 It was first indicated as the active site carboxylate 
involved in fixation of the basic nitrogen commonly observed in typical CYP2D6 substrates 
and it was the first residue subjected to site directed mutagenesis. Although mutation led 
to a decreased CYP2D6 activity, the carboxylate group of D301 is not directed into the 
active site in our CYP2D6 homology model or in the recently reported substrate-free 
CYP2D6 crystal structure.19 Another active site carboxylate, E216 was rather suggested to 
be the main actor responsible for interaction with the basic nitrogen atom in the substrate 
.91,92 In the CYP2D6 crystal structure and in our CYP2D6 homology model the side-chain of 
this residue is indeed directed into the active site and is predicted to be an important 
residue involved in substrate binding in the homology model (Table 2). Our homology 
model and the CYP2D6 crystal structure indicate that the negative effect on the catalytic 
activity of mutating D301 is indirect. D301 is suggested to position residue F120, which 
interacts with the aromatic moiety of the substrate. A mutation in position 301 (with the 
exception of D301E) disturbs the position of F120 and affects substrate binding through 
the aromatic interaction. Mutation of active site residue S304 was found to have no effect 
on substrate turnover. In the homology model as well as in the crystal structure the 
hydroxyl group of this residue is in a conformation that enables formation of a H-bond 
with substrates bound in the active site (Table 2). However, the conformation of S304 
also favors H-bond formation with the backbone carbonyls of A300 in the crystal structure 
and with the carbonyl backbone of D301 in the homology model, leaving the hydrogen 
bond donor site of S304 unavailable for substrate hydrogen acceptor groups. Mutation of 
M374 into V374 (the latter being the actual residue in wild-type CYP2D6 81,82) was shown 
to have an effect on the stereoselectivity of metropolol metabolism. V374 is suggested to 
be an important substrate-binding residue in the homology model (Table 2), and M374 is 
part of the active site of the crystal structure. 
Table 4 and Figures 2 and 3 show that site-directed mutagenesis studies have 
primarily focused on residues located in or near the active site (e.g., SRSs 1, 2, 4, 5 and 6) 
and near the N-terminus. So far, no studies have been described on residues located in 
SRS3. As shown in Table 2 and Figure 3, our homology model suggest that this 
substrate recognition site does not directly interact with ligands when positioned in the 
vicinity of the heme catalytic center. This part of CYP2D6 may however, be involved in 
substrate access and/or product exit. In the crystal structure Q244 is directed towards the 
active site, while this residue forms a H-bond with the backbone of L110 in the homology 
model. Table 2 and Figure 4 suggest that several other active site residues are probably 
interacting with ligands as well (e.g., V104 (SRS1), L213 (SRS2), and V308 (SRS4)) 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Recently, a series of site-directed mutagenesis studies were performed in our group, 
which were guided by the CYP2D6 homology model described above. We selected two 
phenylalanines, F120 and F483, suggested to be involved in substrate binding, as 
indicated by the interaction fingerprint analysis between the CYP2D6 protein structure and 
typical CYP2D6 substrates (Table 2). F120 is predicted to interact with the aromatic 
moiety present in most CYP2D6 substrates, while F483 is predicted to more sterically 
influence substrate binding. Introduction of a negatively charged residue on position 106 
(isoleucine in wild-type CYP2D6) was predicted to influence the positioning of E216, 
alterating the shape and character of the active site cavity, and therefore affecting 
substrate binding to CYP2D6. Two active-site threonines, T309 and T312, were subjected 
to site-directed mutagenesis experiments although they were not predicted to be directly 
involved in substrate binding. Multiple amino acid sequence alignments of CYPs 
(drnelson.utmem.edu/CytochromesP450.html) indicate T309 to be a highly conserved 
threonine among fairly all CYPs and in a series of CYPs this residue was experimentally 
shown to be involved in oxygen activation.93-99  
Table 4 summarizes the influence of these active site mutations on the catalytic 
efficiency of CYP2D6 to metabolize four typical CYP2D6 substrates, 7-methoxy-4-
(aminomethyl)-coumarin (MAMC), dextromethorphan, bufuralol and 3,4-
methylenedioxymethamphetamine (MDMA). In the following paragraphs, these mutants 
will be described in more detail. In addition to enzyme kinetics studies, we have used 
aryldiazenes to gain information on CYP2D6 active site topology. These probes react with 
the heme iron to form σ-bonded aryl–iron complexes. Upon oxidation of the complex with 
ferricyanide, the aryl group migrates from the heme iron to one of the neighboring four 
porphyrin nitrogens.100 Studies with CYPs for which crystal structures are available have 
shown that the regiochemistry of the migration is largely dependent on the steric 
constraints within the enzyme’s active site and that quantification of the N-
arylprotoporphyrin IX thus formed provides an estimate of the available space above each 
of the four heme pyrroles.100 The effects of the mutants on the catalytic efficiency and 
active-site shape of CYP2D6 were again rationalized by comparing automated docking 




The metabolism of MAMC and MDMA by the CYP2D6 I106E mutant was greatly reduced as 
compared to wild-type and although products were detected, they were in such low 
quantities that kinetic parameters for these reactions could not be determined 34. The 
metabolism of dextromethorphan and bufuralol was also affected by the I106E mutation 
albeit to a lesser extent.  Trace amounts of other metabolites of bufuralol by CYP2D6 (i.e. 
6-OH bufuralol, 4-OH bufuralol and ∆1’,2’ bufuralol89) were also observed with the I106E 
mutant but could not be accurately quantified. 
Recent reports have highlighted the importance of E216 in substrate binding and 
orientation of amine substrates through an electrostatic interaction.91,92 According to our 
homology model, E216 is located above pyrrole D of the heme moiety at a vertical 
distance of roughly 12 Å. In the wild-type, the sidechain of I106 lies within 5 Å of the 
carboxylate group of E216. Also in the recently solved substrate-free CYP2D6 crystal 
structure, E216 is located at 12 Å above pyrrole D and is I106 located within 5 Å of E216, 


























Figure 7: Panel A schematically depicts the catalytic profiles for four typical CYP2D6 substrates and 
changes in metabolism upon the I106E mutation. Panels B and C show three-dimensional 
representations of the CYP2D6 homology model structure. In the close up view of the active site 
(panel C) only the green coloured protein backbone ribbon segments presented in the side view 
(panel B) are shown. In panel B, the positions of the B’-helix, F-G loop, and I-helix are indicated. 
Side chains of residues mutated in this study (with the exception of E216) are shown in purple ball-
and-stick form. The backbone atoms of residues forming H-bonds with the side-chains of D301 
(F120), T309 (A305 and T310) and T312 (V308) (indicated as dotted white lines) are shown in 




Strikingly, the substitution of phenylalanine at position 120 into an alanine led to a 
completely abolished MAMC O-demethylating activity of CYP2D6.32 On the other hand, 
bufuralol metabolism was hardly affected, nor was the dextromethorphan O-
demethylation. The F120A mutant did form 3-hydroxymorphinan, the double demethylated 
form of dextromethorphan, which was not detected using wild-type CYP2D6. MDMA was 
demethylenated by both mutant and wild-type CYP2D6 to 3,4-
dihydroxymethamphetamine. In addition the mutant formed two additional metabolites; 
3,4-methylenedioxyamphetamine (MDA) and N-hydroxy-3,4-methylenedioxymeth-
amphetamine (N-OH-MDMA). Inhibition experiments of dextromethorphan O-














        MAMC    bufuralol            dextromethorphan         MDMA 
 
Site of metabolism observed in wild-type ( ), I106E mutant ( ), both wild-type and I106E 
















values for quinine were equal. These data indicate the importance of F120 in the 
selectivity and regiospecificity of substrate binding and catalysis by CYP2D6. 
Figure 8 summarizes the changes in the metabolic profiles for these compounds due to 
the F120A mutation and offers a rationalization in terms of docking poses for 
dextromethorphan. In the mutant additional docking poses were observed, in which the 
orientations of dextromethorphan allows for N-demethylation. In the CYP2D6 crystal 
structure F120 is positioned and oriented in the same way as in our homology model 
(Figure 6). In agreement with the positioning of F120 indicated by the crystal structure 
and the homology model,  the N-aryl-PPIX ratio obtained with the CYP2D6 F120A mutant 
featured an increased migration of the probes to the nitrogen atoms of pyrrole C and D 
which in the wild-type enzyme remained inaccessible.34 The greater extent of migration to 
ND, suggests that in the wild-type protein the phenyl group of F120 extends significantly 




Figure 8: In panel A, differences in regiospecificity of metabolism between wild-type and  F120A 
mutant CYP2D6 is presented. In panels B and C, binding orientation of dextromethorphan 
automatically docked in the active site of the homology models of CYP2D6 using Autodock with 
standard conditions 47. In wild-type CYP2D6, the orientation of dextromethorphan (in yellow) with 
its O-methyl pointing towards the heme is favoured (panel B), in the F120A mutant two distinct 
orientations, supporting both N-demethylation (in magenta) as O-demethylation (in yellow) were 
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Replacement of F483 by A resulted in a 30-fold lower Vmax for bufuralol 1’-hydroxylation, 
while the Km was hardly affected.33 Mutation of F483 to isoleucine or tryptophan did not 
affect the 1’-hydroxylation of bufuralol at all in an earlier study.106 The Vmax for 3,4-
methylenedioxy-methylamphetamine O-demethylenation on the other hand decreased 
only two-fold, whereas the effect on the Km was much larger. For dextromethorphan, in 
addition to dextrorphan (O-demethylation) and 3-methoxymorphinan (N-demethylation), 
two other metabolites were formed that could not be detected for the wild-type. The 
substrate MAMC was not metabolised at all by CYP2D6 F483A mutant. These data show 
that next to F120, residue F483 plays a very important role in the metabolism of typical 















Figure 9: In panel A, differences in regiospecificity of metabolism between wild-type and F483A 
mutant CYP2D6 are presented. In panels B and C, energetically most favourable binding 
orientations of R- (in yellow) and S-bufuralol (in magenta) in the active site of the homology models 
of CYP2D6 as determined by automated docking studies.80 In wild-type CYP2D6 the orientation of 
R-bufuralol corresponding to 4-hydroxylation is favoured, while the orientation of S-bufuralol 
corresponds to C1’-hydroxylation (panel B). In the F483A mutant the orientation of S-burfuralol 
corresponds to C1’-hydroxylation and R-bufuralol is non-reactive (panel C). 
 
The influence of F483 on metabolism was found to be strongly substrate-dependent, as 
is summarized in Figure 9. For S-bufuralol the changes in metabolic profile due to the 
mutation is rationalized based on automated docking experiments presented in panels B 
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Site of metabolism observed in wild-type ( ), F483A mutant ( ), both ( ), both although low 







respect to the heme iron that is catalytically active, while more of such conformations are 
observed in the wild-type. In our homology model, the backbone of F483 is located at the 
same position as in the recently solved substrate-free crystal structure of CYP2D6, but the 
phenylring is directed differently towards the active site. In the homology model, the 
phenyl-ring of F483 has turned towards the active site, maximizing hydrophobic contacts 
with the substrate, while in the crystal structure, F483 forms an intermediate substrate 
binding pocket with E216 at the entrance of the solvent channel. 
 
T309V 
Mutation of T309 into a valine led to up to twenty-fold decreases in turnover rates of 
bufuralol 1-hydroxylation, dextromethorphan and MAMC O-demethylation and  MDMA O-
demethylenation, while binding affinities and formation of uncoupling products did not 
change.35 The T309V mutant CYP2D6 showed increased dextromethorphan and MDMA N-
dealkylation rates and thus product ratios of dextromethorphan and MDMA metabolism but 
also of bufuralol oxidation were altered. The use of cumene hydroperoxide instead of 
NADPH to support oxidation however, returned O-demethylating and O-demethylenating 
activity of the T309V mutant to the same level as in wild-type. These results indicate that 
T309 is a key determinant in maintaining the relative ratios of the potential reactive 
oxygen species that determine the ultimate products formed by CYP2D6. 
Figure 10: In panel A, differences in regiospecificity of metabolism between wild-type and T309V 
mutant CYP2D6 are presented. Panel B presents the alignment of the I-helix protein sequences 
(drnelson.utmem.edu/CytochromesP450.html) showing the conserved threonine residue (indicated 
with a triangle) of CYPs in which this residue was experimentally shown to be involved in oxygen 
activation.93-99 
 
The T309V mutant is instable over time and large amounts of P420 are formed during 














       MAMC    bufuralol            dextromethorphan         MDMA 
Site of metabolism observed in wild-type ( ), T309V mutant ( ), both ( ), both although low 
amounts for T309V ( ). 
B 
CYP        Species                                              I-helix sequence                                         Last resid
101          P. putida 268
102A2     B. Megaterium 284
107A       S. erythraea 261
55A1       F. oxysporum 258
1A2         Rat 335
2B4         Rabbit 318
2E1         Rabbit 319
2C5         Rabbit 314
2D6        Human 325
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homology model that shows that it is involved in stabilizing a distortion in the I helix by 
providing hydrogen bonds to the carbonyl groups of A305 and G306 (Figure 7). In the 
CYP2D6 crystal structure, T309 is positioned and oriented in the same way as in our 
homology model (Figure 6). It has been shown that mutation of the homologous T268 
residue in CYP10295 or T252 in CYP1015,94 to Ala or Ile cause various degrees of  
conformational changes in the I-helix.  Our model likewise shows that T312 is involved in 
stabilizing the distortion in the I helix as well by providing a  hydrogen bond to the 
carbonyl group of V308. Mutation of that residue could have a conformational effect on 
the I helix similar to that observed with the T309V mutant and hence give the same N-
alkylprotoporphyrin-IX ratios.34 Figure 10 summarizes the changes in metabolic profiles 
for the test compounds and depicts the sequence alignment of the I-helices of several iso-
enzymes for which the structural role of the homologue of T309 was experimentally 
determined. The threonine mutants of the bacterial CYPs 101, 102A1, and fungal CYP55A1 
were crystallized94,95,97 and so are mammalian CYPs 2B49 and 2C512, the latter structure 
was used to build the CYP2D6 model. In CYP107A, the A245T mutant was shown to 
oxidize alternative substrates99, and in CYPs 1A2, 2B4, and 2E1 the conserved threonine 
residues were also subjected to mutagenesis studies.93,96,98 
 
3.4 Summary and perspectives 
In this chapter we described the construction, refinement and validation of the CYP2D6 
homology model that is used in our laboratory for the prediction and rationalisation of 
CYP2D6 substrate metabolism and CYP2D6-ligand interactions as described in this thesis 
and other work.32-37 The model could explain reported site-directed mutagenesis data. For 
example, the model indicates that E216, and not D301, is the main actor responsible for 
interaction with the basic nitrogen atom in the substrate. D301 however, is involved in 
stabilizing the B/C-loop (containing F120) and mutation of this residue can thus affect 
substrate binding indirectly. Furthermore, based on the model, new CYP2D6 mutants were 
constructed and studied in our lab, and also for these mutants a rationalization of 
experimentally observed characteristics could be achieved. The influence of two active 
phenylalanines, F120 (located in substrate recognition site (SRS 1) and F483 (SRS6), on 
metabolism by CYP2D6 were found to be strongly substrate-dependent. Our homology 
model suggests that F120 is involved in direct π-π interactions with aromatic rings of 
substrates, while F483 is less involved in direct substrate interaction but is rather sterically 
influencing substrate binding. The F120A and F483A are studied in more detail in refs 
32,33,36. I106 (SRS1) is not directly interacting with substrates, but the I106E mutation 
introduces an electrostatic repulsion with the negative charge of E216 (SRS2)34, an active 
site residue already shown to be crucial for metabolism of typical CYP2D6 substrates. In 
this way, the mutation potentially causes shifts in the F- and G-helices leading to an 
alteration of the shape and character of the active site cavity. The highly conserved T309 
(SRS4) also does not directly interact with ligands, but is a key determinant in maintaining 
the relative ratios of the potential reactive oxygen species that determine the ultimate 
products formed by CYP2D6.35 Future combined Resonance Raman and QM/MM studies 
will focus on the elucidation of the role of T309 in CYP2D6-mediated metabolism 
[Bonifacio & Groenhof et al., unpublished results]. Table 4 summarizes the influence of 
the I106E, F120A, T309V, and F483A mutations on the catalytic efficiency of CYP2D6 to 
metabolize four typical CYP2D6 substrates, 7-methoxy-4-(aminomethyl)-coumarin 
(MAMC), dextromethorphan, bufuralol and 3,4-methylenedioxymethamphetamine (MDMA). 
CYP2D6-substrate interaction fingerprint analysis of docked substrates in our homology 
model (Table 2) suggest that several other active site residues are probably interacting 
with ligands as well (e.g., V104 (SRS1), L213 (SRS2), and V308 (SRS4)), opening the way 
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  RR spectroscopy (ref 107)  
a) Predicted property: ‘Affinity’ (spectral dissociation constant Ks or concentration required for 50% inhibition of 
the metabolism of a specific substrate (IC50)); Catalytic Site Prediction (CSP) 
b) Method of prediction and validation: Automated docking (AD) of substrates in homology model to predict 
site of catalysis; Molecular dynamics (MD) simulations to predict site of catalysis or affinity (Thermodynamic 
Integration method); Combined with pharmacophore model (P); Site-directed mutagenesis (SM) studies used 
for refinement and validation of sequence alignment and/or homology model. 
 
Further validation and applications of the CYP2D6 homology model are described this 
thesis and in refs 32-37 and involve the prediction of metabolic sites in substrates, the 
affinity of ligands to the protein and Ks and IC50 values. As is described in Table 5, a 
variety of methods was applied, such as automated docking experiments, molecular 
dynamics simulations, free energy calculations using Thermodynamic Integration (TI), 
random acceleration molecular dynamics simulations (RAMD) and statistical methods 
aimed at predicting affinities. 
Very recently the crystal structure of substrate-free CYP2D6 was solved.19 Our homology 
model was found to agree with most of the details of this crystal structure. Structural 
differences between the homology model and crystal structure were the same differences 
observed between substrate-free and substrate-bound structures of other CYPs, 
suggesting that these conformational changes are required upon substrate binding. The 
recently solved CYP2D6 crystal structure further validates our homology modeling 
approach and demonstrates on one hand the success and accuracy of the state of the art 
of CYP homology modeling. On the other hand it shows that computational chemistry is a 
useful and valuable tool to provide models for substrate-bound complexes of CYPs which 
give insight into CYP-ligand interactions. This information is essential for successful pre-
experimental virtual screening, as well as accurate hypothesis generation for in vitro 
studies in drug discovery and development. 
 
References 
(1) Goeptar, A. R.; Scheerens, H.; Vermeulen, N. P. Oxygen and xenobiotic reductase activities of 
cytochrome P450. Crit Rev Toxicol 1995, 25, 25-65. 
(2) Guengerich, F. P. Common and uncommon cytochrome P450 reactions related to metabolism and 
chemical toxicity. Chem Res Toxicol 2001, 14, 611-650. 
(3) Zanger, U. M.; Raimundo, S.; Eichelbaum, M. Cytochrome P450 2D6: overview and update on 
pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004, 369, 23 - 37. 
(4) Bertilsson, L.; Dahl, M. L.; Dalen, P.; Al-Shurbaji, A. Molecular genetics of CYP2D6: clinical relevance 
with focus on phychotropic drugs. Br J of Clin Pharmacol 2002, 53, 111 - 122. 
(5) Hishiki, T.; Shimada, H.; Nagano, S.; Egawa, T.; Kanamori, Y. et al. X-ray crystal structure and 
catalytic properties of Thr252Ile mutant of cytochrome P450cam: roles of Thr252 and water in the 
active center. J Biochem (Tokyo) 2000, 128, 965-974. 
(6) Oscarson, M. Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine. 
Clin Chem Lab Med 2003, 41, 573 - 580. 
Carving out key positions 
 120
 
(7) Ingelman-Sundberg, M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical 
consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005, 5, 6-13. 
(8) Yano, J. K.; Hsu, M. H.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. Structures of human microsomal 
cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat Struct Mol Biol 2005, 12, 822-823. 
(9) Scott, E. E.; He, Y. A.; Wester, M. R.; White, M. A.; Chin, C. C. et al. An open conformation of mammalian 
cytochrome P450 2B4 at 1.6-A resolution. Proc Natl Acad Sci U S A 2003, 100, 13196-13201. 
(10) Scott, E. E.; White, M. A.; He, Y. A.; Johnson, E. F.; Stout, C. D. et al. Structure of mammalian 
cytochrome P450 2B4 complexed with 4-(4-chlorophenyl)imidazole at 1.9-A resolution: insight into 
the range of P450 conformations and the coordination of redox partner binding. J Biol Chem 2004, 
279, 27294-27301. 
(11) Wester, M. R.; Johnson, E. F.; Marques-Soares, C.; Dansette, P. M.; Mansuy, D. et al. Structure of a 
substrate complex of mammalian cytochrome P450 2C5 at 2.3 A resolution: evidence for multiple 
substrate binding modes. Biochemistry 2003, 42, 6370-6379. 
(12) Williams, P. A.; Cosme, J.; Sridhar, V.; Johnson, E. F.; McRee, D. E. Mammalian microsomal 
cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional 
diversity. Mol Cell 2000, 5, 121-131. 
(13) Wester, M. R.; Johnson, E. F.; Marques-Soares, C.; Dijols, S.; Dansette, P. M. et al. Structure of 
mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 A resolution: evidence for an 
induced fit model of substrate binding. Biochemistry 2003, 42, 9335-9345. 
(14) Schoch, G. A.; Yano, J. K.; Wester, M. R.; Griffin, K. J.; Stout, C. D. et al. Structure of human 
microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem 
2004, 279, 9497-9503. 
(15) Williams, P. A.; Cosme, J.; Ward, A.; Angove, H. C.; Matak Vinkovic, D. et al. Crystal structure of 
human cytochrome P450 2C9 with bound warfarin. Nature 2003, 424, 464-468. 
(16) Wester, M. R.; Yano, J. K.; Schoch, G. A.; Yang, C.; Griffin, K. J. et al. The structure of human 
cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. J Biol Chem 2004, 279, 
35630-35637. 
(17) Yano, J. K.; Wester, M. R.; Schoch, G. A.; Griffin, K. J.; Stout, C. D. et al. The structure of human 
microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol 
Chem 2004, 279, 38091-38094. 
(18) Williams, P. A.; Cosme, J.; Vinkovic, D. M.; Ward, A.; Angove, H. C. et al. Crystal structures of human 
cytochrome P450 3A4 bound to metyrapone and progesterone. Science 2004, 305, 683-686. 
(19) Rowland, P.; Blaney, F. E.; Smyth, M. G.; Jones, J. J.; Leydon, V. R. et al. Crystal structure of human 
cytochrome P450 2D6. J Biol Chem 2006, 281, 7614-7622. 
(20) de Graaf, C.; Vermeulen, N. P.; Feenstra, K. A. Cytochrome p450 in silico: an integrative modeling 
approach. J Med Chem 2005, 48, 2725-2755. 
(21) de Groot, M. J.; Kirton, S. B.; Sutcliffe, M. J. In silico methods for predicting ligand binding 
determinants of cytochromes P450. Curr Top Med Chem 2004, 4, 1803-1824. 
(22) Li, H. Y.; Poulos, T. L. The structure of the cytochrome p450BM-3 haem domain complexed with the 
fatty acid substrate, palmitoleic acid. Nature Structural Biology 1997, 4, 140-146. 
(23) Haines, D. C.; Tomchick, D. R.; Machius, M.; Peterson, J. A. Pivotal role of water in the mechanism of 
P450BM-3. Biochemistry 2001, 40, 13456-13465. 
(24) Li, H.; Poulos, T. L. Conformational dynamics in cytochrome P450-substrate interactions. Biochimie 
1996, 78, 695-699. 
(25) Cupp-Vickery, J. R.; Garcia, C.; Hofacre, A.; McGee-Estrada, K. Ketoconazole-induced conformational 
changes in the active site of cytochrome P450eryF. J Mol Biol 2001, 311, 101-110. 
(26) Podust, L. M.; Poulos, T. L.; Waterman, M. R. Crystal structure of cytochrome P450 14alpha -sterol 
demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc Natl 
Acad Sci U S A 2001, 98, 3068-3073. 
(27) Park, S. Y.; Yamane, K.; Adachi, S.; Shiro, Y.; Weiss, K. E. et al. Thermophilic cytochrome P450 
(CYP119) from Sulfolobus solfataricus: high resolution structure and functional properties. J Inorg 
Biochem 2002, 91, 491-501. 
(28) Hasemann, C. A.; Kurumbail, R. G.; Boddupalli, S. S.; Peterson, J. A.; Deisenhofer, J. Structure and function 
of cytochromes P450: a comparative analysis of three crystal structures. Structure 1995, 3, 41-62. 
(29) Mestres, J. Structure conservation in cytochromes P450. Proteins 2005, 58, 596-609. 
(30) Li, H. Cytochrome P450. Handbook of metalloproteins; Wiley: Chichester, 2001; pp 267-282. 
(31) Gotoh, O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from 
comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 1992, 267, 83-90. 
(32) Keizers, P. H.; Lussenburg, B. M.; de Graaf, C.; Mentink, L. M.; Vermeulen, N. P. et al. Influence of 
phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-
methoxy-4-(aminomethyl)-coumarin metabolism. Biochem Pharmacol 2004, 68, 2263-2271. 
(33) Lussenburg, B. M.; Keizers, P. H.; de Graaf, C.; Hidestrand, M.; Ingelman-Sundberg, M. et al. The 
role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent. Biochem 
Pharmacol 2005, 70, 1253-1261. 
Chapter 3 
 121
(34) van Waterschoot, R. A.; Keizers, P. H.; de Graaf, C.; Vermeulen, N. P.; Tschirret-Guth, R. A. Topological 
role of cytochrome P450 2D6 active site residues. Arch Biochem Biophys 2006, 447, 53-58. 
(35) Keizers, P. H.; Schraven, L. H.; de Graaf, C.; Hidestrand, M.; Ingelman-Sundberg, M. et al. Role of 
the conserved threonine 309 in mechanism of oxidation by cytochrome P450 2D6. Biochem Biophys 
Res Commun 2005, 338, 1065-1074. 
(36) Keizers, P. H.; van Dijk, B. R.; de Graaf, C.; van Vught-Lussenburg, B. M.; Vermeulen, N. P. et al. 
Metabolism of N-substituted 7-methoxy-4-(aminomethyl)-coumarins by cytochrome P450 2D6 
mutants indicates additional substrate interaction points. Xenobiotica 2006, in press. 
(37) Stortelder, A.; Keizers, P. H.; Oostenbrink, C.; De Graaf, C.; De Kruijf, P. et al. Binding of 7-methoxy-
4-(aminomethyl)-coumarin to wild-type and W128F mutant cytochrome P450 2D6 studied by time-
resolved fluorescence spectroscopy. Biochem J 2006, 393, 635-643. 
(38) Venhorst, J.; ter Laak, A. M.; Commandeur, J. N.; Funae, Y.; Hiroi, T. et al. Homology modeling of rat 
and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental 
ligand-binding specificities. J Med Chem 2003, 46, 74-86. 
(39) Sali, A.; Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 
1993, 234, 779-815. 
(40) Notredame, C.; Higgins, D. G.; Heringa, J. T-Coffee: A novel method for fast and accurate multiple 
sequence alignment. J Mol Biol 2000, 302, 205-217. 
(41) Rost, B.; Liu, J. The PredictProtein server. Nucleic Acids Res 2003, 31, 3300-3304. 
(42) Cuff, J. A.; Clamp, M. E.; Siddiqui, A. S.; Finlay, M.; Barton, G. J. JPred: a consensus secondary 
structure prediction server. Bioinformatics 1998, 14, 892-893. 
(43) Kneller, D. G.; Cohen, F. E.; Langridge, R. Improvements in protein secondary structure prediction by 
an enhanced neural network. J Mol Biol 1990, 214, 171-182. 
(44) Laskowski, R. A.; Macarthur, M. W.; Moss, D. S.; Thornton, J. M. Procheck - a Program to Check the 
Stereochemical Quality of Protein Structures. Journal of Applied Crystallography 1993, 26, 283-291. 
(45) Colovos, C.; Yeates, T. O. Verification of protein structures: patterns of nonbonded atomic 
interactions. Protein Sci 1993, 2, 1511-1519. 
(46) Luthy, R.; Bowie, J. U.; Eisenberg, D. Assessment of protein models with three-dimensional profiles. 
Nature 1992, 356, 83-85. 
(47) Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E. et al. Automated docking using a 
Lamarckian genetic algorithm and an empirical binding free energy function. Journal of Computational 
Chemistry 1998, 19, 1639-1662. 
(48) Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental 
construction algorithm. J Mol Biol 1996, 261, 470-489. 
(49) Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic 
algorithm for flexible docking. J Mol Biol 1997, 267, 727-748. 
(50) Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-ligand 
docking using GOLD. Proteins 2003, 52, 609-623. 
(51) Wang, R. X.; Liu, L.; Lai, L. H.; Tang, Y. Q. SCORE: A new empirical method for estimating the 
binding affinity of a protein-ligand complex. Journal of Molecular Modeling 1998, 4, 379-394. 
(52) Goodford, P. J. A computational procedure for determining energetically favorable binding sites on 
biologically important macromolecules. J Med Chem 1985, 28, 849-857. 
(53) Lindahl, E.; Hess, B.; van der Spoel, D. GROMACS 3.0: a package for molecular simulation and 
trajectory analysis. Journal of Molecular Modeling 2001, 7, 306-317. 
(54) van Gunsteren, W. F.; Billeter, S. R.; Eising, A. A.; Hunenberger, P. H.; Kruger, P. et al. Biomolecular 
simulation: The GROMOS96 manual and user guide 1996. 
(55) Strobl, G. R.; von Kruedener, S.; Stockigt, J.; Guengerich, F. P.; Wolff, T. Development of a 
pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and 
inhibition studies. J Med Chem 1993, 36, 1136-1145. 
(56) de Groot, M. J.; Ackland, M. J.; Horne, V. A.; Alex, A. A.; Jones, B. C. Novel approach to predicting 
P450-mediated drug metabolism: Development of a combined protein and pharmacophore model for 
CYP2D6. Journal of Medicinal Chemistry 1999, 42, 1515-1524. 
(57) de Groot, M. J.; Ackland, M. J.; Horne, V. A.; Alex, A. A.; Jones, B. C. A novel approach to predicting 
P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative 
metabolite predictions using a combined protein and pharmacophore model for CYP2D6. Journal of 
Medicinal Chemistry 1999, 42, 4062-4070. 
(58) Meyer, U. A.; Gut, J.; Kronbach, T.; Skoda, C.; Meier, U. T. et al. The molecular mechanisms of two 
common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 
isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica 1986, 16, 449-464. 
(59) Islam, S. A.; Wolf, C. R.; Lennard, M. S.; Sternberg, M. J. A three-dimensional molecular template for 
substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. Carcinogenesis 
1991, 12, 2211-2219. 
(60) Koymans, L.; Vermeulen, N. P.; van Acker, S. A.; te Koppele, J. M.; Heykants, J. J. et al. A predictive 
model for substrates of cytochrome P450-debrisoquine (2D6). Chem Res Toxicol 1992, 5, 211-219. 
Carving out key positions 
 122
 
(61) Wolff, T.; Distelrath, L. M.; Worthington, M. T.; Groopman, J. D.; Hammons, G. J. et al. Substrate 
specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using 
immunochemical inhibition and chemical modeling. Cancer Res 1985, 45, 2116-2122. 
(62) de Groot, M. J.; Bijloo, G. J.; Martens, B. J.; van Acker, F. A.; Vermeulen, N. P. A refined substrate 
model for human cytochrome P450 2D6. Chem Res Toxicol 1997, 10, 41-48. 
(63) de Groot, M. J.; Bijloo, G. J.; van Acker, F. A.; Fonseca Guerra, C.; Snijders, J. G. et al. Extension of a 
predictive substrate model for human cytochrome P4502D6. Xenobiotica 1997, 27, 357-368. 
(64) Afzelius, L.; Masimirembwa, C. M.; Karlen, A.; Andersson, T. B.; Zamora, I. Discriminant and 
quantitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitors using alignment 
independent GRIND descriptors. J Comput Aided Mol Des 2002, 16, 443-458. 
(65) Lüdemann, S. K.; Lounnas, V.; Wade, R. C. How do substrates enter and products exit the buried 
active site of cytochrome P450cam? 1. Random expulsion molecular dynamics investigation of ligand 
access channels and mechanisms. Journal of Molecular Biology 2000, 303, 797-811. 
(66) Pearlman, D. A.; Case, D. A.; Caldwell, J. W.; Ross, W. S.; Cheatham, T. E. et al. Amber, a Package 
of Computer-Programs for Applying Molecular Mechanics, Normal-Mode Analysis, Molecular-Dynamics 
and Free-Energy Calculations to Simulate the Structural and Energetic Properties of Molecules. 
Computer Physics Communications 1995, 91, 1-41. 
(67) Kabsch, W.; Sander, C. Dictionary of protein secondary structure: pattern recognition of hydrogen-
bonded and geometrical features. Biopolymers 1983, 22, 2577-2637. 
(68) Livingstone, C. D.; Barton, G. J. Protein sequence alignments: a strategy for the hierarchical analysis 
of residue conservation. Comput Appl Biosci 1993, 9, 745-756. 
(69) Engh, R. A.; Huber, R. Accurate Bond and Angle Parameters for X-Ray Protein-Structure Refinement. 
Acta Crystallographica Section A 1991, 47, 392-400. 
(70) Morris, A. L.; MacArthur, M. W.; Hutchinson, E. G.; Thornton, J. M. Stereochemical quality of protein 
structure coordinates. Proteins 1992, 12, 345-364. 
(71) Kirton, S. B.; Kemp, C. A.; Tomkinson, N. P.; St-Gallay, S.; Sutcliffe, M. J. Impact of incorporating the 
2C5 crystal structure into comparative models of cytochrome P450 2D6. Proteins 2002, 49, 216-231. 
(72) Hess, B.; Bekker, H.; Berendsen, H. J. C.; Fraaije, J. G. E. M. LINCS: A linear constraint solver for 
molecular simulations. Journal of Computational Chemistry 1997, 18, 1463-1472. 
(73) Berendsen, H. J. C.; Postma, J. P. M.; van Gunsteren, W. F.; DiNola, A.; Haak, J. R. Molecular-
dynamics with coupling to an external bath. Journal of Chemical Physics 1984, 81, 3684-3690. 
(74) Keizers, P. H.; de Graaf, C.; de Kanter, F. J. J.; Oostenbrink, C.; Feenstra, K. A. et al. Metabolic regio- 
and stereoselectivity of Cytpchrome P450 2D6 towards 3,4-methylenedioxy-N-alkyl-amphetamines: In 
silico Predictions and experimental validation. J. Med. Chem. 2005, 48, 6117-6127. 
(75) Ekins, S.; De Groot, M. J.; Jones, J. P. Pharmacophore and three-dimensional quantitative structure 
activity relationship methods for modeling cytochrome P450 active sites. Drug Metabolism and 
Disposition 2001, 29, 936-944. 
(76) de Groot, M. J.; Ekins, S. Pharmacophore modeling of cytochromes P450. Advanced Drug Delivery 
Reviews 2002, 54, 367 - 383. 
(77) Koymans, L. M.; Vermeulen, N. P.; Baarslag, A.; Donne-Op den Kelder, G. M. A preliminary 3D model 
for cytochrome P450 2D6 constructed by homology model building. J Comput Aided Mol Des 1993, 7, 
281-289. 
(78) de Groot, M. J.; Vermeulen, N. P.; Kramer, J. D.; van Acker, F. A.; Donne-Op den Kelder, G. M. A 
three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of 
P450 101, P450 102, and P450 108. Chem Res Toxicol 1996, 9, 1079-1091. 
(79) de Graaf, C.; Pospisil, P.; Pos, W.; Folkers, G.; Vermeulen, N. P. Binding Mode Prediction of 
Cytochrome P450 and Thymidine Kinase Protein-Ligand Complexes by Consideration of Water and 
Rescoring in Automated Docking. J Med Chem 2005, 48, 2308-2318. 
(80) de Graaf, C.; Oostenbrink, C.; Keizers, P. H.; van der Wijst, T.; Jongejan, A. et al. Catalytic Site 
Prediction of and Virtual Screening Accuracy of Cytochrome P450 2D6 Substrates by Consideration of 
Water and Rescoring in Automated Docking. J Med Chem 2006, 49, 2417-2430. 
(81) Gonzales, F. J.; Vilbois, F.; Hardwick, J. P.; McBride, O. W.; Nebert, D. W. et al. Human debrisoquine 
4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D 
locus to chromosome 22. Genomics 1988, 2, 174 - 179. 
(82) Kimura, S.; Umeno, M.; Skoda, R. C.; Meyer, U. A.; Gonzalez, F. J. The human debrisoquine 4-
hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related 
gene, and a pseudogene. Am J Hum Genet 1989, 45, 889-904. 
(83) Modi, S.; Paine, M. J.; Sutcliffe, M. J.; Lian, L. Y.; Primrose, W. U. et al. A model for human 
cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding. 
Biochemistry 1996, 35, 4540-4550. 
(84) Modi, S.; Gilham, D. E.; Sutcliffe, M. J.; Lian, L. Y.; Primrose, W. U. et al. 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome 
P450 reductase. Biochemistry 1997, 36, 4461-4470. 
Chapter 3 
 123
(85) De Rienzo, F.; Fanelli, F.; Menziani, M. C.; De Benedetti, P. G. Theoretical investigation of substrate 
specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4. J Comput Aided Mol Des 2000,14, 93-116. 
(86) Snyder, R.; Sangar, R.; Wang, J. B.; Ekins, S. Three-dimensional quantitative structure activity 
relationship for CYP2D6 substrates. Quantitative Structure-Activity Relationships 2002, 21, 357-368. 
(87) Ellis, S. W.; Hayhurst, G. P.; Smith, G.; Lightfoot, T.; Wong, M. M. et al. Evidence that aspartic acid 
301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J Biol Chem 
1995, 270, 29055-29058. 
(88) Mackman, R.; Tschirret-Guth, R. A.; Smith, G.; Hayhurst, G. P.; Ellis, S. W. et al. Active-site 
topologies of human CYP2D6 and its aspartate-301 --> glutamate, asparagine, and glycine mutants. 
Arch Biochem Biophys 1996, 331, 134-140. 
(89) Hanna, I. H.; Kim, M. S.; Guengerich, F. P. Heterologous expression of cytochrome P450 2D6 
mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in 
structural integrity. Arch Biochem Biophys 2001, 393, 255-261. 
(90) Guengerich, F. P.; Miller, G. P.; Hanna, I. H.; Martin, M. V.; Leger, S. et al. Diversity in the oxidation 
of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate 
electrostatic bonding. Biochemistry 2002, 41, 11025-11034. 
(91) Guengerich, F. P.; Hanna, I. H.; Martin, M. V.; Gillam, E. M. Role of glutamic acid 216 in cytochrome 
P450 2D6 substrate binding and catalysis. Biochemistry 2003, 42, 1245-1253. 
(92) Paine, M. J.; McLaughlin, L. A.; Flanagan, J. U.; Kemp, C. A.; Sutcliffe, M. J. et al. Residues glutamate 
216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in 
cytochrome P450 2D6. J Biol Chem 2003, 278, 4021-4027. 
(93) Furuya, H.; Shimizu, T.; Hirano, K.; Hatano, M.; Fujii-Kuriyama, Y. et al. Site-directed mutageneses of 
rat liver cytochrome P-450d: catalytic activities toward benzphetamine and 7-ethoxycoumarin. 
Biochemistry 1989, 28, 6848-6857. 
(94) Raag, R.; Poulos, T. L. Crystal-Structures of Cytochrome-P-450cam Complexed with Camphane, 
Thiocamphor, and Adamantane - Factors Controlling P-450 Substrate Hydroxylation. Biochemistry 
1991, 30, 2674-2684. 
(95) Yeom, H.; Sligar, S. G.; Li, H.; Poulos, T. L.; Fulco, A. J. The role of Thr268 in oxygen activation of 
cytochrome P450BM-3. Biochemistry 1995, 34, 14733-14740. 
(96) Vaz, A. D.; Pernecky, S. J.; Raner, G. M.; Coon, M. J. Peroxo-iron and oxenoid-iron species as 
alternative oxygenating agents in cytochrome P450-catalyzed reactions: switching by threonine-302 
to alanine mutagenesis of cytochrome P450 2B4. Proc Natl Acad Sci U S A 1996, 93, 4644-4648. 
(97) Park, S. Y.; Shimizu, H.; Adachi, S.; Nakagawa, A.; Tanaka, I. et al. Crystal structure of nitric oxide 
reductase from denitrifying fungus Fusarium oxysporum. Nat Struct Biol 1997, 4, 827-832. 
(98) Vaz, A. D.; McGinnity, D. F.; Coon, M. J. Epoxidation of olefins by cytochrome P450: evidence from 
site-specific mutagenesis for hydroperoxo-iron as an electrophilic oxidant. Proc Natl Acad Sci U S A 
1998, 95, 3555-3560. 
(99) Xiang, H.; Tschirret-Guth, R. A.; Ortiz De Montellano, P. R. An A245T mutation conveys on 
cytochrome P450eryF the ability to oxidize alternative substrates. J Biol Chem 2000, 275, 35999-
36006. 
(100) Ortiz de Montellano, P. R. Arylhydrazines as probes of hemoprotein structure and function. Biochimie 
1995, 77, 581-593. 
(101) Masuda, K.; Tamagake, K.; Okuda, Y.; Torigoe, F.; Tsuzuki, D. et al. Change in enantioselectivity in 
bufuralol 1''-hydroxylation by the substitution of phenylalanine-120 by alanine in cytochrome P450 
2D6. Chirality 2005, 17, 37-43. 
(102) Flanagan, J. U.; Marechal, J. D.; Ward, R.; Kemp, C. A.; McLaughlin, L. A. et al. Phe120 contributes to 
the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel 
dextromethorphan metabolite. Biochem J 2004, 380, 353-360. 
(103) McLaughlin, L. A.; Paine, M. J.; Kemp, C. A.; Marechal, J. D.; Flanagan, J. U. et al. Why is quinidine 
an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding. J Biol 
Chem 2005, 280, 38617-38624. 
(104) Lightfoot, T.; Ellis, S. W.; Mahling, J.; Ackland, M. J.; Blaney, F. E. et al. Regioselective hydroxylation 
of debrisoquine by cytochrome P4502D6: implications for active site modelling. Xenobiotica 2000, 30, 
219-233. 
(105) Ellis, S. W.; Rowland, K.; Ackland, M. J.; Rekka, E.; Simula, A. P. et al. Influence of amino acid 
residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of 
metoprolol. Biochem J 1996, 316. 
(106) Smith, G.; Modi, S.; Pillai, I.; Lian, L. Y.; Sutcliffe, M. J. et al. Determinants of the substrate specificity 
of human cytochrome P-450 CYP2D6: design and construction of a mutant with testosterone 
hydroxylase activity. Biochem J 1998, 331 ( Pt 3), 783-792. 
(107) Bonifacio, A.; Keizers, P. H.; Commandeur, J. N.; Vermeulen, N. P.; Robert, B. et al. Binding of 
bufuralol, dextromethorphan, and 3,4-methylenedioxymethylamphetamine to wild-type and F120A 
mutant cytochrome P450 2D6 studied by resonance Raman spectroscopy. Biochem Biophys Res 


























































































Binding mode prediction of cytochrome P450 and thymidine kinase protein-
ligand complexes by consideration of water and rescoring in automated 
docking 
 
Chris de Graaf,‡* Pavel Pospisil,§* Wouter Pos,‡ Gerd Folkers,§ and Nico P.E. 
Vermeulen‡ 
 
‡Leiden Amsterdam Center for Drug Research (LACDR)/Division of Molecular Toxicology, 
Department of Chemistry and Pharmacochemistry, Vrije Universiteit, The Netherlands 
§Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH 
Zurich, Switzerland. 
*Both authors contributed equally 
 
 
The popular docking programs AutoDock, FlexX and GOLD were used to predict binding 
modes of ligands in crystallographic complexes including X-ray water molecules or 
computationally predicted water molecules. Isoenzymes of two different enzyme systems 
were used, namely Cytochromes P450 (n=19) and thymidine kinases (n=19) and three 
different “water” scenarios: i.e. docking (i) into water-free active sites, (ii) into active sites 
containing crystallographic water molecules, and (iii) into active sites containing water 
molecules predicted by a novel approach based on the program GRID. Docking accuracies 
were determined in terms of the root mean square deviation (RMSD) accuracy and, newly 
defined, in terms of the ligand catalytic site prediction (CSP) accuracy. Considering both X-
ray and predicted water molecules and the subsequent pooling and rescoring of all 
solutions (generated by all three docking programs) with the SCORE scoring function 
significantly improved the quality of prediction of the binding modes both in terms of 










Automated molecular docking methods have frequently been used to predict energetically 
favorable conformations and orientations of ligands in the interior structure of proteins. 
These methods combine search algorithms to generate different poses (docking), and 
scoring functions to determine the tightness of protein-ligand interactions1. Several 
docking algorithms and scoring functions have been described in the past few years, but 
docking (prediction of binding orientation) and scoring (prediction of binding free energy) 
accuracies of docking-scoring combinations still vary with selected protein target and 
physicochemistry of protein-ligand interactions2,3. Currently, there are several ‘open issues’ 
in automated docking, such as the inclusion or omission of explicit water molecules in the 
ligand binding pocket4,5. Despite the fact that water molecules can play an essential role in 
ligand-protein binding6-8, concrete water molecules are usually not taken into account in 
docking studies. Although many scoring functions used for automated docking include an 
energy term accounting for the free energy of desolvation of a ligand upon binding to a 
protein and occlusion of the ligand binding site from solvent (hydrophobic effect)9-12, most 
docking methods ignore water-mediated interactions between proteins and ligands. FlexX 
has been extended with an algorithm for integration and placement of water molecules 
during docking13,14, but the average improvement of docking accuracy was small. With the 
SLIDE docking program, it is possible to predict conserved binding site water molecules, 
which are displaced during docking if collisions with a ligand cannot be resolved by 
iterative translations.15 To include solvation effects, Glide docks explicit water molecules 
into the binding site for each energetically competitive ligand pose and employs scoring 
terms that measure the exposure of various functional groups to the explicit waters16. 
Structural water heterogeneity was recently successfully incorporated into the program 
AutoDock for predicting binding modes of HIV-1 protease inhibitors by using two weighted 
average methods of combining multiple target structures within a single grid of interaction 
energies.17 
Despite the lack of effective automated algorithms for including waters ‘on-the-fly’ 
during the docking process, fixed explicit water molecules have been used in several 
docking programs. However, only a few docking studies are reported which evaluate the  
effects of fixed water molecules in ligand-protein binding sites. Moreover, very few studies 
show significant effects of these water molecules on docking accuracy. When two specific 
water molecules present in the crystal structure of Factor Xa were taken into account 
during the docking of synthetic inhibitors, it was observed that all inhibitors formed an 
essential hydrogen bond with one of the two active site water molecules18. In contrast, the 
inclusion of explicit water molecules in crystal structures of influenza virus neuraminidase 
did not significantly improve the docking performance of GOLD for ligands forming water-
mediated contacts, but it did decrease docking accuracy of ligands displacing waters19. 
Validation of the GOLD docking program20 with the CCDC/Astex test-set without 
consideration of discrete water molecules showed that docking accuracies for subsets of 
structures without water-mediated protein-ligand interactions were significantly higher 
than accuracies for subsets with water-mediated interactions.21 The program GRID22 has 
been successfully used to select X-ray water molecules for the docking of carbohydrate 
derivatives to heat-labile Enterotoxin with an earlier version of AutoDock.23 Structural 
effects of water molecules on the docking performance were also evaluated for EUDOC.24 
It was concluded that EUDOC may fail to make correct predictions of ligand-receptor 
complexes when the information of structural water molecules in the binding site is not 
available. 
Automated docking can be used to select potential protein-specific substrates from large 
chemical databases and to predict ADME-properties of new drugs and drug candidates.25,26 
In the present study, automated docking strategies will be applied to two 
pharmacologically relevant biotransformation systems, namely Cytochromes P450 and 
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thymidine kinases. Cytochromes P450 (CYPs) are hemoproteins which catalyse the 
oxidation and reduction of a wide variety of endogenous and xenobiotic compounds.27,28 
They generally detoxify potentially hazardous compounds, but in a number of cases non-
toxic parent compounds are bioactivated into toxic metabolites, and procarcinogens into 
their ultimate carcinogens.29 Automated docking has primarily been applied to refine and 
validate CYP pharmacophore models and protein homology models, as was for example 
recently done for CYP2D6.30,31 Regarding CYPs, methodological research on automated 
docking approaches has mainly been focused on FlexX, including cross-docking32 and the 
use of different FlexX-scoring combinations33. These docking studies, however, did not 
consider the effect of water molecules. Caffeine and 2-amino-3-methylimidazo[4,5-
f]quinoline (MeIQ) together with water molecules placed in the vicinity of their molecular 
electrostatic potential (MEP) minima were docked into a water-free binding site of a 
CYP1A2 homology model using AutoDock34. This study, however did not demonstrate 
important effects of considering “ligand-anchored” water molecules. Thymidine kinases 
(TKs) phosphorylate thymidine and other nucleic acid bases that are subsequently 
phosphorylated by other enzymes and incorporated into the DNA. The Herpes simplex 
virus type 1 thymidine kinase (HSV1 TK) for example phosphorylates pyrimidine and 
purine analogs that are triphosphorylated to inhibit cellular DNA polymerase or to cause 
toxic effects when incorporated into DNA.35 Most antiviral-based therapies exploit the large 
substrate acceptance of HSV1 TK relative to the human isoenzyme. An extensive 
evaluation of different docking programs with respect to their docking accuracy and 
different docking-scoring combinations with respect to their scoring accuracy, and ability 
to select HSV1 TK substrates from a chemical database was described previously.2 The 
same enzyme was recently also considered for the evaluation of the docking and scoring 
performance of Glide.16,36 These studies did not consider the effect of water molecules, 
however. Recently, the presence of active site water molecules was shown to have a large 
impact on the results of virtual screening for typical HSV1 TK substrates with a sequential 
DOCK-FlexX combination37. A water-free active site was more suitable for purine-like 
structures, whereas an active site filled with two essential X-ray water molecules was more 
suitable for pyrimidine-like compounds. 
The primary aim of the present study was to find optimal docking strategies for binding 
mode prediction of ligands of two pharmacologically relevant enzyme systems, by 
evaluating the performance of various docking-scoring combinations, and considering the 
presence and absence of active site water molecules. The enzyme systems chosen for this 
purpose were Cytochrome P450s (CYPs) and thymidine kinases (TKs). Concretely, 19 
crystallized P450- and 19 TK-ligand complexes were selected for docking. In order to test 
the incorporation of water molecules in the docking process, three scenarios were pursued 
based on whether docking was performed: into i) a water free protein active site (N), ii) 
an active site containing X-ray water molecules as a solid part of the protein (X), and iii) 
an active site containing water molecules whose positions were un-arbitrarily predicted by 
a novel GRID-based protocol (P). All ligand-protein complexes were predicted by three 
selected docking programs, namely AutoDock, FlexX and GOLD. Moreover, the resulting 
docking poses were scored and ranked using the native scoring function implemented in 
the respective docking programs and the stand-alone scoring function SCORE. Docking 
accuracy was examined as root mean square deviation (RMSD) of heavy atoms of ligand 
docking poses from the reference X-ray structure, and as a newly defined criterion for 
docking accuracy, namely catalytic site prediction (CSP) accuracy. This new endpoint of 
binding mode prediction can be used to reflect whether and how a putative ligand will be 
enzymatically transformed, and thus as an analysis tool in virtual screening applications. 
Beside the use of three water scenarios (including not only X-ray water molecules, but also 
computationally predicted waters), three different docking algorithms, (re)scoring, and two 
cases of hard docking targets (presence of waters, various ligand acceptance and 
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presence of prosthetic group (heme) or cofactor (ADP) in the active site), this study 
presents one of the first comprehensive evaluations of the effects of the incorporation of 
active site water molecules on automated molecular docking. 
 
4.2 Results 
Prediction of active site water molecules 
Docking simulations were performed using three water scenarios: without water molecules 
(N), with water molecules present in the X-ray structure (X), and with predicted water 
molecules (P). Numbers of X-ray water molecules (x), predicted water molecules (p), and 
correctly predicted water molecules (c) in the vicinity (≤ 4.0 Å) of ligand atoms, and their 
interactions with reference ligand structure were analysed to examine the correctness of 
the new water prediction method applied in this study, both for CYPs and TKs  (Figure 1A 
and B). 
CYP – In many cases, the locations of X-ray active site water molecules and their 
interactions with CYP ligands (filled balls, see Figure 1A) were well predicted (“c” ≥ 1), 
concretely with 2-phenylimidazole (pdb code: 1phe, CYP101), 6-deoxyerythronolide B 
(1jio, CYP107), dimethylsulphophenazole derivative (1n6b, CYP2C5), diclofenac (1nr6, 
CYP2C5) and epothilone D (1pkf, Cyt P450EpoK) (see Figure 1A). In the case of almost all 
CYP101-terpene structures (2cpp, 2cp4, 4cpp, 6cpp, 7cpp, 8cpp), up to 2 water molecules 
were predicted to be close to the respective ligand, while not present in the X-ray 
structure (“p - c” = nr. of false positives). Water molecules ligated to the heme Fe-atom 
according to crystallographic studies (4cpp, 6cpp, 7cpp, 1phe) are not predicted (“x - c” = 
nr. of false positives). However, preliminary docking studies with a water molecule 
positioned at 1.8 Å above the heme iron atom did not have an overall positive effect on 
docking accuracy (data not shown here). 
TK – In almost all TK-complexes including thymidine derivatives, the locations of X-ray 
active site water molecules and their interactions with pyrimidine rings and sugar 
mimicking groups were correctly predicted (“c” ≥ 1) (see Figure 1B). For purines, less X-
ray active site water locations were correctly predicted and the occurrence of false 
positives (“p - c”) and false negatives (“p - x”) was shown to be highly compound specific. 
Interestingly, up to 4 false positives were predicted in case of the phosphorylated 
thymidine metabolite (1osn, VZV TK). No water molecules were accurately predicted for 
therapeutically used ganciclovir (1ki2, TK HSV1) and penciclovir (1ki3, TK HSV1) (false 
negatives). 
 
Binding mode prediction 
Binding modes of CYP-  and TK-ligand complexes were predicted using the docking 
programs AutoDock, FlexX, and GOLD in combination with their native scoring function 
and the SCORE scoring function, while considering the three different water scenarios (N, 
X, and P respectively). These 18 (3 (water scenarios) x 3 (docking algorithms) x 2 (scoring 
functions)) docking strategies were tested by assessing their ability to reproduce the 
experimental binding orientations of protein-ligand complexes of five CYP isoenzymes and 
three TK isoenzymes in terms of RMSD accuracy and CSP accuracy. Concrete results for 
each individual protein-ligand complex in terms of RMSD accuracy are presented in Table 
1, while the statistics of RMSD and CSP accuracy are presented in Figures 2A and B, and 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 1: Docking results for each protein-ligand complex in terms of RMSD accuracy. Letters N (no 
water), X (X-ray water) and P (predicted water) indicate the different scenarios concerning the 
presence or absence of water molecules. Cases in which RMSD values are below 2 Å of:  
- only nr. 1 ranked solutions according to the program implemented scoring functions (I) 
- only nr. 1 ranked solutions according to the stand-alone SCORE scoring function (S) 
- nr. 1 ranked solutions according to both the program implemented and stand-alone SCORE 
scoring functions (B) 
- any of the docking solutions, but not considered as nr. 1 ranked solutions by either the 
program implemented or stand-alone SCORE scoring functions (•). 
 
 CYP   TK 
 AutoDoc
k 
FlexX GOLD   AutoDock FlexX GOLD 
 N X P N X P N X P   N X P N X P N X P 
cam 
1akd 














2cp4   • I I I B B B  1e2iB  •        
2cpp    S S S B B B  1e2j • S S •   • I  
4cpp  S     S B B  1e2k B B B B B B B B B 
5cpp    S S S B B B  1e2m B B B N X S B B B 
6cpp S S S • • •  •   1e2n B B B      B 
7cpp  •  B B B  B   1e2p B B B B B B B B B 
8cpp  • S •  •     1ki2 B B B I B S B B B 
1mpw S  I B B B     1ki3 B B B B B B B B B 
1phd   • • I I S I   1ki4 B B B    B B B 
1phe   B S B B     1ki6 B B B I B B B B B 
1phf   • • • I   S  1ki7 B B B    B B B 
1phg   B    B B B  1ki8 S B B  B B B S B 
1p2y • • • B B B B B B  2vtk B B B B B B • B B 



















































































































          
1nr6 I B B   • • • •            
 
Incorporation of active site water molecules in automated docking studies 
CYP - The incorporation of X-ray water molecules increased the docking accuracy of the 
various docking-scoring combinations.  The relative averaged increase (RAI) of the RMSD 
accuracy was increased (19% for AutoDock (AD), 11% for FlexX (F), and 22% for GOLD 
(G)), considering successfully docked complexes (RMSD <2 Å) (Figure 2A). In addition, 
the RAI of the CSP accuracy was improved (7% for AD, 16% for F, and 13% for G, Figure 
2C). The presence of predicted water molecules during docking studies was shown to 
strongly improve RMSD accuracy (RAI of 70% for AD, 32% for F, and 7% for G), and CSP 
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accuracy of various docking-scoring combinations (RAI of 5% for AD, 13% for F, and 9% 
for G). The RMSD accuracy of the optimal docking-scoring combination for CYP without 
water (GOLD-SCORE) was increased with 16% and 10% by respectively including X-ray 
and predicted water molecules, while the CSP accuracy (AutoDock-SCORE) was increased 
with 11% and 0% respectively. Table 1 shows that the performance of AutoDock in 
finding reliable solutions for several CYP101 (cam) terpene (4cpp, 8cpp) and imidazole 
(1phe, 1phg) analogs, and the ligands of CYP107 (EryF) (1jio, shown in Figure 3) and 
CYP2C5 (1n6b, 1nr6), improved by including X-ray and/or predicted active site water 
molecules. For several ligand molecule types and different CYP isoenzymes, RMSD 
accuracy of FlexX (1phd, 1phe, 1phf, 1jio, 1izo, 1n6b) and GOLD (4cpp, 7cpp, 1phd, 1phf, 
1n6b) was also improved by the incorporation of water. 
TK - Compared to the “no water” scenario (N), RMSD accuracy for thymidine kinases in 
the presence of X-ray waters resulted in RAI of 17% for AD, 35% for F, and 0% for G 
(Figure 2B). The RAI of the CSP accuracy was also increased (8% for AD, 27% for F, and 
8% for G) (Figure 2D). The presence of predicted water molecules during docking 
simulations was also found to improve RMSD accuracy (RAI of 23% for AD, 12% for F, 
and 23% for G), as well as CSP accuracy of various docking-scoring combinations (RAI of 
17% for AD, 7% for F, and 8% for G). The RMSD accuracy of the optimal docking-scoring 
combinations for TK without water (AutoDock-SCORE) was increased with 15% by 
including either X-ray or predicted water molecules, while the CSP accuracy (AutoDock-
SCORE) was increased with 11% and 0% by including X-ray and predicted water 
molecules, respectively. The performance of AutoDock in finding reliable docking solutions 
of the pyrimidine ligands thymidine in TK HSV1 (1e2j), and EHV-4 TK (1p6x), and 5-
bromovinyldeoxyuridine (1ki8, TK HSV1, shown in Figure 3), and the R-stereoisomer of 
acyclic purine ligand 9-hydroxypropyladenine (1e2iA, TK HSV1), is increased by 
incorporating X-ray and/or predicted water molecules in the protein active site (Table 1).  
The RMSD accuracy of FlexX (1e2iA, 1ki8) and GOLD (1e2j, 1p6x, 1e2n, 2vtk) also 
increased for at least two of these ligands by the consideration of explicit X-ray and/or 
predicted active site water molecules. 
 
RMSD vs. CSP accuracy 
CYP – Generally, the different docking approaches were much more accurate in catalytic 
site prediction (CSP, correct indication of site(s) of oxidation and occurrence of covalent 
binding (Figure 2C)) than in reproducing actual X-ray binding conformations of CYP-
ligand complexes (Figure 2A). For example, in water scenario P, AutoDock was shown to 
be the best docking algorithm with respect to CSP accuracy (AD (up to 84%) > G >> F), 
while in only up to 48% of the CYP test cases, AutoDock was able to rank as top solution a 
docking pose within 2 Å RMSD of the X-ray structure. GOLD was found to be superior to 




Figure 2 (next page): Docking accuracy of different automated docking approaches for CYP and 
TK in terms of RMSD (2A and B) and CSP accuracy (2C and D), considering different scenarios with 
respect to the presence of water (N: no water; X: X-ray water; P: predicted water). Abbreviations 
on x-axis correspond to: Ā, Average RMSD distributions and CSP accuracy for all solutions of each 
docking study; I, RMSD distributions and CSP accuracy for nr. 1 ranked solutions according to the 
program implemented scoring function; S, RMSD distributions and CSP accuracy for nr. 1 ranked 
solutions according to SCORE; C, RMSD distributions and CSP accuracy for poses closest to the 
experimentally determined structure or accurately predicting the catalytic site, whatever its ranking. 
Upper bars and lower bars in panels A and B correspond to percentages RMSD ≤ 1.0 Å and RMSD 
>1.0 Å, ≤ 2.0 Å, respectively. Bars in panels C and D correspond to  percentages correctly predicted 
catalytic site. 
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TK - Different docking approaches were equally successful in predicting sites of 
phosphorylation (CSP) in TK substrates (Figure 2D) as in reproducing X-ray binding 
conformations (Figure 2B). AutoDock was shown to be the best in predicting TK-ligand 
binding modes, both with respect to RMSD (AD > G >> F) as well as to CSP accuracy (AD 
> G >> F).   
 
Rescoring 
CYP – Re-ranking of the poses generated by each of the three different docking 
algorithms with the scoring function SCORE improved the docking performance of almost 
all docking-water scenario combinations (docking strategies). This is reflected by an 
increase in docking accuracy both in terms of RMSD (relative increase of up to 58%) and 
CSP accuracy (relative increase of up to 45%) when compared to re-ranking with the 
program implemented scoring function only. Rescoring of all pooled poses generated by 
AutoDock, GOLD and FlexX with SCORE (S) yielded higher docking accuracies than those 
obtained with single docking-scoring combinations (Figure 2A): 53% vs. 16% (AD-AD) 
(AutoDock docking algorithm in combination with the AutoDock scoring function) to 53% 
(G-S) for the single docking-scoring combinations without water; 74% vs. 26% (AD-AD) to 
64% (G-G) with X-ray water molecules; and 74% vs. 41 (AD-AD) to 58% (G-S) with 
predicted waters. Rescoring ‘pooled’ solutions of the different docking algorithms yielded 
CSP accuracies comparable to those obtained with the AutoDock-SCORE combination. 
Concerning the RMSD accuracies obtained with AutoDock and FlexX, and the CSP accuracy 
obtained with FlexX, there is a big difference between the chance of finding a reliable 
solution (Ā) and the propensity of the docking algorithm to find a reliable solution, 
whatever its ranking (C). In contrast, this difference was smaller for the CSP accuracy of 
AutoDock and both the CSP and RMSD accuracy of GOLD. 
TK – Re-ranking generated by each of the three different docking algorithms with the 
scoring function SCORE was not observed to improve docking performance neither in 
terms of RMSD nor CSP accuracy of the various docking-water scenario combinations. 
However, rescoring of all pooled poses generated by AutoDock, GOLD and FlexX with 
SCORE yielded docking accuracies comparable to those obtained with the most accurate 
single docking-scoring combination (Figure 2B): 74% vs. 47% (F-S) (FlexX docking 
algorithm in combination with the SCORE scoring function) to 74% (AD-S) for the single 
docking-scoring combinations for docking without water; 90% vs. 63% (F-F) to 90% (AD-
S) with X-ray water molecules; and 90% predicted water molecules (vs. 58% (F-S) to 
90% (AD-S)). Rescoring ‘pooled’ solutions of all three docking algorithms yielded CSP 
accuracies comparable to those obtained with the AutoDock-SCORE approach. Concerning 
the RMSD accuracies obtained with AutoDock and FlexX and the CSP accuracy obtained 
with FlexX, a big difference between Ā and C was observed. In the case of the RMSD 
accuracy obtained with GOLD, and the CSP accuracy obtained with AutoDock and GOLD 
this difference was much smaller. 
 
 
Figure 3 (next page): The effect of water and rescoring on docking accuracy. The role of water 
in predicting binding modes of 6-deoxyerythronolide B in the binding pocket of CYP107 (1jio) (top), 
and 5-bromovinyldeoxyuridine in HSV1 TK (1ki8) (bottom), using AutoDock and different water 
scenarios (no water (N, left panel), X-ray water (X, middle panel), predicted water (P, right panel)). 
Orientations of docking solutions (white carbon atoms) ranked as nr. 1 with the scoring function of 
AutoDock (cyan carbon atoms) and SCORE (purple carbon atoms) are compared with those 
observed in the crystal structure (yellow). Water oxygen atoms are depicted in blue. The figures 
were prepared using Molscript 38 and Raster3D.39 
 
 











   
   













The primary aim of the present study was to develop optimal docking strategies for 
binding mode and catalytic site prediction of ligands of two pharmacologically relevant 
biotransformation enzyme systems, namely CYP and TK, by evaluating the performance of 
various docking-scoring combinations, and considering the effects of active site water 
molecules. 
 
The effect of active site water molecules on docking accuracies 
Despite the fact that water molecules can play an essential role in ligand-protein binding6-
8, only few studies show that consideration of concrete active site water molecules 
improves the accuracy of automated docking. The novel GRID-based water prediction 
protocol used in this work was shown to strongly improve the docking accuracy of the 
three docking programs AutoDock, FlexX and GOLD. The increase in docking accuracy due 
to the incorporation of X-ray water molecules was comparable to the effect of predicted 
water molecules. Results presented in Figure 1A and B show that many water locations 
and water-mediated protein-ligand interactions are correctly predicted. In the case of CYP, 
false positive water molecules are predicted as well. It must be stated, however, that 
crystal structure determinations are normally unable to detect disordered or mobile water 
molecules40. This leaves the possibility open that there are water molecules involved in 
protein-ligand binding which are not resolved in crystal structures. Indeed, it is shown that 
these additional predicted water molecules placed on energetically favorable locations in 
binding pockets (false positives), improve the docking accuracy of many CYP complexes, 
by mediating protein-ligand interactions and ‘fixating’ ligand molecules close to the centre 
of the protein active site (Table 2). The present study shows that for five CYP  
isoenzymes and three TK isoenzymes prediction of water locations, based on the energy 
landscape of the active site surface, was an appropriate method leading to satisfactory 
results. Docking into binding pockets with predicted water molecules generally yielded 
higher docking accuracies than binding mode predictions using the X-ray water molecules. 
The positions of X-ray waters in the active site are highly ligand-protein complex specific, 
while the predicted water scenario is largely ligand-independent. 
In principle, there are still some caveats associated with the use of the current predicted 
water docking strategy. If ligands of variable size are to be docked, one might use several 
differently shaped and sized solvated protein binding pockets for a target, containing 
different numbers and configurations of water molecules. Such a procedure will 
significantly increase the computational effort, however. Moreover, this strategy will still 
not take the replacement of water molecules by functional groups of ligands fully into 
account, as ligands can possess different functional groups and can be differently 
positioned in the active site. Docking poses in differently solvated binding pockets should 
be compared based on scoring functions, however, at this stage it is not fully clear yet 
how docking scores obtained from structures containing different numbers of bound 
waters should be compared. Future evaluation of the present predicted water approach on 
a wider range of ligands and protein targets will show whether or not such an extended 
predicted water scenario is generally applicable and useful for virtual screening 
approaches, including docking into apo-enzymes. 
 
Protein-ligand complex specific docking accuracy 
Docking accuracies of AutoDock, FlexX and GOLD were found to be protein-ligand complex 
specific. The performance of all docking-scoring combinations to predict top ranked 
docking poses within 2 Å from the X-ray structure, was much higher for TK-ligand 
complexes, than for CYP-ligand complexes. This might be explained by the fact that the 
binding pockets of the respective CYP isoenzymes are larger than those of the TK 
isoenzymes. Concerning CYP docking, GOLD resulted in a significantly higher RMSD 
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accuracy than the two other docking programs. AutoDock was superior with respect to 
RMSD accuracy and catalytic site prediction (CSP) accuracy in the case of TK, while 
AutoDock RMSD accuracy was rather low for CYP-ligand binding modes. Previous docking 
studies comparing the RMSD docking accuracy of FlexX and GOLD showed GOLD to give 
superior results2,3, while two recent comparative studies also demonstrated that the 
relative performance of AutoDock, FlexX and GOLD41,42 varied with the selected protein 
target. As protein-dependent docking accuracies were also observed in the present study, 
it is suggested that, prior to docking studies determining unknown binding modes of 
protein-ligand complexes, one should find the best docking algorithm for a specific protein 
target by using a test set of protein-ligand X-ray structures. For most proteins, however, a 
sufficiently large set of experimentally determined structures is not yet available. 
It is known from literature that the docking accuracy of docking-scoring combinations 
may not only vary with the protein target, but also with the physicochemistry of protein-
ligand interactions2,3. The CYP ligands included in this work are small and rigid apolar 
terpene substrates and phenylimidazole inhibitors covalently bound to the heme Fe-atom 
of CYP101, as well as larger and more polar macrocycles of CYP107 and Cyt P450EpoK, 
flexible long-chained aliphatic palmitoleic acid substrate of Cyt P450BSβ, and moderately 
flexible aromatic substrates of CYP2C5. Selected TK complexes were nucleic acid bases of 
two general classes: pyrimidine and purine derivatives. Generally, all selected TK 
isoenzymes have a polar active site including an ADP cofactor or SO42- ion. In comparison 
to the CYPs, this active site of TKs is rather small. The AutoDock docking algorithm and 
scoring function were not capable of accurately reproducing the binding conformations of 
the relatively small and rigid, apolar camphor and phenylimidazole derivatives in the 
CYP101 (Table 1). In contrast,  AutoDock was very successful in reproducing the binding 
conformations of rigid, big polar macromolecules 6-deoxyerythronolide B and epothilone 
D, the flexible palmitoleic acid, the moderately flexible sulphaphenazole derivative and 
diclofenac in other P450 isoenzymes, especially when taking active site water molecules 
into consideration. AutoDock was also able to predict correct binding modes of almost all 
TK ligands (both pyrimidine and purine derivatives). The GOLD algorithm and scoring 
function was not very suitable for some camphor and imidazole derivatives but was 
appropriate for all other CYP and TK ligands. For both enzyme systems, the docking 
accuracy of the FlexX algorithm and scoring function was more docking-case specific than 
ligand type specific. 
 
Influence of input ligand geometry and convergence of docking simulations on 
docking accuracy  
Several protein-ligand complexes used in this study, were also incorporated in single and 
comparative evaluations of  AutoDock, FlexX, or GOLD described by others for Cyt 
CYPs10,20,21,32,42,43, as well as for TK2,41, be it without taking the presence of explicit water 
molecules into account. The RMSD accuracy results presented in these studies are not 
always consistent with RMSD accuracies obtained in the present study. Most likely this is 
due to the effect of input ligand geometries and orientations16,32, and the number of 
independent docking runs used (convergence of the docking simulation)44 on the 
performance of the docking programs. In the present study, the ligands were energy 
minimized and unarbitrarily translated to the midpoint of the protein active site, rather 
than the usual approach in which the X-ray conformation is used as starting structure. The 
latter method may yield biased results as the ligand is already in an energetically favorable 
conformation and orientation (energy minimum). Regarding TK, small conformational 
changes in the TK HSV1 binding sites used in this work, compared to the (lower 
resolution) protein structure (pdb-code 1kim) used in other studies, might explain 




Catalytic site prediction accuracy  
Prediction of metabolite formation is increasingly seen as essential for the discovery and 
development of new drugs and drug candidates31. In order to predict whether and how a 
putative ligand will be enzymatically transformed, we have introduced a novel docking 
accuracy criterion, called catalytic site prediction (CSP). No matter what docking approach 
was used, the qualitative predictions of catalytic sites in ligands were found to be very 
accurate compared to the more quantitative criterion of RMSD accuracy, even though a 
non-linear relationship between both parameters is undisputed. Consequently, the CSP 
accuracy could be used as a powerful new analysis tool in virtual screening applications to 
select hits (i.e. substrates, products and inhibitors) from chemical databases without 
manual and visual inspection. The need for computational approaches to predict likely 
sites of metabolism, or ‘soft spots’, is also expressed by the recent development of other 
molecular modelling methods for this purpose45. 
 
Rescoring 
The CYP and TK docking performance of each of the three docking programs showed a 
significant improvement by re-ranking the ligand poses with the scoring function SCORE. 
The positive effect of rescoring was most pronounced in the case of CYP. Docking 
accuracy (RMSD and CSP) was found to be even more improved (in the case of CYP), or 
comparable to the most accurate docking-scoring combination (in the case of TK) by 
rescoring all ‘pooled’ AutoDock, GOLD and FlexX docking runs with SCORE, no matter 
which water scenario was taken into account. These remarkable findings show that 
scoring/rescoring is an essential aspect of automated docking, and even predominates 
docking, a conclusion in agreement with previously published comparisons2,44,46. By using 
different docking algorithms, one can search conformational space more extensively and, 
by inference, one is more likely to find ‘correct’ binding conformations among the large 
ensembles of docking solutions. The success of a, here proposed strategy of using multiple 
docking programs was recently also demonstrated by the evaluation of ConsDock3, a 
program developed for the consensus analysis of all possible poses generated by DOCK47, 
FlexX, and GOLD. It is therefore advised to rescore the ‘pooled’ solutions of multiple 
docking algorithms with a robust separate scoring function, and to include active site 
water molecules in docking simulations. Future studies still have to determine whether 
better results can be achieved by using other scoring functions or consensus scoring 
approaches46. The present study proved SCORE to be very suitable for this purpose. 
 
4.4 Conclusions 
The present study concerns a first comprehensive evaluation of the effects of explicit 
active site water molecules on molecular docking based binding mode prediction with 
three different docking programs, namely AutoDock, FlexX and GOLD. Scenarios 
considering crystallographically determined and computationally predicted active site water 
molecules tested on two sets of therapeutically important protein-ligand systems (i.e. 
Cytochromes P450 (CYPs) and thymidine kinases (TKs)) turned out to perform better than 
docking approaches that omit water molecules in terms of RMSD accuracy. The scenario 
including predicted water molecules was comparable or better than the scenario including 
X-ray water molecules. Future research should be focused on a more diverse description 
of multiple water configurations in the active site, combined with a robust scoring function 
properly taking solvent configurations into account. A newly defined endpoint of docking 
accuracy was the catalytic site prediction (CSP) accuracy, in the present systems 
corresponding to sites of oxidation, covalent binding and/or phosphorylation. As the 
catalytic sites were accurately predicted by the (water incorporated) docking strategies, 
the CSP accuracy criterion can also be used for virtual screening applications. Rescoring of 
poses with the stand-alone scoring function SCORE significantly improved the docking 
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accuracy of each of the three docking algorithms, especially, when rescoring was 
performed on ‘pooled conformations’ produced by all three docking programs. Pooled 
scoring is advised to be used, especially when the computational chemist has no 
appropriate protein-ligand test set available to find an optimal docking strategy. The 
presented docking strategies, considering active site water molecules and (pooled) 
rescoring, mark an alternative development in ligand-protein binding mode and catalytic 
site prediction. They can be used not only to select potential protein-specific substrates 
and to predict probable sites of catalysis, but also to refine and evaluate homology 
models, and to generate energetically favorable starting structures for advanced molecular 
dynamics simulations. 
 
4.5 Computational Methods 
Preparation of ligand and target molecules 
Ligand input files have been generated with Sybyl 6.8 (TRIPOS Inc., St. Louis). First, ligand 
structures were extracted from the Protein Databank (pdb) file (containing only non-hydrogen 
atoms). After proper assignment of Tripos atom types48, hydrogen atoms were added to the ligands 
(assuming a physiological pH of 7.4) and partial atomic charges were calculated using the 
Gasteiger-Marsili method. Subsequently, ligands were energy-minimized in vacuo using the Tripos 
force field and translated to the centre of the active site as determined by PASS49. This procedure 
guarantees that the ligand input structure for docking has no “X-ray information” of the pdb 
structure. X-ray structures served as reference structures for the calculation of the RMSD and CSP 
accuracy (see below). Figure 1A and B show the molecular structures of all ligands of the CYP and 
TK enzyme systems. 19 Structures of CYP-ligand complexes were selected from 45 complexes 
deposited at the Protein databank. The excluded complexes are either variations on CYP-terpene, 
or CYP-imidazoles, complexes occupying two ligands simultaneously, large covalently bound 
inhibitors in the CYP protein structure, CYP-alkylcyanide complexes. Complexes in which the 
orientation of the ligand did not correspond to experimentally determined biotransformation 
products were also excluded from this study to be able to make a clear comparison between the 
RMSD and CSP accuracies of the docking strategies used. From 25 TK complexes deposited at the 
Protein databank, analogously, 19 structures were selected excluding complexes with lower 
resolutions and complexes with large polyphosphate ligands resolved to study the intermediate 
state50. Since many TKs are dimers, those monomers with more X-ray waters present in the active 
site were selected.  In the case of 1e2i, with stereoisomers each binding in two different binding 
modes, one stereoisomer-specific mode from each monomer was selected. In order to have also an 
equine protein-ligand complex in the TK test set, VZV TK with ((E)-5-(2-bromovinyl)-2’-
deoxyuridine-5’-monophosphate) (pdb-code 1osn) was included in the analysis, even though this is 
a structure with a monophosphorylated product. In both enzyme systems, heme moiety (CYP), 
cofactor ADP (TK) or sulphate ions (TK) were considered as a part of the protein and Tripos atom 
types were defined accordingly. Following the standard program protocols10,13,20, protein structures 
were protonated using the Biopolymer module in Sybyl. For the AutoDock studies, Kollman united 
atom and Gasteiger-Marsili partial charges were assigned to the protein and ligand structures, 
respectively.  
 
Consideration of active site water molecules 
In order to test the incorporation of water molecules in the docking process, three scenarios were 
pursued based considering the presence or absence of water in the protein active site: without 
water molecules (N), with water molecules solved in the X-ray structure (X), and with water 
molecules predicted using a protocol based on the program GRID22 and a ligand-based cut off (P). 
To predict the energetically favorable positions of water molecules in the interior structure of the 
protein target (scenario P), a rectangular grid box of 21.75 x 21.75 x 21.75 Å3 with grid points 
separated by 0.333 Å, centred on the midpoint of the ligand binding pocket, was automatically 
hydrated with 25 water molecules (using an energy cut-off value of 5 kcal/mol) within the GRID21 
version of GREATER (www.moldiscovery.com/docs/grid21). An AutoDock 3.0 tool, pdb-volume, was 
used to calculate the dimensions of a ‘minimal’ box for the different ligands. Predicted water 
molecules situated within at least 4.5 Å, or half the length of the largest ligand box-dimension from 
the active site centre, were excluded from the docking studies. The positions of the hydrogen 
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atoms of both crystallized (scenario X) and predicted water (scenario P) molecules were optimised 
using DOWSER51. Due to the fact that this program only carries out calculations on buried water 
molecules with an energy cut off of 12 kcal/mol, the DOWSER algorithm had to be adapted for this 
purpose (the modified code for DOWSER is available upon request). It was essential to modify the 
AutoGrid program (part of the AutoDock package) to enable docking in the presence of water. This 
program was changed so that it considered an oxygen atom bound to two hydrogen atoms as a 
potential hydrogen bond acceptor, as was done in an earlier AutoDock study23 (the modified code 
for AutoGrid is available upon request). 
 
Docking studies 
Automated docking studies were performed with three different docking algorithms, AutoDock 3.0 
(‘Lamarckian’ genetic algorithm)10, FlexX 1.10 (incremental construction algorithm13, as 
implemented in Sybyl 6.8) and GOLD 1.2 (‘Darwinian’ genetic algorithm)20. As scoring is a very 
important second aspect of automated docking methodologies, it was decided to investigate the 
effect of re-scoring: the process of re-prioritisation of  docking solutions (primarily ranked by the 
‘native’ scoring function implemented in the docking program) with an additional stand-alone 
scoring function. Preliminary docking studies in CYP and TK, showed that among different “stand-
alone” scoring functions (SCORE11, scoring functions included in the Sybyl CScore module (TRIPOS 
Inc., St. Louis) and X-SCORE suite12), SCORE was either the best one (for CYPs) or very well 
performing (for TKs) in selecting docking conformations with the lowest RMSD-values from all 
docking poses generated by the three different docking algorithms (data not shown here). To limit 
the amount of data on docking accuracies to be presented, only the rescoring results of SCORE 
were therefore shown. SCORE parameters were developed for the heme residue in CYPs44 as well 
as AutoDock, FlexX and SCORE parameters for ADP and SO42- in TKs, consistent with the heme, 
NADP+ and SO42- Tripos atom types (used by GOLD), respectively (see supplemental material). For 
all docking parameters, standard values were used as described for AutoDock10, FlexX52 and GOLD 
(“standard default settings”)20, except the amount of independent docking runs performed for each 
docking simulation. Multiple docking runs can increase the performance of docking programs5, as 
was shown specifically in the case of AutoDock44. To meet aspects of calculation time and data size 
on one hand, and convergence criteria and statistical relevance on the other hand, 50 independent 
docking runs were performed for each docking case. The active site centre determined by PASS is 
taken as AutoDock affinity grid centre, probe location for FlexX studies, and the starting position of 
the GOLD flood fill algorithm. AutoDock affinity grid calculations were carried out with the same 
grid box as used for the prediction of positions of active site water molecules. The FlexX binding 
pocket is defined as the amino acid residues within 7 Å from the ‘translated’ ligand structure (see 
above). In this way, active sites of approximately the same size were used in all three docking 
programs. 
 
Analysis of docking results 
Two different criteria were used for determining the docking accuracy of different docking 
approaches:  
• Root mean square deviation (RMSD) of heavy atoms of ligand docking poses from the 
reference X-ray structure, referred to as RMSD accuracy. RMSD values were calculated 
comparing all non-hydrogen atoms of the ligands with respect to the experimental X-ray 
structure binding modes using the g_rms tool of the Gromacs package53. Test cases were 
considered to be successfully docked and very accurately docked when RMSD-values were 
lower than 2.0 and 1.0 Å, respectively3,21,32,54,55. 
• Percentage of docking solutions with binding modes corresponding to experimentally 
determined major biotransformation products, referred to as catalytic site prediction (CSP) 
accuracy. Ligand atoms were considered to be potential sites of oxidation (CYP substrates) 
or covalent binding (CYP phenylimidazole inhibitors) when they were within 5.5 Å from the 
CYP heme Fe-atom, and potential sites of phosphorylation (TK substrates) within 5.0 Å from 
HSV1 TK Glu-83, VZV TK Glu-48 or EHV-4 TK Glu-60 carboxylate oxygen atoms (see also 






RMSD and CSP accuracies are presented as:  
• Average RMSD distributions and average percentages of successful catalytic site predictions 
for all solutions of each docking study (illustrating the chance of finding a reliable solution) 
(Ā).  
• RMSD distributions and CSP accuracy for nr. 1 ranked solutions according to the program 
implemented scoring function (reflecting the ability of the program implemented scoring 
functions to properly rank poses after the docking procedure) (I). 
• RMSD distributions and CSP accuracy for nr. 1 ranked solutions according to the scoring 
function SCORE (reflecting the ability of SCORE to properly rank poses after the docking 
procedure) (S). 
• RMSD distributions and CSP accuracy for poses closest to the experimentally determined 
structure (the propensity of the docking algorithms to find a reliable solution, whatever its 
ranking) (C). 
 
In the case of ligands experimentally determined to bind in two orientations in the same protein 
binding pocket (e.g., CYP: 1akd, 8cpp, 1p2y, and 1n6b, and TK: 1e2i), RMSD and CSP accuracies 
were determined by comparing docking poses closest to the X-ray binding mode. To compare the 
‘overall’ difference in performance of the different docking-scoring combinations and water 








where Ā, I, and S indicate the RMSD or CSP accuracies defined above for the scenario without 
active site water N, and a water scenario W (either with X-ray waters (X) or predicted waters (P)). 
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Automated docking strategies successfully applied to binding mode predictions of ligands 
in Cyt P450 crystal structures in an earlier study [de Graaf et al. J. Med. Chem. 2005, 7, 
2308-2318], were used for the catalytic site prediction (CSP) of 65 substrates in a refined 
and validated CYP2D6 homology model. Consideration of water molecules at predicted 
positions in the active site and rescoring of pooled ligand docking results from four 
different docking programs (AutoDock, FlexX, GOLD-Goldscore, GOLD-Chemscore) with 
the SCORE scoring function enabled successful predictions of the experimentally reported 
sites of catalysis of more than 80% of the substrates. Three different database docking 
algorithms (FlexX, GOLD-Goldscore, GOLD-Chemscore) were subsequently used in 
combination with six scoring functions (Chemscore, DOCK, FlexX, GOLD, PMF, SCORE) to 
assess the ability of docking-based virtual screening methods to prioritize 20 known 
CYP2D6 substrates seeded into a drug-like chemical database of 980 compounds (in the 
absence and presence of active site water molecules). Finally, the optimal docking strategy 
in terms of virtual screening accuracy, GOLD-Chemscore with consideration of active-site 
water (60% of known substrates recovered in the top 5% of the ranked drug-like 
database), was verified experimentally: it was successfully used to identify high-affinity 
CYP2D6 ligands among a larger proprietary database (19.619 entries) and to discriminate 
between high affinity and medium affinity ligands. 
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5.1 Introduction 
Automated molecular docking has become an important computational method for 
predicting protein-ligand interactions, guiding lead finding and optimisation in drug 
discovery.2,3 It combines search algorithms to generate multiple conformations and 
orientations of ligands within the binding site of proteins, with scoring functions to 
determine the tightness of protein-ligand interactions.4 Several docking algorithms and 
scoring functions have been described in the past few years, and very recently, several 
comparative studies of available docking tools have been reported.1,5-17 Accuracies of 
docking (prediction of binding orientation), scoring (prediction of absolute binding free 
energy) and ranking (discrimination of active from random compounds) of different 
combinations of docking algorithms and scoring functions still depend on the protein 
target and the physicochemistry of the protein-ligand interactions.1,18 This suggests that a 
docking-scoring strategy should be specifically optimised for the system under study. 
Other unresolved issues in automated docking are the consideration of protein flexibility 
and the inclusion or omission of explicit water molecules in the ligand binding pocket.19,20 
In the present study, automated docking strategies, that were successfully applied to 
the binding mode prediction of Cytochrome P450-ligand crystal structures in an earlier 
study,20 will be used for binding mode prediction and structure-based virtual screening of 
substrates of one of the most relevant drug metabolizing Cytochromes P450 (CYP) 
isoenzymes, being the human CYP2D6. Cytochromes P450 are hemoproteins which 
catalyse the oxidation and reduction of a wide variety of endogenous and xenobiotic 
compounds.21,22 They generally detoxify potentially hazardous compounds, but in a 
number of cases non-toxic parent compounds are bioactivated into toxic metabolites, or 
procarcinogens into their ultimate carcinogens.23 Although the expression levels of CYP2D6 
are only 2% of all hepatic CYPs, it is the second most important drug metabolizing enzyme 
after CYP3A4, and involved in the metabolism of about 30% of the currently marketed 
drugs.24,25 Large interindividual differences exist in CYP2D6 activity, due to gene 
multiplicity and polymorphisms, thus further increasing its clinical importance.26,27 The 
early identification of potential CYP2D6 substrates and prediction of their metabolism is 
therefore advantageous in the discovery and development of new drugs. CYP2D6 is one of 
the CYP isoforms studied most extensively using molecular modeling.28 Several homology 
model structures of CYP2D6 have been built (e.g.29-31), refined and validated 
experimentally, by site-directed mutagenesis studies and NMR spin lattice relaxation rate 
measurements, and are consistent with pharmacophore models (notably 3D-QSAR) of 
inhibitors and substrates.32,33 
Automated docking approaches have been successfully applied for the prediction of the 
site of catalysis in substrates, the refinement and validation of CYP homology models and 
the construction of pharmacophore models.28 Very recently, improved docking strategies 
for binding mode prediction of crystallized CYP-ligand complexes were described, which 
considered active site water and rescoring of ‘pooled’ conformations from different docking 
programs.20 In another recent study, an optimized scoring function describing heme-ligand 
interactions was used.34 Although automated docking has been frequently used for binding 
mode prediction of CYP-ligand complexes, structure-based virtual screening studies of 
chemical databases against Cytochromes P450 are scarce. Experimentally determined 
binding affinities of 11 different CYP101(cam)-ligand complexes showed no clear 
correlation with values from different C-Score scoring functions on CYP101(cam)-ligand 
crystal structures nor on complexes produced by the automated docking program FlexX.35 
Nevertheless, the docking and scoring could still be used to prioritize virtual screening hits 
of a chemical database against a CYP101(cam) crystal structure and a CYP3A4 homology 
model.35 Early virtual screening studies were also performed with the docking program 
DOCK to identify selective substrates,36 and imidazole inhibitors37 for wildtype and L244A 
mutant CYP101 (cam) from 20.000 and 3.508 compound databases, respectively. Very 
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recently, no significant correlations were found between two training sets of respectively 
21 and 30 experimental Ki values and GOLD-Chemscore docking scores on a CYP2D6 
homology model.38 In the same study, a weak correlation was found between 
experimental IC50 values and docking scores of a small database of 33 compounds, but 
nevertheless docking scores could be successfully used to discriminate between weak (IC50 
> 10 µM) and strong inhibitors (IC50 < 10 µM).38 
Here, we present an extensive automated docking study for the catalytic site prediction 
(CSP) of human CYP2D6 substrates as well as the first automated docking-based virtual 
screening for high affinity substrates of CYP2D6 in a large chemical database. The primary 
aim of the present study was to find optimal docking strategies for binding mode 
prediction and virtual screening of CYP2D6 substrates by evaluating the performance of 
various docking-scoring combinations, and considering the presence and absence of 
active-site water molecules. The automated docking approaches recently applied to 
binding mode prediction of Cyt P450-ligand crystal structures,20 were used for the catalytic 
site prediction (CSP) of 65 substrates of CYP2D6 (see Table 1) and tested with respect to 
their ability to prioritize 20 known CYP2D6 substrates seeded into a chemical database of 
980 drug-like compounds.1 Docking was performed with four different docking algorithms: 
AutoDock39 (‘Lamarckian’ genetic algorithm, AD), FlexX40 (incremental construction 
algorithm, F), and GOLD-GOLD (GG) and GOLD-Chemscore (GC) (in which the GOLD41 
(‘Darwinian’ genetic algorithm) docking simulation is guided by the Goldscore41 and the 
Chemscore42 scoring function, respectively14). The active site of our carefully refined and 
validated CYP2D6 homology model30,43,44 was either considered to be water-free (N) or 
containing water molecules whose positions were unarbitrarily predicted by a novel GRID-
based45 protocol (W).20 The resulting docking poses were scored and ranked using the 
scoring function implemented in the docking program and a number of stand-alone 
scoring functions (those implemented in the CScore module (Chemscore42, D-Score46, F-
Score40, G-Score41, PMF47) and SCORE48). Finally, the optimal docking strategy was verified 
experimentally: it was used to identify high-affinity CYP2D6 ligands among a larger 
proprietary database (19.619 entries) and to discriminate between high affinity and 
medium affinity ligands. 
 
5.2 Results 
Catalytic Site Prediction 
The percentage of docking solutions with binding modes corresponding to experimentally 
determined major biotransformation products, referred to as catalytic site prediction (CSP) 
accuracy (see Materials and Methods), was used as the criterium for determining docking 
accuracy of different docking approaches. Catalytic sites of 65 known CYP2D6 substrates 
were predicted using the docking algorithms AutoDock (AD), FlexX (F), and GOLD (in 
which the docking simulation is guided by either the Goldscore (GG) or the Chemscore 
(GC) scoring function). Docking algorithms were used in combination with their native 
scoring functions and the SCORE (S) scoring function, with (W) and without (N) the 
consideration of water molecules at predicted positions in the active site of our refined and 
validated CYP2D6 homology model.30,43,44 In addition, docking poses generated by all four 
docking algorithms were pooled and rescored with SCORE. CSP results of each ligand-
protein complex by the 18 docking approaches (i.e., 4 docking algorithms x 2 water 
scenarios x 2 scoring functions + pooled conformations with and without active-site water) 
are listed in Table 1. Also indicated are the relative average increase percentages (RAI, 
see Materials and Methods) of CSP accuracy due to consideration of water and rescoring 
with SCORE for these approaches.  
The statistical CSP accuracy is graphically summarized in Figure 1. The presence of 
predicted water molecules during docking studies was shown to strongly improve CSP 
accuracy of all docking-scoring combinations (see Table 1 and Figure 1). CSP accuracies 
CYPs, drugs, and dock’m all 
 150
using FlexX (RAIwater = 43%) and AutoDock (30%) were more improved by the 
consideration of water than the docking performance of GOLD-Goldscore (20%)  and 
GOLD-Chemscore (14%). The CSP accuracy of the optimal docking-scoring combination 
for CYP2D6 without water (AutoDock-SCORE) was increased by 33% by including 
predicted active site water molecules. An illustrative example of the effect of active site 
water molecules on CSP is shown in Figure 2. 
The CSP accuracies of the AutoDock, FlexX, GOLD-Goldscore and GOLD-Chemscore 
programs were more docking-case specific than ligand type specific. No strong correlations 
could be found between CSP accuracy and molecular weight or the number of rotational 
bonds. Docking results were in many cases sensitive towards small differences in chemical 
structure of the substrate. This is most clearly examplified by the fact that for all docking 
programs stereoisomer-dependent (amiflamine, metoprolol, fluoxetine, tolterodine, 
venlafaxine, carteolol, propranolol, bufuralol, MDMA, MDEA, MDPA, promethazine, 
citalopram, azelastine), regioisomer-dependent (m- and p-tyramine) and MDMA- and 
MAMC-derivative-dependent CSP accuracies were observed (see Table 1). Re-ranking of 
the poses generated by each of the three different docking algorithms with the scoring 
function SCORE improved the docking performance of almost all docking-water scenario 
combinations (docking strategies). This is reflected by an increase in CSP accuracy (RIscore 
of up to 27%, see Figure1 and Table 1) as compared to ranking with the scoring 
function implemented in the respective docking program. 
 
Figure 1: Cataltytic site prediction accuracy of different automated docking approaches 
for 65 CYP2D6 substrates, considering different scenarios with respect to the presence of water (N: 
no active-site water (light grey); W: water at predicted positions in the active site (dark grey)). 
Abbreviations on the x-axis correspond to: Ā, Average CSP accuracy for all solutions of each 
docking study; I, CSP accuracy for nr. 1 ranked solutions according to the scoring function 
implemented in the docking program; S, CSP accuracy for nr. 1 ranked solutions according to 
SCORE; C, CSP accuracy for poses accurately predicting the experimentally determined catalytic 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Rescoring of all pooled poses generated by AutoDock (AD), FlexX (F), GOLD-Goldscore 
(GG), and GOLD-Chemscore (GC) using the SCORE scoring function (S) yielded equal or 
higher CSP accuracies than those obtained with single docking-scoring combinations 
(Figure 1): 68% (pooled conformations rescored with SCORE) vs. 20% (FlexX docking 
algorithm in combination with the FlexX scoring function; F-F) to 69% (GC-S) for the 
single docking-scoring combinations without water; 80% (pooled-SCORE) vs. 33% (F-F) to 



















Figure 2: R-propranolol docked in the binding pocket of CYP2D6, using FlexX in the absence (left 
panel) and presence (right panel) of active site water. Orientations of 50 docking solutions (white) 
ranked as nr. 1 with the scoring function of  FlexX (yellow) and SCORE (purple) are compared. 
Amino acid residues involved in substrate binding (F120, E216, F483, D301) are shown. Water 
oxygen atoms are depicted in blue and the active-site water molecule observed to mediate protein-
ligand hydrogen bond is indicated (WHB). 
 
Evaluation of Virtual Screening strategies 
The virtual screening accuracies of three different automated docking strategies was 
subsequently evaluated in terms of hit rate and yield (see Materials and Methods) of 20 
known CYP2D6 substrates (see Table 1) among the top-ranked docking solutions of a 
chemical database of 1000 drug-like compounds. Three docking algorithms (FlexX, GOLD-
Goldscore and GOLD-Chemscore) were used in combination with six different scoring 
functions (Chemscore, DOCK, FlexX, Goldscore, PMF, SCORE), with and without the 
consideration of active site water molecules, yielding in total 3 x 6 x 2 = 36 different 
docking strategies. AutoDock was not applied in our virtual screening studies as this 
docking algorithm is not fast enough for this purpose. For clarity, only the results of the 
three docking programs in combination with the scoring function implemented in the 
program and the best performing stand-alone scoring function (at top 5%) are shown in 
Table 2 and Figure 3. Results for all docking-scoring combinations are available as 
supplementary material. Virtual screening for high affinity CYP2D6 substrates was 
consistently improved by including active site water, but the accuracy of virtual screening 
depended strongly on the docking-scoring combination. Hit rates and yields of FlexX 
docking were unsatisfactory low, and even by rescoring with DOCK and consideration of  
active site water, the virtual screening accuracy of FlexX docking resulted in hit rates and 
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The virtual screening accuracy of GOLD-Goldscore docking was even lower, resulting in a 
maximum yield and hit rate of 4% and 10%, respectively, including active-site water and 
using either the Goldscore or PMF scoring function (at top 5%). GOLD-Chemscore docking 
in combination with the Chemscore scoring function, however, clearly outperformed all 
other docking-scoring combinations with respect to virtual screening accuracy, represented 
by a yield and hit rate of 24% and 60%, respectively (at top 5%), when active-site water 
molecules were included. 
 
Virtual Screening for high affinity CYP2D6 substrates  
An initial proprietary database of 5.760 structures was enriched by generating stereo-
isomers and tautomers for each compound, yielding 19.619 entries in total. The most 
successful virtual screening docking strategy (GOLD-Chemscore, with consideration of 
active-site water molecules) was used to screen and rank this database against our 




















Figure 4: Distribution of Chemscore scores of the 19.619 compound proprietary database. The 
experimentally tested samples (of eight compounds) at the top 0.1% (~45-48 kJ/mol) and top 10% 
(~36 kJ/mol) of the database, shown in Tables 4-5, are indicated with arrows. 
 
The affinities (as reflected by IC50’s) of four typical CYP2D6 inhibitors and substrates 
(Table 3), and eight top 0.1% (Table 4) and eight top 10% (Table 5) ranked 
compounds were determined experimentally. Stereo-isomers (of BS7840, BS7581, and 
BS7565) and tautomers (GBR30111) of the selected hits were found to have 
approximately the same docking scores. Among the eight top 0.1% ranked compounds, 
four compounds had an inhibitory capacity for CYP2D6 close to that of quinidine (IC50 < 
0.3 µM), one compound comparable to that of dextromethorphan and quinine (1-10 µM), 
two comparable to that of sparteine (10-100 µM), while one compound had negligible 
inhibitory capacity for CYP2D6 (>200 µM). Among the eight top 10% ranked compounds, 
no compounds had an inhibitory capacity for CYP2D6 close to that of quinidine, one 
compound comparable to that of dextromethorphan and quinine, three comparable to that 
of sparteine, and four had negligible inhibitory capacity for CYP2D6. Using an IC50 < 10 µM 
to define a CYP2D6 inhibitor (as was done in another study38), hit rates of the 
experimentally tested samples at the top 0.1% and top 10% ranked scorers were 63% 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































The primary aim of the present study was to find optimal docking strategies for catalytic 
site prediction and virtual screening of CYP2D6 substrates by evaluating the performance 
of various docking-scoring combinations, and considering the presence and absence of 
active site water molecules. 
 
The effect of water on CSP accuracy and virtual screening accuracy 
Despite the fact that water molecules can play an essential role in ligand-protein 
binding,50-52 explicit water molecules are usually not taken into account in automated 
docking studies. Many scoring functions used for automated docking include an energy 
term accounting for the hydrophobic effect,39,48,53,54 but only few docking programs allow 
for explicit water-mediated interactions between proteins and ligands during the docking 
simulation.7,55-57 Furthermore, only a few docking studies are reported which evaluate the 
effects of water molecules at specific locations in the ligand-protein binding sites,20,58-66. 
More and more of these studies show significant effects of active-site water molecules on 
docking accuracy and virtual screening accuracy. The current study shows that water 
molecules placed on energetically favorable locations in the CYP2D6 binding pocket, 
improve the CSP and virtual screening accuracy of automated docking. The active site 
water molecules were observed to both mediate protein-ligand interactions and ‘fixate’ 
ligand molecules close to the center of the protein active site (see Figure 2). In an earlier 
paper we discussed the possible caveats associated with the use of the GRID-algorithm to 
predict water-positions in the current docking strategy: the need for differently solvated 
binding pockets of a protein target (containing different numbers and configurations of 
water molecules) to accomodate ligands of variable size and topology.20 Linked to this are 
increased computational efforts and the necessary use of scoring functions for comparison 
of docking scores obtained from ligand-protein complexes containing different numbers of 
bound waters. 
 
Substrate- and docking strategy-specific CSP accuracy 
It is known from literature that the docking accuracy of docking-scoring combinations may 
not only vary with the protein target, but also with the physicochemistry of protein-ligand 
interactions.1,18 The set of 65 CYP2D6 substrates (among which 32 stereo-isomers) 
included in this work has a broad chemical and structural diversity (see Table 1). The 
substrates contain up to 4 hydrogen-bond acceptors, up to 5 hydrogen bond donors, and 
have molecular weights ranging from 138 to 478 (80% with MW = 250-500). The number 
of rotatable bonds, reflecting conformational flexibility, ranges from 0 to 14. All 
compounds contain a positively charged nitrogen atom at physicological pH, a typical 
pharmacophoric feature of CYP2D6 ligands,32,33 with the exception of progesterone and 
spirosulfonamide. The latter substrate was found to be one of the most difficult docking 
cases in terms of catalytic site prediction.  
No clear correlations could be found between CSP accuracy and molecular weight or 
the number of rotational bonds. Docking results were in many cases sensitive towards 
small differences in chemical structure of the substrate as demonstrated by the fact that 
all four docking programs (AutoDock, FlexX, GOLD-Goldscore and GOLD-Chemscore) 
showed stereoisomer-dependent, regioisomer-dependent and MDMA- and MAMC-
derivative-dependent CSP accuracy. This indicates that very subtle differences may play a 
crucial role in accurately predicting the site of metabolism. It should be noted that most 
experimental CYP2D6 metabolism studies have only reported results on racemic mixtures. 
Ligand descriptors alone will not likely be able to catch these effects, but the inclusion of 
protein target coordinates (and water molecules) appears crucial for the CSP. 
The docking performance of each of the four docking programs showed a significant 
improvement by re-ranking the ligand poses with the scoring function SCORE. The positive 
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effect of rescoring was most pronounced in the case of AutoDock (see Table 1 and 
Figure 1). Rescoring all ‘pooled’ AutoDock, FlexX, GOLD-Goldscore and GOLD-Chemscore 
docking runs with SCORE yielded CSP accuracies comparable to the most accurate 
docking-scoring combination, with and without the consideration of active-site water 
molecules. These findings show that scoring/rescoring is an essential aspect of automated 
docking, and even predominates docking, a conclusion in agreement with previously 
published comparisons.1,67,68 Comparing the overall CSP accuracy of the optimal docking 
strategies for each docking algorithm (including active-site water and rescoring with 
SCORE), AutoDock is shown to be only slightly better than GOLD-Chemscore and GOLD-
Goldscore (CSP accuracies of 82%, 80% and 80%, respectively), but superior to FlexX 
(CSP accuracy of 38%). Previous docking studies comparing the RMSD docking accuracy 
of FlexX and GOLD-Goldscore showed GOLD-Goldscore to give superior results,1,9,18,  while 
two recent comparative studies demonstrated that the relative performance of AutoDock, 
FlexX and GOLD-Goldscore varied with the selected protein target.5,10 The docking 
accuracies of GOLD-Goldscore and GOLD-Chemscore were found to be comparable in an 
earlier study.14 
 
Database- and docking strategy-specific virtual screening accuracy 
The 980 drug-like compound database used for the evaluation of virtual screening 
strategies spans the range of chemical properties of the 20 known CYP2D6 substrates 
added to this database, with the exception of debrisoquine, MDPA and EMAMC. These 
compounds have slightly lower molecular weights (MW) than compounds in the database 
(MW = 250-500). The molecular weights of the proprietary database of 19.619 entries 
range from 68 to 820 (80% with MW = 250-500). Recently, Verdonk et al. suggested that 
studies aimed at validating particular protein-ligand docking-based virtual screening 
methods should use libraries containing compounds with physico-chemical properties 
similar to the actives.15 For the training of different docking-based virtual screening 
methods, we used the Rognan database,1 because this database is used in previous 
comparative docking studies.1,9 For the validation of our virtual screening strategy, we 
wanted a database that was pharmaceutically relevant and available for direct 
experimental verification. Nevertheless, we did not bias the database to have an identical 
distribution of properties, as this is not likely the case in a physical screen carried out in 
the context of drug discovery. Furthermore, it can be assumed that focused databases 
have a higher probability of already containing actual high affinity ligands than ‘random’ 
drug like databases do. This could then result in the underestimation of the virtual 
screening accuracies of docking strategies. 
Virtual screening accuracies were found to be highly docking-scoring combination 
dependent, as was found in pervious comparative docking studies.1,5,6,8,9,12,15,69 The best 
docking-based virtual screening strategy, i.e. GOLD-Chemscore with the Chemscore 
scoring function and including active-site water, was found to be superior to all other 
strategies. 
 
Virtual screening hits for CYP2D6 
Seven of the eight top 0.1% hits found by virtual screening with GOLD-Chemscore (and 
considering water) of the proprietary database of 19.619 compounds against CYP2D6 
contained a tricyclic dibenzo moiety and six contained a positively charged nitrogen, which 
is part of the established CYP2D6 pharmacophore models of inhibitors and substrates.32,33 
Only one compound, BS7129, contained no hydrogen bond donors or hydrogen bond 
acceptors. This compound was actually the only false-positively screened hit (IC50 > 200 
µM) among the top 0.1% ranked scorers. It should be noticed that compound BS7129 
does not contain a positively charged nitrogen atom. Therefore a combined CYP2D6 
2D/3D-pharmacophore-search70 and structure-based virtual screening might exclude this 
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false positive from the top ranked hits. On the other hand, compound GBR 30111 does not 
have a positively charged nitrogen atom either, but it does contain a hydrogen bond donor 
which forms a hydrogen bond with E216 (like R-propranolol in Figure 2) and does show 
affinity for CYP2D6 (IC50 value of 60 µM). This illustrates that docking-based virtual 
screening methods might enable the discovery of leads with chemical features and 
structures dissimilar from known actives, thus extending the possibilities of drug design. 
False-positive hits nevertheless may highlight particular weaknesses of a docking scoring 
function.69 All top 0.1% scorers were predicted to be binding to the CYP2D6 binding 
pocket in about the same binding mode, with their tricyclic dibenzo moiety stacked 
between the F120 and F483 and (with the exception of BS7129) forming an electrostatic 
interaction with the negatively charged carboxylic group of E216. These amino acid 
residues were previously found to be key determinants in CYP2D6-mediated metabolism in 
site-directed mutagenesis studies.44,49,71-73 BS7129 was found to have a tight steric fit in 
the CYP2D6 binding pocket, expressed by a high lipophilic score (Elip) and relatively low 
protein-ligand clash (Eclash) and ligand-internal energy (Eint) scores in the GOLD-Chemscore 
docking score.14 
Two of the eight hits sampled at the top 10% scorers contained a positively charged 
nitrogen atom, GB12819 (IC50 = 1.21 µM) and BS 9086 (IC50 = 40 µM), via which chemical 
group these compounds were found to interact with E216 in the docked CYP2D6-ligand 
complex structure. The first compound is actually the only high affinity (<10 µM38) 
CYP2D6 inhibitor found in this sample. The top 10% ranked scorers are structurally more 
diverse than the top 0.1% scorers, and also more diverse in affinity. Two top 10% scorers, 
BS9086 and BS8558, contain a tricyclic dibenzo group, as also observed in seven of the 
eight top 0.1% structures, but only the first compound appeared to have medium affinity 
(40 µM) for CYP2D6. 
 
CSP accuracy versus virtual screening accuracy 
Some comparative docking studies show that the ability of docking methods to predict 
binding modes of protein-ligand complexes is not correlated with their relative virtual 
screening performance.1,69 Others, however, did find both properties to be correlated,9,13 
while yet others find this correlation to be target- and docking method- dependent.6 These 
discrepancies imply that docking strategies should be separately optimized for the purpose 
of binding mode/catalytic site prediction and virtual screening. However, if a docking 
method is good in prioritizing known actives, while the generated binding modes do not 
resemble known binding modes, then it is hard to understand the basis of success and 
failure.6 Such a docking method would be useful for lead identification, but less valuable 
with respect to lead optimization. This problem might in principle be solved by the 
complementary use of pharmacophore restraints, structural knowledge about the way 
ligands typically bind to a given target, to guide database docking experiments.15,74-76 In 
the present study, AutoDock, GOLD-Goldscore, and GOLD-Chemscore, in combination with 
the SCORE scoring function and with active-site water, are equally good docking strategies 
in terms of CSP accuracy (82%, 80% and 80%, respectively). AutoDock was not applied in 
our virtual screening studies, as the AutoDock algorithm is not fast enough for this 
purpose. The GOLD-Chemscore algorithm, combined with its native Chemscore scoring 
function and considering active site water molecules, was superior to other approaches in 
terms of virtual screening accuracy. Moreover, this CSP and virtual screening strategy was 
able to select experimentally validated high-affinity inhibitors from another, larger 
database of 19.169 drug-like compounds. 
 
Protein target specific training of docking strategies 
Docking (binding mode or CSP) and scoring accuracy of docking-scoring combinations are 
often shown to vary considerably with the selected target protein, physicochemical details 
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of target-ligand interactions1,5,6,13,15,16 and even depend on fine details of the protein 
structure.77,78 In the current study, it was shown that both docking accuracy and virtual 
screening accuracy for CYP2D6 is highly docking strategy dependent. Therefore, a 
docking-scoring strategy should be tailored to the system of interest, and preferably be 
based on a training set of ligand-bound protein crystal structures. In the absence of such 
a training set (which is the case for CYP2D6), other sorts of experimental data, like regio-
specificity of metabolism (binding mode prediction/CSP accuracy, as applied to CYP2D6 in 
the present study), binding affinity determinations (scoring/ranking accuracy, as applied to 
CYP2D6 in the present study) and site-directed mutagenesis studies (binding mode 
prediction/relevance of specific amino acid residues for binding, as applied to CYP2D6 in 
other studies43,44,49) can be used to validate docking strategies. 
 
5.4 Conclusions 
We presented an extensive docking study for the catalytic site prediction (CSP) of human 
CYP2D6 substrates and the first automated docking-based virtual screening for high 
affinity ligands of this enzyme from a large chemical database. The presence of water 
molecules at predicted positions in the active site during docking studies was shown to 
strongly improve CSP accuracy and virtual screening accuracy of various docking-scoring 
combinations. The CSP accuracy of the AutoDock, FlexX, GOLD-Goldscore and GOLD-
Chemscore programs were more docking-case specific than ligand-specific, and the virtual 
screening accuracy depended strongly on the combination of docking program and scoring 
function. Rescoring of the poses generated by each of the three different docking 
algorithms with the scoring function SCORE improved the CSP accuracy of almost all 
docking-water scenario combinations (docking strategies).  GOLD-Chemscore docking in 
combination with the Chemscore scoring function (and with consideration of active-site 
water molecules) clearly outperformed the other docking-scoring combinations with 
respect to virtual screening accuracy and was also one of the most accurate strategies 
with respect to CSP. This docking strategy was validated experimentally: it was 
successfully used for the selection of high-affinity inhibitors of CYP2D6 from a large 
proprietary database. A selection of top-ranked (top 0.1%) compounds included 
significantly more high-affinity inhibitors than a selection of medium-ranked (top 10%) 
compounds. The current study shows that protein target specific training of automated 




Preparation of CYP2D6 substrate and protein input structures 
A set of 65 known CYP2D6 substrates (including 32 stereoisomers) was selected for this study, 
based on the availability of experimental information on CYP2D6-catalysed product formation and 
affinity for CYP2D6 (Km < 200 µM). The protein homology model of CYP2D6 was constructed, 
refined and validated as described in.30,43,44 Also the preparation of protein and substrate input 
structures, definition of the binding pocket, and the GRID-based45 prediction of energetically 
favorable positions of active-site water molecules was performed as described earlier.20 The 
substrate dextromethorpan was used to determine the ligand-based cut-off for the exclusion of 
water molecules too close to the active-site centre. 
 
Automated Docking Methodology for Catalytic Site Prediction 
Automated docking studies were performed with four different docking algorithms, AutoDock 3.039, 
FlexX 1.1040 (as implemented in Sybyl 6.8) and GOLD 2.141 using the Goldscore and Chemscore 
fitness functions.14 As scoring is a very important second aspect of automated docking 
methodologies, it was decided to investigate the effect of re-scoring: the process of re-prioritisation 
of  docking solutions (primarily ranked by the ‘native’ scoring function implemented in the docking 
program) with an additional stand-alone scoring function. Earlier studies with Cyt P450 and TK 
Chapter 5 
 165
crystal structures20 showed that the docking performance of AutoDock, FlexX and GOLD was 
significantly improved in terms of atomic root mean square displacement (RMSD) and catalytic site 
prediction (CSP) accuracy by re-ranking the ligand poses with the scoring function SCORE.48 In the 
current study, the docking accuracy of different docking approaches was evaluated with respect to 
their CSP accuracy:20 The percentage of docking solutions with binding modes corresponding to 
experimentally determined major biotransformation products. Ligand atoms were considered to be 
potential sites of oxidation when they were within 6.0 Å from the CYP2D6 heme Fe-atom. 
 
CSP accuracies are presented as:  
• Average percentages of successful catalytic site predictions for all solutions (50) of each 
docking study (illustrating the chance of finding a reliable solution) (Ā).  
• CSP accuracy for nr. 1 ranked solutions according to the program implemented scoring 
function (reflecting the ability of the program implemented scoring functions to properly 
rank poses after the docking procedure) (I). 
• CSP accuracy for nr. 1 ranked solutions according to the scoring function SCORE (reflecting 
the ability of SCORE to properly rank poses after the docking procedure) (S). 
• CSP accuracy for poses closest to the experimentally determined structure (the propensity 
of the docking algorithms to find a reliable solution, whatever its ranking) (C). 
 
To compare the ‘overall’ difference in performance of the different docking-scoring combinations 
and water scenarios (referred to as docking strategies), the terms relative increase by rescoring 
with SCORE (RIscore) and relative averaged increase by the consideration of water (RAIwater) are 
defined: 
 
RIscore = (XS – XI)/XI 
 
3




where Ā, I, and S indicate the CSP accuracies defined above for water scenario X (without active 
site water (N), and with predicted active-site water molecules (W)). 
 
Preparation of three-dimensional chemical databases 
For the evaluation of the virtual screening performance of different docking strategies a database 
was prepared consisting of 980 randomly selected compounds from a 3D database (in mol2 format) 
of 1.000 drug like molecules previously described1 and the 20 known CYP2D6 substrates 
highlighted in Table 1. A second, larger proprietary 3D database was prepared for the 
identification of “new” potential high-affinity CYP2D6 ligands and to evaluate the ability of optimal 
docking strategies to discriminate between high-affinity, medium affinity and low-affinity ligands. A 
2D database of 5.760 compounds was converted into 3D structures (in mol2 format) using the 
program MOE (v. 2004. Chemical Computing Group:. Montreal, Canada). Subsequently, structures 
were washed (filtering counter ions and solvents), energy minimized and MOE was used for the 
generation of all possible stereoisomers for the database (yielding 9.706 entries). The database was 
tautomerised using AGENT2.0.79 AGENT generated approximately two tautomers per compound in 
the database (yielding 19.619 entries in total). For some compounds, AGENT did not generate any 
tautomer, for others up to seven tautomers. On average, two stereoisomers were generated for 
each compound in the original database and two tautomers were generated for each stereoisomer. 
After tautomerization, explicit hydrogen atoms were added to the database in Sybyl 6.8. 
 
Automated Docking Methodology for Virtual Screening 
FlexX 1.10 and the two GOLD 2.1 automated docking tools (using the Goldscore and Chemscore 
fitness functions14) were used for virtual screening of the two databases (respectively the combined 
database of 980 drug-like molecules and 20 known CYP2D6 substrates and the proprietary 
database of in total 19.619 molecules). Standard FlexX settings and GOLD default 4 settings were 
used. All ligands for which a docking solution had been found were rescored using the Cscore 
module of Sybyl6.62 (including the scoring functions Chemscore42, DOCK46, FlexX40, Goldscore41, 
PMF47) and the scoring function SCORE (as part of a spl-script used by Bissantz et al.1). It should be 
CYPs, drugs, and dock’m all 
 166
noted that FlexX scores calculated either from FlexX or Cscore are very similar,1 while Chemscore 
and GOLD scores calculated by the GOLD program differ from those calculated by Sybyl, and thus 
cannot be compared.80 Therefore, the Chemscore, FlexX, and GOLD scores proposed by Sybyl were 
discarded when the scoring function was coupled to the corresponding docking procedure. 







where N is the total number of compounds in the hit list, nTF the number of true hits found in the 
hit list, and nT the total number of true hits in the database. 
 
IC50 determinations 
The pSP19T7LT plasmid containing bicistronically human CYP2D6 with a C-terminal His6-tag and 
human NADPH-cytochrome P450 reductase, was kindly provided by Prof. Dr. Ingelman-Sundberg. 
E. coli JM109 were obtained from DSMZ (Braunschweig, Germany). The pSP19T7LT plasmid 
containing CYP2D6 was transformed into Escherichia coli strain JM109. Expression and membrane 
isolation was carried out as described.44 The compounds tested (Tables 4 and 5) were taken from a 
proprietary database. 7-methoxy-4-(aminomethyl)-coumarin (MAMC) and  7-hydroxy-4-
(aminomethyl)-coumarin (HAMC were synthesized before as described.81 Dextromethorphan 
hydrobromide, debrisoquine sulfate and quinidine sulfate dihydrate were obtained from Sigma (St 
Louis, MD, USA). All other chemicals were of analytical grade and obtained from standard suppliers. 
MAMC O-demethylation reactions by CYP2D6 were carried out in 96 wells plates, in a total 
volume of 200 µl.44 The reaction mixture consisted of  5 mM MgCl2 in KPi buffer, 50 µM MAMC, E. 
coli membranes corresponding to 40 nM CYP2D6 and different concentrations of inhibitor. The 
inhibitors were dissolved in DMSO and stored as 20 to 100 mM stocks at –20˚ C. The reactions 
were initiated by the addition of an NADPH regenerating system, resulting in final concentrations of 
0.1 mM NADPH, 0.3 mM glucose-6-phosphate, and 0.4 units/ml glucose-6-phosphate 
dehydrogenase. The reactions were allowed to proceed  for 30 min at 37°C and fluorescence of the 
samples was subsequently measured on a Victor2 1420 multilabel counter (Wallac, Oy, Finland) 
using λex= 405nm, λem= 460nm. 
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Table I: Validation of virtual screening strategies for the selection of high-affinity CYP2D6 
substrates. Description of CYP2D6 hit lists generated by three docking programs in combination 
with the program implemented scoring function and stand-alone scoring functions (at top 5%) and 
with (W) and without (N) the consideration of active site water molecules. A hit list is generated 
from the top-scoring compounds selected at a given treshold. Hit rate (rH) and yield (y) are 
calculated as described in the Methods section. 








Top 2.5% Top 5% Top 10%  
   rH (%) y (%) rH (%) y (%) rH (%) y (%)  
FlexX Chemscorea N 0 0 0 0 2 10  
 DOCKa N 0 0 4 10 14 70  
 FlexXa N 0 0 0 0 0 0  
 Goldscore N 8 10 6 15 5 25  
 PMFa N 4 5 4 10 2 10  
 SCORE N 0 0 0 0 1 5  
 Chemscorea W 0 0 2 5 5 25  
 DOCKa W 0 0 12 30 15 75  
 FlexX W 0 0 2 5 5 25  
 Goldscore W 4 5 6 15 7 35  
 PMFa W 0 0 2 5 2 10  
 SCORE W 0 0 0 0 0 0  
          
GOLD-Goldscore Chemscorea N 4 5 2 5 1 5  
 DOCKa N 0 0 2 5 6 30  
 FlexXa N 0 0 2 5 1 5  
 Goldscore N 4 5 2 5 1 5  
 PMFa N 0 0 0 0 0 0  
 SCORE N 0 0 0 0 0 0  
 Chemscorea W 0 0 0 0 2 10  
 DOCKa W 0 0 2 5 6 30  
 FlexXa W 0 0 0 0 2 10  
 Goldscore W 0 0 4 10 3 15  
 PMFa W 8 10 4 10 6 30  
 SCORE W 0 0 0 0 0 0  
          
GOLD-Chemscore Chemscore N 12 15 10 25 7 35  
 DOCKa N 0 0 2 5 6 30  
 FlexXa N 0 0 0 0 0 0  
 Goldscorea N 0 0 4 10 3 15  
 PMFa N 0 0 0 0 0 0  
 SCORE N 0 0 0 0 0 0  
 Chemscore W 36 45 24 60 15 75  
 DOCKa W 0 0 0 0 5 25  
 FlexXa W 0 0 0 0 3 15  
 Goldscorea W 0 0 2 5 1 5  
 PMFa W 12 15 8 20 7 35  
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Metabolic regio- and stereoselectivity of cytochrome P450 2D6 
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A series of 3,4-methylenedioxy-N-alkylamphetamines (MDAAs) were automatically docked 
and subjected to molecular dynamics (MD) simulations in a Cytochrome P450 2D6 
(CYP2D6) protein model. The predicted substrate binding orientations, sites of oxidation 
and relative reactivities were compared to experimental data of wild-type and F120A 
mutant CYP2D6. Automated docking results were not sufficient to accurately rationalize 
experimental binding orientations of 3,4-methylenedioxy-N-methylamphetamine (MDMA) in 
the two enzymes as measured with spin lattice relaxation NMR. Nevertheless, the docking 
results could be used as starting structures for MD simulations. Predicted binding 
orientations of MDMA and sites of oxidation of the MDAAs derived from MD simulations 
matched well with the experimental data. It appeared that the experimental results were 
best described in MD simulations considering the nitrogen-atoms of the MDAAs in neutral 
form. Differences in regioselectivity and stereoselectivity in the oxidative metabolism of the 
MDAAs by the F120A mutant CYP2D6 were correctly predicted and the effects of the 
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6.1 Introduction 
Cytochromes P450 (CYPs) are heme containing enzymes which can be found in virtually all 
living organisms. This large family of enzymes is capable of oxidizing and reducing a broad 
range of endogenous and exogenous substrates, such as steroids, carcinogens and drugs. 
1,2 In humans one of the most relevant drug metabolizing CYPs is CYP2D6. Although the 
expression levels of CYP2D6 are only 2% of all hepatic CYPs, following CYP3A4, it is the 
second most important drug metabolizing enzyme, involved in the metabolism of about 
30% of the currently marketed drugs, including β-blockers, neuroleptics, antidepressants 
and antiarythmics.3-5 Large interindividual differences exist in CYP2D6 activity, due to gene 
multiplicity and polymorphisms, thus further increasing its clinical importance.6,7 The 
rationalization and prediction of potential CYP2D6 substrates is therefore advantageous in 
the discovery and development of new drugs. Nowadays the first crystal structures of 
mammalian CYPs are becoming available.8-10 However, so far a crystal structure of CYP2D6 
remains to be resolved and any structural information on this enzyme still depends on 
homology modeling, mutagenesis and spectroscopic studies.  
CYP2D6 is one of the CYP isoforms studied most extensively using molecular modeling. 
11 Several homology model structures of CYP2D6 have been built, refined and validated 
experimentally. The homology models of CYP2D6 suggest substrates to interact with two 
or three aromatic/hydrophobic residues, F120 and Phe483 and a carboxylic acid residue, 
E216 or D301.12,13 The relevance of these residues was supported by site-directed 
mutagenesis studies,14-18 and these interactions are consistent as well with those derived 
from pharmacophore models of inhibitors and substrates.19,20 Molecular modeling can 
provide information on active site characteristics and the importance of specific amino acid 
residues in enzyme-substrate interactions, but it can also be used to rationalize and predict 
regio- and stereoselectivity in metabolism by CYPs. It has recently also been shown that 
automated docking can successfully be applied to predict sites of oxidation in substrates 
using CYP crystal structures.21 MD simulations in addition can account for distributions of 
multiple binding conformations and thus give a more comprehensive description of 
multiple sites of oxidation in substrates catalyzed by CYPs.22-25  
In this study a molecular modeling approach has been used to study the binding 
orientation and the sites of oxidation of a series of 3,4-methylenedioxy-N-
alkylamphetamines (MDAAs), or XTC analogues, by CYP2D6. The primary aim was to 
evaluate an integrated molecular modeling approach to rationalize and predict substrate 
binding and metabolism by CYP2D6. When regioselectivity and stereoselectivity in drug 
metabolism and the effect of active site mutations can be rationalized for a series of 
closely related compounds, such an approach can be considered as accurate and reliable. 
The molecular modeling predictions were based on a homology model of CYP2D6. Reactive 
substrate poses were generated using automated docking and were obtained from MD 
simulations of wild-type and mutant CYP2D6 protein containing all three MDAAs. Two 
different protonation states of the basic nitrogen-atom were studied, as it is known that 
this can drastically influence the oxidation by CYP2D6.26 The computational predictions 
were validated experimentally. The effects of mutating F120 into alanine on the binding 
modes and metabolic products were studied for five MDAAs, i.e. 3,4-methylenedioxy-N-
methylamphetamine (MDMA) and its stereoisomers, 3,4-methylenedioxy-N-
ethylamphetamine (MDEA) and 3,4-methylenedioxy-N-propylamphetamine (MDPA). For 
the recently described F120A mutant large effects on the regioselective oxidation of MDMA 
were demonstrated.16 Dissociation constants for the three MDAAs were determined by 
spectral titration. The metabolic products were analyzed and furthermore, the binding 
orientations of MDMA in the wild-type and mutant active sites were explored 
experimentally by NMR spin lattice relaxation rate measurements, a technique previously 





Expression and Purification of Wild-type and F120A Mutant CYP2D6  
The expression levels of both wild-type and F120A mutant CYP2D6 were similar as 
described previously.16 The enzymes which contained a C-terminal 6 x histidine tag were 
purified using Ni-NTA-agarose. Eluting the enzymes from the Ni-NTA-agarose using 
imidazole led to a large amount of enzyme in the high spin state, even after overnight 
dialysis high spin remained the predominant state. Therefore 0,2 mM L-histidine was 
preferred as eluting agent over imidazole, because it did not cause a change in spin state 
after dialysis yielding pure enzymes which were stable for at least four hours at 24° C in 
the presence of 5% glycerol and 100 µM of substrate as assessed by CO-difference 
spectroscopy. Hardly any P420 (i.e. inactive CYP detected as an absorbance maximum at 
420 nm in the CO-difference spectrum) was present in the batches of purified enzyme. 
 
Spectral Titration of Substrates to the Enzymes 
The addition of all MDAAs to purified wild-type or F120A mutant CYP2D6 led to a type I 
change in the visible absorbance spectrum. By titration of the compounds to the solutions 
of enzyme the spectral dissociation constants Ks could be estimated (using Equation 1, 
data shown in Table 1). While there were minor differences in affinity between the wild-
type and the mutant, for both enzymes a slightly lower Ks was found for MDEA and MDPA 
than for MDMA. The enantiomers of MDMA had about equal affinity for the wild-type, but a 
slight preference towards S-MDMA was observed for the mutant enzyme. 
 
Table 1: Estimated dissociation constants, Ks, (µM) of the substrates for wild-type and F120A 
mutant CYP2D6.  
 Wild-type  F120A  
Substrate Ks   Ks  
R/S-MDMA 28 ± 3  28 ± 2 
R-MDMA 43 ± 6  53 ± 2 
S-MDMA 40 ± 5  38 ± 4 
MDEA 19 ± 2  15 ± 4 
MDPA 18 ± 1  12 ± 2 
All values are the means ± S.D. of at least two independent experiments as described in the Materials and 
Methods. R/S-MDMA refers to the racemic mixture of 3,4-methylenedioxy-N-methylamphetamine (MDMA), R-
MDMA and S-MDMA to the pure R- and S-isomer of MDMA respectively. For the corresponding N-ethyl and N-
propyl amphetamines (MDEA and MDPA) racemic mixtures were used. 
 
 
Metabolism of MDAAs 
As reported previously, 16 MDMA is oxidized by the F120A mutant to MDA and N-OH-
MDMA, in addition to 3,4-OH-MA, the only product formed by the wild-type enzyme 
(Figure 1). Elongation of the N-methyl chain to an ethyl or propyl yielded the 
corresponding products after incubation with both enzymes. MDEA was O-demethylenated 
by wild-type and mutant CYP2D6 and additionally the mutant N-dealkylated and N-
hydroxylated MDEA. A fourth oxidation product of MDEA by the mutant was detected at tR 
18.5 min, with a m/z of 222, fragmenting to m/z 163. This product could be the aldehyde- 
or keto-form of ω- or ω-1-hydroxylation respectively.  
































Figure 1: Scheme of 3,4-methylenedioxy-N-alkylamphetamines (MDAAs) oxidation by F120A 
mutant CYP2D6. The MDAAs are O-demethylenated to 3,4,-dihydroxy-N-alkylamphetamine (1), N-
dealkylated to 3,4-methylenedioxyamphetamine (2), N-hydroxylated to 3,4-methylenedioxy-N-
hydroxy-N-alkylamphetamine (3) or ω/ω-1-hydroxylated to 3,4-methylenedioxy-ω/ω-1-hydroxy-N-
alkylamphetamine (4). The C3 methyl is indicated, R is methyl, ethyl and propyl for MDMA, MDEA 
and MDPA respectively. 
 
MDPA was O-demethylenated by wild-type and the mutant CYP2D6, the latter enzyme also 
N-dealkylated and N-hydroxylated this substrate. A peak with m/z of 254 was found at 
19.2 min with the mutant, indicating a double hydroxylation. No fragmentation took place 
so the positions of the hydroxyl groups remain unknown. Product formation from all 
substrates was linear for at least 10 min for both enzymes under the conditions used, so 
the kinetic parameters were determined for the major products (Table 2).  
 
Table 2: Product formation of MDAAs oxidation by wild-type and F120A mutant CYP2D6.  
   Wild-type  F120A 
Substrate Product Structure  Km Vmax Km Vmax 
R/S-MDMA 3,4-OH-MA 1 1.9 ± 0.5 1.2 ± 0.4a 11.8 ± 3.8 2.2 ± 0.0a 
  MDA 2 - c - c 14.5 ± 2.4 3.5 ± 0.1b 
 N-OH-
MDMA 
3 - c - c 11.2 ± 1.4 7.1 ± 0.5a 
R-MDMA 3,4-OH-MA 1 2.7 ± 0.4 1.2 ±0.2a 13.2 ± 0.6 2.4 ± 0.1a 
 MDA 2 - c - c 26.1 ± 3.3 5.9 ± 0.7b 
 N-OH-
MDMA 
3 - c - c 20.6 ± 2.5 10.7 ± 
1.3a 
S-MDMA 3,4-OH-MA 1 3.3 ± 0.5 1.2 ± 0.0a 4.9 ± 0.1 2.4 ± 0.0a 
 MDA 2 - c - c 10.3 ± 0.6 3.8 ± 0.1b 
 N-OH-
MDMA 
3 - c - c 6.9 ± 0.6 8.4 ± 0.4a 
MDEA 3,4-OH-EA 1 1.1 ± 0.1 1.2 ± 0.2a 3.3 ± 0.0 2.9 ± 0.2a 
 MDA 2 - c - c 4.5 ± 0.8 4.2 ± 0.1b 
 N-OH-MDEA 3 - c - c 5.7 ± 0.3 1.4 ± 0.1a 
MDPA 3,4-OH-PA 1 1.0 ± 0.1 1.3 ± 0.1a 5.2 ± 0.6 7.5 ± 0.6a 
 MDA 2 - c - c 9.1 ± 0.5 7.3 ± 1.8b 
 N-OH-MDPA 3 - c - c 28.0 ± 6.5 3.0 ± 0.2a 
All values are the means of at least two independent experiments ± S.D. as described under Materials and 
Methods. Structure numbers refer to products drawn in Figure 1, Km expressed in µM, a Vmax expressed in 1 x 





The overall rate of oxidation by the F120A mutant was higher than that of wild-type 
CYP2D6 for all MDAAs. The rates for O-demethylenation were two to five-fold higher for 
the mutant and the fact that more products are formed indicate an even higher increase in 
oxidation rates. To quantify the turnover rates, synthetic reference compound was only 
available for MDA, for the other products turnover rates were only compared in relative 
terms. Because the fluorescence peak areas of equal concentrations of MDA, MDMA, MDEA 
and MDPA are equal, it is likely that the N-alkyl chain has no influence on the fluorescence 
yield of the compounds, and therefore reasonable this holds true for the O-
demethylenated and N-hydroxylated products of the MDAAs as well.  
The turnover rates of MDMA, MDEA and MDPA were equal for wild-type CYP2D6 (Table 
2). The catalytic efficiency (Vmax/Km) indicated that MDPA is oxidized most efficient and 
MDMA the least efficient (Figure 2A). The mutant showed a higher catalytic efficiency in 
O-demethylenating MDPA over MDMA and MDEA, while the efficiency in N-hydroxylation 
was the highest for MDMA (Figure 2B-D). MDEA and MDPA were N-dealkylated more 
efficiently than MDMA. So elongation of the N-alkyl chain leads to an altered catalytic 

































































Figure 2: Vmax / Km product ratio’s (min-1 · µM-1 for N-dealkylation, AU for the other products) for 
the O-demethylation by wild-type (grey left), and O-demethylation (grey right), N-dealkylation 
(blank) and N-hydroxylation (diagonal stripe) by F120A mutant CYP2D6 of the different MDAAs.  

























Figure 3: Ratio’s of S-MDMA catalytic efficiency (Vmax / Km ) over R-MDMA catalytic efficiency 
(Vmax/Km) by wild-type (in gray), and by F120A mutant CYP2D6 (in black) for the products 3,4,-
dihydroxy-N-alkylamphetamine (3,4-OH MA), 3,4-methylenedioxyamphetamine (MDA) and 3,4-
methylenedioxy-N-hydroxy-N-alkylamphetamine (N-OH-MDMA). 
 
Stereoselectivity in MDMA oxidation by wild-type CYP2D6 was hardly found (Figure 3).  
However, the mutant enzyme showed at least two-fold lower Km values for all three 
products of S-MDMA when compared to R-MDMA, while the Vmax values for the products of 
both enantiomers did not differ (Table 2). Eventually these changes lead to a different 
product ratio for the enantiomers: O-demethylenation is more prominent for S-MDMA then 
for R-MDMA, followed by N-hydroxylation and N-dealkylation (Figure 3). 
 
NMR Spin Lattice Relaxation Rate Measurements  
Enzyme bound MDMA hydrogen atom to heme iron distances were determined by spin 
lattice relaxation NMR to validate the computationally predicted distances. The 1H-NMR 
spectrum of MDMA in presence of glycerol and each of the two enzyme was well resolved, 
all signals of the different hydrogen atoms were clearly visible (Figure 4). Because the 
doublet of  the C3 methyl (δ 1.18), and the singlets of the N-methyl (δ 2.61), and 
methylene (δ 5.89) hydrogen atoms could be best quantified and are the most distal 
groups in MDMA, these were used to determine the substrate orientation in the active site 
of the two enzymes (inversion recovery spectra shown in Supplementary Data). An 
increase in Tl of the MDMA hydrogen atoms was found after reducing the enzymes with 
dithionite, indicating that the paramagnetic effect of the enzymes was diminished. From 
the Tl the distances from the methylene, C3 and N-methyl hydrogen atoms to the heme 
iron atom were calculated (using Equation 2) and tabulated (in Table 3). The fast 
exchange condition (see Methods section) was validated by measuring the temperature 
dependence of RlP from 281° K to 307° K (see Supplementary data). For the three groups 
of hydrogen atoms studied, there was a linear increase of RlP with the reciprocal 
temperature (1/T), showing that the exchange between substrate molecules in the enzyme 
active site and in solution is fast on the NMR timescale. Only minor differences were 
observed for the hydrogen atoms to iron distances, between the enantiomers of MDMA 
and each of the two enzymes. The measured hydrogen atoms to iron distances indicate 
that the methylene moiety is closest to the heme iron, at about 6.4 Å, the N-methyl is the 
most distal to the heme at about 7.3 Å and the C3 hydrogen atoms are at a distance of 



















Figure 4: 1H NMR spectrum of 20 mM R-MDMA in deuterated Kpi-glycerol in presence of 5 µM 
F120A mutant CYP2D6 showing the resonance assignments.  
 
Table 3: Hydrogen atom to heme iron distances (Å) of the MDMA enantiomers to wild-type and 
F120A mutant CYP2D6 as determined by NMR spin lattice relaxation rate measurements and by 
molecular dynamics (MD) simulations of neutral and charged MDMA.  
  wild-type  F120A 
Position  R-MDMA S-MDMA R-MDMA S-MDMA 
Methylene (δ 5.89) NMR 6.4  6.3  6.4  6.5  
 MD (charged) 3.5 3.6 4.6 3.1 
 MD (neutral) 4.3 4.5 5.0 5.5 
N-methyl (δ 2.61) NMR 7.3  7.2  7.5  7.2  
 MD (charged) 11.0 10.1 10.1 9.4 
 MD (neutral) 5.9 6.5 8.4 6.0 
C3 (δ 1.18) NMR 6.9  6.7  6.6  6.7  
 MD (charged) 11.8 11.0 8.7 11.5 
 MD (neutral) 5.3 6.6 6.9 6.5 
NMR derived values are the means of at least two independent measurements with S.D. less then 5%, as 
described in the Materials and Methods. MD simulations derived values are averaged over time and for three 
individual runs, starting from different docking poses, according to equation 4. 
 
Automated Docking Studies 
All automatically docked poses of the MDAAs, in two protonation states and in both 
enzymes were found to be predominantly within a reactive distance of 6 Å from the heme 
iron atom (69% and higher, Table 4A). Of these reactive poses, the large majority 
corresponded to O-demethylenation (62-100%). The relative occurrence of docking poses 
corresponding to N-dealkylation (0-38%) and N-hydroxylation (0-13%) of the MDAAs was 
found to be enzyme, stereoisomer, and protonation state dependent. In both enzymes, the 
neutral forms of the compounds showed the widest range of reactive substrate 
orientations, whereas the wild-type allowed for more diversity. This observation is in 
contrast with the experimental finding that wild-type CYP2D6 only catalyzes O-
demethylenation, while the F120A mutant allows for alternative product formation. Three 
distinct, energetically most favorable automatically docked poses were selected of all 
MDAAs as starting conformations for MD calculations, an example of charged R-MDMA 
being shown (Figure 5). These three distinct docked poses could be generally described 
as one binding orientation corresponding to O-demethylenation, with the substrate 
nitrogen atom in close contact with E216 (pose 1, generated by AutoDock), another 
corresponding to O-demethylenation, with the substrate nitrogen atom placed between 
E216 and D301 (pose 2, generated by GOLD) and one corresponding to N-dealkylation or 
N-hydroxylation (pose 3, generated by AutoDock). In cases where pose 3 was not 
-OCH2O- -CCH3 
-NCH3 
Dynamic dancing with XTC 
 182
observed for the substrate in the charged form (see Table 4A), the corresponding pose of 










Figure 5: Molecular dynamics (MD) simulations starting orientations of charged R-MDMA, 
generated by automated docking studies in wild-type (A) and F120A mutant (B) CYP2D6 homology 
models. Two orientations are corresponding to demethylenation, with the substrate nitrogen-atom 
either in close contact with E216 (pose 1, in yellow) or placed between E216 and D301 (pose 2, in 
cyan). A third orientation is corresponding to N-demethylation or N-hydroxylation (pose 3, in 
purple). Water oxygen atoms, as predicted by GRID (see Materials and Methods section), are 
depicted in blue. 
 
MD Simulations 
Simulations of the enzymes with substrates bound in the active site, starting from the 
three different automatically docked poses, remained stable during 10 ns unrestraint MD at 
300° K, with final atom-positional root-mean-square deviation values of 1.3 to 3.8 Å. 
Throughout the simulations structure determining hydrogen-bonds were observed and the 
majority of the orientations of the substrates in the enzymes were within a reactive 
distance to the iron atom (74% and higher, Table 4B). The substrates appeared to have 
considerable freedom within the binding site. Complete reorientation from the initial 
coordinates was frequently observed, indicating that the unrestrained MD simulations 
sampled the substrate conformational space sufficiently. The distances between substrate 
hydrogen atoms and the heme iron atom of wild-type and F120A mutant CYP2D6 were 
derived for two different protonation states of the MDMA enantiomers, by averaging the 
distances over the three simulations (using Equation 4) and these were subsequently 
compared to experimentally determined distances (Table 3). Relatively large differences 
in averaged hydrogen atom to iron distances were found within individual MD simulations 
starting from different substrate docking poses. However, averaged distances of individual 
MD simulations of the same protonation state and starting from the same docking pose, 
were approximately equal. An exception was the difference in averaged distance of the 
methylenedioxy hydrogen atoms of both neutral MDMA enantiomers in simulations starting 
from pose 3 (corresponding to N-demethylation/hydroxylation) in wild-type CYP2D6 (~ 7.5 
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Also the averaged distances derived from all three simulations of individual protonation 
states were approximately the same for the different MDMA enantiomers in wild-type and 
F120A mutant CYP2D6. The averaged hydrogen atom to heme iron distances of the 
neutral MDMA enantiomers agreed well with the distances determined by NMR spin lattice 
relaxation rate measurements. Apparently, considering the substrates to be neutral 
describes the experimental situation best. With the exception of the N-methyl and C3 
hydrogen atoms of R-MDMA in the F120A mutant, all hydrogen atom to heme iron 
distances calculated from MD simulations of neutral MDMA enantiomers were shorter than 
the experimentally derived distances. The methylenedioxy hydrogen atom to heme iron 
distances were slightly lower than those of the N-methyl and C3 hydrogen atoms. In 
contrast, the averaged N-methyl and C3 hydrogen atom to heme iron distances of the 
charged MDMA enantiomers violated the experimental distances consistently. 
For all MDAAs, differences between the averaged enzyme-substrate interaction energies 
calculated using SCORE, were within 3 kJ/mol (~kT) for all three MD simulations of the 
same protonation states and within 5 kJ/mol for all six MD simulations. The relative 
weights of the MD simulations of the three starting orientations used in the Boltzmann 
averaging (Equation 5, see Methods section) over the simulations ranged between 0.11 
and 0.54. 
 
Table 5: Enzyme-substrate interactions (%) during MD simulations.   
Enzyme-substrate interactions during the MD simulations were monitored in terms of the occurrence of atom-
atom distances of 3.5 Å or less between the F/A120 side-chain and the MDAA ring system, representing 
aromatic/van der Waals interactions and hydrogen bonds between the E216 carboxylate oxygen atoms and the 
MDAA nitrogen-atom. Values of neutral and charged substrates were averaged. 
 
Already during the equilibration time, or soon after the start of the MD simulations with 
charged MDAAs, reorientation of pose 3 into pose 1 (corresponding to O-demethylenation) 
occurred. In the case of MDEA, this led to non-reactive binding orientations outside of the 
binding pocket, forming a hydrogen bond between its protonated nitrogen and the 
carboxylate group of E216 (Table 4B and Figure 5). Relatively high probabilities of O-
demethylenation poses were found for neutral MDAAs (>58%), although orientations 
corresponding to N-demethylation/hydroxylation were also observed, except for MDPA in 
wild-type CYP2D6. N-demethylation or N-hydroxylation of neutral MDAAs had significant 
higher probabilities in the F120A mutant than in wild-type CYP2D6. Furthermore, substrate 
dependent catalytic regioselectivity was observed for the mutant: elongation of the N-alkyl 
chain led to a decreased N-hydroxylation efficiency with an optimal N-dealkylation 
efficiency for MDEA (Table 4B). These trends were equal to those found experimentally 
and became even more pronounced when the MDAAs were averaged over enantiomers, 
over protonation states and Boltzmann weighted (Figure 6).  
Significant stereoselective differences in the probabilities of O-demethylenation vs. N-
demethylation/hydroxylation were not observed for wild-type CYP2D6. The F120A mutant 
however, did in all cases discriminate the enantiomers of the neutral MDAAs. Differences 
between the probabilities of N-demethylation and N-hydroxylation of MDMA enantiomers 
were found and R-MDPA was found in orientations leading to N-demethylation and ϖ-
hydroxylation more often than S-MDPA (Table 4B).  
  Wild-type  F120A 
Substrate  VdW/arom.F120 H-bond E216 VdW/arom. A120 H-bond E216 
MDMA R 81 65 12 54 
 S 80 69 23 47 
MDEA R 55 51 2 46 
 S 66 70 1 57 
MDPA R 71 74 5 52 
 S 81 52 7 61 
Chapter 6 
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Figure 6: Probabilities (%) of reactive binding orientations corresponding to O-demethylenation 
(grey), N-dealkylation (blank), N-hydroxylation (diagonal stripe), and ω-hydroxylation (black), of 
the MDAAs in wild-type (A) and in F120A mutant (B) CYP2D6, as derived from 12 MD simulations. 
Shown are the Boltzmann weighted averages of two different protonation states and three different 
docking poses (examples in Figure 5), and assuming a 1:1 ratio between R- and S-enantiomers. 
 
Enzyme-substrate interactions observed in the MD simulations of neutral MDAAs showed 
a significant decrease in van der Waals/aromatic interactions with residue 120 in the 
F120A mutant compared to wild-type CYP2D6 (Table 5). Furthermore, a small decrease in 
hydrogen-bond interactions with the carboxylic acid of E216 was observed for the F120A 
mutant as a direct result of the relatively high probability of binding orientations 
corresponding to N-dealkylation or N-hydroxylation. In both wild-type and F120A mutant 
CYP2D6 however, hydrogen-bond interactions were found to be significantly decreased for 
neutral MDAAs (up to 23% on average for each enantiomer) when compared to charged 
MDAAs (up to 92% on average for each enantiomer). During the MD-simulations, water 
molecules were primarily observed to fill the part of the active site which is connected with 
a so called “water channel”, 31 which was already partially occupied by predicted water 
molecules in the automated docking starting structures (Figure 5). These water molecules 
were found to form H-bonds with the substrate. At most, one water molecule was 
observed in other regions of the active site. 
 
6.3 Discussion 
The primary aim of this study was to develop an integrated molecular modeling approach 
to analyze substrate oxidation by CYP2D6. When regioselectivity and stereoselectivity in 
metabolic oxidation and the effect of enzyme active site mutations can be visualized and 
quantified using a series of related compounds, such an approach could be a useful tool in 
the rationalization and prediction of metabolism. Using this approach the experimentally 
determined binding modes and the product formation of a series of MDAAs by wild-type 
and F120A mutant CYP2D6 could be rationalized. 
 
Substrate Binding Orientations 
In the present study, molecular modeling was used to explain the apparent discrepancy 
between experimentally observed differences in regioselective oxidation and the 
stereoselective preference by the F120A mutant towards MDMA (Figure 1) and the 
average substrate orientation in the mutant and wild-type active sites as determined by 
NMR spin lattice relaxation rate measurements (Table 3). The average hydrogen atom to 
iron distances calculated from the Tl of the MDMA enantiomers in both enzymes were 
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the distances between the hydrogen atoms at potential sites of oxidation in MDMA and the 
heme iron atom were somewhat larger than comparable distances found in CYP X-ray 
structures (4-6 Å) they were within the ranges of distances determined in other NMR 
studies.27-30 This difference can be explained by the fact that experimentally determined 
distances are averages of all possible substrate orientations during access to, residence in 
and exit from the active site. As a result they contain more information then just that of a 
reactive substrate orientation. NMR spin lattice relaxation rate measurements have been 
used before to determine the orientation of codeine in CYP2D6, where the measured 
hydrogen atoms to iron atom matched the orientation expected from codeine’s metabolic 
profile.28 Codeine is a more rigid and bulky substrate than MDMA which may explain the 
good match. Caffeine, a small and low affinity substrate of CYP1A2 was also subject of 
NMR spin lattice relaxation rate measurements, but the orientation found of caffeine did 
not match the metabolic profile.30 From other experimental studies it is known that 
substrates can be quite mobile in CYP active sites,32 and the existence of multiple substrate 
binding modes and substrate mobility in CYP2D6 is clearly supported by our molecular 
modeling studies. Averaged distances derived from the present studies, considering three 
distinct automatically docked substrate binding modes of the MDAAs in combination with 
long MD simulations, were in good agreement with the experimentally determined 
metabolic profiles when considering the MDAAs to be in their neutral form (Table 3). Still, 
this does not explain the experimentally observed change in regioselective oxidation and 
stereoselective preference of the F120A mutant towards MDMA compared to wild-type. So 
it is likely that a small substrate like MDMA is very mobile in the CYP2D6 active site and 
that the reactivity of possible sites of oxidation determines also what products are being 
formed.  
 
Regioselectivity and Stereoselectivity in Oxidation 
Experimentally observed trends in regioselectivity of the oxidation of the MDAAs by wild-
type and F120A mutant CYP2D6 (Table 2) were in good agreement with the relative 
probabilities of different binding modes of the MDAAs observed in the MD simulations 
(Table 4B). In the wild-type enzyme, only O-demethylenation was observed 
experimentally, while in the F120A mutant also N-demethylation and N-hydroxylation 
occurred. The molecular modeling studies showed that N-demethylation/hydroxylation 
probabilities for neutral MDAAs were significantly higher in F120A mutant than in the wild-
type enzyme (Table 4B). Both the experimental and modeling studies showed a 
decreased N-hydroxylation efficiency with elongation of the N-alkyl chain and the highest 
MDA formation efficiency for MDEA. Stereoselectivity in oxidation of MDMA by wild-type 
CYP2D6 was hardly found experimentally neither predicted by molecular modeling. 
However, the experimentally observed preference for S-MDMA by the F120A mutant could 
not be rationalized by molecular modeling. This may be due to the fact that the 
stereoselectivity is predominantly caused by a difference in Km and not in Vmax, while the 
affinities of substrates to enzymes were not predicted in a rigorous manner in this study. 
However, the small violations of the calculated to the experimentally determined hydrogen 
atom to iron distances for neutral R-MDMA bound to the F120A mutant do indicate that 
this enantiomer experiences more difficulties to find its optimum orientation in the binding 
pocket. 
 
Influence of F120A Mutation on Oxidation Reactions 
By removing the phenyl ring of F120 more space is created in the active site of CYP2D6 
and a specific aromatic interaction point is eliminated.16 From the MD simulations it 
became clear that this space was not occupied by the MDAAs, nor by water molecules, but 
that critical substrate interactions were lost after mutating F120 into an alanine (Table 5). 
This observation and the fact that the stereo- and regioselectivity of the mutant enzyme 
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differed from wild-type shows that F120 is important for specific interactions with the 
MDAAs in CYP2D6. There is not sufficient space in the active sites of wild-type or the 
F120A mutant CYP2D6 to accommodate two molecules of the MDAAs at the same time. 
However, it could be possible that two substrate molecules bind simultaneously to different 
parts of the protein e.g. in the active site and in substrate access channels,31 or in a 
peripheral binding site.9  
 
Combination of Automated Docking and MD simulations 
In earlier studies it was shown that automated docking can successfully be applied to 
predict sites of oxidation by CYPs.21 In contrast, the current study shows that automated 
docking alone is not suitable for accurate determination of relative probabilities of different 
substrate binding modes and for discrimination between substrates and enzymes of high 
similarity, such as regio/stereoisomers and mutants of enzymes. In order to reproduce the 
experimental data, which are an average over many different substrate and enzyme 
orientations in time, a dynamic treatment of both  substrate and enzyme is required. Only 
when averaging over different positions and orientations was taken into account, 
experimentally determined substrate hydrogen atoms to heme iron atom distances could 
be reproduced accurately. The experimentally observed differences in substrate oxidation 
by wild-type and F120A mutant CYP2D6 could only be explained from the different binding 
modes observed in the MD simulations. Multiple and extensive MD simulations are needed 
to catch subtle differences between substrates, enzyme structures and their dynamics. 
 
Substrate Protonation States.  
The molecular modeling was performed with neutral and charged substrates because this 
markedly influenced the binding and mobility of the MDAAs in the active site of the two 
enzymes. Even though the MDAAs in physiological solution will occur predominantly in 
their charged form, the preferred protonation state within the binding pocket can differ 
significantly, thus reductions of apparent pKa values for substrates upon binding to CYP2D6 
of up to 2 pH units have been reported.26 From a direct comparison between the 
experimentally derived hydrogen atom to heme iron distances and the computationally 
determined values it became clear that the MD simulations reproduced the experimental 
data best when the MDAAs were represented in their neutral form. 
 
6.4 Conclusions 
The approach of combining automated docking and MD simulations in a protein model was 
a successful way to rationalize the oxidative metabolism of a series of 3,4-methylenedioxy-
N-alkylamphetamines (MDAAs) by CYP2D6. Differences in oxidative metabolism of these 
closely related substrates could be predicted in details like regioselectivity and 
stereoselectivity. Furthermore, the effects of the active site F120A mutation on the 
substrate selectivity could be rationalized. The presented integrated modeling method is a 
promising tool in the prediction of the metabolic properties of new (drug-like) compounds 




The pSP19T7LT plasmid containing human 2D6 with a C- terminal His6-tag bicistronically co-
expressed with human NADPH-cytochrome P450 reductase was kindly provided by Prof. Dr. 
Ingelman-Sundberg. 3,4-methylenedioxy- N-alkylamphetamines (MDAAs) were synthesized as 
described before. 33,34 S- and R-MDMA.HCl were obtained from the division of Neurioscience and 
Behavioral Research of the National Institute on Drug Abuse (Bethesda, MD USA). Emulgen 911 
was purchased at KAO Chemicals (Tokyo, Japan). Ni-NTA-agarose was from Qiagen (Westburg, 
Leusden, The Netherlands). All other chemicals were of analytical grade and obtained from 
standard suppliers. 
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Expression and Purification of CYP2D6 
Both the F120A mutant and the wild-type pSP19T7LT plasmids were transformed into Escherichia 
coli, strain JM109. Expression and membrane isolation was carried out as described. 16 Membranes 
were resuspended in 0.4% of the original culture volume of KPi-glycerol buffer (50 mM potassium 
phosphate buffer, pH 7.4, 10% glycerol) and CYP contents were determined by CO difference 
spectra. 35  
Enzymes were solubilized from membranes by stirring in KPi-glycerol supplemented with 0.5% 
Emulgen 911 for 2 h at 4°C. Insoluble parts were removed by centrifugation (60 min, 120,000 g at 
4 °C). The supernatant was incubated, gently rocking, with Ni-NTA agarose for 30 min at 4 °C. The 
Ni-NTA agarose was retained in a polypropylene tube with porous disc (Pierce, Perbio Science, 
Ettenleur, The Netherlands), washed with KPi-glycerol buffer containing 2 mM histidine. CYP2D6 
was eluted with 0.2 M histidine. After overnight dialysis in KPi-glycerol buffer the sample was 
concentrated on a Vivaspin 20 filtration tube (10.000 MWCO PES, Sartorius, Nieuwegein, The 
Netherlands). For NMR spin lattice relaxation rate measurements the buffer was exchanged for 
deuterated KPi-glycerol buffer by repeated rounds of adding a larger volume of deuterated buffer 
and concentrating. Deuterated KPi-glycerol buffer was made by repeated rounds of evaporating 
water or D2O from a KPi buffer and dissolving the residue again in D2O. Then 5% of glycerol was 
added and traces of iron were removed with Chelex 100 (Biorad, Richmond CA). 
 
Optical Titrations 
Dissociation constants of substrates to the enzymes were determined by spectral titration, 
according to the method of Jefcoate.36,37 Spectra were taken at room temperature on a Pharmacia 
Ultrospec 2000 spectrometer. In short, 1 ml of  0.5 µM purified enzyme in KPi-glycerol buffer was 
divided over two cuvettes, to the first 5 µl of a 1 mM solution of compound in the same buffer was 
added, to the second the same volume of just buffer. Difference spectra from 350 to 450 nm were 
taken before, and after each addition of compound. The difference in absorbance at 390 and 425 
was plotted against the substrate concentration to estimate the dissociation constant (Ks) using 
Equation (1) in Graph Pad Prism 4.0 software, where B is the absorbance difference (390-425), 






= max       (1) 
 
 
Metabolism of MDAAs 
Metabolic reactions were carried out in 200 µl 50 mM KPi pH 7.4, 5 mM MgCl2 supplemented with 
10 concentrations ranging from 0 to 200 µM of one of the MDAAs and E. coli membranes 
corresponding to 25 nM wild-type or F120A mutant CYP2D6. After 5 min of pre-incubation at 37 °C, 
the reactions were initiated with an NADPH regenerating system, resulting in final concentrations of 
0.2 mM NADPH, 0.3 mM glucose-6-phosphate, and 0.4 units/ml glucose-6-phosphate 
dehydrogenase. The reaction was allowed to proceed for 10 min before it was stopped by the 
addition of 20 µl 23% HClO4. After centrifugation (10 min, 6800 g), 30 µl aliquots of the 
supernatant were analyzed by HPLC. To measure O-demethylenation, analytes were separated 
isocratically using a C18 column (Phenomenex Luna 5u 150 x 4.6) with a mobile phase consisting 
of 22% acetonitrile and 0.1% triethylamine, set to pH 3 with HClO4 at a flow rate of 0.6 ml/min. 
Other oxidation products were found using the same column with a gradient (A: 5% ACN with 20 
mM ammonium acetate, B: 90% ACN with 10 mM ammonium acetate). All oxidation products were 
detected by fluorescence (λex= 280 nm, λem= 320 nm) and identified by LC-MS. Peak areas of all 
products were quantified by Shimadzu Class VP 4.3 software and analyzed using non linear 
regression with one site binding in Graph Pad Prism 3.0.  
 
LC-MS  
To identify the metabolic products of the MDAAs, incubations were carried out for 15 min as 
described above with 100 µM of MDMA, MDEA or MDPA and E. coli membranes corresponding to 50 
nM wild-type or F120A CYP2D6. Volumes of 100 µl supernatant were injected and separated using 
a C18 column (Phenomenex Luna 5u 150 x 4.6) with a flow rate of 0.6 ml/min and analyzed by MS. 
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The analytes were eluted using a gradient starting with a 5% ACN eluens, supplemented with 20 
mM ammonium acetate for 7 min, then increasing linearly to 90% ACN with 10 mM ammonium 
acetate in 14 min and kept there for 5 min. APCI positive ionization was used on a LCQ Deca mass 
spectrometer (Thermo Finnigan, Breda, The Netherlands), vaporizer temperature 450 °C, N2 as 
sheath (40 psi) and auxiliary gas (10 psi), needle voltage 6000 V, heated capillary 150 °C.  
Products of MDMA metabolism: 3,4-OH-MA (tR: 9.5 min., m/z 182, MS/MS: m/z 151), MDA (tR: 
17.0 min., m/z 180, MS/MS: m/z 163) and N-OH-MDMA (tR: 20.4 min., m/z 210, MS/MS: m/z 163). 
Products of MDEA metabolism: 3,4-OH-EA (tR: 13.0 min., m/z 196, MS/MS: m/z 151), MDA (tR: 17.0 
min., m/z 180, MS/MS: m/z 163) N-OH-MDEA (tR: 21.6 min., m/z 224, MS/MS: m/z 163) a fourth 
product was detected for the mutant (tR 18.5 min., m/z 222, MS/MS: m/z 163). Products of MDPA 
metabolism: 3,4-OH-PA (tR: 16.0 min., m/z 210, MS/MS: m/z 151), MDA (tR: 17.0 min., m/z 180, 
MS/MS: m/z 163), N-OH-MDPA (tR: 23.4 min., m/z 238, MS/MS: m/z 163) a fourth product was 
detected for the mutant (tR: 19.2 min m/z 254, no fragmentation observed). 
 
NMR Spin Lattice Relaxation Rate Measurements. 
Distances from substrate hydrogen atoms to the enzyme heme iron atom were calculated from 
their longitudinal relaxation rates determined using 1H NMR.27-30  1H NMR measurements were 
performed on a Bruker Avance 400 MHz spectrometer, signals were referenced to HDO at 4.75 
ppm. Longitudinal relaxation times (Tl) of substrate hydrogen atoms were measured with a 
standard inversion recovery sequence of 180°-τ-90°. The spectra were recorded with 20 values of 
τ, ranging from 0.1 to 12.5 s and a relaxation delay of 5-10 x Tl. The temperature  was kept at 300 
K, except for the variable temperature experiments. Tl was determined by plotting peak areas 
against delay times τ and exponential fitting (It = A +Be-τ/ Tl) with Bruker XWINNMR software. The 










++ −= COFelFellP TTR   (2) 
 
Where +3,FelT is the relaxation time of substrate hydrogen atoms in the presence of ferric 
enzyme, and COFelT ++2,  is the relaxation time in the presence of ferrous CO-bound enzyme. The 
hydrogen atoms to iron atom distance, rNMR can be calculated from RlP using the simplified Solomon 
and Bloembergen equation 27,38 (Equation 3) 
 
6/1))(( clP
NMR FRCr τα=    (3) 
 
Where C is a constant taking into account the spin state as well as other nuclear and electronic 
factors, with a value of 813 for high spin CYP, 30 α is the fraction of enzyme bound substrate, 
determined as the ratio of the concentration of enzyme and the sum of the substrate concentration 
and its spectral dissociation constant (Ks). F(τc) is a function of the correlation time τc, for which the 
value of 3x10-10 s is taken, as determined for CYP2D6 by others.28  In the calculations of hydrogen 
atoms to heme distances according to eqs. 2 and 3, the assumption has been made that on the 
NMR time-scale there is a fast exchange between substrate molecules in solution and in the 
enzyme active site. This was verified by measuring the temperature dependence of 1/Tl, which 
should show a linear increase with the reciprocal value of the temperature.29,30 
In a typical experiment 5 µM of enzyme and 20 mM of substrate was used in a volume of 500 µl. 
Recording the spectra for relaxation times determination with oxidized enzyme took about an hour, 
then sodium dithionite was added and the sample was treated for 30 sec with CO to do the 
measurements with the reduced CO-bound enzyme.  
 
Homology Modeling 
A protein homology model of CYP2D6 was constructed based on the crystal structures of 
dimethylsulphophenazole derivative and diclofenac bound rabbit CYP2C5 (PDB codes 1N6B and 
1NR6, respectively). 39,40 Homology modeling, model refinement and model validation was 
performed according to the approach described previously.12 Shortly, a hundred CYP2D6 models 
were generated with the restraint-based comparative modeling program Modeller,41 using the same 
amino acid alignment as before.12 Subsequently, three models were selected with the best loop 
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conformations as determined by visual inspection, stereochemical parameters using PROCHECK, 42 
and side-chain environment using Errat43 and Verify3D.44 Homology models had approximately the 
same protein quality check scores as the crystal structure templates. Finally, one single model was 
selected which could accommodate codeine best in the experimental binding orientation.28 This 
final model was validated on its ability to reproduce substrate binding orientations corresponding to 
metabolic profiles with AutoDock,45 FlexX,46 and GOLD47 automated docking studies.48 The final 
model of wild-type CYP2D6 was used as a template for modeling of the F120A mutant. The Phe 
residue at position 120 was mutated to Ala using the homology module of Insight II (Biosym. San 
Diego, USA), after which an energy minimization and a 1 ps MD simulation with position restraints 
on the protein backbone was carried out as described under “MD Simulations”. 
 
Automated Docking Studies. 
The R-, and S-enantiomers of MDMA, MDEA and MDPA in their neutral and charged forms were 
docked into the active site of the CYP2D6 homology model using AutoDock and GOLD. Active site 
water molecules, predicted using a protocol based on the program GRID49 and a ligand-based cut 
off were included. The preparation of enzyme and substrate structures in the automated docking 
studies were performed using default settings and predicted water molecules as described before. 
21 For each substrate, 50 independent AutoDock and GOLD docking runs were performed using 
default parameter values. Docking poses generated by both docking algorithms were clustered 
(maximum root-mean square deviations between members of the cluster of 1 Å) and re-scored 
with the SCORE scoring function.50 The three energetically most favorable, distinct docking poses of 
each MDAA species were selected as starting structures for MD calculations, yielding in total 12 (3 
docking poses times 2 enatiomers, times 2 protonation states) simulations for each substrate in 
both wild-type and F120A mutant CYP2D6. 
 
MD Simulations 
Substrate conformations selected from the automated docking studies were used as starting 
structures for MD simulations, using the GROMACS molecular simulation package51 and the 
GROMOS-96 force field, parameter set 43A1.52,53 Heme parameters were taken from this parameter 
set, and additionally, a covalent bond was defined between the heme iron atom and the sulfur 
atom of C443 with an ideal bond distance of 0.240 nm. Enzyme including substrate and heme, was 
energy minimized in vacuum using the steepest descent method, first with harmonic position 
restraints using a force constant of 1000 kJ mol-1 nm-2 on all non-hydrogen atoms, then without 
position restraints. Subsequently, pre-equilibrated water was added in a dodecahedral box with a 
minimum distance of 1 nm between the enzyme and box edges, followed by minimization. For 1 ps, 
the water was allowed to relax, while the whole enzyme was position restrained. Then, first only 
the side chains of the residues not involved in substrate binding were released for 1 ps, next also 
the backbone of these residues for 10 ps. Finally, only the backbone of the binding residues were 
restrained for 100 ps. The equilibration scheme was followed by an unrestrained 10 ns MD 
production run. MD simulations were carried out with a time step of 1 fs, a cut-off of 1 nm and a 
relative dielectric constant of 1.0. The LINCS algorithm was used to constrain the length of all 
covalent bonds.54 Pressure was maintained at 1 bar and temperature at 300° K by weak coupling to 
an external bath,55 with relaxation times of 0.1 and 1.0 ps respectively. Coordinates were saved at 
a 1.0 ps interval for subsequent analysis. Enzyme-substrate interactions were estimated using the 
SCORE scoring function and averaged over the trajectories. 
 
MD Simulations Analysis 
Hydrogen atoms to iron atom distances rMD for different protonation states of the MDMA 
enantiomers were derived from MD simulations by averaging distances (r) observed in the three 
independent simulations with different starting positions as: 
 
rMD = (〈r -6〉)-1/6   (4) 
 
These distances could directly be compared to the experimentally obtained distances rNMR,(Equation 
3). 
Sites of oxidation were predicted based on enzyme-substrate conformations generated by 
automated docking and MD simulations. Distances of 6.0 Å or less between the heme iron and an 
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atom in the substrate (e.g. corresponding to O-demethylenation, N-dealkylation, N-hydroxylation, 
or ω-hydroxylation) were considered as reactive in the sense that activation of the C-H bond by the 
heme-Fe-O moiety is possible.56 Site of oxidation predictions were performed to determine both 
substrate reactivity (expressed in the number of reactive MD configurations out of the total) and 
regioselectivity. The catalytic regioselectivity was calculated by determining which site of oxidation 
was closest to the heme iron atom for each reactive docking pose or MD configuration. Enzyme-
substrate interactions during the MD simulations were monitored in terms of the occurrence of 
atom-atom distances of 3.5 Å or less between the F/A120 side-chain and the MDAA ring system 
(representing aromatic/van der Waals interactions) and hydrogen bonds between the E216 
carboxylate oxygen atoms and the MDAA N-atom. Substrate reactivity, regioselectivity and enzyme 
substrate interactions were calculated for any given protonation state, stereo- and regio-isomer, as 
a Boltzmann weighted average over the three independent MD simulations with different substrate 
starting orientations. The average of an individual simulation i was weighted by a relative 
probability pi, which was calculated from the average enzyme substrate interaction estimates as 
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Figure I: 1H NMR spectra after the inversion recovery sequence of 180°-τ-90°, of 20 mM racemic 
MDMA in deuterated Kpi-glycerol in presence of 5 µM wild-type CYP2D6 with τ varying from 0.1 to 
12.5 s from front to back.  
 
 













Figure II: Temperature dependence of Tl relaxation rates for the hydrogen atoms of N-methyl (δ 
2.61) of +/- MDMA in wild-type CYP2D6. The positive slope indicates that the fast exchange 
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Detailed molecular dynamics (MD) simulations have been performed to reproduce and 
rationalize the experimental finding that the F483A mutant of CYP2D6 has lower affinity 
for R-propranolol than for S-propranolol. Wild-type (WT) CYP2D6 does not show this 
stereospecificity. The thermodynamic integration approach was used to calculate the free 
energy differences between all combinations of R- and S-propranolol complexed to wild-
type and F483A mutant CYP2D6 (end-points). Based on differences between multiple 
calculations connecting the same end-point and the closure of the thermodynamic cycles, 
it was clear that not all simulations have converged sufficiently. The approach that 
calculates the free energies of exchanging R-propranolol with S-propranolol in the F483A 
mutant relative to the exchange free energy in WT was able to reproduce the 
experimental binding data. Careful inspection of the end-points of the simulations involved 
in this approach, allowed for a molecular interpretation of the observed differences. R-
propranolol forms fewer hydrogen bonds than S-propranolol, both in WT and in the F483A 
mutant. The mutation causes a loss of favourable hydrophobic interactions, which can be 
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7.1 Introduction 
The superfamily of Cytochrome P450 (CYP) enzymes constitutes the most important phase 
I metabolic enzymes. CYPs generally detoxify pharmacologically active and potentially 
hazardous compounds, but in a number of cases non-toxic parent compounds are 
bioactivated into pharmacologically or toxicologically active metabolites, or procarcinogens 
into their ultimate carcinogens.1,2 Although the expression levels of CYP2D6 represent only 
2% of all hepatic CYPs, it is the second most important drug metabolizing enzyme after 
CYP3A4, and involved in the metabolism of about 15-30% of the currently marketed 
drugs.3,4 Large interindividual differences exist in CYP2D6 activity, due to gene multiplicity 
and polymorphisms further emphasizing its clinical importance.5-7 The early identification 
of potential CYP2D6 substrates and prediction of their metabolism is therefore 
advantageous in the discovery and development of new drugs. 
Experimentally, the active site of CYP2D6 can be probed by site directed mutagenesis 
studies as described in Chapter 3 and e.g., refs 8-12. Such experiments can be designed 
from structural models of enzyme-substrate complexes and the observed effect of 
mutations on metabolism and inhibition can subsequently be rationalized at an atomic 
resolution by modeling approaches. One mutant of CYP2D6 that was proposed based on 
computational models, is the F483A mutant.8 The effect of this mutation on substrate 
binding affinities and orientations was shown to be strongly dependent on the substrate. 
For example, the metabolism of MAMC was no longer observed in the F483A mutant and 
metabolism of bufuralol was reduced. On the other hand no effects on the MDMA 
metabolism were found, while for dextrometorphan several alternative metabolites were 
observed. The binding affinity of these compounds did not seem to be influenced 
significantly by the mutation. Only for the substrate R-propranolol was the affinity reduced 
by a factor 20 upon mutation. Interestingly, a large stereospecific affinity in the mutant 
CYP2D6 was observed, but not in wild-type (WT). The metabolites formed from both R- 
and S-propranolol remained the same upon mutation of the enzyme. 
In this study, we explore the stereospecific binding of propranolol to wild-type CYP2D6 
and the F483A mutant. The spectral dissociation constants obtained were computationally 
rationalized. Computational tools may offer an atomic resolution often lacking in 
experiments. In the present case, one expects that subtle differences in the protein-ligand 
interactions in WT CYP2D6 or in the F483A mutant have a determining influence on the 
observed affinities. In order to catch such subtle differences a static approach based on 
protein-ligand structures only will not likely suffice, but rather the structure and dynamics 
of protein-ligand interactions have to be taken into account, for instance by molecular 
dynamics (MD) simulation. In CYPs it was shown that docking and scoring strategies can 
be applied to accurately predict binding modes and to select high affinity compounds from 
chemical databases (e.g. CYP101, CYP2D6 and CYP3A4) (Chapter 5, refs 13-17). However, 
the scoring functions available in docking programs show little or no correlation with 
(experimental) binding affinity for these CYPs.16,17 In the case of MDMA binding to CYP2D6 
(WT and F120A mutant) it was shown that a dynamic view on the interaction was required 
to rationalize experimental findings (Chapter 6). Detailed MD simulations also offer the 
possibility to calculate the free energy difference between complexes of different proteins 
and ligands. 
Previously, successful free energy calculations have been reported using different 
methods. The linear interaction energy (LIE) method18 was used for CYP101,19 CYP1A1,20 
free energy perturbation (FEP) calculations21,22 for CYP10123,24 and a combination of MD 
simulations, entropy estimates and Poisson-Boltzmann calculations (MMPB-SA)25 for 
CYP2B4.26 
A remaining hurdle in the accurate calculation of CYP ligand binding affinity, however, is 
the diversity of binding modes of substrates, stemming from a flexible binding cavity that 
is large in relation to the size of the substrates. Subsequently, for many substrates the 
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binding mode in CYPs is not as strictly defined as is the case for many other more 
substrate specific enzymes. This introduces sampling problems, prohibiting the application 


















































Figure 1: Four different approaches to calculate the differences in binding affinities of R-propranol 
(R) and S-propranolol (S) to wild-type (WT) and F483A mutant (F483A) CYP2D6, making use of 
different thermodynamic cycles (described in the text). Simulations at the initial and final stages 
along the solid arrows are labeled with a small letter (also referred to in the text  and in Table 2).  
 
In the case of R- and S-propranolol binding to WT CYP2D6 and the F483A mutant, 
several approaches can be made, making use of different thermodynamic cycles.27 We 
distinguish four of such approaches, which are exemplified in Figure 1.  
1. Calculate the free energy of inversion of R-propranolol into S-propranolol in 
solution and when bound to protein (WT or F483): ∆Gfreeinv, ∆GWTinv and ∆GF483Ainv. 
From this approach the relative binding affinities of R- and S-propranolol in protein 
(WT or F483A) can be obtained (∆∆GWTbind(R,S) and ∆∆GF483Abind(R,S)). 
2. Calculate the free energy of inversion of R-propranolol into S-propranolol when 
bound to WT and when bound to the F483A mutant: ∆GWTinv and ∆GF483Ainv. From this 
approach 1:     
∆∆GWTbind(R,S)  = ∆GWTbind(S) - ∆GWTbind(R) = ∆GWTinv - ∆Gfreeinv 
∆∆GF483bind(R,S)  = ∆GF483bind(S) - ∆GF483bind(R) = ∆GF483inv - ∆Gfreeinv 
     
approach 2:     
∆∆Gtransfer(R,S)  = ∆Gtransfer(S) - ∆Gtransfer(R) = ∆GF483inv - ∆GWTinv 
 
approach 3: 
    
∆∆GRbind(WT,F483A)  = ∆GRbind(F483) - ∆GRbind(WT) = ∆GRmut - ∆Gunboundmut 
∆∆GSbind(WT,F483A)  = ∆GSbind(F483) - ∆GSbind(WT) = ∆GSmut - ∆Gunboundmut 
 
approach 4: 
    
∆∆Gexchange(WT, F483A)  = ∆Gexchange(F483) - ∆Gexchange(WT) = ∆GSmut - ∆GRmut 
     
∆Gcycle = ∆GWTinv +  ∆GSmut - ∆GF483inv - ∆GRmut 
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the relative free energy of transfer from WT to F483A for R- and S-propranolol can 
be obtained (∆∆Gtransfer(R,S)). 
3. Calculate the free energy of mutating the phenylalanine sidechain into an alanine 
at position 483 in a substrate free protein model and a substrate (R- or S- 
propranolol) bound protein model: ∆Gunboundmut ∆GRmut and ∆GSmut. From this the 
relative binding affinities of the ligand (R- or S-propranolol) to WT and F483A can be 
obtained (∆∆GRbind(WT,F483A) and ∆∆GSbind(WT,F483A)). 
4. Calculate the free energy of mutating the phenylalanine sidechain into an alanine 
at position 483 in a R-propranolol bound protein model and in a S-propranolol bound 
protein model: ∆GRmut and ∆GSmut. From this the relative free energy of exchanging 
R-propranolol by S-propranolol in WT and the F483A mutant can be obtained 
(∆∆Gexchange(WT,F483A)). 
 
Each of these approaches yields information that can be compared directly to the 
experimentally determined differences in binding affinities of R- and S-propranolol to WT 
and F483A CYP2D6. ∆Gfreeinv, representing the inversion of the stereocenter of propranolol 
free in solution, should equal zero. Because free energy is a state function, combinations 
of individual free energy terms defined above can be found that should sum up to exactly 
zero (∆Gcycle). Comparisons of calculated to experimental values and to theoretically 
defined values will be used to determine which of the approaches is most accurate and 




Dissociation constants of the substrates to the enzymes were determined by spectral titration, 
according to the method of Jefcoate.28 Spectra were taken at room temperature on a Pharmacia 
Ultrospec 2000 spectrometer. In short, 1 ml of 0.5 µM purified enzyme in a 50 mM potassium 
phosphate buffer, pH 7.4 containing 10% glycerol, was divided over two cuvettes, to the first 5 µl 
of a 1 mM solution of R- or S-propranolol in the same buffer was added, to the second the same 
volume of just buffer. Difference spectra from 350 to 450 nm were taken before, and after each 
addition of compound. The substrates themselves did not show absorbance in this spectral range at 
the concentrations used. The difference between the absorbance at 390 nm and 425 nm was 








= max            (1) 
 
where B is the absorbance difference (390-425) and Bmax is the absorbance difference when  
[S] → ∞.  
 
CYP2D6-propranolol model 
Coordinates for a ligand bound model of cytochrome P450 were obtained from homology modeling 
as described in chapter 3. Very recently a model based on the crystal structure of this isoenzyme 
has been published, but this involves a ligand-free conformation of the protein. For other CYPs (e.g. 
2C5) it was shown that significant conformational changes within the active site take place upon 
substrate binding.29-31 For this reason we chose to rather use the ligand-bound homology model, 
which was validated in earlier simulations studies.32 For a detailed description of the homology 
model and a comparison with the crystal structure we refer to Chapter 3. Initial coordinates for R-
propranolol in complex with the protein model were obtained by an automated docking approach as 
described in Chapter 4. 
 
Molecular dynamics simulations 
Molecular dynamics simulations and free energy calculations were performed along all solid angles 
in the thermodynamic cycles in Figure 1. All molecular dynamics simulations were performed using 
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a preliminary version of the GROMOS05 programme.33 Interaction parameters were taken from the 
GROMOS 43A1 force field.34,35 For propranolol, parameters were determined according to analogy 
to protein functional groups (see supplementary material). The GROMOS force field is a united 
atom force field, treating aliphatic hydrogen atoms together with the carbon atoms to which they 
are bound as a single interaction site. The wild-type protein was solvated in a rectangular periodic 
box containing 5314 (ligand free simulation) or 5306 (with R-propranolol bound) SPC water 
molecules.36 For the simulations of propranolol free in solution, the simulation box contained 2367 
water molecules. After an initial energy minimization in which the protein was positionally 
restrained, simulations were started at a temperature of 300 K, maintaining harmonic restraints 
with force constant 2500 kJ/mol/nm2 on all solute atoms.  
The system was carefully heated up and equilibrated as described in Chapter 6. Bond lengths 
were constrained at their minimum energy values using the SHAKE algorithm37 allowing for a 
timestep of 2 fs. Nonbonded interactions were calculated using a triple range cutoff scheme. 
Interactions within a short range cutoff of 0.8 nm were calculated at every time step from a pairlist 
that was generated every 5 steps. Longer range interactions within a cutoff of 1.4 nm were 
calculated at pairlist generation and kept constant between updates. To account for electrostatic 
interactions beyond the long range cutoff, a reaction field contribution to the energies and the 
forces was calculated.38 The temperature was kept constant by coupling solute and solvent degrees 
of freedom separately to a temperature bath of 300 K and using a relaxation time of 0.1 ps.39 
Constant pressure was maintained by isotropically coupling to a weak pressure bath of 1 atm using 
a relaxation time of 0.5 ps and an estimated isothermal compressibility of 4.575.10-4 (kJ mol-1 nm-3)-1. 
 
Free energy calculations 
Free energies were calculated along the solid arrows in Figure 1, using the thermodynamic 
integration method.22,40 The arrows in this figure connect an initial (A) and a final (B) state, which 
can be defined as: 1) R-propranolol (A) vs. S-propranolol (B) free in solution; 2) R-propranolol (A) 
vs. S-propranolol (B) bound to wild-type and F483A mutant CYP2D6, respectively; 3) unbound wild-
type (A) vs. unbound F483A mutant CYP2D6; 4) wild-type (A) vs. F483A mutant (B) binding R- and 
S-propranolol, respectively. The Hamiltonians describing the initial and final states of each process 
were related using a coupling parameter λ, such that at λ = 0 the Hamiltonian described the initial 
state and at λ = 1, it described the final state of the process. Simulations were performed at a 
number of discreet λ-values and the free energy was obtained by numerical integration of the 









drHGBA  (2) 
 
Where <>λ represents an ensemble average obtained at the specified value of λ, r and p are the 
positions and momenta of all particles in the system. Free energies of mutating residue 483 and of 
R/S inversion of propranolol were calculated as shown Figure 2. Processes involving the inversion 
of the chiral center of propranolol were performed in a two-step process.41,42 First one stereoisomer 
was transformed into a planar intermediate (I), using 6 simulations for the integration of equation 
(2). The intermediate state was subsequently transformed into the alternative stereoisomer, using 
again 6 equidistant values of λ. Processes involving the transformation of residue 483 were 
obtained from 11 simulations at equidistant λ-values. Aromatic atoms in F483 were changed into 
non-interacting dummy atoms, while Cβ was changed from a CH2 group into a CH3 group. The 
nonbonded interactions at intermediate λ-values were described using the soft-core approach to 
avoid singularities in the derivative.43 No changes were made in the covalent interactions. 20 ps of 
equilibration were followed by 200 ps of data collection at every λ-value. Statistical error estimates 
on the ensemble averages were obtained using block averages.44 Simulations with relative large 
statistical errors were prolonged for another 200 ps, and additional points were added wherever 
needed to obtain a smooth profile of <∂H/∂λ> as a function of λ. A more empirical error estimate 
was obtained by comparing calculated free energy values associated with a forward process and 
the corresponding reverse process, also called hysteresis. An average free energy estimate from the 
forward and backward processes can be calculated using boltzmann weighted averages using:45,46 
 
[ ]( )TkGTkGBaverage BbackwardBforward eeTkG //21ln ∆−∆− +−=∆  (3) 
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A total of 76 simulations (6 x 2 x 6 + 4 added λ-points) were performed involving R/S inversions 
and 72 simulations (6 x 11 + 6 added λ-points) were performed involving F/A mutations. This leads  
























Figure 2: Schemes describing the (reversible) inversion of R- into S-propranolol and the 
(reversible) mutation of the residue on position 483 in CYP2D6 (F (WT) into A (mutant)). The 
planar propranolol intermediate is indicated by “I”, non-interacting dummie atoms in the A483 





Both the propranolol enantiomers displayed a type I binding spectrum when added to 
wild-type CYP2D6, as derived from a decrease of the Soret maximum at 417 nm, and the 
appearance of a shoulder at 380 nm, which is typical for type I binding of a substrate.28 
The affinity of the wild-type enzyme for the R- and S-enantiomers was similar (Table 1).  
 
Table 1: Ks values (µM) of S- and R-propranolol for wild-type and F483A mutant CYP2D6. 
Ks (µM) Ligand 
wild-type F483A 
S-propranolol 26 ± 6 23 ± 2 
R-propranolol 19 ± 3 376 ± 26 
All values are the means of at least two independent experiments ± S.D as described in the experimental 
procedures. 
 
The addition of S-propranolol to the F483A mutant gave the same results as obtained for 
wild-type CYP2D6. The addition of R-propranolol to the F483A mutant of CYP2D6 did also 
lead to a type I spectrum, however, the affinity was 20-fold lower compared to the wild-
type enzyme.  
 
Computational approaches 
Simulations at the initial and final stages along the solid arrows in Figure 1 have been 























































four of such simulations of 200 ps were performed, labeled with small letters in Figure 1. 
The four simulations included the end points of at least two different processes (R/S-
inversion or F/A mutation) allowing for a comparison of convergence at every state. 
The atom-positional root-mean-square deviation of Cα atoms with respect to the initial 
homology model, remained stable throughout the simulations, with maximum values of 
0.25 nm. For a 464 residue protein (the N-terminus of the homology model is truncated by 
33 residues, see chapter 3) such values are reasonable and indicate simulations of a 
stable protein structure. 
 
Binding mode orientation 
The active site of CYP2D6 is formed by substrate recognition sites (SRS) 1 (B-C loop), 2 
(F-helix), 4 (I-helix), 5 (β1-4) and 6 (β4-1). Figure 3 displays a top view of the active site 
with interacting residues displayed in stick. The protonated nitrogen atom and the 
hydroxyl group of propranolol can form a hydrogen bond network with the negatively 
charged carboxylate of E216 (not visible in Figure 3, but shown in Figure 5). Two 
binding modes for the naphthalene moiety can be distinguished (see Figure 3). In WT 
CYP2D6, propranolol occupies a hydrophobic cavity formed by F120, V308, V370, and 
F483 (binding mode 1). In the F483A mutant, a larger cavity becomes available and SRS5 
slightly shifts. The naphthalene moiety of propranolol now occupies a cavity formed by 




Figure 3: Representative snapshots of two distinct binding modes observed in simulations of WT 
CYP2D6 (binding mode 1, left panel) and the F483A mutant (binding mode 2, right panel). 
Propranolol is depicted in yellow sticks and hydrophobic substrate binding amino acid residues are 
depicted in grey ball-and-sticks. Two geometric features used to discriminate between the two 
binding modes are displayed: the distance between the nitrogen atom of heme pyrrole ring B (NB) 
and the C5 atom of R-propranolol and the angle defined by the Cζ atom in F120, the C5 atom in R-
propranolol and the Cβ in V370. 
 
In order to distinguish these binding modes, an atomic distance and an angle are defined 
in Figure 3. The distance between the heme NB atom and the C5 atom of propranolol will 
be larger in binding mode 2. The angle defined by the Cζ atom in F120, the C5 atom of 
propranolol and the Cβ in V370 will approach 180 in binding mode 2. Table 2 presents the 
average values of the NB-C5 distance and the Cζ-C5-Cβ angle over the end-point 
simulations, together with the average number of hydrogen bonds between propranolol 
and E216. The presence of a hydrogen bond was determined using geometric criteria: a 
donor-acceptor distance of at most 0.25 nm and a H-bond angle of at least 135°. 
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Alternative hydrogen bonds partners of propranolol were not observed for significant 
periods of time. 
 
Table 2: The average values of the geometric features defined in Figure 3 together with the 
average number of hydrogen bonds between propranolol and E216 for the different MD-simulations 
at the initial and final stages of the inversion and mutation processes defined in Figure 1. The 
results belonging to approach 2 (defined in Figure 1) are displayed in bold.  






e R-propranolol WT 2.2 4.7 90 
f   2.2 5.4 111 
g S-propranolol WT 2.4 4.7 92 
h   2.6 4.5 87 
i R-propranolol F483A 2.1 8.3 159 
j   2.4 8.0 138 
k S-propranolol F483A 2.7 10.5 117 
l   2.1 8.6 134 
q R-propranolol WT 2.4 6.6 157 
r   2.2 4.8 103 
s S-propranolol WT 1.5 4.6 88 
t   2.2 4.8 83 
u R-propranolol F483A 2.5 4.9 104 
v   2.5 5.2 101 
w S-propranolol F483A 1.7 5.0 90 





Figure 4: The values of <∂H/∂λ> as a function of λ for the calculation of the following free energy 
values. Panel 1: ∆Gfreeinv forward (solid) and backward (dotted). Panel 2: ∆GWTinv forward (solid) and 
backward (dotted), ∆GF483Ainv forward (dashed) and backward (dot-dash). Panel 3: ∆Gunboundmut 
forward (solid) and backward (dotted). Panel 4: ∆GRmut forward (solid) and backward (dotted); 
∆GSmut forward (dashed) and backward (dot-dash). 
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Free energy calculations 
The values of <∂H/∂λ> as a function of λ are displayed in Figure 4 for all thermodynamic 
integration simulations. Values for the backward processes are multiplied by -1, for ease of 
comparison to the forward processes. Free energy estimates for all processes were 
obtained by a simple trapezoid integration of these curves and the resulting free energies 
are presented in Table 3. Using the definitions in Figure 1, the different relative free 




The primary aim of this study was to reproduce and rationalize the experimental finding 
that the F483A mutant of CYP2D6 has lower affinity for R-propranolol than for S-
propranolol, using detailed molecular dynamics (MD) simulations. From these simulations, 
free energy estimates for all processes in Figure 1 have been derived, which are 
presented in Table 3. The error estimates in Table 3 should be considered as statistical 
error estimates, indicating the statistical precision of the calculation. The absolute 
accuracy, however, is more difficult to determine. Three criteria that may give an 
indication of the accuracy can be distinguished. First, the hysteresis, defined as the 
difference between performing a process in the forward and backward directions, yields 
information on the convergence of the directions. At infinite sampling times, the hysteresis 
will be equal to zero.  
 
Table 3: Free energy estimates, the resulting average free energies, and the relative free energies 
for all processes defined in Figure 1 and compared to experimentally determined values.  
 forward backward averagea hysteresisb 
∆Gfreeinv -0.4 ± 1.5 -1.0 ± 1.8 -0.7 0.6 
∆GWTinv 10.6 ± 1.5 19.1 ± 1.7 12.2 8.5 
∆GF483Ainv 3.6 ± 2.1 6.8 ± 1.9 4.7 3.2 
∆Gunboundmut 35.8 ± 3.0 36.0 ± 3.5 35.9 0.2 
∆GRmut 36.8 ± 2.0 40.2 ± 2.7 38.0 3.4 
∆GSmut 50.5 ± 4.3 41.3 ± 2.5 42.9 9.2 
∆Gcycle 20.7 ± 11.4 13.4 ± 8.8 12.5  
     
   averagea experimental 
approach 1:     
∆∆GWTbind(R,S)   12.9 0.8 
∆∆GF483Abind(R,S)   5.4 -6.9 
     
approach 2:     
∆∆Gtransfer(R,S).   -7.5 -7.7 
     
approach 3:     
∆∆GRbind(WT,F483A)   2.1 7.4 
∆∆GSbind(WT,F483A)   7.0 0.3 
     
approach 4:     
∆∆Gexchange(WT,F483A)   5.0 -7.1 
a) Average determined according to equation 3 
b) Hysteresis, defined as the difference between performing a process in the forward and backward directions, 
yields information on the convergence of the two independent calculations. 
 
In Table 3, two cases can be observed with relatively large hystereses, the R/S inversion 
of propranolol in WT CYP2D6 and the F/A mutation in S-propranolol bound protein. In the 
other cases the hysteresis falls within the statistical uncertainty. Second, using the studied 
processes, one can obtain cyclic pathways along which the sum of free energies should be 
equal to zero. In Table 3, such a pathway is presented as ∆Gcycle. It is clear that the 
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present calculations do not meet this criterion, with values of ∆Gcycle larger than the 
statistical uncertainty. This indicates that not all free energy calculations have converged 
properly. The third criterion is the ability to reproduce experimental data. Knowing that not 
all simulations have reached convergence, this last criterion allows us to determine if any 
of the four approaches mentioned in the introduction can still be used to rationalize the 
experimental data at an atomic level. 
 
Free energies of binding: approaches 1 and 3 
In the first approach, the relative free energies of binding R- and S-propranolol are 
determined for both proteins. This approach uses a simulation of the R/S-inversion free in 
solution, of which the free energy value should fundamentally equal zero. As can be seen 
in Table 3, indeed ∆Gfreeinv is calculated to be 0 within the error estimate. However, the 
relative free energies ∆∆GWTbind(R,S) and ∆∆GF483Abind(R,S) do not correspond to the 
experimentally determined value. The inversion process of propranolol when bound to the 
protein seems to be too unfavourable. Still, this may be due to a systematic contribution in 
the protein simulations, which would cancel in approach 2, where only free energies 
resulting from simulations of the propranolol inversion when bound to the protein are 
compared. 
In the third approach, the relative free energies of binding R- and S-propranolol to the 
WT and mutant CYP2D6 protein are calculated and compared. The mutation in the ligand-
free protein shows the smallest hysteresis in Table 3. The obtained value of ∆∆GRbind 
(WT,F483A) is within 4 kJ/mol of the experimental value, which is within the statistical 
uncertainty, but not satisfactory. The value of ∆∆GSbind(WT,F483A) is even further from the 
experimental value. Note that the value of ∆GSmut shows the largest hysteresis, indicating 
that particularly these simulations may not have converged properly. An indication of the 
convergence can be obtained by comparing simulations k and l to simulations w and x in 
Figure 1. in terms of the structural properties. From the average distance and angle in 
Table 2, we can see that in simulations w and x, the naphthalene moiety of S-propranolol 
binds in binding mode 2, while in simulations k and l, S-propranolol still orients according 
to binding mode 1 (see Figure 2). This difference indicates that the processes (R/S 
inversion in the mutant protein, or F/A mutation with S-propranolol bound) do not 
converge to the same end point. This is also reflected by significant differences in H-bond 
counts (see Table 3): S-propranolol forms more H-bonds with E216 in the F483A mutant 
in simulations k and l than it does in simulations w and x. A similar difference in the 
average number of hydrogen bonds between S-propranolol and E216 in WT is observed 
when comparing simulations g and h with simulations u and v. This indicates that S-
propranolol occupies a different area in phase space during the F/A mutation than during 
the other simulations leading to the same end-points. With these observations, we also 
find an explanation for the non-zero value of ∆Gcycle. Since not all end-points of the 
simulations are connected, the calculated cycle is not complete.  
 
Free energies of transfer and exchange: approaches 2 and 4 
Approach 4 uses the same mutational processes with propranolol bound to the protein as 
were used in approach 3. From these values the free energies of exchanging R-propranolol 
by S-propranolol in the mutant relative to WT (∆∆Gexchange(WT,F483A)) can be obtained. As 
was discussed above, the F/A mutation with S-propranolol bound does not converge to the 
same end-points. For this reason it should not be expected that the value of 
∆∆Gexchange(WT,F483A) will correspond to the experimental data (Table 3).    
The only approach for which the calculated free energies match the experimental data 
appears to be approach 2. In this approach the free energy of transferring R-propranolol 
from WT CYP2D6 to the F483 mutant is calculated relative to the free energy of 
transferring S-propranolol (∆∆Gtransfer(R,S)). The obtained value lies only 0.2 kJ/mol from 
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the experimental value, which is well within the statistical error estimate of the 
calculations. It is also within kBT (~2.5 kJ/mol), corresponding to thermal fluctuations, 
which is the accuracy that can be expected from free energy calculations.47,48 
In summary, the approaches using protein mutations (i.e., 3 and 4) do not converge 
sufficiently to reproduce the experimental data. A systematic error in the R/S inversion for 
protein-bound propranolol disqualifies approach 1, but still allows for a comparison with 
approach 2 (the inversion in the different proteins), which does yield free energy values in 
agreement with the experimental data. From Figure 4 it can be seen that <∂H/∂λ> takes 
much larger values in the processes involving a mutation than in the processes involving 
an inversion. It has been shown earlier that free energy calculations involving smaller 
structural changes and smaller energy barriers yield more accurate free energy estimates 
than integrations involving large changes in <∂H/∂λ>41,49 
Possibly, better results with lower hysteresis and cycle closure, could be obtained by 
further extending the length of the simulations and by adding more λ-points.49,50 Another 
possible source of error could be the fact that a substrate bound homology model was 
used, which has slightly different properties than the recently solved substrate-free crystal 
structure. However, we conclude that the changes required in the active site of CYP2D6 
upon ligand binding are so large51,52 that the use of the homology model is justified. In 
addition, CYP2D6 will remain a challenging target for computational approaches, because 
of the broad range of inhibitors and substrates and the multiple binding modes observed 
for these.53 
Now that we have determined that approach 2 meets the third accuracy criterion best, 
we can investigate the molecular basis for the lower affinity of the F483A mutant for R-
propranolol at an atomic resolution. 
 
Structural rationalization 
In order to rationalize the difference in affinity for R- and S-propranolol upon mutation of 
residue 483, we can compare the observed binding modes in simulations e-l in Figure 1. 
Representative orientations of propranolol in the binding cavities of WT and mutant 
protein in these simulations are presented in Figure 5. In all simulations propranolol is 
involved in a salt bridge between the protonated nitrogen atom and the negatively 
charged E216 in the protein. Together with the propranolol hydroxyl group, these three 
moieties form a dynamic hydrogen bond network. The average number of hydrogen bonds 
observed throughout the simulations, however varies for different combinations of R/S-
propranolol and WT/F483A proteins. Already in WT (simulations e-h), we observed fewer 
hydrogen bonds for R-propranolol than for S-propranolol (see Table 2 and Figure 5). 
 For both stereoisomers, the naphthalene moiety orients itself according to binding 
mode 1, it fits snugly into a hydrophobic pocket formed by V308, V370, and F483 (pocket 
1, see Figures 3 and 5). Upon the F483A mutation, the size of the pocket increases, 
which opposes tight hydrophobic interactions. The naphthalene moiety now occupies the 
pocket formed by F120, V370, V374 and A483 (pocket 2), according to binding mode 2, as 
indicated by a small value of the heme-NB to propranolol-C5 distance (see Table 2). A 
large value of the Cζ-C5-Cβ angle indicates that a position between F120 and V370 is 
occupied. In the F483A mutant, R-propranolol binds in pocket 2 without significant 
decrease in the average number of hydrogen bonds (simulations i and j), compared to the 
simulations performed in WT (e and f). When S-propranolol binds in pocket 2 in F483A, 
hydrogen bond interactions are lost, in particular the propranolol-OH to E216-Oε hydrogen 
bond is observed only for 50 % of the time in simulation l. This hydrogen bond can be 
regained by moving away from F120 and V370 (angle Cζ-C5-Cβ decreases) in simulation k. 
In fact the average number of hydrogen bonds in this simulation is even larger than for S-
propranolol in WT, compensating the lack of tight hydrophobic interactions at the 
naphthalene moiety. R-propranolol cannot compensate for this loss. 

































Figure 5: Representative orientations of R- and S-propranolol in the binding cavities of WT and 
mutant CYP2D6 observed during the MD-simulations at points defined in Figure 1 and included in 
approach 2: e (WT:R), g (WT:S), i (F483A:R), and k (F483A:S). R-propranolol forms fewer 
hydrogen bonds than S-propranolol, both in WT and in the F483A mutant. The mutation causes a 
loss of favourable hydrophobic interactions, which can be compensated by increased hydrogen 
bond formation by S-propranolol, but not by R-propranolol. 
 
In summary, the following picture arises. R-propranolol forms fewer hydrogen bonds 
than S-propranolol, both in WT and in the F483A mutant. The mutation causes a loss of 
favourable hydrophobic interactions, which can be compensated by increased hydrogen 




Detailed molecular dynamics (MD) have been performed to reproduce and rationalize the 
experimental finding that the F483A mutant of CYP2D6 has lower affinity for R-propranolol 
than for S-propranolol. Wild-type (WT) CYP2D6 does not show this stereospecificity. Four 
different approaches to calculate the free energy differences have been investigated and 
were compared to the experimental binding data. From the differences between 
calculations based on forward and backward processes and the closure of the 
thermodynamic cycles, it was clear that not all simulations have converged sufficiently. 
The approach that calculates the free energies of exchanging R-propranolol with S-
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propranolol in the F483A mutant relative to the exchange free energy in WT accurately 
reproduced the experimental binding data. Careful inspection of the end-points of the 
simulations involved in this approach, allowed for a molecular interpretation of the 
observed differences.  
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Figure I: Chemical structure of propranolol. Atom numbers (left label) and partial charges in e (right label). If 
no charge is quoted, it is zero. Force field parameters for propranolol are listed in Tables I-V. 
 
Table I:  Integer (van der Waals) atom type codes (IACs) 
atomi IAC  atomi IAC 
1 14  16 17 
2 12  17 11 
3 14  18 17 
4 5  19 11 
5 18  20 17 
6 18  21 11 
7 13  22 17 
8 12  23 11 
9 3  24 11 
10 18  25 17 
11 13  26 11 
12 3  27 17 
13 11  28 11 
14 11  29 17 
15 11    
 
Table II:  Bond types 
atomi  atom j bond type  atomi  atom j bond type  atomi  atom j bond type 
1 2 26 11 12 17 19 21 15 
2 3 26 12 13 12 19 20 3 
2 4 20 13 14 15 21 23 15 
4 7 20 13 28 15 21 22 3 
4 5 2 14 15 15 23 24 15 
4 6 2 14 23 15 24 26 15 
7 8 26 15 17 15 24 25 3 
8 9 17 15 16 3 26 28 15 
8 11 26 17 19 15 26 27 3 
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Table III: Bond angle types 
atomi atomj atomk angle type  atomi atomj atomk angle type 
1 2 3 14  17 19 20 24 
1 2 4 12  20 19 21 24 
2 4 7 20  19 21 22 24 
2 4 5 17  22 21 23 24 
2  4 6  17  23 24 25 24 
3 2 4 12  25 24 26 24 
4 7 8 12  24 26 27 24 
5 4 6 9  27 26 28 24 
5 4 7 10  13 28 29 24 
6 4 7 10  26     28 29 24 
8 11 12 12  26     28 29 24 
8 9 10 11  26     28 29 24 
11 12 13 11  26     28 29 24 
12 13 14 26  26     28 29 24 
12 13 28 26  26     28 29 24 
14 13 28 26  15 17 19 26 
14 15 16 24  17 19 21 26 
13 14 15 26  19 21 23 26 
13 14 23 26  14 23 21 26 
15 14 23 26  14 23 24 26 
14 15 17 26  21 23 24 26 
15 17 19 26  23 24 26 26 
16 15 17 24  24 26 28 26 
15 17 18 24  13 28 26 26 
18 17 19 24      
         
  R/S-propranolol  7 8 9 14 
  R/S -propranolol  7 8 11 14 
  R/S -propranolol  9 8 11 14 
  I-propranolol  7 8 9 25 
  I-propranolol  7 8 11 25 
  I-propranolol  9 8 11 25 
 
Table IV: Improper dihedral types 
atomi atomj atomk atoml angle type  atomi atomj atomk atoml angle 
type 
15 14 16 17 1  14 15 17 19 1 
17 15 18 19 1  14 23 24 26 1 
19 17 20 21 1  15 14 23 21 1 
21 19 22 23 1  15 17 19 21 1 
24 23 25 26 1  17 19 21 23 1 
26 24 27 28 1  19 21 23 14 1 
28 13 26 29 1  23 14 15 17 1 
2 1 3 4 2  23 14 21 24 1 
13 12 14 28 1  23 24 26 28 1 
13 14 23 24 1  24 26 28 13 1 
14 13 15 23 1  28 13 14 23 1 
14 13 28 26 1       
           
    R-propranolol 8 7 11 9 2 
    S-propranolol 8 7 9 11 2 
    I-propranolol 8 7 11 9 1 
 
Table V: Dihedral types 
atomi atomj atomk atoml angle 
type 
 atomi atomj atomk atoml angle 
type 
7 8 9 10 12  7       8 11 12 17 
1 2 4 7 14  8 11 12 13 17 
2 4 7 8 14  11 12 13 28 2 
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Substrate specificity of cytochrome P450 enzymes may be determined not only by the 
characteristics of the active site itself but also by the (dynamic) selectivity of access routes 
to the active site. In addition, enzyme kinetics may be influenced by the substrate binding 
and product unbinding process and associated protein dynamics. We have used random 
acceleration molecular dynamics (RAMD) simulations to investigate the routes and 
mechanisms via which substrates may enter and products may exit the buried active site 
of CYP2D6. Three dominant pathways were identified, which were rather substrate and 
substrate protonation state dependent. E216 was shown to play an important role in 
substrate egress, suggesting that E216 is not only crucial for substrate binding in the 
active site, but that it is also involved in directing the substrate towards the active site via 
electrostatic steering. Substrate/product egress via the three pathways is furthermore 
accompanied by large displacement of segments in the BC loop, FG loop and F and G 
helices and involve rotation of aromatic and aliphatic residues, and loss of internal protein 
H-bonds. We propose the following mechanism for substrate access into and product exit 
from CYP2D6: Hydrophobic substrates coming from the membrane enter the protein via a 
pathway termed pw2a, and their hydrophilic products leave via pw2c and/or the solvent 
channel, while soluble substrates enter (and their products leave) via pw2c and/or the 
solvent channel. From our RAMD studies hypotheses can be derived which can be tested 
experimentally, such as site-directed mutagenesis studies of non-active site residues lining 
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8.1 Introduction 
In chapters 3 to 7 we have shown how specific residues in the CYP2D6 active (e.g. 
E216, F120, and F483) influence substrate affinity and specificity, and metabolic 
regiospecificity. Substrate specificity of Cytochrome P450 (CYP) enzymes however, may be 
determined not only by the characteristics of the active site itself but also by the 
(dynamic) selectivity of access routes to the active site. In addition, enzyme kinetics may 
be influenced by the substrate binding and product unbinding process and associated 
protein dynamics.1 The buried active site of many CYPs implies that the protein must 
undergo dynamic motion to allow substrates to enter the active site and products to leave 
the active site.2,3 
In the past years, more and more experimental and molecular modeling studies have 
tried to explore the pathways and mechanisms via which substrates enter and products 
exit CYPs. Experimental methods applied to investigate substrate entrance (product exit) 
into (from) CYPs, are site-directed mutagenesis1,4-7, antibody labeling8, and fluorescence 
spectroscopy.9-11 Simulating ligand egress from the CYP active site computationally is a 
challenging exercise because the timescale of ligand egress is orders of magnitude greater 
than the times (typically ~1-10 ns) for which the protein dynamics can be simulated using 
standard molecular dynamics simulation techniques. Nevertheless, several modeling 
studies on ligand egress from CYPs have been described in the past years. Table 1 gives 
an overview of the substrate entrance / producs exit channels observed in CYP structures. 
A thermal motion pathway analysis of B-factors in the crystal structure of CYP101 (P450 
cam) with camphor bound revealed the existence of three distinct pathway families. Exit 
channels were explored by molecular dynamics (MD) simulations by imposing an artificial 
expulsion force on the substrate in addition to the forces due to the standard force field.12 
This random acceleration molecular dynamics (RAMD) method (formerly known as random 
expulsion MD) was used in simulations of the palmitoleic acid bound structure of CYP102 
(P450 BM3), a system for which a substrate-access channel is closed in the substrate-
bound and open in the substrate-free crystal structure.13 RAMD simulations reproduced 
the closing motion.14,15 It was further applied to complexes of CYP101 with camphor, 
endo-borneol allyl ether and 5-hydroxy camphor (metabolic product of camphor). The 
three ligand expulsion pathways of CYP101 observed by RAMD matched well with three 
putative ligand channels found by thermal motion pathway analysis.16 In a complementary 
study, estimates of the relative probabilities of ligand passage through the three channels 
were computed using steered molecular dynamics (SMD) and adiabatic mapping.17 The 
REMD and SMD approaches combined with essential dynamics (ED) analysis were used for 
6-deoxyerythronolide B bound CYP107A (P450 EryF), and the results obtained for this 
complex were compared to those for CYP101 and 102.18 Several possible exit/entrance 
routes in each enzyme were identified and one route, located between the F/G loop, the 
β1 sheet and either the B’ helix (CYP101 and 102) or B’/B loop (CYP107), was common to 
all three proteins. The mechanisms of substrate entrance and/or product exit along this 
pathway, however, were different for each of the three isoforms and apparently adapted 
to the properties of the substrate. Based on this observation, it is suggested that the 
characteristics of the active site itself may not be the only determinant of substrate 
specificity.  The access channel properties may thus play a key role by kinetic modulation 
of substrate recognition.18 Recently, RAMD was applied to rabbit CYP2C5. In contrast, in 
this CYP, egress is predominantly by pathway 2c. This route requires the rupture of an 
intra-protein hydrogen bond between a lysine amino group in the G-helix and a valine 
backbone carbonyl oxygen in the B’-helix. Taken together, the results for these four P450s 
suggest that while substrate entrance and product egress may both be by pw2a in the 
three soluble bacterial P450s, in the mammalian CYP2C5, substrate entrance and product 
egress may take place by pw2c. Very recently, open channels leading to the active site of 
currently available CYP crystal structures were analyzed, providing experimental evidence 
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for the existence of four substrate exit/entrance routes that were identified by MD 
simulation.3 Recent MD-studies have also identified ligand egress channels in insect 
CYP6B1 (pw1, solvent channel)1, rat CYP2B1 (pw2c, pw2e, solvent channel)19, and human 
CYP2C9 (pw2a, solvent channel).20  
The aim of the current study is to investigate the routes and mechanisms via which 
substrates may enter and products may exit the active site of CYP2D6. For these 
investigations we have used the RAMD simulation protocol developed by Wade and co-
workers.16 According to this method, acceleration with a regularly updated random 
direction is applied to the ligand to find expulsion routes during a relatively short but 
otherwise standard MD simulation. In the current study RAMD is for the first time applied 
to a human CYP2D6 homology model (Chapter 3), based on CYP2C5 crystal 
structures.21,22 Figure 1 displays potential exit channels in the 2D6 homology model 
observed in the current RAMD study or by mapping the pathways observed in earlier 
studies to the corresponding residues in the 2D6 model. We have described the egress 
pathways of two compounds: dextromethorphan (DXM) and R-MDMA (MDR), the latter 
compound in its neutral form (MDR0) as well as its positively charged form (MDR+). Three 
dominant pathways were identified, and based on detailed analysis of protein structural 
changes and protein-ligand interactions, molecular mechanisms have been proposed for 
substrate egress via these pathways. From these studies hypotheses can be derived which 
can be tested by experiments, such as site-directed mutagenesis studies of non-active site 
residues lining the substrate egress pathways. Based on initial simulation data, one such 
mutant is proposed and included in the calculations. In the L110C/Q244C mutant a 
cysteine brigde can be formed, possibly blocking product release through pw2c. 
 
Table 1: Overview of open access channels observed in CYP crystal structures3 and earlier (RA)MD 
simulations with CYPs 101,16 102,14-16 10718, 6B1,1 2B1,19 2C5,23 and 2C920, and the secondary 
structure elements lining these pathways. 
pw Egress via secondary 
structure elements 
method CYP 
    
1 C/C’ and H or L helices X-ray 51 
  MD 101, 6B1 
    
2a B’ helix/BB’ loop/BC loop, 
FG loop, β1 (and a/A helix)* 
X-ray 101, 102, 108, 119, 152, 154, 55, 2B4, 2C5, 
2C9, 3A4 
  MD 101, 102, 107, 2C9 
    
2b B/B’ loop, β1 and β3 sheets MD 101 
    
2c BC loop, G and I helices  X-ray 2C5, 2D6 
  MD 101, 107, 2B1, 2C5 
    
2d N-terminus, a and A helices MD 102 
    
2e through BC loop X-ray epok, 51, 2B4, 2C5, 3A4 
  MD 107, 2B1, 2C5 
    
3 F and G helices or EF loop MD 2C5 
    
solv E, F, and I helices, β4 sheet  X-ray CYP102, 119, 175, 2C5, 2C8, 2C9, 2D6, 3A4 
  MD 2B1, 2C5, 2C9, 6B1 
    
othera  MD 2C5 
aOther routes not previously identified in crystal structures or simulations as potential active site channels for 
substrate or product passage. 
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Figure 1:  Potential substrate and product egress pathways in CYP2D6, and the 
secondary structure elements and Cα atoms (colored balls) lining them. The highlighted 
residues are either those observed in the current RAMD study (pws 2a.I, 2a.II, 2c, 2e, 3.I, 
3.II and the solvent channel), or those observed in RAMD-studies with CYP101, CYP102 




8.2 Results and Discussion 
Substrate egress pathways in CYP2D6 are substrate and substrate protonation 
state dependent 
For every ligand (DXM, MDR+, MDR0) RAMD simulations were performed in both the 
wildtype and in the L110C/Q244C mutant, using a set of six different simulation settings, 
defined in Table 2. These parameters were chosen on the basis of preliminary simulations 
of CYP2C5. RAMD-simulations performed with higher force constants showed very large 
distortion of the secondary structure of CYP2D6 (data not shown here). This leads to a 
total of 36 simulations, as described in the methods section. The details of these 
simulations, resulting in ligand expulsion from wild-type and L110C/Q244C mutant 
CYP2D6, are given in Tables 3 and 4.  
 
Table 2: Summary of RAMD-simulations performed with wildtype and L110C/Q244C mutant 
CYP2D6 
 RAMD settingsa seedb 
simulation N rmin  
I 20 0.001 seed1 
II 40 0.001 seed1 
IIIa 20 0.005 seed1 
IVa 40 0.005 seed1 
IIIb 20 0.005 seed2 
IVb 40 0.005 seed2 
a) A, the magnitude of the acceleration resulting from the random expulsion force acting on the centre of 
mass of the ligand, is kept on a constant value of 0.05 kcal/g/Å  for all simulations. The direction of the force is 
kept for N time steps of 2 fs. If, during this time period, a specified distance, rmin, is covered by the substrate 
molecule, the direction of the force is maintained, otherwise a new direction is chosen randomly. These 
parameters were chosen on the basis of preliminary simulations of CYP2C5, so that artefactual distortion of the 
secondary structure was minimal while still permitting ligand egress to be observed within a reasonable 
simulation time; b) Simulation settings III and IV were performed with two different random number seeds for 
generation of initial velocities. 
 
Table 3: The residues and secondary structure elements lining egress pathways observed in 
RAMD-simulations performed in wild-type (WT) and L110C/Q244C mutant (MUT) CYP2D6 together 
with the observation frequencies of the pathways in the simulations. 
pw residues frequency 
2a a I: F51, Q52, (A helix), L73, A74 (β1 sheet), E216, G218, E222 (F-G loop), F483 
(β4 sheet) 
II: P102, P103, V104, I106, F120, L121 (BB’-loop), L210, Q211, L220, R221, 




2c T107 c, V109, L110, G111, F112 c, Q117 c (B’ helix), E216 (F-helix), K239, V240, 
L241, Q244, F247, D252 b c (G-helix), R296 c, I297 c, P300, D301, S304 (I-helix) 
4 (WT) 
4 (MUT)b 
2e P102, P103, V104, T107, Q108, G111, P114, L121 (B-C loop) 2 (WT) 
2 (MUT) 
3 a I: D207, L208, A209, E211, E215, E216 (F-helix), K239, F243 (G-helix) 
II: C191, R193, F195, R201, R204, E216 (F-helix), V240, A246, F247, Q250, 
L251, E253, L254, L257 (G-helix) 
3 (WT) 
3 (MUT) 
solvent L206, A209, Q210, L213, K214, E216 (F-helix), S304, M307, V308 (I-helix), 
F483, L484 (β4 sheet) 
4 (WT) 
2 (MUT) 
other d S304, V308, T313, W316 (I-helix), V363, Q364, F366, I369 (K-helix), V485 (β4 
sheet) 
1 (MUT) 
a) Two different variations on the 2a and 3 pathways could be defined, labelled I and II; b) Egress via 
pathway 2c in the L110C/Q244C mutant is accompanied by large distortion of secondary structure elements; 
c) Residues lining pathway 2c in the mutant which do not line pathway 2c in wild-type CYP2D6; d) Other route 
not previously identified in crystal structures or simulations as potential active site channels for substrate or 
product passage. 
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Table 4: Observed routes and parameters used in the RAMD simulations resulting in substrate 
expulsion for the complexes of dextromethorphan (DXM), charged R-MDMA (MDR+), and neutral R-
MDMA (MDRo) with wild-type and L110C/Q244C mutant CYP2D6.  
 pw a sim. b length 
(ps)   
Max.  
Cα RMSF c 
res. d Exit via e 
wild-type      
DXM 2a.I I 74 3.9 F51 F51, Q52, G218 
 2a.I IIIa 289 2.7 G218 F51, A74, E222 
 2c IVb 206 3.7 Q244 L110, Q244 
 2c IIIb 96 2.9 Q244 L110, Q244 
 2c IVa 178 5.4 L110 L110, L241 
 3.I II 140 2.3 E216 E216, K239 
       
MDR+ 2c I 76 2.7 V240 I109, Q244, F247 
 2e IIIb 400 2.0 G212 D100, P103, Q108 
 solvent II 175 1.2 D207 L206, L213, Q210 
 solvent IVa 172 2.3 L213 L213, V308, L484 
 solvent IVb 27 2.5 L213 L213, V308 
 3.I IIIa 28 1.4 V229 E211, E215, K239 
       
MDRo 2a.II I 262 1.2 L224 P103, N225 
 2a.II IIIa 76 1.4 P103 P102, V104, R221 
 2a.II IVa 17 0.8 N225 P103, N225 
 2e IIIb 85 1.9 Q108 P102, P103, V104, Q108  
 3.II IVb 39 2.7 L254 R196, E257 
 solvent II 72 1.9 L213 L213, V308, T312, L484 
       
L110C/Q244C mutant     
DXM 2a.I IIIa 111 2.8 E216 F51, Q52, G218 
 2c f I 182 2.6 Q244 G111, Q117, C244, F247 
 2c f IIIb 209 2.8 E216 T107, I109, V240 
 3.I IVb 102 1.9 A209 D207, L208, E211, F243 
 3.II II 128 2.6 L254 R201, L251, L254 
 solvent IVa 131 3.9 L213 L206, A209, L213, L484 
       
MDR+ 2a.I IVa 193 2.1 E216 P103, V104, N225 
 2c f I 268 2.7 L248 C110, L248 
 2e II 280 1.5 Q108 P103, Q108, P114 
 solvent IVb 22 2.2 E216 L213, E215, F481 
 none g IIIa - - - - 
 none g IIIb - - - - 
       
MDR0 2a.II IIIa 32 1.3 P103 P103, P105, N225 
 2a.II IVa 65 2.8 E216 Q51, E216, G218 
 2c f I 228 3.9 L248 F112, D252 
 2e IIIb 116 1.1 L121 P103, Q108, P114 
 3.II IVb 199 1.4 R204 L208, F243, A246 
 other II 110 1.2 W316 W316, F366 
a) Two different variations on the 2a and 3 pathways could be defined. b RAMD simulation settings as defined 
in Table 2; c) Maximal Cα root-means-square fluctuation observed during the simulation; d)  Residue with the 
highest Cα RMSF; e)  Residues via which the substrate exits the protein; f)  Egress via pathway 2c is 
accompanied by large distortions of secondary structure motifs; g)  No substrate egress observed after 1600 
ps RAMD simulation. 
 
Figure 2 (see next page): CYP2D6-substrate hydrogen bond interactions (left panels) and Cα 
root-mean-square-fluctuations (RMSFs, right panels) during the RAMD simulations belonging to 
egress pathways pw2a, pw2c, and the solvent channel. H-bond and RMSF patterns belonging to the 
same simulation have the same color. All protein-substrate H bonds are interactions between the 
E216 carboxylate group and the protonated nitrogen atom of the substrate, with the exception of 
the second part of the DXM.IIIb simulation (pw2c) where the hydrogen bond switches to the OE1 
atom of Q244. The position of secondary structure elements (A helix,  BC loop, F and G helices, FG 
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The ligand exit trajectories were clustered into pws based on the secondary structure 
elements lining them, as defined in earlier RAMD studies (see Table 1).12,16,18,23,24 Two 
variations on pathways 2a and 3, could be observed and these variations seem to be 
rather substrate-specific. The exit region for pathway 2a.I (used by DXM in wild-type 
CYP2D6) is located between the A helix and the F-G loop, and is also observed in RAMD 
studies performed with palmitoleic acid in CYP102.16 The exit region for pathway 2a.II 
(used by MDR0) is located between the B’-B loop and the F-G loop, and is also observed in 
RAMD studies performed with camphor in CYP10116 and 6-DEB in CYP107.18 The exit 
regions of pathways 3.I (used by DXM and MDR+) and 3.II (MDR0) are located between 
the F-G loop, and near the E/F loop, respectively. 
In wild-type CYP2D6, there are four predominant pathways, pw2a (I and II), 2c, 3, and 
egress via the solvent channel. Also pw2e was observed. Pathways were found to be 
rather substrate-dependent: pw2c and 2a.I were predominant pathways for the relatively 
bulky and rigid dextromethorphan, the solvent channel25 was the predominant pathway for 
the smaller and more flexible positively charged R-MDMA, while pw2a.II was the 
predominant pathway for neutral R-MDMA. For each substrate, only one simulation via 
pw3 was observed. For this reason, only egress pathways 2a, 2c and egress via the 
solvent channel are discussed below. Figure 2 presents the CYP2D6-substrate hydrogen 
bond interactions and the Cα root-mean-square-fluctuations (RMSFs) during the RAMD 
simulations belonging to these three pathways. 
The carboxylate group of E216 is believed to form a salt bridge with positively charged 
nitrogen atoms in typical CYP2D6 substrates.26,27 The equilibrated starting structures of the 
RAMD simulations also show this interaction between E216 and R-MDMA and 
dextromethorphan and during most of the substrate egress pathways, the ligand-protein 
salt bridge is so stable that the initially buried aromatic moiety off the substrate is expelled 
first and the substrate is only able to leave the protein after breakage of this salt link 
(Figure 2). All simulations show some movement of the HI loop, and most show 
movement of the L’L loop, which probably can be attributed to the normal global dynamics 
of the CYP2D6 homology structure. Depending on the pathway, movements are observed 
in the A helical region, BC loop/B’ helix, F and G helices and FG loop region, and β4 sheet 
region, which accommodate the substrate egress process (Figure 2). These movements 
seem to be rather large, and could be an artifact of the MD simulations.16 Large plasticity 
of the BC loop and FG loop regions has, however, been observed for other CYPs,  e.g. by 
ligand-induced conformational changes28,29 or even by an interaction of the FG loop of 
another CYP protein within the active site.30 
 
Egress via pathway 2c involves substrate-protein and intraprotein H-bond 
breakage 
Substrate egress along pw2c was observed to occur via two different mechanisms. 
According to both mechanisms, final substrate exit occurs via the G helix (L241, Q244, 
F247) and the B’ helix (I109, L110) (Table 4 and Figure 3), but they differ in the 
substrate-protein H bond interaction pattern along the egress pathway. The location of the 
substrate exit pathway and the structural changes occurring during the simulation of DXM 
using RAMD parameters IIIb (denoted as DXM.IIIb from now on) are shown in Figure 3. 
In simulations DXM.IIIb and DXM.IIIa, the H-bond between the protonated nitrogen atom 
of the substrate and the E216 carboxylate group is broken in an early stage of the 
simulation (Figures 2 and 3). The positively charged nitrogen moves towards a polar 
subpocket at the edge of the active site, formed by Q244 (G-helix) and D301 and S304 (I-
helix). In the DXM.IIIb simulation, the protein-substrate H-bond is maintained via 
interaction with Q244, resulting in the loss of an internal H bond between Q244 and the 
backbone of L110 (Figures 2 and 3). In both simulations, the protonated nitrogen is 
Chapter 8 
 223






Figure 3: Egress of dextromethorphan (cyan sticks) via pw2c (following the yellow line), 
accompanied by breakage of a dextromethorphan(DXM)-E216 H-bond and an internal H-bond 
between Q244 and the backbone of L110, large movements in the G helix and minor movement of 
the B’ helix. Substrate exit occurs via these two residues (depicted in ball-and-stick) and the 
secondary structures of the G and B’ helices at the beginning (green) and at the end (purple) of the 
RAMD simulation are highlighted. The view in this figure is rotated ca. 900 about the horizontal axis 
with respect to the view in Figure 1. 
 
Substrate egress along pw2c involves large movements in the G-helix (Figure 2). Final 
substrate exit occurs via the FG loop region (G218, E222) and the N-terminal region after 
the A helix (F51, Q52) and/or the β1 sheet (A74) (Table 4 and Figure 3).  
According to an alternative pw2c egress mechanism (simulations DXM.IIIb and MDR+.I), 
the H bond interaction between the substrate and E216 is maintained throughout the 
simulation, and only after disruption of this H-bond, the substrate is able to leave the 
protein. Substrate egress is accompanied by large movement of the FG loop region and 
the B’ helix (Figure 2). 
Based on these RAMD simulations, a double mutant of CYP2D6 was constructed, in 
which L110 (in the B’ helix) and Q244 (in the G-helix) were both mutated into a cysteine, 
allowing for the formation of a cysteine bridge between the B’- and G-helices. This 
cysteine bridge in principle blocks pw2c, but also the mutant RAMD-simulations show 
egress via pw2c, although in these simulations large distortions of secondary structure 
elements were observed. Cross-linking of C29 and C194 with bis-maleimidohexane in 
Y29C/A194C double mutant CYP101 showed that these residues are important for 
modulating substrate access and exit in an earlier study.4 Experimental site-directed 
mutagenesis studies to block pw2c and the other identified egress pathways in CYP2D6 
(i.e. pw2a and the solvent channel) can be designed to validate these simulations. 
Evidence for ligand passage via pw2c in other members of the CYP2 subfamily is provided 
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Pw2c is not observed to be open in the substrate-bound CYP2C5 crystal structures (PDB: 
1N6B21 and 1NR622) used as templates for the construction of the CYP2D6 homology 
model. The pathway is however open to a water probe in the lower resolution substrate-
free structure of CYP2C5 (PDB: 1DT6),32 as well as in the recently solved CYP2D6 crystal 
structure.33 (RA)MD simulations identified pw2c as a potential substrate access/product 
exit pathway in CYP10116,17 and 107,18 and suggested pw2c to be the major pathway for 
CYP2C523 and 2B119 (Table 1). 
 
Egress via pathway 2a involves substrate-protein hydrogen-bond breakage and 
rotation of aromatic side-chains 
The mechanism of substrate egress along pw2a is dependent of the substrate nitrogen 
formal charge. The location of the substrate exit pathway and the structural changes 
occurring during simulation DXM.IIIa are shown in Figure 4. In simulations with positively 
charged dextromethorphan (DXM.I and DXM.IIIA), the H-bond/ionic salt link between the 
protonated nitrogen atom of the substrate and the E216 carboxylate group is maintained 
throughout the simulation (Figures 2 and 4). F483 blocks the pw2a exit and forms 
aromatic interactions with the substrate. Only after reorientation of the phenyl ring of this 
residue and disruption of the dextromethorphan-E216 H-bond, the substrate is able to 
leave the protein. The side chains of F483, and, in the final substrate exit stage, F51, act 
as doors that are pushed open via transitions of the side-chain torsions χ1 and χ2 (Figure 
4). Flipping of aromatic residues was also observed in RAMD studies with CYP101.16 In the 
homology model starting structure, the phenyl-ring of F483 is turned towards the active 
site, maximizing hydrophobic contacts with the substrate, while in the RAMD snapshot 
facilatiting substrate exit (Figure 4), as well as in the recently solved CYP2D6 crystal 
structure,33 F483 forms an intermediate substrate binding pocket with E216 at the 
entrance of the solvent channel. Substrate egress is accompanied by large movements in 
the F helix and FG loop, and smaller movements in the β4 sheet (Figure 2). Final 
substrate exit occurs via the FG loop region (G218, E222) and the N-terminal region after 
the A helix (F51, Q52) and/or the β1 sheet (A74) (Table 4 and Figure 4). 
In simulations with neutral R-MDMA (MDR0.I, MDR0.IIIa and MDR0.IVa) that make use 
of pw2a, the H-bond/ionic salt link between the protonated nitrogen atom of the substrate 
and the E216 carboxylate group is already broken at the beginning of the simulation 
(Figure 2). Final substrate exit occurs via the FG loop region (N221, R225) and the BB’-
loop region (P103, V104) (Table 4) and subtrate egress is accompanied by relatively 
smaller structural changes, compared to simulations with positively charged substrates 
(Figure 2). 
Site directed mutagenesis studies support a substrate access/product exit channel in the 
region of pw2a in CYP1014,5, but not in CYP2B1.7,19 In the crystal structures of CYP101, 
102, 108, 119, 152, 154, 55, 2B4, 2C5, 2C9, and 3A4, pw2a is open to a water probe.3 
Molecular wires have been used to trap the open pw2a conformational states of 
CYP10134,35, and in the recently determined CYP2B4 structure pw2a can even open wide 
enough to allow another protein (the other P450 molecule in the crystallographic dimer) to 
penetrate into the active site.30 (RA)MD simulations in CYP10116,17, 10214-17, 10718, and 







Figure 4: Egress of dextromethorphan (cyan sticks) via pw2a.I (following the yellow line), 
accompanied by breakage of dextromethorphan-E216 H-bond, reorientation of F483, and 
movements in the F helix, FG loop, and the β4 sheet. Final substrate exit occurs via E222 
and F51. The secondary structures of the F helix, FG loop, the β4 sheet, and the loop 
between the A helix and the β1 sheet, as observed at the beginning (green) and at the end 
(purple) of the RAMD simulation, are highlighted. The view in this figure is rotated ca. 900 
about the horizontal axis and 1800 about the vertical axis with respect to the view in 
Figure 1. 
 
Egress via the solvent channel involves substrate-ligand hydrogen-bond 
breakage and rotation of aliphatic side-chains 
Like many CYP crystal structures, the CYP2D6 homology model has a small opening 
between the F and I helices and the β4 sheet, referred to as the solvent channel.25 The 
channel has been suggested to be important for controlling proton access to the active 
site, and in the current CYP2D6 RAMD it is identified as a potential substrate egress 
pathway. The location of the substrate exit pathway and the structural changes occurring 
during simulation MDR+.IVa are shown in Figure 5. 
The charged E216 residue is positioned in close vicinity to the opening of the solvent 
channel. In all RAMD trajectories along the solvent channel, the H-bond/ionic salt link 
between the protonated nitrogen atom of the substrate and the E216 carboxylate group is 
maintained throughout almost the whole simulation (Figures 2 and 5). 
Substrate egress involves movements in the F-helix and the FG loop, but these 
movements are generally smaller than those observed during substrate egress via pw2a 
and pw2c (Figure 2). Final substrate exit occurs via the I helix (V308, M309, T312), the F 
helix and FG loop region (L206, A209, Q210, L213, E222) and the β4 sheet (L484). 
Residue L484 rotates upon the release of the substrate (Table 4 and Figure 5).  
In the crystal structures of CYP102, 119, 175, 2C5, 2C8, 2C9, 2D6 and 3A4, the solvent 
channel is open to a water probe,3 and (RA)MD simulations in CYP2B119, 2C523, 2C920, and 
6B11 suggest the solvent channel as a potential substrate egress pathway for these CYPs 
(Table 1). 
 




Figure 5: Egress of positively charged R-MDMA (cyan sticks) via the solvent channel (following the 
yellow line), accompanied by reorientation of L484, movements in the F helix and FG loop, and loss 
of an ionic salt link between the substrate and E216 (in ball-and-stick). Substrate exit occurs via 
L213 in the F helix, V308 in the I helix, and L484 in the β4 sheet. The secondary structures of the F 
helix, the FG loop, the β4 sheet, and the I helix, as observed at the beginning (green) and at the 
end (purple) of the RAMD simulation, are highlighted. The view in this figure is rotated ca. 900 
about the horizontal axis and 1200 counter clockwise about the vertical axis with respect to the view 
in Figure 1. 
 
Electrostatic steering by E216 
For all three dominant egress pathways (pw2a, pw2c and the solvent channel) in CYP2D6, 
and also for most of the other pws observed in the current RAMD studies, E216 plays an 
important role in the mechanism of substrate egress. Only in pw2c it seems more likely 
that the substrate/product interacts with another polar binding pocket in the vicinity of 
D301 and Q244 at the edge of the active site, after entering or before leaving the protein. 
Trajectories along pw2c show that pronounced ligand-E216 H-bond interactions involve 
larger distortion of the FG loop and B’ helix (Figure 2). Based on the analysis of the 
RAMD simulations along pw2c and the solvent channel, a common mechanism of 
substrate entrance or product release can be proposed for these pathways. The positively 
charged nitrogen atom of the substrate is electrostatically directed to the side-chain of 
E216 and a stable salt link is formed. The apolar moiety of the substrate diffuses through 
pw2a or the solvent channel involving shorter ranged hydrophobic interactions. Both pw2a 
and the solvent channel are flanked by hydrophobic residues, presumably serving as the 
substrate-docking region. Also based on the currently solved CYP2D6 crystal structure, the 
substrates have been proposed to dock into such a hydrophobic subpocket (between E216 
and F483) before entering the active site.33 During the egress process along pw2a and the 
solvent channel, substrate/product egress is accompanied by rotation of aromatic and 
aliphatic residues, but generally also by large displacement of segments in the BC loop, FG 
loop and F and G helices. These large structural distortions could be an artifact of the MD 
simulations,16 but large flexibility of the BC loop and FG loop regions has been observed 
for other CYPs,  e.g. by ligand-induced conformational changes28,29 or even by interactions 
of the FG loop of another CYP protein within the active site.30 The series of RAMD 
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simulations performed with neutral R-MDMA (MDR0) show that by removing the salt link 
between the substrate and E216 (i.e.  in the absence of electrostatic steering) other 
egress pathways are used, involving less distortion of secondary structure elements. This 
suggests that substrate entrance and product exit in CYP2D6 depends of the 
substrate/product formal charge. 
Earlier experimental studies already supported the idea that the binding mode36 and 
affinity37 of ligands in the active site of CYP2D6 is not only dependening on the charge of 
substrate binding residues,27 but that it is also dependent on the pKa of the ligand. The 
apparent pKa for substrates was even reported to decrease upon binding to CYP2D6 
(making the substrate less basic).36 In chapter 6 we described simulations of MDMA in a 
charged and in a neutral state. There, it appeared that using the neutral parameters to 
describe MDMA were better suited to reproduce the experimental NMR data. For this 
reason, a neutral description of MDMA was taken into account here as well, Interestingly, 
the neutral form of MDMA again results in the least distortive simulation of the protein. 
Note, however, that these findings may only give an indication of the quality of the force 
field parameters and not necessarily imply that MDMA binds in a neutral form to CYP2D6. 
In summary, our RAMD studies suggest that E216 is not only crucial for substrate binding 
in the active site,27 but that it also plays an important role in directing the substrate 
towards the active site via electrostatic steering.  
 
Substrate passage through the membrane and docking to a hydrophobic 
subpocket 
In vivo, CYP2D6, like other mammalian CYPs, is attached to a lipid membrane. It has been 
hypothesized that in soluble, bacterial CYPs, pw2a is used as both substrate access and 
product egress route and that the process of channelling through this passage may 
contribute to substrate recognition.18 For membrane bound CYPs, other mechanisms for 
substrate access/product exit have been proposed: (i) a one-way route by which 
hydrophobic substrates access the enzyme from the membrane by pw2a and hydroxylated 
products egress along pw2c or pw2e; and (ii) a two-way route for access and egress, 
along pw2c, for soluble compounds.2,3,23 
Trypsin digestion studies in CYP1A2,38,39 antibody accessibility studies in CYP2B140 and 
CYP2C532, and recent tryptophan fluorescence scanning studies in CYP2C241 indicate that 
the following parts of mammalian CYPs are inserted into the membrane: the N-terminus 
untill the A-helix (corresponding to (approximately) residues 1-50 in CYP2D6), after the A-
helix (~65-75), in β sheet 2-2 (~390-395), and the F-G loop (~220-230). This suggests 
that the residues identified in the current RAMD studies to be located around the entrance 
of pw2a.I and (most of the residues located) around the entrance of pw2a.II are either 
inserted into the lipid bilayer, or near or within the phospholipid headgroup region of the 
membrane. The region around the entrances of pws 2c, 2e, 3.I, and 3.II are expected to 
be not embedded in the membrane. Lipophilic substrates in the membrane might 
therefore be extracted into the CYP2D6 active site by pw2a and expelled in their 
hydroxylated form by pw2c and/or the solvent channel. The current RAMD studies in 
CYP2D6 also support this hypothesis by indicating pathways 2a and 2c as the most 
important pathways, with pathway 2a being predominantly used by the neutral (MDR0) 
and thus more hydrophobic substrate. In addition, the solvent channel is identified as a 
potential egress pathway for hydrophobic ligands. These finding do, however, imply that 
for a proper description of the dynamics of substrate entrance and product exit in CYP2D6, 
protein-membrane (and substrate-membrane) interactions should be taken into account. 
Analysis of the CYP51 crystal structure suggests that pw2e must close in order for pw2a 
to open, thus providing synchronization between substrate access and product egress via 
different routes.42 Based on the CYP152A crystal structure, pw2e is proposed to permit 
water to escape from the active site after its generation in the peroxygenation reaction.43 
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The 2e pathway has also been observed in the current RAMD studies in CYP2D6, but only 
in 2 out of 18 simulations in the wild-type protein. Therefore, we propose pw2c and the 
solvent channel to be potential access and exit channels for hydrophylic substrates and 
products, respectively, while pw2a may serve as substrate access channel for hydrophobic 
substrates entering the protein from the membrane. 
 
Perspective: Experimental validation of RAMD studies 
From the current CYP2D6 RAMD studies hypotheses can be derived which can be  tested 
experimentally, such as site-directed mutagenesis studies of non-active site residues lining 
the substrate egress pathways. In the L110C/Q244C mutant a cysteine brigde can be 
formed, possibly blocking product release through pw2c. A L110C/Q244C mutant 
potentially forming a cysteine brigde was proposed to block pw2c, but also for the other 
identified egress pathways in CYP2D6 (i.e. pw2a and the solvent channel) such mutants 
can be proposed. In addition, experimental approaches such as (time-resolved ) 
fluorescence spectroscopy, measuring the emission of tryptophan residues (and of the 
substrate), can be used to analyze possible local conformational changes in CYPs upon 
substrate binding.9-11 In fact, this method has recently been applied to CYP2D6, showing 
contraction of the protein caused by substrate binding.11 Mutagenesis of more tryptophan 
residues will, however, be needed to localize the flexible parts of CYP2D6.  
A complete interpretation of these mutations would also require the calculation of free 
energy profiles for ligand passage, as was done by using steered MD and adiabatic 
mapping for CYP101 and CYP102.17 Nevertheless, the egress pathways identified in the 
current RAMD studies are in line with earlier RAMD work on CYP crystal structures. 
Furthermore, we have observed a distribution of possible egress pathways, which is 
different from the distribution of pathways in CYP2C5 (the template used to construct the 
CYP2D6 homology model). This suggests that our data are not biased by the homology 
modeling template, but rather a result of the specific structural and chemical 
characteristics of CYP2D6 and its substrates. 
8.3 Conclusions 
We have used RAMD simulations to investigate the routes and mechanisms via which 
substrates may enter and products may exit the active site of CYP2D6. Three dominant 
pathways were identified, and based on detailed analysis of structural changes within the 
protein and protein-ligand interactions, molecular mechanisms have been proposed for 
substrate egress via these pathways. E216 was shown to play an important role in 
substrate egress along pw2a and the solvent channel. After entering or before leaving the 
protein via pw2c, substrates/products are more likely to interact with another polar 
binding pocket in the vicinity of D301 and Q244 at the edge of the active site. This 
suggests that E216 is not only crucial for substrate binding in the active site, as was 
shown in earlier studies, but that it is also involved in directing the substrate towards the 
active site via electrostatic steering.  Substrate/product egress via the three pathways is 
furthermore accompanied by large displacement of segments in the BC loop, FG loop and 
F and G helices. Egress via pw2a involves rotation of aromatic residues, egress via the 
solvent channel involves the rotation of aliphatic residues, while egress via pw2c is 
accompanied by loss of an internal protein H-bond. 
We propose the following general mechanism for substrate access into and product exit 
from CYP2D6: Hydrophobic substrates coming from the membrane enter the protein via 
pw2a, and their hydrophilic products leave via pw2c and/or the solvent channel, while 
soluble substrates enter (and their products leave) via pw2c and/or the solvent channel. 
From our RAMD studies hypotheses can be derived which can be  tested experimentally, 






The simulations of CYP2D6 were based on a refined and validated homology model (Chapter 3). 
The energetically most favorable docking poses of DXM, MDR0, and MDR+, according to a 
previously reported automated docking protocol (chapters 4 and 5),44,45 were used as starting 
configurations for the MD-simulations. 
The enzyme complexes, was solvated in periodic boxes containing TIP3P water molecules.46 In 
addition four Na+ ions were added  to neutralize the system, placed in energetically favourable 
locations using the GRID program.47 Interactions were calculated according to the AMBER99 force 
field,48 using particle-mesh-ewald summation to include the longrange electrostratic forces. Van der 
Waals interactions were calculated using a cutoff of 8.5 Å. A modified version of the AMBER 
program (Version 8, http://amber.scripps.edu) was used, including the RAMD routines.16,18 Heme 
parameters were kindly supplied Dr. Danni Harris.49 Substrate force-field parameters were derived 
using the antechamber program50 and partial charges for the substrates were derived using the 
RESP procedure described in ref 51. The systems were energy-minimized for 200 steps and then 
subjected to MD simulation at 300 K and 1 bar for 1 ns, using the Berendsen approach to keep the 
temperature and the pressure constant.52 The RAMD simulations were started from the coordinates 
obtained after the 1 ns equilibration simulation, when the systems were well equilibrated as 
indicated by the backbone root-mean-square devitation. RAMD trajectories were analysed using the 
tools provided in the AMBER, GROMACS,53 and GROMOS54 packages. 
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The primary aim of the investigations described in this thesis was to obtain knowledge on 
the structure and dynamics of CYP2D6-ligand interactions, enabling the rationalization and 
prediction of drug metabolism by this specific Cytochrome P450 enzyme, and offering new 
approaches for the study of CYP-ligand interactions in general. Our work particularly focused 
on three lines of research: 1) The construction and validation of a high-quality CYP2D6 
homology model; 2) The development of methods for the prediction of CYP-ligand 
interactions in a high-throughput fashion; 3) The description of the dynamics of CYP-ligand 
interactions by using experimental and in silico techniques in an integrative way. These three 
lines are addressed in the different chapters of this thesis. 
 
Chapter 1 gives a general introduction into the background and context of the research 
presented in the thesis. Early consideration of not only drug potency, but also ADME 
(absorption, disposition, metabolism and excretion) properties and toxicity is increasingly 
seen as essential for efficient discovery and development of new drugs and drug candidates. 
Today, drug lead compounds are discovered and optimized by an integrative process of in 
silico modeling, in vitro screening, and in vivo testing. Drug metabolism primarily determines 
the fate of a compound entering the body. Absent, reduced or increased activity of enzymes 
involved in drug metabolism can lead to therapeutic failure or adverse drug effects. 
Understanding biotransformation enzymes and their mechanisms of action is therefore 
invaluable in the process of drug discovery and development. CYPs, and particularly CYP2D6, 
play an important role in drug metabolism. CYP2D6 is the second most important drug 
metabolizing enzyme after CYP3A4. Large interindividual differences exist in CYP2D6 activity 
due to genetic polymorphisms, further emphasizing its clinical importance. The early 
identification of potential CYP2D6 substrates and prediction of their metabolism is therefore 
advantageous in the discovery and development of new drugs. Computational chemistry is a 
most suitable tool to predict metabolic stability and sites of metabolism in potential drugs. 
Predictive in silico database approaches and quantitative structure-activity relationships 
(QSARs) derived from physicochemical (1D) and topological (2D) properties of CYP ligands 
provide robust but rough classifications of the metabolic stability and inhibition potency of 
substrates and inhibitors, respectively, without yielding much insight into the possible 
(molecular) background of the mode of action involved. The structure-based (3D) molecular 
modeling methods, on the other hand, aim to be insightful as well as predictive and were 
applied in this thesis to gather knowledge concerning the structure and dynamics of CYP2D6-
ligand interactions. Of all human CYPs the CYP2D6 isoenzyme is a particularly suited model 
system to investigate the structure and dynamics of protein-ligand interactions. 
Chapter 2 presents in an integrative manner structure-based computational approaches 
used to understand, rationalize and predict the activity and substrate selectivity of CYPS, as 
well as the possibilities and limitations of these approaches now and in the future.1 One can 
divide structure-based models and methods into: i) ligand-based models (QM calculations on 
substrates, pharmacophore-, and QSAR-models), ii) protein-based models (crystal structures, 
homology models and various ways in which this structural information is analyzed and 
applied), and iii) ligand-protein interaction based models (e.g. automated docking and 
molecular dynamics simulations to describe ligand binding orientation, protein-ligand 
dynamics and ligand binding affinity). Apart from earlier mechanism-based ab initio 
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calculations on substrates, also pharmacophore modeling of ligands (i.e. both substrates and 
inhibitors) and protein homology modeling in combination with automated docking and 
molecular dynamics simulations have been used successfully for the rationalization and 
prediction of metabolite formation by several  CYP isoenzymes. In the past six years, the 
number of available crystal structures, especially for mammalian and human CYP-isoforms, 
has increased significantly. In addition, the lack of detailed structural knowledge for many 
other isoforms is being overcome in part by the prediction of CYP structures using computer-
aided homology modeling techniques in combination with small-molecule pharmacophore 
models and mechanism-based ab initio and semi-empirical calculations. A great variety of in 
silico modeling approaches have been applied to CYP enzymes, thereby successfully adding 
to our understanding of CYP structure and function in a way that is complementary to 
experimental studies. Another clear trend in many recent computational studies is the 
combination of multiple modeling techniques to arrive at meaningful and successful 
rationalizations of experimental data, and interpretations and predictions of  CYP function. 
 
Chapter 3 focuses on research line 1, i.e. the construction and validation of a high-
quality CYP2D6 homology model. Experimentally, the active site of CYP2D6 can be probed by 
site-directed mutagenesis studies. Such studies can be designed from structural models of 
enzyme-substrate complexes and the observed effect of mutations on metabolism and 
inhibition of metabolism can subsequently be rationalized at an atomic resolution by 
modeling approaches. Chapter 3 presents the construction, refinement and validation of the 
CYP2D6 homology model used in our laboratory for the prediction and rationalisation of 
CYP2D6 substrate metabolism and CYP2D6-ligand interactions. The protein model could 
explain reported site-directed mutagenesis data (for example, mutation of E216 and D301). 
Furthermore, based on the model, new CYP2D6 mutants were constructed and studied in 
our laboratory, and also for these mutants a rationalization of experimentally observed 
characteristics could be achieved (i.e. I106E, F120A, T309V, F483A). An analysis of the 
CYP2D6-substrate interaction fingerprint of docked substrates in the homology model 
suggests that several other active site residues are probably interacting with ligands as well, 
opening the way for further mutagenesis studies. Importantly, our homology model was 
found to agree with most of the details of the recently solved substrate-free CYP2D6 crystal 
structure. Structural differences between our homology model and the crystal structure were 
the same as the differences observed between substrate-free and substrate-bound 
structures of other CYPs, suggesting that these conformational changes are required upon 
substrate binding. The CYP2D6 crystal structure further validates our homology modeling 
approach and clearly demonstrates on one hand the success and accuracy of state of the art 
CYP homology modeling. On the other hand, we have shown that computational chemistry is 
a useful and valuable tool to provide models for substrate-bound complexes of CYPs which 
give insight into CYP-ligand interactions. This conclusion strongly supports the validitiy of 
homology models as a valuable approach for successful pre-experimental virtual screening, 
as well as accurate hypothesis generation for in vitro studies in drug discovery and 
development. 
 
Chapters 4 and 5 involve research line 2, i.e. the development of improved methods 
for the prediction of CYP-ligand interactions in a high-throughput fashion. In Chapter 4 the 
popular docking programs AutoDock, FlexX and GOLD were used to predict binding modes of 
ligands in crystallographic complexes including X-ray water molecules or computationally 
predicted water molecules.2 Isoenzymes of two different enzyme systems were used, namely 
Cytochromes P450 (n=19) and thymidine kinases (n=19) and three different “water” 
scenarios: i.e. docking (i) into water-free active sites, (ii) into active sites containing 
crystallographic water molecules, and (iii) into active sites containing water molecules 
predicted by a novel approach based on the program GRID. Docking accuracies were 
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determined in terms of the root mean square deviation (RMSD) accuracy and, newly defined, 
in terms of the ligand catalytic site prediction (CSP) accuracy. Considering both X-ray and 
predicted water molecules and the subsequent pooling and rescoring of all solutions 
(generated by all three docking programs) with the SCORE scoring function significantly 
improved the quality of prediction of the binding modes both in terms of RMSD and CSP 
accuracy.  
In Chapter 5, the automated docking strategies successfully applied to binding mode 
predictions of ligands in CYP crystal structures in chapter 4, were used for the catalytic site 
prediction of 65 substrates in our refined and validated CYP2D6 homology model.3 
Consideration of water molecules at predicted positions in the active site and rescoring of 
pooled ligand docking results from four different docking programs (AutoDock, FlexX, GOLD-
Goldscore, GOLD-Chemscore) with the SCORE scoring function enabled successful 
predictions of the experimentally reported sites of catalysis of more than 80% of the 
substrates. Three different database docking algorithms (FlexX, GOLD-Goldscore, GOLD-
Chemscore) were subsequently used in combination with six scoring functions (Chemscore, 
DOCK, FlexX, GOLD, PMF, SCORE) to assess the ability of docking-based virtual screening 
methods to prioritize 20 known CYP2D6 substrates seeded into a drug-like chemical 
database of 980 compounds (in the absence and presence of active site water molecules). 
Finally, the optimal docking strategy in terms of virtual screening accuracy, GOLD-Chemscore 
with consideration of active-site water (60% of known substrates recovered in the top 5% of 
the ranked drug-like database), was verified experimentally: it was successfully used to 
identify high-affinity CYP2D6 ligands among a larger proprietary database (19,619 entries) 
and to discriminate between high affinity and medium affinity ligands. 
 
Chapters 6, 7, and 8 focus on research line 3, i.e. the description of the dynamics of 
CYP-ligand interactions by using several different experimental and in silico techniques (in an 
integrative way). In Chapter 6 a series of 3,4-methylenedioxy-N-alkylamphetamines 
(MDAAs) were automatically docked and subjected to molecular dynamics (MD) simulations 
in our CYP2D6 protein model.4 The predicted substrate binding orientations, sites of 
oxidation and relative reactivities were compared to experimental data of wild-type and 
F120A mutant CYP2D6. Automated docking results were not sufficient to accurately 
rationalize experimental binding orientations of 3,4-methylenedioxy-N-methylamphetamine 
(MDMA) in the two enzymes as measured with spin lattice relaxation NMR. However, the 
docking results could be used as starting structures for MD simulations. Predicted binding 
orientations of MDMA and sites of oxidation of the MDAAs derived from MD-simulations 
matched well with the experimental data. It appeared that the experimental results were 
best described in MD-simulations considering the nitrogen-atoms of the MDAAs in neutral 
form. Differences in regioselectivity and stereoselectivity in the oxidative metabolism of the 
MDAAs by the F120A mutant CYP2D6 were correctly predicted and the effects of the F120A 
mutation could be rationalized as well. 
Detailed molecular dynamics simulations have also been performed in Chapter 7 to 
reproduce and rationalize the experimental finding that the F483A mutant of CYP2D6 has 
lower affinity for R-propranolol than for S-propranolol.5 Wild-type (WT) CYP2D6 does not 
show this stereospecificity. The thermodynamic integration approach was used to calculate 
the free energy differences between all combinations of R- and S-propranolol complexed to 
wild-type and F483A mutant CYP2D6 (end-points). Based on differences between multiple 
calculations connecting the same end-point and the closure of the thermodynamic cycles, it 
was clear that not all simulations have converged sufficiently. The approach that calculates 
the free energies of exchanging R-propranolol with S-propranolol in the F483A mutant 
relative to the exchange free energy in WT was able to reproduce the experimental binding 
data. Careful inspection of the end-points of the simulations involved in this approach, 
allowed for a molecular interpretation of the observed differences. R-propranolol forms fewer 
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hydrogen bonds than S-propranolol, both in WT and in the F483A mutant. The mutation 
causes a loss of favourable hydrophobic interactions, which can be compensated by 
increased hydrogen bond formation by S-propranolol, but not by R-propranolol. 
Substrate specificity of Cytochrome P450 enzymes may be determined not only by the 
characteristics of the active site itself but also by the (dynamic) selectivity of access routes to 
the active site. In addition, enzyme kinetics may be influenced by the substrate binding and 
product unbinding process and associated protein dynamics. In Chapter 8 we have used 
random acceleration molecular dynamics (RAMD) simulations to investigate the routes and 
mechanisms via which substrates may enter and products may exit the buried active site of 
CYP2D6. Three dominant pathways were identified, which were rather substrate and 
substrate protonation state dependent. E216 was shown to play an important role in 
substrate egress, suggesting that E216 is not only crucial for substrate binding in the active 
site, but that it is also involved in directing the substrate towards the active site via 
electrostatic steering. Substrate/product egress via the three pathways is furthermore 
accompanied by large displacement of segments in the BC loop, FG loop and F and G helices 
and involve rotation of aromatic and aliphatic residues, and loss of internal protein H-bonds. 
We propose the following mechanism for substrate access into and product exit from 
CYP2D6: Hydrophobic substrates coming from the membrane enter the protein via a 
pathway termed pw2a, and their hydrophilic products leave via pw2c and/or the solvent 
channel, while soluble substrates enter (and their products leave) via pw2c and/or the 
solvent channel. From our RAMD studies hypotheses can be derived which can be tested 
experimentally, such as site-directed mutagenesis studies of non-active site residues lining 
the substrate egress pathways. 
 
9.2 Conclusions and Perspectives 
The work presented in this thesis has led to a well validated protein model of CYP2D6, and 
based on that, to an in-depth exploration and understanding of two different aspects of 
Cytochrome P450-ligand interactions: binding modes and binding affinities. We have 
developed methods which can successfully predict in which conformation and orientation 
substrates and inhibitors bind to the CYP2D6 isoenzyme (binding modes), how tight these 
ligands bind (binding affinity), and how binding mode and binding affinity are influenced by 
specific structural and chemical characteristics of the ligand and the protein. The 
computational approaches in this work have also opened areas that may stimulate and guide 
further investigations. The most important conclusions with respect to the possibilities and 
limitations of CYP-ligand binding mode and affinity predictions, and future perspectives for 
new areas in computational and experimental CYP research are discussed below and 
summarized in Table 1.  
 
Structures, Crystals, and Computers: 
Inducing the fit, shaping the mould, carving out key positions 
CYPs share the same general three-dimensional fold6 and for all CYPs six substrate 
recognition sites (SRSs) have been assigned.7 However, our modeling and site-directed 
mutagenesis studies suggest that only specific amino acid residues located in these SRSs are 
actually directly involved in CYP2D6-ligand binding, while other residues have an indirect 
effect on ligand binding and catalysis by i) influencing the protein conformation and shape of 
the active site; ii) stabilizing catalytically active heme-oxygen intermediates; iii) controlling 
substrate entrance and/or product exit.8-12 Furthermore, in our studies the roles of specific 
residues in CYP2D6 mediated metabolism have been shown to be rather substrate-specific 
(see Chapters 3, 6, and 7).4,5,12 Chapter 2 shows that several CYP isoforms have only 
been crystallized in a non-active ligand-bound state,1 and for some it is not known whether 
the crystal structure corresponds to an active state or not.13-15 It is important to note that 
this may render the crystal structure of a certain CYP isoenzyme not directly applicable to 
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e.g. explaining observed substrate selectivity and product formation by the enzyme. Ligand-
induced16-20 and temperature-dependent21 changes in the size, shape and hydration of the 
active sites of several CYPs are also observed, and these are likely to underlie the capacity of 
many CYPs to metabolize substrates that are diverse in size and structure and to generate 
different metabolic products from these substrates. Computational chemistry is an especially 
useful and valuable tool to provide dynamic models for substrate-bound complexes of CYPs 




Docking and scoring dependence, water molecules, and protein flexibility  
Several docking algorithms and scoring functions have been described in the past few years, 
but docking (structure prediction) and scoring (prediction of binding free energy) accuracy of 
docking-scoring combinations still vary with the selected target and the physicochemistry of 
target-ligand interactions.22,23 This observation suggests that, prior to automated docking 
studies, one should find optimal docking-scoring strategies for targeted systems by 
evaluating their docking and scoring accuracy for a training set of protein-ligand X-ray 
structures (as was done for CYPs in Chapter 4).2 In the absence of such a training set, 
other sorts of experimental data, like regio-specificity of metabolism (binding mode 
prediction/CSP accuracy), binding affinity determinations (scoring/ranking accuracy) and 
site-directed mutagenesis studies (binding mode prediction/relevance of specific amino acid 
residues for binding) can be used to validate docking strategies (as was done for CYP2D6 in 
Chapter 5).3 
In addition to the problem of protein-ligand complex specificity of docking performance, 
there are also other critical issues in automated docking, such as ligand-induced 
complementarity (the accommodation of full flexibility of both ligand and protein),24 and the 
inclusion, or omission, of explicit water molecules in the ligand binding pocket.25 In the past 
several years, automated docking has been established as a standard modeling tool to 
predict ligand-protein binding modes and affinities in lead discovery and optimization.26 
Benchmarks have been defined,22,23 and more and more approaches have been developed 
which tackle the problems of finding the optimal docking and scoring combination for a given 
target,27 active site solvation,28 and protein flexibility.24 In Chapters 4 and 5 novel docking 
strategies are described to predict the locations of active-site water molecules in CYPs and to 
include them in automated docking simulations.2,3 However, to be able to describe the 
docking of ligands to protein targets in an even more accurate way, it is suggested to focus 
on the development of docking search algorithms that also optimize the positions of several 
water molecules during the docking process. To our knowledge, no docking tool has been 
properly validated which, in addition to the ligand and the protein, also considers fully 
‘flexible’ water molecules as a ‘third’ partner in protein-ligand interactions.  
 
Dynamic Distributions: 
Multiple binding modes, multiple entrance/exit channels, multiple substrates 
Chapters 4 and 5 concluded that automated docking can successfully be applied to predict 
sites of oxidation in substrates using CYP crystal structures and CYP homology models. 
However, Chapters 6 and 7 show that automated docking alone is not suitable for accurate 
determination of relative probabilities of different substrate binding modes and protein-ligand 
interactions for discrimination between substrates and enzymes of high similarity, such as 
regio/stereoisomers and mutants of enzymes. These subtle differences in protein-ligand 
binding modes and interactions can have a determining influence on the observed affinities 
and metabolite distributions. Computational tools offer insight at an atomic resolution often 
lacking in experiments. In order to reproduce and rationalize experimental data, which are 
an average over many different substrate and enzyme conformations and orientations over 
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time, a dynamic treatment of both substrate and enzyme is required. MD simulations in 
addition can account for distributions of multiple binding conformations and thus give a more 
comprehensive description of multiple sites of oxidation in substrates catalyzed by CYPs 
(Chapter 6)4 and of CYP-ligand interactions (Chapter 7).5 Multiple extensive MD 
simulations are needed to catch subtle differences between substrates, enzyme structures 
and their dynamics. A remaining hurdle in the accurate calculation of CYP ligand binding 
modes and affinities is the diversity of binding modes of ligands, stemming from a flexible 
binding cavity that is large in relation to the size of the substrates. Consequently, for many 
ligands (i.e. substrates and inhibitors) the binding mode in CYPs is not as strictly defined as 
is the case for many other more substrate and inhibitor specific enzymes.29 This potentially 
introduces sampling problems,30,31 prohibiting the application of MD based methods that can 
provide the most accurate free-energy calculations. 
Substrate specificity of CYPs may be determined not only by the characteristics of the 
active site itself (as investigated in Chapters 3, 4, 5, 6 and 7)2-5 but also by the (dynamic) 
selectivity of access routes to the active site. In addition, enzyme kinetics may be influenced 
by the substrate binding and product unbinding process and associated protein dynamics. 
The generally buried active site of many CYPs implies that the protein must undergo dynamic 
motion to allow substrates to enter and products to leave the active site.32,33 We have 
explored the routes and mechanisms via which substrates may exit the active site of CYP2D6 
in Chapter 8. The hypotheses derived from these studies should still be tested 
experimentally, e.g. by site-directed mutagenesis studies of non-active site residues lining 
the substrate egress pathways and spectroscopic techniques to localize regions of 
conformational flexibility in the protein. 
Mammalian CYPs are inserted into the membrane by means of a hydrophobic N-terminal 
helical anchor and some hydrophobic loop regions located around the entrance of pw2a 
(Chapter 8).34 To facilitate crystallization of mammalian membrane-bound CYPs residues in 
these regions have been truncated and mutated into more hydrophilic residues, 
respectively.35 Although these mutated constructs have been shown to be catalytically active, 
the mutations might cause significant conformational changes. Even when one assumes that 
the actual shape of the active site of CYPs is not much influenced by CYP-membrane 
interactions, association to the membrane can have a significant effects on protein (FG loop) 
flexibility, and for a proper description of the dynamics of substrate entrance and product 
exit in CYP2D6, protein-membrane (and substrate-membrane) interactions should be taken 
into account. 
Some CYPs are capable to bind several substrates simultaneously, occupying the same or 
different binding sites. This results in unusual enzyme kinetics. This hypothesis is supported 
by kinetic models36 and crystal structures,37,38 but modeling studies describing and predicting 
allosterism are still very scarce.39,40 Methodological problems linked to the computational 
prediction of allosterism are the identification of alternative binding pockets, the sequence of 
binding events, and the proper description of ligand-ligand interactions. Atypical kinetics 
have been reported for CYP2D6,10,41 spectroscopic studies indicate that substrates may 
associate to CYP2D6 at different sites,42 and alternative substrate binding pockets can be 
identified along potential substrate access channels in CYP2D6 (Chapter 8). The capability 
of CYP2D6 to bind multiple ligands at the same time, may potentially have a great impact on 
the prediction of CYP2D6 mediated metabolism, and computational research is needed to 
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CYP in Silico Velocitas: 
Catalytic steps, catalytic components, relative rates 
A yet unresolved challenge in computational drug metabolism research is the accurate 
quantitative prediction of metabolite formation ratios and turnover rates. For accurate 
prediction of reactivities of substrate catalytic sites, the dependence on kinetic factors and 
the influence of the active site electrostatic potential should be accounted for. This, in 
turn, depends on details of the protein structure and the binding conformation and 
orientation of the substrate. The absence of certain predicted metabolites may be due to 
slow conversion compared to other metabolic reactions, from competing metabolic 
pathways or from other enzymes. In many cases it is possible to identify rate-limiting 
steps (which may vary between CYP isoforms and between substrates of the same 
isoform). These imply that product formation will be dominated by the characteristics of 
that particular step, greatly simplifying the complexity of the prediction.43 In the oxidation 
of ethanol and acetaldehyde by CYP2E1,44 a slow step occurs after product formation, 
although it is not product release perse. In the catalytic cycles of CYP1A2,45 CYP2D6,46 and 
CYP3A4,47 C-H bond breaking is only partially rate-limiting. However, the rates of all the 
various individual steps are considerably higher than the overall kcat, and the contributions 
of several steps must be considered to understand rates of CYP1A245 and CYP2D6 
reactions.46 Therefore accurate quantitative computational estimates of (relative) rates of 
CYP mediated metabolism in principle can only be made when the quantitative description 
of all the catalytic steps in the CYP catalytic cycle (as depicted in Figure 6 of Chapter 1 
and Figure 1 of Chapter 2) are properly combined. 
Even when the relative rates of the different catalytic steps can be predicted, it should 
be kept in mind that chemical reactivity alone, without taking into consideration the 
orientation of the substrate in the CYP active site (with respect to the heme), is not likely 
able to predict the correct site of metabolism in a CYP substrate.48 For CYP2D6 and many 
other CYPs, the orientation of the substrate in the active site might even be the most 
important factor determining catalytic regiospecificity, as Chapters 4, 5 and 6 showed 
that automated docking and molecular dynamics simulations are already very successful in 
predicting the major sites of metabolism and to provide qualitative predictions of product 
distributions.2-4 Chapter 6, however, also showed that a small substrate like MDMA is 
very mobile in the CYP2D6 active site and that the reactivity of possible sites of oxidation 
also determines what products are being formed.4 For a proper quantitative description of 
product distributions surely the combined probabilities of reaction accessibility (i.e. 
proximity to the heme reactive species) and  intrinsic reactivity of sites in the substrate 
should be estimated. Recently, such a combined modeling approach was successfully used 
to predict sites of metabolism in various CYPs, and indicated that the relative contributions 
of substrate docking and intrinsic reactivity factors was isoenzyme dependent.48,49 
Another remaining challenge in predicting product formation in CYPs is the elucidation of 
the relevant reactive heme-iron-oxygen species that is ultimately responsible for the 
chemistry of the enzyme reaction, and the coupling between the kinetics of the reaction 
cycle of the heme-iron-oxygen moiety and the dynamics of substrate and oxygen and 
release of the product. Elucidation of the reaction cycle of CYPs is complicated by the 
different influences of the substrate, sequence of events and rate-limiting step between 
different isoforms.43 The development of QM and combined QM/MM methodologies to 
describe catalytic species in the CYP catalytic cycle has evolved rapidly over the past 
years.50-54 Recent extensive QM/MM calculations on CYP2C9, CYP2B4, CYP3A4, and 
CYP101, revealed that the differences in the electronic structure of Compound I for one 
isoform to another are not significantly larger than those derived from different MD 
snapshots and from different starting crystal structures of the same isoform.55 
Furthermore, QM/MM calculations of H-abstraction barriers in CYP101 were found to be 
dependent on subtle differences in protein-water configuration.56 In addition, recent 
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combined experimental and modeling studies indicate that the highly conserved I-helix 
threonine residue in CYPs (T309 in CYP2D6) plays not only an important role in 
maintaining the balance of multiple oxygenating species (Chapter 3, refs 10,57), but also 
influences heme spin state distributions by interacting with heme bound water or 
molecular oxygen [Groenhof and Bonifacio, unpublished results 2006, ref 58]. 
The studies in this thesis have focused on the description of interactions between CYPs 
and small ligand molecules. The interaction of CYPs with other proteins, however, is also 
an important phenomenon to take into account when describing CYP mediated 
metabolism. Electrons are transferred from NAD(P)H to CYPs via electron transfer proteins 
(e.g. see Figure 6 in Chapter 1 and Figure 1 in Chapter 2). These mostly consist of 
either a membrane-bound NADPH reductase (like in mammalian CYPs) or a soluble 
reductase and a two-iron-sulfur cluster ferredoxin shuttle protein (in most soluble bacterial 
CYPs) that together deliver the electrons. There is evidence for favorable electrostatic 
interactions between CYPs and a number of their electron transfer partners.59 CYPs may 
also interact with other CYPs and form oligomers.38 CYP-reductase interactions are even 
thought to have an allosteric effect on substrate binding and metabolic regiospecificity,60 
although such an effect has not been shown for CYP2D6.61 Although structures of the 
individual components, and even a crystal structure of the complex between the heme- 
and FMN-binding domains of bacterial CYP102 have been solved,59 no crystal structure has 
yet been determined of a complex of a mammalian CYP with its non-covalently bound 
electron transfer protein(s). Thus, modeling studies play an important role in the 
interpretation of mutational and spectroscopic data on CYP protein–protein 
interactions.62,63 With the development of more and more accurate and efficient protein-
protein docking methods64 possibly involving experimentally determined geometrical 
constraints,65 more and more accurate structural models of CYP-protein complexes can be 
generated.62 
 
CYP in Silico Applicatus 
Which drugs, which CYPs, which metabolites? 
The protein model of CYP2D6 and the methods described in this thesis can be used for 
pre-experimental virtual screening purposes, as well as accurate hypothesis generation for 
in vitro studies in drug discovery and development. From binding mode predictions the site 
of metabolism and the number and relevance of reactive metabolic positions can be 
estimated. Moreover, binding affinity predictions give insight into substrate specificity and 
into the potential of a compound to inhibit the metabolism of other drugs by CYPs (drug-
drug interactions). 
Since pharmacological activity, toxicity, bioavailability, distribution, and final elimination 
all depend on metabolic biotransformations, the prediction of metabolic stability and the 
identification of potential sites of metabolism in a putative drug molecule can be a 
significant help in designing new compounds with better pharmacokinetic and safety 
profiles. Metabolic stability of compounds can generally be determined in a high-
throughput fashion. Recently, some attempts for high-throughput metabolite identification 
have been reported,66,67 but generally, the experimental methods for early identification of 
metabolites is still low throughput and requires considerable amounts of compound. 
Computational chemistry is therefore an especially suitable tool to rapidly predict 
metabolic stability and sites of metabolism in potential drugs.48 When the site of 
metabolism is known, metabolically labile compounds can be stabilized by removing, 
replacing or protecting metabolically susceptible groups.68 Similarly, the formation of toxic 
metabolites can be avoided by chemically protecting the metabolically labile moieties. 
Finally, knowing the site of metabolism is essential for the design of pro-drugs, where the 
compound needs to be metabolized in order to become active69, and also for drugs 
showing excessively long half lives. Modifying functional groups in drug lead compounds 
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that are essential for binding to metabolic enzymes may affect the binding affinity for 
these enzymes as well as their metabolic regiospecificity.  
Another yet unresolved challenge in computational drug metabolism research is the 
construction of combined models for multiple biotransformation enzymes (like different 
CYP isoenzymes), enabling the prediction of the relative kinetics of different reaction 
pathways and prediction of the relative affinities of drugs for different enzymes. This 
would give insight into the relative importance of different enzymes in the formation of 
different metabolites and might finally lead to the prediction of (the kinetics of) complete 
metabolic pathways of drugs. 
In principle such combined biotransformation models could be combined with specific 
structure-based ligand-receptor interaction models. Drug leads found to have high affinity 
for receptors are often found to have a high affinity for CYPs as well. For example, 
serotonin transporters70 and (aminergic) GPCRs71 show high affinity for typical CYP2D6 
substrates. This can lead to undesired drug-drug interactions and adverse drug effects. 
Several ideas can be postulated to address the problem of protein specificity in affinity and 
metabolism of drugs by CYPs. The methods can roughly be divided into two groups. In the 
first approach one could use known methods to rationalise the binding and/or metabolism 
by several target proteins, and subsequently try to relate the differences in protein-ligand 
interactions to molecular differences in the substrates. Such ligand-based pharmacophore 
models have been defined for several individual CYPs72 and receptor targets73,74, but 
studies to predict and rationalize differences in protein specificity are relatively scarce.41,75-
77 Alternatively, one can use computational methods to train a model on the specificity 
between targets, i.e. the difference between metabolism or binding affinities. Instead of 
virtually screening a chemical database against a specific CYP isoenzyme to search for 
high (or low) affinity substrates or inhibitors, one can for example also try to recover the 
most likely (CYP iso)enzyme target for a given ligand ((CYP iso)enzyme specificity).78 
Another possibility would be to train 3D-QSAR models on differences in binding affinity of 
the same compound for different targets, instead of training on differences in affinity of 
different compounds for the same target. This will automatically point at the molecular 
elements that are most important to obtain substrates with e.g. a high affinity for one 
target and a low affinity for another target. Once one would be able to understand and 
predict the molecular reasons for isoenzyme and receptor specificities in binding and 
possibly metabolism, even more powerful tools for computer-aided drug design will evolve. 
 
In summary, hit identification and lead development could be helped significantly if 
during the design process care can be taken to prevent CYP2D6 activity. In this thesis we 
have described the development of computational methodologies by the integrative use of 
molecular modeling with site-directed mutagenesis studies, enzymology, and 
spectroscopical studies. The developed techniques described in this thesis were 
successfully applied to predict CYP2D6 affinity, to predict regiospecificity of CYP2D6 
mediated metabolism, and to define the characteristics of CYP2D6 and its ligands 
determining CYP2D6-drug interactions, and can be seen as model approaches for other 
CYPs. Furthermore, the combination of computational and experimental techniques used 
in this thesis is a promising approach for the investigation of pharmaceutically relevant 
targets of which structural information is lacking. Combining computational interaction 
models between proteins and drugs (and their metabolites) will enable the development of 
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Interacties tussen cytochromen P450 en medicijnen: 
Het voorspellen van bindingsoriëntaties en bindings-
affiniteiten in CYP2D6 met behulp van computer-
simulaties. 
 
Arsenicum, strychnine, curare, botuline, koolmonoxide en cyaankali, bekende gifstoffen die 
in lage doses tot de dood kunnen lijden. Parcelsus stelde halverwege de zestiende eeuw 
echter al dat in feite “al het voedsel en alle drank, als men er te veel van gebruikt, vergift 
is”. Uitlaatgassen, sigarettenrook, asbest, weekmakers in plastic, voortdurend worden we 
blootgesteld aan giftige stoffen. Het lichaam is gelukkig uitgerust met mechanismen om de 
schade van deze stoffen zoveel mogelijk te beperken. Het lichaam kan zich van gifstoffen 
ontdoen door deze verbindingen met behulp van enzymen om te zetten in stoffen die 
minder giftig zijn. Deze omzettingsproducten zijn beter in water oplosbaar en kunnen 
daardoor gemakkelijker via de nieren worden uitgescheiden. Enzymen zijn eiwitten die 
chemische reacties sneller kunnen laten verlopen en de belangrijkste enzymen die kunnen 
ontgiften zijn de zogenaamde Cytochroom P450 (CYP) enzymen. Door de omzetting van 
lichaamsvreemde stoffen kunnen echter ook verbindingen met een hogere giftigheid 
ontstaan. Deze actieve stoffen kunnen binden aan DNA, vetten of eiwitten en hierdoor de 
normale celgroei ernstig verstoren. Remming van CYP enzymen door lichaamsvreemde 
stoffen kan ook ongewenste gevolgen hebben. Via dit mechanisme wordt het 
lichaamseigen metabolisme van bijvoorbeeld hormonen verstoord en kunnen ongewenste 
effecten optreden, zoals leververgiftiging of kanker. Daarnaast zetten CYPs ook stoffen om 
die een heilzame werking kunnen hebben, zoals medicijnen. 
Er zijn zo’n 60 verschillende menselijke CYP-enzymen bekend en de omzettingscapaciteit 
van CYPs verschilt per persoon. Dit leidt ertoe dat niet iedereen hetzelfde reageert op een 
bepaalde dosis van een geneesmiddel. Het tempo waarin een geneesmiddel uit het 
lichaam wordt uitgescheiden is immers bepalend voor de medicijn-concentratie in het 
bloed, hetgeen weer van invloed kan zijn op het effect het geneesmiddel. De variatie in 
omzettingssnelheid is grotendeels erfelijk bepaald. Sommige CYP-enzymen zijn genetisch 
polymorf, dat wil zeggen dat er mutante vormen van dit specifieke CYP enzym voorkomen 
die door mutatie een andere enzymactiviteit hebben. Daarnaast zijn ook andere factoren 
van invloed op de activiteit van CYP-enzymen. Stoffen in tabaksrook kunnen bijvoorbeeld 
de aanmaak van bepaalde CYPs verhogen, terwijl medicijnen die interacties aangaan met 
CYPs de omzetting van andere medicijnen kunnen blokkeren. Het is van belang om bij de 
ontwikkeling van nieuwe medicijnen in te schatten in welke mate deze verbindingen 
worden omgezet door de CYP-enzymen in individuen met verschillende CYP-activiteit, en 
welke producten hierbij worden gevormd. Hiervoor zijn verschillende methoden 
beschikbaar, waaronder zogenaamde 'high throughput screening’ technieken waarbij op 
een snelle manier stoffen in de reageerbuis (in vitro) worden getest op affiniteit voor 
CYPs. Tegenwoordig kan men dit echter ook met computertechnieken (in silico) uitvoeren. 
Het katalytisch centrum van CYP-enzymen, de plek in het eiwit waar de daadwerkelijke 
chemische reactie plaatsvindt, is een heem-molecuul met een ijzeratoom. Wanneer 
geneesmiddelen worden opgenomen in de bindingsholte van CYP-enzymen worden ze op 
die plaatsen geoxideerd die het meest reactief zijn en die zich het dichtst bij het 
ijzeratoom bevinden. Computermodellen kunnen worden ingezet om de oriëntaties en 
reactiviteit van geneesmiddelen in CYP-enzymen en de interactie krachten (affiniteiten) 
met CYP-enzymen te voorspellen. 
Ongeveer een kwart van de geneesmiddelen die op de markt zijn, wordt door het unieke 
CYP2D6-enzym gemetaboliseerd. Vele geneesmiddelen zoals antidepressiva, neuroleptica, 
bèta-blokkers en antiarrhythmica zijn substraten van CYP2D6. Tevens is CYP2D6 genetisch 
polymorf: veel mensen hebben een sterk verlaagde of sterk verhoogde CYP2D6-activiteit. 
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Wetenschappelijke studies naar de wijze waarop medicijnen interacties aangaan met het 
CYP2D6-enzym zijn daarom van belang voor de ontwikkeling van veilige en efficiënte 
medicijnen, en computermodellen kunnen in een vroeg stadium bij dit ontwikkelingsproces 
worden ingezet. De centrale vraag van dit proefschrift luidt dan ook: op welke manieren 
kunnen we met computersimulaties voorspellen hoe medicijnen zich in de bindingsholte 
van CYP2D6 oriënteren en wat hun affiniteit is met de CYP2D6 bindingsholte? 
 
In Hoofdstuk 2 wordt een overzicht gegeven van de belangrijkste computersimulatie 
studies ter beschrijving van CYP-enzymen. De in deze studies beschreven 
computermodellen zijn ofwel gebaseerd op de liganden (remmers, substraten) van een 
bepaalde CYP, gebaseerd op de CYP-eiwit structuur, ofwel gebaseerd op de beschrijving 
van interacties tussen CYPs en hun liganden. Om de functie en structuur van CYPs zo 
nauwkeurig mogelijk te kunnen beschrijven wordt  tegenwoordig steeds meer gebruik 
gemaakt van combinaties van verschillende modellen en benaderingen. 
 
Computermodellen kunnen niet alleen gebruikt worden om verklaringen te geven voor 
de resultaten van experimentele studies in het laboratorium, maar ook om hypotheses op 
te stellen en voorspellingen te doen ten aanzien van de uitkomsten van experimenten. Op 
deze manier kan de computer worden gebruikt om laboratoriumexperimenten te 
ontwerpen, terwijl de uitkomsten van deze experimenten op hun beurt weer kunnen 
worden gebruikt om het computermodel te testen en te verfijnen. We hebben de 
kristalstructuren van substraatgebonden vormen van een verwant CYP-enzym gebruikt als 
mal voor de vervaardiging van een computer(homologie)model van CYP2D6. In 
Hoofdstuk 3 laten we zien hoe we dit homologie model hebben gebruikt om aminozuren 
in de bindingsholte van CYP2D6 te identificeren die invloed kunnen hebben op de manier 
waarop medicijnen kunnen binden aan het CYP2D6-enzym. In het laboratorium bleken 
deze voorspellingen inderdaad te kloppen en de effecten van de mutaties van deze 
aminozuren bleken zelfs substraatafhankelijk. Op deze manier konden we enerzijds 
aantonen dat belangrijke details van ons drie-dimensionale computermodel 
overeenkwamen met de werkelijkheid. Anderzijds leverden deze experimentele 
validatiestudies weer nieuwe inzichten op ten aanzien van CYP2D6-substraat interacties 
die we konden proberen te verklaren en voorspellen met onze computermodellen. Sterker 
nog, aan het einde van het in dit proefschrift beschreven promotie-onderzoek verscheen 
er een kristalstructuur van CYP2D6 die in grote mate overeenkomt met ons 
computermodel. 
 
In Hoofdstukken 4 en 5 hebben we zogenaamde “automated docking” technieken 
gebruikt om te voorspellen in welke oriëntaties medicijnen binden aan CYP-enzymen en 
hoe sterk de interactiekrachten zijn tussen medicijnen en CYPs. De bindingsoriëntatie van 
het medicijn ten opzichte van het katalytisch centrum van de CYP, het ijzeratoom van de 
heemgroep, bepaalt of het medicijn wordt omgezet en welke omzettingsproducten hierbij 
worden gevormd. De sterkte van de interactie, ofwel de bindingsaffiniteit van een medicijn 
voor een bepaalde CYP, is van invloed op de mate waarin het medicijn wordt omgezet. 
Tevens bepaalt de bindingsaffiniteit in welke mate een medicijn A een ander medicijn B uit 
de CYP kan verdringen en op deze manier de omzetting van medicijn B kan remmen. 
Docking technieken maken gebruik van een docking algoritme om mogelijke 
bindingsoriëntaties te genereren en scoring functies om de energetisch meest gunstige 
oriëntatie te selecteren. Er zijn veel verschillende docking algoritmes en scoring functies 
ontwikkeld in de afgelopen jaren. Het is daarom van belang om te weten met welke 
benaderingen de meest nauwkeurige voorspellingen kunnen worden gedaan ten aanzien 
van CYPs (Hoofdstuk 4) en CYP2D6 in het bijzonder (Hoofdstuk 5). Normaal gesproken 
worden watermoleculen buiten beschouwing gelaten tijdens docking simulaties, maar in 
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veel CYPs die wij hebben bestudeerd bleek het meenemen van watermoleculen in de 
berekeningen juist een positieve invloed te hebben op onze voorspellingen. Uiteindelijk 
hebben we met de optimale docking strategiëen de relatieve bindingsaffiniteiten van 
20.000 moleculen met CYP2D6 voorspeld (virtual screening) en verbindingen geselecteerd 
met de hoogste docking scores. Deze verbindingen bleken na experimentele tests in het 
laboratorium ook daadwerkelijk een hoge affiniteit voor CYP2D6 te bezitten. 
 
Subtiele verschillen in de chemische structuur van medicijnen en enzymen kunnen 
significante effecten hebben op hun onderlinge interacties (substraat bindingsorientaties 
en bindingsaffiniteiten). Om deze verschillen in interacties nauwkeurig te kunnen 
voorspellen is een tijdsafhankelijke beschrijving van het enzym-substraat complex vereist. 
Moleculaire dynamica (MD) simulaties zijn bij uitstek een methode om de bewegingen van 
enzym-substraat complexen in de tijd te beschrijven. Tijdens deze simulaties laten we de 
atomen van het systeem bewegen volgens de wetten van Newton en op die manier 
nemen we meerdere conformaties van het enzym-substraat complex mee in onze 
berekeningen. Hoofdstuk 6 laat zien dat we door een combinatie van automated docking 
en veel langdurige MD-simulaties in staat waren om experimenteel bepaalde 
bindingsoriëntaties van MDMA en MDMA-analogen te voorspellen. MDMA, beter bekend als 
partydrug XTC, werd vroeger gebruikt als afslankmiddel. De experimentele resultaten 
waren gebaseerd op spectroscopische metingen van kernspinresonantie (NMR) van 
protonen van XTC en op metingen van de kinetiek van de vorming van specifieke 
metabolieten door CYP2D6. Aan de hand van de spectroscopische metingen kan de 
gemiddelde afstand van de protonen tot het ijzeratoom van de heemgroep worden 
bepaald, terwijl de enzymologische metingen aangeven welke delen van het substraat zich 
het dichtst bij het ijzeratoom bevinden. Onze MD-simulaties voldeden zowel aan de 
spectroscopische als aan de enzymologische metingen. Op deze manier konden we zelfs 
verklaren waarom XTC stereo-isomeren zich verschillend oriënteren in normale (wild-type) 
en gemuteerde vormen (fenylalanine 120 naar alanine) van CYP2D6. 
In Hoofdstuk 7 hebben we MD-simulaties en de zogenaamde Thermodynamische 
Integratie (TI) methode gebruikt om de affiniteit te voorspellen van propranolol  stereo-
isomeren (een bèta-blokker medicijn) met wild-type en gemuteerde (fenylalanine 483 naar 
alanine) CYP2D6. De TI-methode maakt gebruik van alchemie: in kleine stapjes wordt 
molecuul A in molecuul B veranderd en aan de hand van de verschillende simulaties met 
deze fysisch onmogelijke verbindingen (“een beetje van A en een beetje van B”) kan het 
verschil in vrije energie tussen moleculen A en B worden afgeleid. Het omzetten van de 
ene stereo-isomeer van propranolol (R) in de andere stereo-isomeer (S) in zowel wildtype 
als F483A-mutante CYP2D6 leverde verschillen in vrije energie op die overeen kwamen 
met experimenteel bepaalde verschillen in affiniteit. Tevens konden de MD-simulaties een 
verklaring geven voor het feit dat R-propranolol minder goed bindt aan de F483A-mutant 
dan aan wild-type, terwijl S-propranolol aan beide vormen van CYP2D6 even goed bindt. 
R- en S-propranolol vormen minder waterstofbruggen in de F483A-mutant, en alleen S-
propranolol kan dit compenseren door meer hydrofobe interacties aan te gaan met de 
F483A-mutant. 
 
Niet alleen de interactiekrachten tussen het medicijn en de CYP in de bindingsholte 
kunnen bepalend zijn voor de mate van omzetting van het medicijn. Ook de manier 
waarop het medicijn deze bindingsholte kan bereiken is een belangrijke factor bij de 
voorspelling van interacties tussen medicijnen en CYPs. We hebben daarom in Hoofdstuk 
8 de mogelijke kanalen onderzocht waarlangs medicijnen kunnen binnenkomen en 
omzettingsproducten het CYP2D6 eiwit weer kunnen verlaten. Deze studies suggereren 
dat slechts bepaalde delen van het CYP2D6 van structuur moeten veranderen om 
verbindingen uit het enzym te laten ontsnappen of juist toegang te verschaffen tot de 
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bindingsholte. Een belangrijke rol schijnt te zijn weggelegd voor de negatief geladen 
glutamaat (E) 216 bij dit proces. Dit negatief geladen aminozuurresidu werkt als een 
anker- en herkenningspunt voor positief geladen CYP2D6-substraten. Ook andere 
aminozuurresiduen die zich langs deze toegangskanalen bevinden zijn potentiële 
kandidaten voor toekomstige experimentele mutatiestudies. 
 
Door het in dit proefschrift beschreven onderzoek hebben we nu een betere kijk op de 
factoren die bepalend zijn voor de wijze waarop medicijnen zich in de bindingsholte van 
CYP2D6 oriënteren en hoe sterk hun affiniteit is voor deze bindingsholte. De in deze 
studies ontwikkelde methodes kunnen worden ingezet tijdens de ontwikkeling van nieuwe 
medicijnen om te voorspellen of deze verbindingen worden omgezet door CYP2D6 en 
welke omzettingsproducten zich hierbij vormen. Op deze manier kan worden vermeden 
dat het medicijn een slechte therapeutische werking heeft in individuen met een 
verhoogde CYP2D6 activiteit (snelle afbraak van het medicijn) of giftige bijverschijnselen 
vertoont als gevolg van verlaagde (langdurig hoge medicijnconcentraties in het bloed) dan 
wel verhoogde (vorming van giftige omzettingsproducten) CYP2D6 activiteit. Tot slot kan 
de geïntegreerde benadering van computersimulatie en experimentele validatie zoals 
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